doc_id,sentence,biomarker,medium,prediction
"PMC 
BMC_Cancer_2010_Aug_16_10_431.txt
",Previous study demonstrated a good correlation between TC/CC genotypes of the VEGF -460 T &#62; C polymorphism and increased serum VEGF levels in colorectal cancer patients [21].,TC,serum,1
"PMC 
BMC_Cancer_2010_Aug_16_10_431.txt
",Previous study demonstrated a good correlation between TC/CC genotypes of the VEGF -460 T &#62; C polymorphism and increased serum VEGF levels in colorectal cancer patients [21].,VEGF,serum,1
"PMC 
BMC_Cancer_2010_Aug_16_10_431.txt
",Previous study demonstrated a good correlation between TC/CC genotypes of the VEGF -460 T &#62; C polymorphism and increased serum VEGF levels in colorectal cancer patients [21].,VEGF,serum,1
"PMC 
BMC_Cancer_2010_Aug_16_10_431.txt
",Previous study demonstrated a good correlation between TC/CC genotypes of the VEGF -460 T &#62; C polymorphism and increased serum VEGF levels in colorectal cancer patients [21].,T,serum,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
",The NPC trial showed that the protective effect of selenium was limited to patients with baseline serum selenium in the lower 2 tertiles [25].,NPC,serum,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","We aim to evaluate the serum expression of MMP-9, NGAL and their complex (MMP-9/NGAL) during the diagnostic work-up of women with breast abnormalities and investigate their correlation with disease severity.

",NGAL,serum,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","We aim to evaluate the serum expression of MMP-9, NGAL and their complex (MMP-9/NGAL) during the diagnostic work-up of women with breast abnormalities and investigate their correlation with disease severity.

",MMP-9,serum,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","Contrary to MMP1, their mRNA expression was detectable in all saliva samples at mean Cp values of 27.7, 28.8 and 31.7 cycles for ACT, B2M and RPS18, respectively.

",mRNA,saliva,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","Contrary to MMP1, their mRNA expression was detectable in all saliva samples at mean Cp values of 27.7, 28.8 and 31.7 cycles for ACT, B2M and RPS18, respectively.

",MMP1,saliva,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","Contrary to MMP1, their mRNA expression was detectable in all saliva samples at mean Cp values of 27.7, 28.8 and 31.7 cycles for ACT, B2M and RPS18, respectively.

",ACT,saliva,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","Contrary to MMP1, their mRNA expression was detectable in all saliva samples at mean Cp values of 27.7, 28.8 and 31.7 cycles for ACT, B2M and RPS18, respectively.

",B2,saliva,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","Contrary to MMP1, their mRNA expression was detectable in all saliva samples at mean Cp values of 27.7, 28.8 and 31.7 cycles for ACT, B2M and RPS18, respectively.

",RPS18,saliva,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
",CA-125 is a high molecular weight glycosylated membrane protein that can be detected in serum and is elevated in more than 80% of patients with ovarian cancer.,CA-125,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Several other clinical and biological factors including serum cancer antigen 125 (CA-125) have been assessed for prognostic and predictive relevance [11,12].

",CA-125,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","In fact, some patients with a lower serum TRACP 5b activity may actually carry a high tumor burden.

",TRACP,serum,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","In our study, the lack of sensitivity to detect salivary expression of MMP1 could have been due to suboptimal procedures for saliva collection, RNA extraction and retro-transcription.",MMP1,saliva,-1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","In our study, the lack of sensitivity to detect salivary expression of MMP1 could have been due to suboptimal procedures for saliva collection, RNA extraction and retro-transcription.",RNA,saliva,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Table 1 Summary of xenograft characteristics

	Basal-like xenograft (MAS98.12)	Luminal-like xenograft (MAS98.06)	
		
	Primary tumor	Xenograft	Primary tumor	Xenograft	
Tumor grade	Grade III IDC	NA	Grade III IDC	NA	
	
Lymph node status	No metastasis	NA	Metastasis to 12 of 25 nodes	NA	
			No distant metastases		
	
Differentiation	Poorly differentiated	Poorly differentiated	Well differentiated	Poorly differentiated	
	
Hormone receptor status	ER-/PgR+**	ER-/PgR-	ER+/PgR+	ER+/PgR+	
	
ERBB2 amplification*	",IDC,Lymph,1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Table 1 Summary of xenograft characteristics

	Basal-like xenograft (MAS98.12)	Luminal-like xenograft (MAS98.06)	
		
	Primary tumor	Xenograft	Primary tumor	Xenograft	
Tumor grade	Grade III IDC	NA	Grade III IDC	NA	
	
Lymph node status	No metastasis	NA	Metastasis to 12 of 25 nodes	NA	
			No distant metastases		
	
Differentiation	Poorly differentiated	Poorly differentiated	Well differentiated	Poorly differentiated	
	
Hormone receptor status	ER-/PgR+**	ER-/PgR-	ER+/PgR+	ER+/PgR+	
	
ERBB2 amplification*	",ERBB2,Lymph,1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Table 1 Summary of xenograft characteristics

	Basal-like xenograft (MAS98.12)	Luminal-like xenograft (MAS98.06)	
		
	Primary tumor	Xenograft	Primary tumor	Xenograft	
Tumor grade	Grade III IDC	NA	Grade III IDC	NA	
	
Lymph node status	No metastasis	NA	Metastasis to 12 of 25 nodes	NA	
			No distant metastases		
	
Differentiation	Poorly differentiated	Poorly differentiated	Well differentiated	Poorly differentiated	
	
Hormone receptor status	ER-/PgR+**	ER-/PgR-	ER+/PgR+	ER+/PgR+	
	
ERBB2 amplification*	",III,Lymph,1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Table 1 Summary of xenograft characteristics

	Basal-like xenograft (MAS98.12)	Luminal-like xenograft (MAS98.06)	
		
	Primary tumor	Xenograft	Primary tumor	Xenograft	
Tumor grade	Grade III IDC	NA	Grade III IDC	NA	
	
Lymph node status	No metastasis	NA	Metastasis to 12 of 25 nodes	NA	
			No distant metastases		
	
Differentiation	Poorly differentiated	Poorly differentiated	Well differentiated	Poorly differentiated	
	
Hormone receptor status	ER-/PgR+**	ER-/PgR-	ER+/PgR+	ER+/PgR+	
	
ERBB2 amplification*	",III,Lymph,1
"PMC 
BMC_Cancer_2010_Aug_17_10_433.txt
","Table 1 Summary of xenograft characteristics

	Basal-like xenograft (MAS98.12)	Luminal-like xenograft (MAS98.06)	
		
	Primary tumor	Xenograft	Primary tumor	Xenograft	
Tumor grade	Grade III IDC	NA	Grade III IDC	NA	
	
Lymph node status	No metastasis	NA	Metastasis to 12 of 25 nodes	NA	
			No distant metastases		
	
Differentiation	Poorly differentiated	Poorly differentiated	Well differentiated	Poorly differentiated	
	
Hormone receptor status	ER-/PgR+**	ER-/PgR-	ER+/PgR+	ER+/PgR+	
	
ERBB2 amplification*	",IDC,Lymph,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Several other studies produced conflicting results regarding the prognostic impact of serum VEGF [27,28,30,32,34-40].",VEGF,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
",P-values from the Pearson-Chi2-Test and from Fisher's exact test (*) are reported for binary correlations with age: &#60;61 years versus 61 years or older; ascites: &#60;500 ml versus &#62;500 ml; residual tumor after surgery: microscopic versus macroscopic; lymph node status: no metastasis versus lymph-node metastasis; grading: G2 versus G3. +/-,G3,ascites,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
",P-values from the Pearson-Chi2-Test and from Fisher's exact test (*) are reported for binary correlations with age: &#60;61 years versus 61 years or older; ascites: &#60;500 ml versus &#62;500 ml; residual tumor after surgery: microscopic versus macroscopic; lymph node status: no metastasis versus lymph-node metastasis; grading: G2 versus G3. +/-,G3,lymph,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
",P-values from the Pearson-Chi2-Test and from Fisher's exact test (*) are reported for binary correlations with age: &#60;61 years versus 61 years or older; ascites: &#60;500 ml versus &#62;500 ml; residual tumor after surgery: microscopic versus macroscopic; lymph node status: no metastasis versus lymph-node metastasis; grading: G2 versus G3. +/-,G3,lymph,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
",P-values from the Pearson-Chi2-Test and from Fisher's exact test (*) are reported for binary correlations with age: &#60;61 years versus 61 years or older; ascites: &#60;500 ml versus &#62;500 ml; residual tumor after surgery: microscopic versus macroscopic; lymph node status: no metastasis versus lymph-node metastasis; grading: G2 versus G3. +/-,G2,ascites,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
",P-values from the Pearson-Chi2-Test and from Fisher's exact test (*) are reported for binary correlations with age: &#60;61 years versus 61 years or older; ascites: &#60;500 ml versus &#62;500 ml; residual tumor after surgery: microscopic versus macroscopic; lymph node status: no metastasis versus lymph-node metastasis; grading: G2 versus G3. +/-,G2,lymph,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
",P-values from the Pearson-Chi2-Test and from Fisher's exact test (*) are reported for binary correlations with age: &#60;61 years versus 61 years or older; ascites: &#60;500 ml versus &#62;500 ml; residual tumor after surgery: microscopic versus macroscopic; lymph node status: no metastasis versus lymph-node metastasis; grading: G2 versus G3. +/-,G2,lymph,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","The aim of the current study was to evaluate the role of serum VEGF-165 and TIMP-1 to monitor therapy and predict clinical outcome in patients with ovarian cancer in comparison to established clinicopathological parameters and CA-125.

",CA-125,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","The aim of the current study was to evaluate the role of serum VEGF-165 and TIMP-1 to monitor therapy and predict clinical outcome in patients with ovarian cancer in comparison to established clinicopathological parameters and CA-125.

",VEGF-165,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","The aim of the current study was to evaluate the role of serum VEGF-165 and TIMP-1 to monitor therapy and predict clinical outcome in patients with ovarian cancer in comparison to established clinicopathological parameters and CA-125.

",TIMP-1,serum,1
"PMC 
BMC_Cancer_2009_Sep_8_9_317.txt
","The gradient-purified stromal cell fraction was resuspended in 100 ml 0.1% bovine serum albumin (BSA)-HBSS, and CD90-Phycoerythrin (PE) mouse monoclonal antibody (1:20, 5E10, BD-PharMingen) or CD13-PE (1:20, WM15, BD-PharMingen) added for 15 min at room temperature in the dark.",WM15,serum,1
"PMC 
BMC_Cancer_2009_Sep_8_9_317.txt
","The gradient-purified stromal cell fraction was resuspended in 100 ml 0.1% bovine serum albumin (BSA)-HBSS, and CD90-Phycoerythrin (PE) mouse monoclonal antibody (1:20, 5E10, BD-PharMingen) or CD13-PE (1:20, WM15, BD-PharMingen) added for 15 min at room temperature in the dark.",CD13-PE,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
",These patients underwent second look surgery and women with persistent disease had higher VEGF serum levels.,VEGF,serum,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Even though the detection of NGAL and MMP-9/NGAL complex in systemic circulation is likely to directly reflect their tissue expression, scarce data are currently available on the significance of their serum measurement in cancer disease.",NGAL,serum,1
"PMC 
BMC_Cancer_2010_Aug_17_10_434.txt
","In addition, metastases in lymph nodes (LNs) as well as the tumour-to-node metastasis (TNM) index with the application of the new 7th version of TNM classification of the lung cancer are indicated.",TNM,lymph,1
"PMC 
BMC_Cancer_2010_Aug_17_10_434.txt
","In addition, metastases in lymph nodes (LNs) as well as the tumour-to-node metastasis (TNM) index with the application of the new 7th version of TNM classification of the lung cancer are indicated.",TNM,lymph,1
"PMC 
BMC_Cancer_2010_Apr_27_10_161.txt
","The polyclonal anti-HCCR serum was tested for its efficiency and specificity by indirect ELISA and Western blot.

",HCCR,serum,1
"PMC 
BMC_Cancer_2010_Apr_27_10_161.txt
","The polyclonal anti-HCCR serum was tested for its efficiency and specificity by indirect ELISA and Western blot.

",ELISA,serum,1
"PMC 
BMC_Cancer_2010_Aug_17_10_437.txt
","In contrast, TL cells, another derivative of the Tca8113 cell line, possess high metastatic potential to regional lymph nodes.",Tca8113,lymph,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","Background
Serum tartrate-resistant acid phosphatase 5b (TRACP 5b) activity is a marker of osteoclast number and is elevated in breast cancer (BC) patients with extensive bone metastasis, which might in turn reflect the tumour burden.",TRACP,Serum,1
"PMC 
BMC_Cancer_2010_Aug_15_10_428.txt
","Aside from MTSS1 expression, survival analysis of other clinicopathological factors also revealed that lymph node metastases and clinical TNM stage were associated with prognosis of the patients with gastric cancer (Figure 2B.C).

",TNM,lymph,1
"PMC 
BMC_Cancer_2010_Aug_15_10_428.txt
","Aside from MTSS1 expression, survival analysis of other clinicopathological factors also revealed that lymph node metastases and clinical TNM stage were associated with prognosis of the patients with gastric cancer (Figure 2B.C).

",MTSS1,lymph,1
"PMC 
BMC_Cancer_2009_Sep_3_9_310.txt
","Table 1 Characteristics of patients in apoptosis biomarker protein expression tissue microarray study

Risk factor	Prevalence of risk factor or clinicopathologic feature
(N = 265)	
Gender (male)	0.66	
Age (years, median)	58	
Tobacco use (yes)	0.60	
Alcohol use (daily or weekly)	0.22	
Family history of upper gastrointestinal cancer (yes)	0.27	
		
Clinico-pathologic feature		
Tumor grade		
 I	0.17	
 II	0.60	
 III	0.23	
 IV	0.004	
Tumor stage		
 1	0.004	
 2	0.13	
 3	0.86	
 4	0.01	
Lymph node metastasis (yes)	0.45	
Degree differentiation (poor)	0.47	
Tissue microarray (TMA) construction
Details of the TMA construction were previously described [5].",III,Lymph,1
"PMC 
BMC_Cancer_2009_Sep_3_9_310.txt
","Table 1 Characteristics of patients in apoptosis biomarker protein expression tissue microarray study

Risk factor	Prevalence of risk factor or clinicopathologic feature
(N = 265)	
Gender (male)	0.66	
Age (years, median)	58	
Tobacco use (yes)	0.60	
Alcohol use (daily or weekly)	0.22	
Family history of upper gastrointestinal cancer (yes)	0.27	
		
Clinico-pathologic feature		
Tumor grade		
 I	0.17	
 II	0.60	
 III	0.23	
 IV	0.004	
Tumor stage		
 1	0.004	
 2	0.13	
 3	0.86	
 4	0.01	
Lymph node metastasis (yes)	0.45	
Degree differentiation (poor)	0.47	
Tissue microarray (TMA) construction
Details of the TMA construction were previously described [5].",TMA,Lymph,1
"PMC 
BMC_Cancer_2009_Sep_3_9_310.txt
","Table 1 Characteristics of patients in apoptosis biomarker protein expression tissue microarray study

Risk factor	Prevalence of risk factor or clinicopathologic feature
(N = 265)	
Gender (male)	0.66	
Age (years, median)	58	
Tobacco use (yes)	0.60	
Alcohol use (daily or weekly)	0.22	
Family history of upper gastrointestinal cancer (yes)	0.27	
		
Clinico-pathologic feature		
Tumor grade		
 I	0.17	
 II	0.60	
 III	0.23	
 IV	0.004	
Tumor stage		
 1	0.004	
 2	0.13	
 3	0.86	
 4	0.01	
Lymph node metastasis (yes)	0.45	
Degree differentiation (poor)	0.47	
Tissue microarray (TMA) construction
Details of the TMA construction were previously described [5].",TMA,Lymph,1
"PMC 
BMC_Cancer_2009_Sep_8_9_317.txt
","The tissue was rinsed with Hanks balanced salt solution (HBSS) and minced for enzymatic digestion overnight at room temperature with 0.2% collagenase type I (Invitrogen, Carlsbad, CA) in RPMI-1640 media supplemented with 5% FBS and 10-8 M dihydrotestosterone or serum-free media on a magnetic stirrer.",HBSS,serum,1
"PMC 
BMC_Cancer_2009_Sep_8_9_317.txt
","The tissue was rinsed with Hanks balanced salt solution (HBSS) and minced for enzymatic digestion overnight at room temperature with 0.2% collagenase type I (Invitrogen, Carlsbad, CA) in RPMI-1640 media supplemented with 5% FBS and 10-8 M dihydrotestosterone or serum-free media on a magnetic stirrer.",RPMI-1640,serum,1
"PMC 
BMC_Cancer_2009_Sep_8_9_317.txt
","The tissue was rinsed with Hanks balanced salt solution (HBSS) and minced for enzymatic digestion overnight at room temperature with 0.2% collagenase type I (Invitrogen, Carlsbad, CA) in RPMI-1640 media supplemented with 5% FBS and 10-8 M dihydrotestosterone or serum-free media on a magnetic stirrer.",FBS,serum,1
"PMC 
BMC_Cancer_2009_Oct_22_9_376.txt
","Our data are also consistent with the conclusions of Silva et al. and Denis et al., who demonstrated that the analysis of CK19 expression can be used to determine the presence of micrometastatic cells, even if these authors performed their assays in blood samples [27,28].

",CK19,blood,-1
"PMC 
BMC_Cancer_2009_Oct_6_9_353.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3531980791410.1186/1471-2407-9-353Research ArticlemiRNAs in lung cancer - Studying complex fingerprints in patient's blood cells by microarray experiments",Cancer1471,blood,-1
"PMC 
BMC_Cancer_2009_Oct_6_9_353.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3531980791410.1186/1471-2407-9-353Research ArticlemiRNAs in lung cancer - Studying complex fingerprints in patient's blood cells by microarray experiments",BMC,blood,-1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Table 3 Correlations between serum concentration of CA-125, TIMP-1 and VEGF and survival

	PFS		OS		
		
	p-value	+/-	",PFS,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Table 3 Correlations between serum concentration of CA-125, TIMP-1 and VEGF and survival

	PFS		OS		
		
	p-value	+/-	",VEGF,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Table 3 Correlations between serum concentration of CA-125, TIMP-1 and VEGF and survival

	PFS		OS		
		
	p-value	+/-	",TIMP-1,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Table 3 Correlations between serum concentration of CA-125, TIMP-1 and VEGF and survival

	PFS		OS		
		
	p-value	+/-	",CA-125,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Table 3 Correlations between serum concentration of CA-125, TIMP-1 and VEGF and survival

	PFS		OS		
		
	p-value	+/-	",OS,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","Previous receiver operative characteristic curve analysis showed that, although serum TRACP 5b activity is highly specific for bone metastasis, its sensitivity is only 80% [12].",TRACP,serum,1
"PMC 
BMC_Cancer_2009_Oct_6_9_353.txt
","The 24 miRNAs used for classification are all contained in the set of 27 most significant mRNAs

Evaluating complex fingerprints
Even single miRNAs with highest MI values are not sufficient to differentiate between blood cells of tumor patients as compared to controls with high specificity.",MI,blood,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Methods
From our original retrospectively collected tumor samples we selected a group of 525 pre-menopausal lymph node-positive patients (adjuvant treatment: CMF, 324 patients; anthracycline-based, 99 patients; no adjuvant chemotherapy, 102 patients).",CMF,lymph,1
"PMC 
BMC_Cancer_2009_Oct_6_9_353.txt
","T1N0	
miRNA extraction and microarray screening
Blood of lung cancer patients and volunteers without known disease was extracted in PAXgene Blood RNA tubes (BD, Franklin Lakes, New Jersey USA).",RNA,Blood,-1
"PMC 
BMC_Cancer_2009_Oct_6_9_353.txt
","T1N0	
miRNA extraction and microarray screening
Blood of lung cancer patients and volunteers without known disease was extracted in PAXgene Blood RNA tubes (BD, Franklin Lakes, New Jersey USA).",RNA,Blood,-1
"PMC 
BMC_Cancer_2009_Oct_6_9_353.txt
","T1N0	
miRNA extraction and microarray screening
Blood of lung cancer patients and volunteers without known disease was extracted in PAXgene Blood RNA tubes (BD, Franklin Lakes, New Jersey USA).",USA,Blood,1
"PMC 
BMC_Cancer_2009_Oct_6_9_353.txt
","T1N0	
miRNA extraction and microarray screening
Blood of lung cancer patients and volunteers without known disease was extracted in PAXgene Blood RNA tubes (BD, Franklin Lakes, New Jersey USA).",USA,Blood,-1
"PMC 
BMC_Cancer_2009_Oct_6_9_353.txt
","Table 1 Information on lung cancer patients and healthy control subjects

blood donors	male	female	
lung cancer patients			
number	9	8	
average age	67	61	
			
healthy subjects			
number	7	12	
average age	43	35	
Table 2 Staging of patients and tumor type

sample	tumor type	clinical stage	
463	adenocarcinoma	T2N0	
464	typical carcinoid	T2N0	
468	adenocarcinoma	T2N0	
469	adenocarcinoma	T2N2	
485	adenocarcinoma	T2N0	
490	adeno squamous carcinoma	T2N0	
492	adenocarcinoma	T2N0	
503	squamous cell carcinoma	T1N0	
507	squamous cell carcinoma	T4Nx	
508	squamous cell carcinoma	T2aN0	
509	squamous cell carcinoma	T2N0	
513	bronchoalveolar carcinoma	T3N0	
514	adenocarcinoma	T2N2	
517	squamous cell carcinoma	T2N0	
523	squamous cell carcinoma	T2N0	
524	squamous cell carcinoma	T3N2	
525	adenocarcinoma	",T2N2,blood,1
"PMC 
BMC_Cancer_2009_Oct_6_9_353.txt
","Table 1 Information on lung cancer patients and healthy control subjects

blood donors	male	female	
lung cancer patients			
number	9	8	
average age	67	61	
			
healthy subjects			
number	7	12	
average age	43	35	
Table 2 Staging of patients and tumor type

sample	tumor type	clinical stage	
463	adenocarcinoma	T2N0	
464	typical carcinoid	T2N0	
468	adenocarcinoma	T2N0	
469	adenocarcinoma	T2N2	
485	adenocarcinoma	T2N0	
490	adeno squamous carcinoma	T2N0	
492	adenocarcinoma	T2N0	
503	squamous cell carcinoma	T1N0	
507	squamous cell carcinoma	T4Nx	
508	squamous cell carcinoma	T2aN0	
509	squamous cell carcinoma	T2N0	
513	bronchoalveolar carcinoma	T3N0	
514	adenocarcinoma	T2N2	
517	squamous cell carcinoma	T2N0	
523	squamous cell carcinoma	T2N0	
524	squamous cell carcinoma	T3N2	
525	adenocarcinoma	",T3N2,blood,1
"PMC 
BMC_Cancer_2009_Oct_6_9_353.txt
","Table 1 Information on lung cancer patients and healthy control subjects

blood donors	male	female	
lung cancer patients			
number	9	8	
average age	67	61	
			
healthy subjects			
number	7	12	
average age	43	35	
Table 2 Staging of patients and tumor type

sample	tumor type	clinical stage	
463	adenocarcinoma	T2N0	
464	typical carcinoid	T2N0	
468	adenocarcinoma	T2N0	
469	adenocarcinoma	T2N2	
485	adenocarcinoma	T2N0	
490	adeno squamous carcinoma	T2N0	
492	adenocarcinoma	T2N0	
503	squamous cell carcinoma	T1N0	
507	squamous cell carcinoma	T4Nx	
508	squamous cell carcinoma	T2aN0	
509	squamous cell carcinoma	T2N0	
513	bronchoalveolar carcinoma	T3N0	
514	adenocarcinoma	T2N2	
517	squamous cell carcinoma	T2N0	
523	squamous cell carcinoma	T2N0	
524	squamous cell carcinoma	T3N2	
525	adenocarcinoma	",T2N2,blood,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","We hypothesized that its expression could be detected in the saliva rinses of patients with HNSCC, where tumor cells are known to desquamate.",HNSCC,saliva,-1
"PMC 
BMC_Cancer_2009_Oct_6_9_353.txt
","For example, in agreement with the up-regulation detected by the Geniom Biochip experiments, the qRT-PCR experiments showed on average an up-regulation of 1.4 fold in blood cells of lung cancer patients as compared to healthy controls for miR 106b.",qRT,blood,-1
"PMC 
BMC_Cancer_2009_Oct_6_9_353.txt
","For example, in agreement with the up-regulation detected by the Geniom Biochip experiments, the qRT-PCR experiments showed on average an up-regulation of 1.4 fold in blood cells of lung cancer patients as compared to healthy controls for miR 106b.",PCR,blood,-1
"PMC 
BMC_Cancer_2009_Oct_6_9_353.txt
","Results
miRNA experiments
We analyzed the expression of 866 miRNAs and miRNA star sequences in blood cells of 17 patients with NSCLC.",NSCLC,blood,-1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","Also in this regard, many post-menopausal women take anti-resorptive drugs to preserve bone health, which may cause apoptosis of osteoclasts and decrease the serum TRACP 5b activity [10].",TRACP,serum,-1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
",Our explanation is that serum TRACP 5b may not reflect the real tumor burden in those patients with lower activities.,TRACP,serum,1
"PMC 
BMC_Cancer_2009_Mar_24_9_91.txt
","From each participating subject who granted his informed consent, a venous blood sample was obtained for PSA determination, a questionnaire consisting of demographic and urologic data (American Urological Association Symptom Index: AUA-SI) was administered, and a DRE was performed by an urologist or urology resident.",PSA,blood,1
"PMC 
BMC_Cancer_2009_Mar_24_9_91.txt
","From each participating subject who granted his informed consent, a venous blood sample was obtained for PSA determination, a questionnaire consisting of demographic and urologic data (American Urological Association Symptom Index: AUA-SI) was administered, and a DRE was performed by an urologist or urology resident.",DRE,blood,1
"PMC 
BMC_Cancer_2009_Mar_24_9_91.txt
","From each participating subject who granted his informed consent, a venous blood sample was obtained for PSA determination, a questionnaire consisting of demographic and urologic data (American Urological Association Symptom Index: AUA-SI) was administered, and a DRE was performed by an urologist or urology resident.",SI,blood,1
"PMC 
BMC_Cancer_2009_Mar_24_9_91.txt
","From each participating subject who granted his informed consent, a venous blood sample was obtained for PSA determination, a questionnaire consisting of demographic and urologic data (American Urological Association Symptom Index: AUA-SI) was administered, and a DRE was performed by an urologist or urology resident.",AUA,blood,1
"PMC 
BMC_Cancer_2010_Apr_27_10_160.txt
","NGX6 was also down-regulated in colorectal carcinomas, and the frequency of down-regulation of NGX6 in colorectal carcinoma tissues with lymph node or distance metastasis (15/16) was significantly greater than in patients without metastasis (25/34) (P &#60; 0.05) [5].",NGX6,lymph,1
"PMC 
BMC_Cancer_2010_Apr_27_10_160.txt
","NGX6 was also down-regulated in colorectal carcinomas, and the frequency of down-regulation of NGX6 in colorectal carcinoma tissues with lymph node or distance metastasis (15/16) was significantly greater than in patients without metastasis (25/34) (P &#60; 0.05) [5].",NGX6,lymph,1
"PMC 
BMC_Cancer_2009_Mar_24_9_91.txt
","Blood samples were taken from each subject for prostate specific antigen (PSA) determination; they underwent a digital rectal examination (DRE), and were subsequently interviewed to obtain demographic and urologic data.",PSA,Blood,1
"PMC 
BMC_Cancer_2009_Mar_24_9_91.txt
","Blood samples were taken from each subject for prostate specific antigen (PSA) determination; they underwent a digital rectal examination (DRE), and were subsequently interviewed to obtain demographic and urologic data.",DRE,Blood,1
"PMC 
BMC_Cancer_2009_Mar_24_9_91.txt
","If the serum PSA level was equal to or above 4.0 ng/ml or the DRE was abnormal, a transrectal biopsy (TRB) was recommended.",PSA,serum,1
"PMC 
BMC_Cancer_2009_Mar_24_9_91.txt
","If the serum PSA level was equal to or above 4.0 ng/ml or the DRE was abnormal, a transrectal biopsy (TRB) was recommended.",DRE,serum,1
"PMC 
BMC_Cancer_2009_Mar_24_9_91.txt
","If the serum PSA level was equal to or above 4.0 ng/ml or the DRE was abnormal, a transrectal biopsy (TRB) was recommended.",TRB,serum,1
"PMC 
BMC_Cancer_2010_Apr_27_10_161.txt
","For growth factor deprivation, the medium was made without serum, EGF, and insulin.",EGF,serum,1
"PMC 
BMC_Cancer_2009_Oct_26_9_379.txt
","Determination of the 8q24 loci genotype
DNA of each subject was extracted from the buffy coat fraction with a Blood Mini Kit (Qiagen K.K., Tokyo, Japan) and assessed using the polymerase chain reaction (PCR) TaqMan method [23] with the 7500 Fast Real-time PCR system (Applied Biosystems, Foster City, CA, USA).",USA,Blood,1
"PMC 
BMC_Cancer_2009_Oct_26_9_379.txt
","Determination of the 8q24 loci genotype
DNA of each subject was extracted from the buffy coat fraction with a Blood Mini Kit (Qiagen K.K., Tokyo, Japan) and assessed using the polymerase chain reaction (PCR) TaqMan method [23] with the 7500 Fast Real-time PCR system (Applied Biosystems, Foster City, CA, USA).",PCR,Blood,1
"PMC 
BMC_Cancer_2009_Oct_26_9_379.txt
","Determination of the 8q24 loci genotype
DNA of each subject was extracted from the buffy coat fraction with a Blood Mini Kit (Qiagen K.K., Tokyo, Japan) and assessed using the polymerase chain reaction (PCR) TaqMan method [23] with the 7500 Fast Real-time PCR system (Applied Biosystems, Foster City, CA, USA).",PCR,Blood,1
"PMC 
BMC_Cancer_2009_Oct_26_9_379.txt
","Determination of the 8q24 loci genotype
DNA of each subject was extracted from the buffy coat fraction with a Blood Mini Kit (Qiagen K.K., Tokyo, Japan) and assessed using the polymerase chain reaction (PCR) TaqMan method [23] with the 7500 Fast Real-time PCR system (Applied Biosystems, Foster City, CA, USA).",DNA,Blood,1
"PMC 
BMC_Cancer_2010_Apr_16_10_145.txt
","Although lymphatics and blood vessels of the breast can basically be discerned using immunohistochemical markers, this is in practice not usually done and lymphatic and blood vessel invasion is lumped as ""lympho-vascular invasion"" (LVI).",LVI,blood,1
"PMC 
BMC_Cancer_2010_Apr_16_10_145.txt
","Although lymphatics and blood vessels of the breast can basically be discerned using immunohistochemical markers, this is in practice not usually done and lymphatic and blood vessel invasion is lumped as ""lympho-vascular invasion"" (LVI).",LVI,blood,-1
"PMC 
BMC_Cancer_2009_Oct_6_9_353.txt
","Using the fully automated Geniom Real Time Analyzer platform, we analyzed the miRNA expression in 17 blood cell samples of patients with non-small cell lung carcinomas (NSCLC) and in 19 blood samples of healthy controls.

",NSCLC,blood,-1
"PMC 
BMC_Cancer_2009_Oct_6_9_353.txt
","Using the fully automated Geniom Real Time Analyzer platform, we analyzed the miRNA expression in 17 blood cell samples of patients with non-small cell lung carcinomas (NSCLC) and in 19 blood samples of healthy controls.

",NSCLC,blood,-1
"PMC 
BMC_Cancer_2009_Oct_20_9_374.txt
","FBS = fetal bovine serum, SF = serum-free.

",FBS,serum,1
"PMC 
BMC_Cancer_2009_Oct_20_9_374.txt
","FBS = fetal bovine serum, SF = serum-free.

",FBS,serum,1
"PMC 
BMC_Cancer_2009_Oct_20_9_374.txt
","FBS = fetal bovine serum, SF = serum-free.

",SF,serum,1
"PMC 
BMC_Cancer_2009_Oct_20_9_374.txt
","FBS = fetal bovine serum, SF = serum-free.

",SF,serum,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","Saliva rinse RNA extraction was carried out using the RNA Isolation Kit on a MagNa Pure Compact instrument (Roche, Meylan, France).

",RNA,Saliva,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","Saliva rinse RNA extraction was carried out using the RNA Isolation Kit on a MagNa Pure Compact instrument (Roche, Meylan, France).

",RNA,Saliva,1
"PMC 
BMC_Cancer_2010_Apr_21_10_155.txt
","In addition, heart rate, blood pressure, and O2 saturation will be recorded prior to, during, and following every intervention session, (2) at the beginning of each week, the exercise physiologist will spend the first 10 minutes of every session discussing any potential negative side-effects of the intervention assignment and any injuries that may have occurred.",O2,blood,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","Table 1 Clinical and histopathological features of the population: A) tissue sample population; B) saliva sample populations

Table 1-A	Table 1-B	
Tissu samples (n = 46)	Saliva samples: Control population (n = 18)	
	Median	Min	Max		Median	Min	Max	
Age	56.7	41.2	77.7	Age	53	32	71	
								
		Qt	%			Qt	%	
Sex	Woman	4	8.7	Sex	Woman	6	33.3	
	Men	42	91.3		Men	12	66.6	
								
Site	Larynx	8	17.4					
	Oral cavity	8	17.4	Saliva samples: HNSCC population (n = 51)	
	Hypopharynx	7	15.2		Median	Min	Max	
	Oropharynx	23	50	Age	59	41	83	
								
T Stage	1	1	2.2			Qt	%	
	2	11	23.9	Sex	Woman	6	11.8	
	3	19	41.3		Men	45	88.2	
	4	15	32,6					
								
N Stage	0	18	39.1	Site	Larynx	5	9.8	
	1	4	8.7		Oral cavity	11	21.7	
	2	23	50		Hypopharynx	8	15.7	
	3	1	2.2		Oropharynx	27	52.8	
								
M Stage	0	46	100	T Stage	1	6	11.8	
	1	0	0		2	12	23.5	
					3	14	27.4	
Grade	1	13	28.3		4	19	37.3	
	2	27	58.7					
	3	6	13	N Stage	0	17	33.2	
					+	34	66.7	
Death	Yes	21	45.7					
	No	25	54.3	M Stage	0	50	1.9	
					1	1	98.1	
Follow-up	Controlled	25	54.3					
	Progression	10	21.7					
	Recurrence	11	23.9					
Qt: quantity

%: percentage

RNA isolation, quality control and cDNA synthesis
To obtain homogeneous and histologically well-characterized samples for RNA analyses, tissue samples were cut with a cryo-microtome into 50-200 slices of 9-mm thickness in RNase-free conditions.",RNA,saliva,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","Table 1 Clinical and histopathological features of the population: A) tissue sample population; B) saliva sample populations

Table 1-A	Table 1-B	
Tissu samples (n = 46)	Saliva samples: Control population (n = 18)	
	Median	Min	Max		Median	Min	Max	
Age	56.7	41.2	77.7	Age	53	32	71	
								
		Qt	%			Qt	%	
Sex	Woman	4	8.7	Sex	Woman	6	33.3	
	Men	42	91.3		Men	12	66.6	
								
Site	Larynx	8	17.4					
	Oral cavity	8	17.4	Saliva samples: HNSCC population (n = 51)	
	Hypopharynx	7	15.2		Median	Min	Max	
	Oropharynx	23	50	Age	59	41	83	
								
T Stage	1	1	2.2			Qt	%	
	2	11	23.9	Sex	Woman	6	11.8	
	3	19	41.3		Men	45	88.2	
	4	15	32,6					
								
N Stage	0	18	39.1	Site	Larynx	5	9.8	
	1	4	8.7		Oral cavity	11	21.7	
	2	23	50		Hypopharynx	8	15.7	
	3	1	2.2		Oropharynx	27	52.8	
								
M Stage	0	46	100	T Stage	1	6	11.8	
	1	0	0		2	12	23.5	
					3	14	27.4	
Grade	1	13	28.3		4	19	37.3	
	2	27	58.7					
	3	6	13	N Stage	0	17	33.2	
					+	34	66.7	
Death	Yes	21	45.7					
	No	25	54.3	M Stage	0	50	1.9	
					1	1	98.1	
Follow-up	Controlled	25	54.3					
	Progression	10	21.7					
	Recurrence	11	23.9					
Qt: quantity

%: percentage

RNA isolation, quality control and cDNA synthesis
To obtain homogeneous and histologically well-characterized samples for RNA analyses, tissue samples were cut with a cryo-microtome into 50-200 slices of 9-mm thickness in RNase-free conditions.",RNA,Saliva,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","Table 1 Clinical and histopathological features of the population: A) tissue sample population; B) saliva sample populations

Table 1-A	Table 1-B	
Tissu samples (n = 46)	Saliva samples: Control population (n = 18)	
	Median	Min	Max		Median	Min	Max	
Age	56.7	41.2	77.7	Age	53	32	71	
								
		Qt	%			Qt	%	
Sex	Woman	4	8.7	Sex	Woman	6	33.3	
	Men	42	91.3		Men	12	66.6	
								
Site	Larynx	8	17.4					
	Oral cavity	8	17.4	Saliva samples: HNSCC population (n = 51)	
	Hypopharynx	7	15.2		Median	Min	Max	
	Oropharynx	23	50	Age	59	41	83	
								
T Stage	1	1	2.2			Qt	%	
	2	11	23.9	Sex	Woman	6	11.8	
	3	19	41.3		Men	45	88.2	
	4	15	32,6					
								
N Stage	0	18	39.1	Site	Larynx	5	9.8	
	1	4	8.7		Oral cavity	11	21.7	
	2	23	50		Hypopharynx	8	15.7	
	3	1	2.2		Oropharynx	27	52.8	
								
M Stage	0	46	100	T Stage	1	6	11.8	
	1	0	0		2	12	23.5	
					3	14	27.4	
Grade	1	13	28.3		4	19	37.3	
	2	27	58.7					
	3	6	13	N Stage	0	17	33.2	
					+	34	66.7	
Death	Yes	21	45.7					
	No	25	54.3	M Stage	0	50	1.9	
					1	1	98.1	
Follow-up	Controlled	25	54.3					
	Progression	10	21.7					
	Recurrence	11	23.9					
Qt: quantity

%: percentage

RNA isolation, quality control and cDNA synthesis
To obtain homogeneous and histologically well-characterized samples for RNA analyses, tissue samples were cut with a cryo-microtome into 50-200 slices of 9-mm thickness in RNase-free conditions.",RNA,Saliva,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","Table 1 Clinical and histopathological features of the population: A) tissue sample population; B) saliva sample populations

Table 1-A	Table 1-B	
Tissu samples (n = 46)	Saliva samples: Control population (n = 18)	
	Median	Min	Max		Median	Min	Max	
Age	56.7	41.2	77.7	Age	53	32	71	
								
		Qt	%			Qt	%	
Sex	Woman	4	8.7	Sex	Woman	6	33.3	
	Men	42	91.3		Men	12	66.6	
								
Site	Larynx	8	17.4					
	Oral cavity	8	17.4	Saliva samples: HNSCC population (n = 51)	
	Hypopharynx	7	15.2		Median	Min	Max	
	Oropharynx	23	50	Age	59	41	83	
								
T Stage	1	1	2.2			Qt	%	
	2	11	23.9	Sex	Woman	6	11.8	
	3	19	41.3		Men	45	88.2	
	4	15	32,6					
								
N Stage	0	18	39.1	Site	Larynx	5	9.8	
	1	4	8.7		Oral cavity	11	21.7	
	2	23	50		Hypopharynx	8	15.7	
	3	1	2.2		Oropharynx	27	52.8	
								
M Stage	0	46	100	T Stage	1	6	11.8	
	1	0	0		2	12	23.5	
					3	14	27.4	
Grade	1	13	28.3		4	19	37.3	
	2	27	58.7					
	3	6	13	N Stage	0	17	33.2	
					+	34	66.7	
Death	Yes	21	45.7					
	No	25	54.3	M Stage	0	50	1.9	
					1	1	98.1	
Follow-up	Controlled	25	54.3					
	Progression	10	21.7					
	Recurrence	11	23.9					
Qt: quantity

%: percentage

RNA isolation, quality control and cDNA synthesis
To obtain homogeneous and histologically well-characterized samples for RNA analyses, tissue samples were cut with a cryo-microtome into 50-200 slices of 9-mm thickness in RNase-free conditions.",RNA,saliva,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","Table 1 Clinical and histopathological features of the population: A) tissue sample population; B) saliva sample populations

Table 1-A	Table 1-B	
Tissu samples (n = 46)	Saliva samples: Control population (n = 18)	
	Median	Min	Max		Median	Min	Max	
Age	56.7	41.2	77.7	Age	53	32	71	
								
		Qt	%			Qt	%	
Sex	Woman	4	8.7	Sex	Woman	6	33.3	
	Men	42	91.3		Men	12	66.6	
								
Site	Larynx	8	17.4					
	Oral cavity	8	17.4	Saliva samples: HNSCC population (n = 51)	
	Hypopharynx	7	15.2		Median	Min	Max	
	Oropharynx	23	50	Age	59	41	83	
								
T Stage	1	1	2.2			Qt	%	
	2	11	23.9	Sex	Woman	6	11.8	
	3	19	41.3		Men	45	88.2	
	4	15	32,6					
								
N Stage	0	18	39.1	Site	Larynx	5	9.8	
	1	4	8.7		Oral cavity	11	21.7	
	2	23	50		Hypopharynx	8	15.7	
	3	1	2.2		Oropharynx	27	52.8	
								
M Stage	0	46	100	T Stage	1	6	11.8	
	1	0	0		2	12	23.5	
					3	14	27.4	
Grade	1	13	28.3		4	19	37.3	
	2	27	58.7					
	3	6	13	N Stage	0	17	33.2	
					+	34	66.7	
Death	Yes	21	45.7					
	No	25	54.3	M Stage	0	50	1.9	
					1	1	98.1	
Follow-up	Controlled	25	54.3					
	Progression	10	21.7					
	Recurrence	11	23.9					
Qt: quantity

%: percentage

RNA isolation, quality control and cDNA synthesis
To obtain homogeneous and histologically well-characterized samples for RNA analyses, tissue samples were cut with a cryo-microtome into 50-200 slices of 9-mm thickness in RNase-free conditions.",RNA,Saliva,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","Table 1 Clinical and histopathological features of the population: A) tissue sample population; B) saliva sample populations

Table 1-A	Table 1-B	
Tissu samples (n = 46)	Saliva samples: Control population (n = 18)	
	Median	Min	Max		Median	Min	Max	
Age	56.7	41.2	77.7	Age	53	32	71	
								
		Qt	%			Qt	%	
Sex	Woman	4	8.7	Sex	Woman	6	33.3	
	Men	42	91.3		Men	12	66.6	
								
Site	Larynx	8	17.4					
	Oral cavity	8	17.4	Saliva samples: HNSCC population (n = 51)	
	Hypopharynx	7	15.2		Median	Min	Max	
	Oropharynx	23	50	Age	59	41	83	
								
T Stage	1	1	2.2			Qt	%	
	2	11	23.9	Sex	Woman	6	11.8	
	3	19	41.3		Men	45	88.2	
	4	15	32,6					
								
N Stage	0	18	39.1	Site	Larynx	5	9.8	
	1	4	8.7		Oral cavity	11	21.7	
	2	23	50		Hypopharynx	8	15.7	
	3	1	2.2		Oropharynx	27	52.8	
								
M Stage	0	46	100	T Stage	1	6	11.8	
	1	0	0		2	12	23.5	
					3	14	27.4	
Grade	1	13	28.3		4	19	37.3	
	2	27	58.7					
	3	6	13	N Stage	0	17	33.2	
					+	34	66.7	
Death	Yes	21	45.7					
	No	25	54.3	M Stage	0	50	1.9	
					1	1	98.1	
Follow-up	Controlled	25	54.3					
	Progression	10	21.7					
	Recurrence	11	23.9					
Qt: quantity

%: percentage

RNA isolation, quality control and cDNA synthesis
To obtain homogeneous and histologically well-characterized samples for RNA analyses, tissue samples were cut with a cryo-microtome into 50-200 slices of 9-mm thickness in RNase-free conditions.",RNA,Saliva,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","Table 1 Clinical and histopathological features of the population: A) tissue sample population; B) saliva sample populations

Table 1-A	Table 1-B	
Tissu samples (n = 46)	Saliva samples: Control population (n = 18)	
	Median	Min	Max		Median	Min	Max	
Age	56.7	41.2	77.7	Age	53	32	71	
								
		Qt	%			Qt	%	
Sex	Woman	4	8.7	Sex	Woman	6	33.3	
	Men	42	91.3		Men	12	66.6	
								
Site	Larynx	8	17.4					
	Oral cavity	8	17.4	Saliva samples: HNSCC population (n = 51)	
	Hypopharynx	7	15.2		Median	Min	Max	
	Oropharynx	23	50	Age	59	41	83	
								
T Stage	1	1	2.2			Qt	%	
	2	11	23.9	Sex	Woman	6	11.8	
	3	19	41.3		Men	45	88.2	
	4	15	32,6					
								
N Stage	0	18	39.1	Site	Larynx	5	9.8	
	1	4	8.7		Oral cavity	11	21.7	
	2	23	50		Hypopharynx	8	15.7	
	3	1	2.2		Oropharynx	27	52.8	
								
M Stage	0	46	100	T Stage	1	6	11.8	
	1	0	0		2	12	23.5	
					3	14	27.4	
Grade	1	13	28.3		4	19	37.3	
	2	27	58.7					
	3	6	13	N Stage	0	17	33.2	
					+	34	66.7	
Death	Yes	21	45.7					
	No	25	54.3	M Stage	0	50	1.9	
					1	1	98.1	
Follow-up	Controlled	25	54.3					
	Progression	10	21.7					
	Recurrence	11	23.9					
Qt: quantity

%: percentage

RNA isolation, quality control and cDNA synthesis
To obtain homogeneous and histologically well-characterized samples for RNA analyses, tissue samples were cut with a cryo-microtome into 50-200 slices of 9-mm thickness in RNase-free conditions.",T,saliva,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","Table 1 Clinical and histopathological features of the population: A) tissue sample population; B) saliva sample populations

Table 1-A	Table 1-B	
Tissu samples (n = 46)	Saliva samples: Control population (n = 18)	
	Median	Min	Max		Median	Min	Max	
Age	56.7	41.2	77.7	Age	53	32	71	
								
		Qt	%			Qt	%	
Sex	Woman	4	8.7	Sex	Woman	6	33.3	
	Men	42	91.3		Men	12	66.6	
								
Site	Larynx	8	17.4					
	Oral cavity	8	17.4	Saliva samples: HNSCC population (n = 51)	
	Hypopharynx	7	15.2		Median	Min	Max	
	Oropharynx	23	50	Age	59	41	83	
								
T Stage	1	1	2.2			Qt	%	
	2	11	23.9	Sex	Woman	6	11.8	
	3	19	41.3		Men	45	88.2	
	4	15	32,6					
								
N Stage	0	18	39.1	Site	Larynx	5	9.8	
	1	4	8.7		Oral cavity	11	21.7	
	2	23	50		Hypopharynx	8	15.7	
	3	1	2.2		Oropharynx	27	52.8	
								
M Stage	0	46	100	T Stage	1	6	11.8	
	1	0	0		2	12	23.5	
					3	14	27.4	
Grade	1	13	28.3		4	19	37.3	
	2	27	58.7					
	3	6	13	N Stage	0	17	33.2	
					+	34	66.7	
Death	Yes	21	45.7					
	No	25	54.3	M Stage	0	50	1.9	
					1	1	98.1	
Follow-up	Controlled	25	54.3					
	Progression	10	21.7					
	Recurrence	11	23.9					
Qt: quantity

%: percentage

RNA isolation, quality control and cDNA synthesis
To obtain homogeneous and histologically well-characterized samples for RNA analyses, tissue samples were cut with a cryo-microtome into 50-200 slices of 9-mm thickness in RNase-free conditions.",T,Saliva,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","Table 1 Clinical and histopathological features of the population: A) tissue sample population; B) saliva sample populations

Table 1-A	Table 1-B	
Tissu samples (n = 46)	Saliva samples: Control population (n = 18)	
	Median	Min	Max		Median	Min	Max	
Age	56.7	41.2	77.7	Age	53	32	71	
								
		Qt	%			Qt	%	
Sex	Woman	4	8.7	Sex	Woman	6	33.3	
	Men	42	91.3		Men	12	66.6	
								
Site	Larynx	8	17.4					
	Oral cavity	8	17.4	Saliva samples: HNSCC population (n = 51)	
	Hypopharynx	7	15.2		Median	Min	Max	
	Oropharynx	23	50	Age	59	41	83	
								
T Stage	1	1	2.2			Qt	%	
	2	11	23.9	Sex	Woman	6	11.8	
	3	19	41.3		Men	45	88.2	
	4	15	32,6					
								
N Stage	0	18	39.1	Site	Larynx	5	9.8	
	1	4	8.7		Oral cavity	11	21.7	
	2	23	50		Hypopharynx	8	15.7	
	3	1	2.2		Oropharynx	27	52.8	
								
M Stage	0	46	100	T Stage	1	6	11.8	
	1	0	0		2	12	23.5	
					3	14	27.4	
Grade	1	13	28.3		4	19	37.3	
	2	27	58.7					
	3	6	13	N Stage	0	17	33.2	
					+	34	66.7	
Death	Yes	21	45.7					
	No	25	54.3	M Stage	0	50	1.9	
					1	1	98.1	
Follow-up	Controlled	25	54.3					
	Progression	10	21.7					
	Recurrence	11	23.9					
Qt: quantity

%: percentage

RNA isolation, quality control and cDNA synthesis
To obtain homogeneous and histologically well-characterized samples for RNA analyses, tissue samples were cut with a cryo-microtome into 50-200 slices of 9-mm thickness in RNase-free conditions.",T,Saliva,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","Table 1 Clinical and histopathological features of the population: A) tissue sample population; B) saliva sample populations

Table 1-A	Table 1-B	
Tissu samples (n = 46)	Saliva samples: Control population (n = 18)	
	Median	Min	Max		Median	Min	Max	
Age	56.7	41.2	77.7	Age	53	32	71	
								
		Qt	%			Qt	%	
Sex	Woman	4	8.7	Sex	Woman	6	33.3	
	Men	42	91.3		Men	12	66.6	
								
Site	Larynx	8	17.4					
	Oral cavity	8	17.4	Saliva samples: HNSCC population (n = 51)	
	Hypopharynx	7	15.2		Median	Min	Max	
	Oropharynx	23	50	Age	59	41	83	
								
T Stage	1	1	2.2			Qt	%	
	2	11	23.9	Sex	Woman	6	11.8	
	3	19	41.3		Men	45	88.2	
	4	15	32,6					
								
N Stage	0	18	39.1	Site	Larynx	5	9.8	
	1	4	8.7		Oral cavity	11	21.7	
	2	23	50		Hypopharynx	8	15.7	
	3	1	2.2		Oropharynx	27	52.8	
								
M Stage	0	46	100	T Stage	1	6	11.8	
	1	0	0		2	12	23.5	
					3	14	27.4	
Grade	1	13	28.3		4	19	37.3	
	2	27	58.7					
	3	6	13	N Stage	0	17	33.2	
					+	34	66.7	
Death	Yes	21	45.7					
	No	25	54.3	M Stage	0	50	1.9	
					1	1	98.1	
Follow-up	Controlled	25	54.3					
	Progression	10	21.7					
	Recurrence	11	23.9					
Qt: quantity

%: percentage

RNA isolation, quality control and cDNA synthesis
To obtain homogeneous and histologically well-characterized samples for RNA analyses, tissue samples were cut with a cryo-microtome into 50-200 slices of 9-mm thickness in RNase-free conditions.",T,saliva,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","Table 1 Clinical and histopathological features of the population: A) tissue sample population; B) saliva sample populations

Table 1-A	Table 1-B	
Tissu samples (n = 46)	Saliva samples: Control population (n = 18)	
	Median	Min	Max		Median	Min	Max	
Age	56.7	41.2	77.7	Age	53	32	71	
								
		Qt	%			Qt	%	
Sex	Woman	4	8.7	Sex	Woman	6	33.3	
	Men	42	91.3		Men	12	66.6	
								
Site	Larynx	8	17.4					
	Oral cavity	8	17.4	Saliva samples: HNSCC population (n = 51)	
	Hypopharynx	7	15.2		Median	Min	Max	
	Oropharynx	23	50	Age	59	41	83	
								
T Stage	1	1	2.2			Qt	%	
	2	11	23.9	Sex	Woman	6	11.8	
	3	19	41.3		Men	45	88.2	
	4	15	32,6					
								
N Stage	0	18	39.1	Site	Larynx	5	9.8	
	1	4	8.7		Oral cavity	11	21.7	
	2	23	50		Hypopharynx	8	15.7	
	3	1	2.2		Oropharynx	27	52.8	
								
M Stage	0	46	100	T Stage	1	6	11.8	
	1	0	0		2	12	23.5	
					3	14	27.4	
Grade	1	13	28.3		4	19	37.3	
	2	27	58.7					
	3	6	13	N Stage	0	17	33.2	
					+	34	66.7	
Death	Yes	21	45.7					
	No	25	54.3	M Stage	0	50	1.9	
					1	1	98.1	
Follow-up	Controlled	25	54.3					
	Progression	10	21.7					
	Recurrence	11	23.9					
Qt: quantity

%: percentage

RNA isolation, quality control and cDNA synthesis
To obtain homogeneous and histologically well-characterized samples for RNA analyses, tissue samples were cut with a cryo-microtome into 50-200 slices of 9-mm thickness in RNase-free conditions.",T,Saliva,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","Table 1 Clinical and histopathological features of the population: A) tissue sample population; B) saliva sample populations

Table 1-A	Table 1-B	
Tissu samples (n = 46)	Saliva samples: Control population (n = 18)	
	Median	Min	Max		Median	Min	Max	
Age	56.7	41.2	77.7	Age	53	32	71	
								
		Qt	%			Qt	%	
Sex	Woman	4	8.7	Sex	Woman	6	33.3	
	Men	42	91.3		Men	12	66.6	
								
Site	Larynx	8	17.4					
	Oral cavity	8	17.4	Saliva samples: HNSCC population (n = 51)	
	Hypopharynx	7	15.2		Median	Min	Max	
	Oropharynx	23	50	Age	59	41	83	
								
T Stage	1	1	2.2			Qt	%	
	2	11	23.9	Sex	Woman	6	11.8	
	3	19	41.3		Men	45	88.2	
	4	15	32,6					
								
N Stage	0	18	39.1	Site	Larynx	5	9.8	
	1	4	8.7		Oral cavity	11	21.7	
	2	23	50		Hypopharynx	8	15.7	
	3	1	2.2		Oropharynx	27	52.8	
								
M Stage	0	46	100	T Stage	1	6	11.8	
	1	0	0		2	12	23.5	
					3	14	27.4	
Grade	1	13	28.3		4	19	37.3	
	2	27	58.7					
	3	6	13	N Stage	0	17	33.2	
					+	34	66.7	
Death	Yes	21	45.7					
	No	25	54.3	M Stage	0	50	1.9	
					1	1	98.1	
Follow-up	Controlled	25	54.3					
	Progression	10	21.7					
	Recurrence	11	23.9					
Qt: quantity

%: percentage

RNA isolation, quality control and cDNA synthesis
To obtain homogeneous and histologically well-characterized samples for RNA analyses, tissue samples were cut with a cryo-microtome into 50-200 slices of 9-mm thickness in RNase-free conditions.",T,Saliva,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","Table 1 Clinical and histopathological features of the population: A) tissue sample population; B) saliva sample populations

Table 1-A	Table 1-B	
Tissu samples (n = 46)	Saliva samples: Control population (n = 18)	
	Median	Min	Max		Median	Min	Max	
Age	56.7	41.2	77.7	Age	53	32	71	
								
		Qt	%			Qt	%	
Sex	Woman	4	8.7	Sex	Woman	6	33.3	
	Men	42	91.3		Men	12	66.6	
								
Site	Larynx	8	17.4					
	Oral cavity	8	17.4	Saliva samples: HNSCC population (n = 51)	
	Hypopharynx	7	15.2		Median	Min	Max	
	Oropharynx	23	50	Age	59	41	83	
								
T Stage	1	1	2.2			Qt	%	
	2	11	23.9	Sex	Woman	6	11.8	
	3	19	41.3		Men	45	88.2	
	4	15	32,6					
								
N Stage	0	18	39.1	Site	Larynx	5	9.8	
	1	4	8.7		Oral cavity	11	21.7	
	2	23	50		Hypopharynx	8	15.7	
	3	1	2.2		Oropharynx	27	52.8	
								
M Stage	0	46	100	T Stage	1	6	11.8	
	1	0	0		2	12	23.5	
					3	14	27.4	
Grade	1	13	28.3		4	19	37.3	
	2	27	58.7					
	3	6	13	N Stage	0	17	33.2	
					+	34	66.7	
Death	Yes	21	45.7					
	No	25	54.3	M Stage	0	50	1.9	
					1	1	98.1	
Follow-up	Controlled	25	54.3					
	Progression	10	21.7					
	Recurrence	11	23.9					
Qt: quantity

%: percentage

RNA isolation, quality control and cDNA synthesis
To obtain homogeneous and histologically well-characterized samples for RNA analyses, tissue samples were cut with a cryo-microtome into 50-200 slices of 9-mm thickness in RNase-free conditions.",Men,saliva,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","Table 1 Clinical and histopathological features of the population: A) tissue sample population; B) saliva sample populations

Table 1-A	Table 1-B	
Tissu samples (n = 46)	Saliva samples: Control population (n = 18)	
	Median	Min	Max		Median	Min	Max	
Age	56.7	41.2	77.7	Age	53	32	71	
								
		Qt	%			Qt	%	
Sex	Woman	4	8.7	Sex	Woman	6	33.3	
	Men	42	91.3		Men	12	66.6	
								
Site	Larynx	8	17.4					
	Oral cavity	8	17.4	Saliva samples: HNSCC population (n = 51)	
	Hypopharynx	7	15.2		Median	Min	Max	
	Oropharynx	23	50	Age	59	41	83	
								
T Stage	1	1	2.2			Qt	%	
	2	11	23.9	Sex	Woman	6	11.8	
	3	19	41.3		Men	45	88.2	
	4	15	32,6					
								
N Stage	0	18	39.1	Site	Larynx	5	9.8	
	1	4	8.7		Oral cavity	11	21.7	
	2	23	50		Hypopharynx	8	15.7	
	3	1	2.2		Oropharynx	27	52.8	
								
M Stage	0	46	100	T Stage	1	6	11.8	
	1	0	0		2	12	23.5	
					3	14	27.4	
Grade	1	13	28.3		4	19	37.3	
	2	27	58.7					
	3	6	13	N Stage	0	17	33.2	
					+	34	66.7	
Death	Yes	21	45.7					
	No	25	54.3	M Stage	0	50	1.9	
					1	1	98.1	
Follow-up	Controlled	25	54.3					
	Progression	10	21.7					
	Recurrence	11	23.9					
Qt: quantity

%: percentage

RNA isolation, quality control and cDNA synthesis
To obtain homogeneous and histologically well-characterized samples for RNA analyses, tissue samples were cut with a cryo-microtome into 50-200 slices of 9-mm thickness in RNase-free conditions.",Men,Saliva,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","Table 1 Clinical and histopathological features of the population: A) tissue sample population; B) saliva sample populations

Table 1-A	Table 1-B	
Tissu samples (n = 46)	Saliva samples: Control population (n = 18)	
	Median	Min	Max		Median	Min	Max	
Age	56.7	41.2	77.7	Age	53	32	71	
								
		Qt	%			Qt	%	
Sex	Woman	4	8.7	Sex	Woman	6	33.3	
	Men	42	91.3		Men	12	66.6	
								
Site	Larynx	8	17.4					
	Oral cavity	8	17.4	Saliva samples: HNSCC population (n = 51)	
	Hypopharynx	7	15.2		Median	Min	Max	
	Oropharynx	23	50	Age	59	41	83	
								
T Stage	1	1	2.2			Qt	%	
	2	11	23.9	Sex	Woman	6	11.8	
	3	19	41.3		Men	45	88.2	
	4	15	32,6					
								
N Stage	0	18	39.1	Site	Larynx	5	9.8	
	1	4	8.7		Oral cavity	11	21.7	
	2	23	50		Hypopharynx	8	15.7	
	3	1	2.2		Oropharynx	27	52.8	
								
M Stage	0	46	100	T Stage	1	6	11.8	
	1	0	0		2	12	23.5	
					3	14	27.4	
Grade	1	13	28.3		4	19	37.3	
	2	27	58.7					
	3	6	13	N Stage	0	17	33.2	
					+	34	66.7	
Death	Yes	21	45.7					
	No	25	54.3	M Stage	0	50	1.9	
					1	1	98.1	
Follow-up	Controlled	25	54.3					
	Progression	10	21.7					
	Recurrence	11	23.9					
Qt: quantity

%: percentage

RNA isolation, quality control and cDNA synthesis
To obtain homogeneous and histologically well-characterized samples for RNA analyses, tissue samples were cut with a cryo-microtome into 50-200 slices of 9-mm thickness in RNase-free conditions.",Men,Saliva,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","Table 1 Clinical and histopathological features of the population: A) tissue sample population; B) saliva sample populations

Table 1-A	Table 1-B	
Tissu samples (n = 46)	Saliva samples: Control population (n = 18)	
	Median	Min	Max		Median	Min	Max	
Age	56.7	41.2	77.7	Age	53	32	71	
								
		Qt	%			Qt	%	
Sex	Woman	4	8.7	Sex	Woman	6	33.3	
	Men	42	91.3		Men	12	66.6	
								
Site	Larynx	8	17.4					
	Oral cavity	8	17.4	Saliva samples: HNSCC population (n = 51)	
	Hypopharynx	7	15.2		Median	Min	Max	
	Oropharynx	23	50	Age	59	41	83	
								
T Stage	1	1	2.2			Qt	%	
	2	11	23.9	Sex	Woman	6	11.8	
	3	19	41.3		Men	45	88.2	
	4	15	32,6					
								
N Stage	0	18	39.1	Site	Larynx	5	9.8	
	1	4	8.7		Oral cavity	11	21.7	
	2	23	50		Hypopharynx	8	15.7	
	3	1	2.2		Oropharynx	27	52.8	
								
M Stage	0	46	100	T Stage	1	6	11.8	
	1	0	0		2	12	23.5	
					3	14	27.4	
Grade	1	13	28.3		4	19	37.3	
	2	27	58.7					
	3	6	13	N Stage	0	17	33.2	
					+	34	66.7	
Death	Yes	21	45.7					
	No	25	54.3	M Stage	0	50	1.9	
					1	1	98.1	
Follow-up	Controlled	25	54.3					
	Progression	10	21.7					
	Recurrence	11	23.9					
Qt: quantity

%: percentage

RNA isolation, quality control and cDNA synthesis
To obtain homogeneous and histologically well-characterized samples for RNA analyses, tissue samples were cut with a cryo-microtome into 50-200 slices of 9-mm thickness in RNase-free conditions.",Yes,saliva,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","Table 1 Clinical and histopathological features of the population: A) tissue sample population; B) saliva sample populations

Table 1-A	Table 1-B	
Tissu samples (n = 46)	Saliva samples: Control population (n = 18)	
	Median	Min	Max		Median	Min	Max	
Age	56.7	41.2	77.7	Age	53	32	71	
								
		Qt	%			Qt	%	
Sex	Woman	4	8.7	Sex	Woman	6	33.3	
	Men	42	91.3		Men	12	66.6	
								
Site	Larynx	8	17.4					
	Oral cavity	8	17.4	Saliva samples: HNSCC population (n = 51)	
	Hypopharynx	7	15.2		Median	Min	Max	
	Oropharynx	23	50	Age	59	41	83	
								
T Stage	1	1	2.2			Qt	%	
	2	11	23.9	Sex	Woman	6	11.8	
	3	19	41.3		Men	45	88.2	
	4	15	32,6					
								
N Stage	0	18	39.1	Site	Larynx	5	9.8	
	1	4	8.7		Oral cavity	11	21.7	
	2	23	50		Hypopharynx	8	15.7	
	3	1	2.2		Oropharynx	27	52.8	
								
M Stage	0	46	100	T Stage	1	6	11.8	
	1	0	0		2	12	23.5	
					3	14	27.4	
Grade	1	13	28.3		4	19	37.3	
	2	27	58.7					
	3	6	13	N Stage	0	17	33.2	
					+	34	66.7	
Death	Yes	21	45.7					
	No	25	54.3	M Stage	0	50	1.9	
					1	1	98.1	
Follow-up	Controlled	25	54.3					
	Progression	10	21.7					
	Recurrence	11	23.9					
Qt: quantity

%: percentage

RNA isolation, quality control and cDNA synthesis
To obtain homogeneous and histologically well-characterized samples for RNA analyses, tissue samples were cut with a cryo-microtome into 50-200 slices of 9-mm thickness in RNase-free conditions.",Yes,Saliva,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","Table 1 Clinical and histopathological features of the population: A) tissue sample population; B) saliva sample populations

Table 1-A	Table 1-B	
Tissu samples (n = 46)	Saliva samples: Control population (n = 18)	
	Median	Min	Max		Median	Min	Max	
Age	56.7	41.2	77.7	Age	53	32	71	
								
		Qt	%			Qt	%	
Sex	Woman	4	8.7	Sex	Woman	6	33.3	
	Men	42	91.3		Men	12	66.6	
								
Site	Larynx	8	17.4					
	Oral cavity	8	17.4	Saliva samples: HNSCC population (n = 51)	
	Hypopharynx	7	15.2		Median	Min	Max	
	Oropharynx	23	50	Age	59	41	83	
								
T Stage	1	1	2.2			Qt	%	
	2	11	23.9	Sex	Woman	6	11.8	
	3	19	41.3		Men	45	88.2	
	4	15	32,6					
								
N Stage	0	18	39.1	Site	Larynx	5	9.8	
	1	4	8.7		Oral cavity	11	21.7	
	2	23	50		Hypopharynx	8	15.7	
	3	1	2.2		Oropharynx	27	52.8	
								
M Stage	0	46	100	T Stage	1	6	11.8	
	1	0	0		2	12	23.5	
					3	14	27.4	
Grade	1	13	28.3		4	19	37.3	
	2	27	58.7					
	3	6	13	N Stage	0	17	33.2	
					+	34	66.7	
Death	Yes	21	45.7					
	No	25	54.3	M Stage	0	50	1.9	
					1	1	98.1	
Follow-up	Controlled	25	54.3					
	Progression	10	21.7					
	Recurrence	11	23.9					
Qt: quantity

%: percentage

RNA isolation, quality control and cDNA synthesis
To obtain homogeneous and histologically well-characterized samples for RNA analyses, tissue samples were cut with a cryo-microtome into 50-200 slices of 9-mm thickness in RNase-free conditions.",Yes,Saliva,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","Table 1 Clinical and histopathological features of the population: A) tissue sample population; B) saliva sample populations

Table 1-A	Table 1-B	
Tissu samples (n = 46)	Saliva samples: Control population (n = 18)	
	Median	Min	Max		Median	Min	Max	
Age	56.7	41.2	77.7	Age	53	32	71	
								
		Qt	%			Qt	%	
Sex	Woman	4	8.7	Sex	Woman	6	33.3	
	Men	42	91.3		Men	12	66.6	
								
Site	Larynx	8	17.4					
	Oral cavity	8	17.4	Saliva samples: HNSCC population (n = 51)	
	Hypopharynx	7	15.2		Median	Min	Max	
	Oropharynx	23	50	Age	59	41	83	
								
T Stage	1	1	2.2			Qt	%	
	2	11	23.9	Sex	Woman	6	11.8	
	3	19	41.3		Men	45	88.2	
	4	15	32,6					
								
N Stage	0	18	39.1	Site	Larynx	5	9.8	
	1	4	8.7		Oral cavity	11	21.7	
	2	23	50		Hypopharynx	8	15.7	
	3	1	2.2		Oropharynx	27	52.8	
								
M Stage	0	46	100	T Stage	1	6	11.8	
	1	0	0		2	12	23.5	
					3	14	27.4	
Grade	1	13	28.3		4	19	37.3	
	2	27	58.7					
	3	6	13	N Stage	0	17	33.2	
					+	34	66.7	
Death	Yes	21	45.7					
	No	25	54.3	M Stage	0	50	1.9	
					1	1	98.1	
Follow-up	Controlled	25	54.3					
	Progression	10	21.7					
	Recurrence	11	23.9					
Qt: quantity

%: percentage

RNA isolation, quality control and cDNA synthesis
To obtain homogeneous and histologically well-characterized samples for RNA analyses, tissue samples were cut with a cryo-microtome into 50-200 slices of 9-mm thickness in RNase-free conditions.",Men,saliva,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","Table 1 Clinical and histopathological features of the population: A) tissue sample population; B) saliva sample populations

Table 1-A	Table 1-B	
Tissu samples (n = 46)	Saliva samples: Control population (n = 18)	
	Median	Min	Max		Median	Min	Max	
Age	56.7	41.2	77.7	Age	53	32	71	
								
		Qt	%			Qt	%	
Sex	Woman	4	8.7	Sex	Woman	6	33.3	
	Men	42	91.3		Men	12	66.6	
								
Site	Larynx	8	17.4					
	Oral cavity	8	17.4	Saliva samples: HNSCC population (n = 51)	
	Hypopharynx	7	15.2		Median	Min	Max	
	Oropharynx	23	50	Age	59	41	83	
								
T Stage	1	1	2.2			Qt	%	
	2	11	23.9	Sex	Woman	6	11.8	
	3	19	41.3		Men	45	88.2	
	4	15	32,6					
								
N Stage	0	18	39.1	Site	Larynx	5	9.8	
	1	4	8.7		Oral cavity	11	21.7	
	2	23	50		Hypopharynx	8	15.7	
	3	1	2.2		Oropharynx	27	52.8	
								
M Stage	0	46	100	T Stage	1	6	11.8	
	1	0	0		2	12	23.5	
					3	14	27.4	
Grade	1	13	28.3		4	19	37.3	
	2	27	58.7					
	3	6	13	N Stage	0	17	33.2	
					+	34	66.7	
Death	Yes	21	45.7					
	No	25	54.3	M Stage	0	50	1.9	
					1	1	98.1	
Follow-up	Controlled	25	54.3					
	Progression	10	21.7					
	Recurrence	11	23.9					
Qt: quantity

%: percentage

RNA isolation, quality control and cDNA synthesis
To obtain homogeneous and histologically well-characterized samples for RNA analyses, tissue samples were cut with a cryo-microtome into 50-200 slices of 9-mm thickness in RNase-free conditions.",Men,Saliva,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","Table 1 Clinical and histopathological features of the population: A) tissue sample population; B) saliva sample populations

Table 1-A	Table 1-B	
Tissu samples (n = 46)	Saliva samples: Control population (n = 18)	
	Median	Min	Max		Median	Min	Max	
Age	56.7	41.2	77.7	Age	53	32	71	
								
		Qt	%			Qt	%	
Sex	Woman	4	8.7	Sex	Woman	6	33.3	
	Men	42	91.3		Men	12	66.6	
								
Site	Larynx	8	17.4					
	Oral cavity	8	17.4	Saliva samples: HNSCC population (n = 51)	
	Hypopharynx	7	15.2		Median	Min	Max	
	Oropharynx	23	50	Age	59	41	83	
								
T Stage	1	1	2.2			Qt	%	
	2	11	23.9	Sex	Woman	6	11.8	
	3	19	41.3		Men	45	88.2	
	4	15	32,6					
								
N Stage	0	18	39.1	Site	Larynx	5	9.8	
	1	4	8.7		Oral cavity	11	21.7	
	2	23	50		Hypopharynx	8	15.7	
	3	1	2.2		Oropharynx	27	52.8	
								
M Stage	0	46	100	T Stage	1	6	11.8	
	1	0	0		2	12	23.5	
					3	14	27.4	
Grade	1	13	28.3		4	19	37.3	
	2	27	58.7					
	3	6	13	N Stage	0	17	33.2	
					+	34	66.7	
Death	Yes	21	45.7					
	No	25	54.3	M Stage	0	50	1.9	
					1	1	98.1	
Follow-up	Controlled	25	54.3					
	Progression	10	21.7					
	Recurrence	11	23.9					
Qt: quantity

%: percentage

RNA isolation, quality control and cDNA synthesis
To obtain homogeneous and histologically well-characterized samples for RNA analyses, tissue samples were cut with a cryo-microtome into 50-200 slices of 9-mm thickness in RNase-free conditions.",Men,Saliva,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","Table 1 Clinical and histopathological features of the population: A) tissue sample population; B) saliva sample populations

Table 1-A	Table 1-B	
Tissu samples (n = 46)	Saliva samples: Control population (n = 18)	
	Median	Min	Max		Median	Min	Max	
Age	56.7	41.2	77.7	Age	53	32	71	
								
		Qt	%			Qt	%	
Sex	Woman	4	8.7	Sex	Woman	6	33.3	
	Men	42	91.3		Men	12	66.6	
								
Site	Larynx	8	17.4					
	Oral cavity	8	17.4	Saliva samples: HNSCC population (n = 51)	
	Hypopharynx	7	15.2		Median	Min	Max	
	Oropharynx	23	50	Age	59	41	83	
								
T Stage	1	1	2.2			Qt	%	
	2	11	23.9	Sex	Woman	6	11.8	
	3	19	41.3		Men	45	88.2	
	4	15	32,6					
								
N Stage	0	18	39.1	Site	Larynx	5	9.8	
	1	4	8.7		Oral cavity	11	21.7	
	2	23	50		Hypopharynx	8	15.7	
	3	1	2.2		Oropharynx	27	52.8	
								
M Stage	0	46	100	T Stage	1	6	11.8	
	1	0	0		2	12	23.5	
					3	14	27.4	
Grade	1	13	28.3		4	19	37.3	
	2	27	58.7					
	3	6	13	N Stage	0	17	33.2	
					+	34	66.7	
Death	Yes	21	45.7					
	No	25	54.3	M Stage	0	50	1.9	
					1	1	98.1	
Follow-up	Controlled	25	54.3					
	Progression	10	21.7					
	Recurrence	11	23.9					
Qt: quantity

%: percentage

RNA isolation, quality control and cDNA synthesis
To obtain homogeneous and histologically well-characterized samples for RNA analyses, tissue samples were cut with a cryo-microtome into 50-200 slices of 9-mm thickness in RNase-free conditions.",Men,saliva,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","Table 1 Clinical and histopathological features of the population: A) tissue sample population; B) saliva sample populations

Table 1-A	Table 1-B	
Tissu samples (n = 46)	Saliva samples: Control population (n = 18)	
	Median	Min	Max		Median	Min	Max	
Age	56.7	41.2	77.7	Age	53	32	71	
								
		Qt	%			Qt	%	
Sex	Woman	4	8.7	Sex	Woman	6	33.3	
	Men	42	91.3		Men	12	66.6	
								
Site	Larynx	8	17.4					
	Oral cavity	8	17.4	Saliva samples: HNSCC population (n = 51)	
	Hypopharynx	7	15.2		Median	Min	Max	
	Oropharynx	23	50	Age	59	41	83	
								
T Stage	1	1	2.2			Qt	%	
	2	11	23.9	Sex	Woman	6	11.8	
	3	19	41.3		Men	45	88.2	
	4	15	32,6					
								
N Stage	0	18	39.1	Site	Larynx	5	9.8	
	1	4	8.7		Oral cavity	11	21.7	
	2	23	50		Hypopharynx	8	15.7	
	3	1	2.2		Oropharynx	27	52.8	
								
M Stage	0	46	100	T Stage	1	6	11.8	
	1	0	0		2	12	23.5	
					3	14	27.4	
Grade	1	13	28.3		4	19	37.3	
	2	27	58.7					
	3	6	13	N Stage	0	17	33.2	
					+	34	66.7	
Death	Yes	21	45.7					
	No	25	54.3	M Stage	0	50	1.9	
					1	1	98.1	
Follow-up	Controlled	25	54.3					
	Progression	10	21.7					
	Recurrence	11	23.9					
Qt: quantity

%: percentage

RNA isolation, quality control and cDNA synthesis
To obtain homogeneous and histologically well-characterized samples for RNA analyses, tissue samples were cut with a cryo-microtome into 50-200 slices of 9-mm thickness in RNase-free conditions.",Men,Saliva,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","Table 1 Clinical and histopathological features of the population: A) tissue sample population; B) saliva sample populations

Table 1-A	Table 1-B	
Tissu samples (n = 46)	Saliva samples: Control population (n = 18)	
	Median	Min	Max		Median	Min	Max	
Age	56.7	41.2	77.7	Age	53	32	71	
								
		Qt	%			Qt	%	
Sex	Woman	4	8.7	Sex	Woman	6	33.3	
	Men	42	91.3		Men	12	66.6	
								
Site	Larynx	8	17.4					
	Oral cavity	8	17.4	Saliva samples: HNSCC population (n = 51)	
	Hypopharynx	7	15.2		Median	Min	Max	
	Oropharynx	23	50	Age	59	41	83	
								
T Stage	1	1	2.2			Qt	%	
	2	11	23.9	Sex	Woman	6	11.8	
	3	19	41.3		Men	45	88.2	
	4	15	32,6					
								
N Stage	0	18	39.1	Site	Larynx	5	9.8	
	1	4	8.7		Oral cavity	11	21.7	
	2	23	50		Hypopharynx	8	15.7	
	3	1	2.2		Oropharynx	27	52.8	
								
M Stage	0	46	100	T Stage	1	6	11.8	
	1	0	0		2	12	23.5	
					3	14	27.4	
Grade	1	13	28.3		4	19	37.3	
	2	27	58.7					
	3	6	13	N Stage	0	17	33.2	
					+	34	66.7	
Death	Yes	21	45.7					
	No	25	54.3	M Stage	0	50	1.9	
					1	1	98.1	
Follow-up	Controlled	25	54.3					
	Progression	10	21.7					
	Recurrence	11	23.9					
Qt: quantity

%: percentage

RNA isolation, quality control and cDNA synthesis
To obtain homogeneous and histologically well-characterized samples for RNA analyses, tissue samples were cut with a cryo-microtome into 50-200 slices of 9-mm thickness in RNase-free conditions.",Men,Saliva,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","Table 1 Clinical and histopathological features of the population: A) tissue sample population; B) saliva sample populations

Table 1-A	Table 1-B	
Tissu samples (n = 46)	Saliva samples: Control population (n = 18)	
	Median	Min	Max		Median	Min	Max	
Age	56.7	41.2	77.7	Age	53	32	71	
								
		Qt	%			Qt	%	
Sex	Woman	4	8.7	Sex	Woman	6	33.3	
	Men	42	91.3		Men	12	66.6	
								
Site	Larynx	8	17.4					
	Oral cavity	8	17.4	Saliva samples: HNSCC population (n = 51)	
	Hypopharynx	7	15.2		Median	Min	Max	
	Oropharynx	23	50	Age	59	41	83	
								
T Stage	1	1	2.2			Qt	%	
	2	11	23.9	Sex	Woman	6	11.8	
	3	19	41.3		Men	45	88.2	
	4	15	32,6					
								
N Stage	0	18	39.1	Site	Larynx	5	9.8	
	1	4	8.7		Oral cavity	11	21.7	
	2	23	50		Hypopharynx	8	15.7	
	3	1	2.2		Oropharynx	27	52.8	
								
M Stage	0	46	100	T Stage	1	6	11.8	
	1	0	0		2	12	23.5	
					3	14	27.4	
Grade	1	13	28.3		4	19	37.3	
	2	27	58.7					
	3	6	13	N Stage	0	17	33.2	
					+	34	66.7	
Death	Yes	21	45.7					
	No	25	54.3	M Stage	0	50	1.9	
					1	1	98.1	
Follow-up	Controlled	25	54.3					
	Progression	10	21.7					
	Recurrence	11	23.9					
Qt: quantity

%: percentage

RNA isolation, quality control and cDNA synthesis
To obtain homogeneous and histologically well-characterized samples for RNA analyses, tissue samples were cut with a cryo-microtome into 50-200 slices of 9-mm thickness in RNase-free conditions.",cDNA,saliva,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","Table 1 Clinical and histopathological features of the population: A) tissue sample population; B) saliva sample populations

Table 1-A	Table 1-B	
Tissu samples (n = 46)	Saliva samples: Control population (n = 18)	
	Median	Min	Max		Median	Min	Max	
Age	56.7	41.2	77.7	Age	53	32	71	
								
		Qt	%			Qt	%	
Sex	Woman	4	8.7	Sex	Woman	6	33.3	
	Men	42	91.3		Men	12	66.6	
								
Site	Larynx	8	17.4					
	Oral cavity	8	17.4	Saliva samples: HNSCC population (n = 51)	
	Hypopharynx	7	15.2		Median	Min	Max	
	Oropharynx	23	50	Age	59	41	83	
								
T Stage	1	1	2.2			Qt	%	
	2	11	23.9	Sex	Woman	6	11.8	
	3	19	41.3		Men	45	88.2	
	4	15	32,6					
								
N Stage	0	18	39.1	Site	Larynx	5	9.8	
	1	4	8.7		Oral cavity	11	21.7	
	2	23	50		Hypopharynx	8	15.7	
	3	1	2.2		Oropharynx	27	52.8	
								
M Stage	0	46	100	T Stage	1	6	11.8	
	1	0	0		2	12	23.5	
					3	14	27.4	
Grade	1	13	28.3		4	19	37.3	
	2	27	58.7					
	3	6	13	N Stage	0	17	33.2	
					+	34	66.7	
Death	Yes	21	45.7					
	No	25	54.3	M Stage	0	50	1.9	
					1	1	98.1	
Follow-up	Controlled	25	54.3					
	Progression	10	21.7					
	Recurrence	11	23.9					
Qt: quantity

%: percentage

RNA isolation, quality control and cDNA synthesis
To obtain homogeneous and histologically well-characterized samples for RNA analyses, tissue samples were cut with a cryo-microtome into 50-200 slices of 9-mm thickness in RNase-free conditions.",cDNA,Saliva,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","Table 1 Clinical and histopathological features of the population: A) tissue sample population; B) saliva sample populations

Table 1-A	Table 1-B	
Tissu samples (n = 46)	Saliva samples: Control population (n = 18)	
	Median	Min	Max		Median	Min	Max	
Age	56.7	41.2	77.7	Age	53	32	71	
								
		Qt	%			Qt	%	
Sex	Woman	4	8.7	Sex	Woman	6	33.3	
	Men	42	91.3		Men	12	66.6	
								
Site	Larynx	8	17.4					
	Oral cavity	8	17.4	Saliva samples: HNSCC population (n = 51)	
	Hypopharynx	7	15.2		Median	Min	Max	
	Oropharynx	23	50	Age	59	41	83	
								
T Stage	1	1	2.2			Qt	%	
	2	11	23.9	Sex	Woman	6	11.8	
	3	19	41.3		Men	45	88.2	
	4	15	32,6					
								
N Stage	0	18	39.1	Site	Larynx	5	9.8	
	1	4	8.7		Oral cavity	11	21.7	
	2	23	50		Hypopharynx	8	15.7	
	3	1	2.2		Oropharynx	27	52.8	
								
M Stage	0	46	100	T Stage	1	6	11.8	
	1	0	0		2	12	23.5	
					3	14	27.4	
Grade	1	13	28.3		4	19	37.3	
	2	27	58.7					
	3	6	13	N Stage	0	17	33.2	
					+	34	66.7	
Death	Yes	21	45.7					
	No	25	54.3	M Stage	0	50	1.9	
					1	1	98.1	
Follow-up	Controlled	25	54.3					
	Progression	10	21.7					
	Recurrence	11	23.9					
Qt: quantity

%: percentage

RNA isolation, quality control and cDNA synthesis
To obtain homogeneous and histologically well-characterized samples for RNA analyses, tissue samples were cut with a cryo-microtome into 50-200 slices of 9-mm thickness in RNase-free conditions.",cDNA,Saliva,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","Table 1 Clinical and histopathological features of the population: A) tissue sample population; B) saliva sample populations

Table 1-A	Table 1-B	
Tissu samples (n = 46)	Saliva samples: Control population (n = 18)	
	Median	Min	Max		Median	Min	Max	
Age	56.7	41.2	77.7	Age	53	32	71	
								
		Qt	%			Qt	%	
Sex	Woman	4	8.7	Sex	Woman	6	33.3	
	Men	42	91.3		Men	12	66.6	
								
Site	Larynx	8	17.4					
	Oral cavity	8	17.4	Saliva samples: HNSCC population (n = 51)	
	Hypopharynx	7	15.2		Median	Min	Max	
	Oropharynx	23	50	Age	59	41	83	
								
T Stage	1	1	2.2			Qt	%	
	2	11	23.9	Sex	Woman	6	11.8	
	3	19	41.3		Men	45	88.2	
	4	15	32,6					
								
N Stage	0	18	39.1	Site	Larynx	5	9.8	
	1	4	8.7		Oral cavity	11	21.7	
	2	23	50		Hypopharynx	8	15.7	
	3	1	2.2		Oropharynx	27	52.8	
								
M Stage	0	46	100	T Stage	1	6	11.8	
	1	0	0		2	12	23.5	
					3	14	27.4	
Grade	1	13	28.3		4	19	37.3	
	2	27	58.7					
	3	6	13	N Stage	0	17	33.2	
					+	34	66.7	
Death	Yes	21	45.7					
	No	25	54.3	M Stage	0	50	1.9	
					1	1	98.1	
Follow-up	Controlled	25	54.3					
	Progression	10	21.7					
	Recurrence	11	23.9					
Qt: quantity

%: percentage

RNA isolation, quality control and cDNA synthesis
To obtain homogeneous and histologically well-characterized samples for RNA analyses, tissue samples were cut with a cryo-microtome into 50-200 slices of 9-mm thickness in RNase-free conditions.",HNSCC,saliva,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","Table 1 Clinical and histopathological features of the population: A) tissue sample population; B) saliva sample populations

Table 1-A	Table 1-B	
Tissu samples (n = 46)	Saliva samples: Control population (n = 18)	
	Median	Min	Max		Median	Min	Max	
Age	56.7	41.2	77.7	Age	53	32	71	
								
		Qt	%			Qt	%	
Sex	Woman	4	8.7	Sex	Woman	6	33.3	
	Men	42	91.3		Men	12	66.6	
								
Site	Larynx	8	17.4					
	Oral cavity	8	17.4	Saliva samples: HNSCC population (n = 51)	
	Hypopharynx	7	15.2		Median	Min	Max	
	Oropharynx	23	50	Age	59	41	83	
								
T Stage	1	1	2.2			Qt	%	
	2	11	23.9	Sex	Woman	6	11.8	
	3	19	41.3		Men	45	88.2	
	4	15	32,6					
								
N Stage	0	18	39.1	Site	Larynx	5	9.8	
	1	4	8.7		Oral cavity	11	21.7	
	2	23	50		Hypopharynx	8	15.7	
	3	1	2.2		Oropharynx	27	52.8	
								
M Stage	0	46	100	T Stage	1	6	11.8	
	1	0	0		2	12	23.5	
					3	14	27.4	
Grade	1	13	28.3		4	19	37.3	
	2	27	58.7					
	3	6	13	N Stage	0	17	33.2	
					+	34	66.7	
Death	Yes	21	45.7					
	No	25	54.3	M Stage	0	50	1.9	
					1	1	98.1	
Follow-up	Controlled	25	54.3					
	Progression	10	21.7					
	Recurrence	11	23.9					
Qt: quantity

%: percentage

RNA isolation, quality control and cDNA synthesis
To obtain homogeneous and histologically well-characterized samples for RNA analyses, tissue samples were cut with a cryo-microtome into 50-200 slices of 9-mm thickness in RNase-free conditions.",HNSCC,Saliva,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","Table 1 Clinical and histopathological features of the population: A) tissue sample population; B) saliva sample populations

Table 1-A	Table 1-B	
Tissu samples (n = 46)	Saliva samples: Control population (n = 18)	
	Median	Min	Max		Median	Min	Max	
Age	56.7	41.2	77.7	Age	53	32	71	
								
		Qt	%			Qt	%	
Sex	Woman	4	8.7	Sex	Woman	6	33.3	
	Men	42	91.3		Men	12	66.6	
								
Site	Larynx	8	17.4					
	Oral cavity	8	17.4	Saliva samples: HNSCC population (n = 51)	
	Hypopharynx	7	15.2		Median	Min	Max	
	Oropharynx	23	50	Age	59	41	83	
								
T Stage	1	1	2.2			Qt	%	
	2	11	23.9	Sex	Woman	6	11.8	
	3	19	41.3		Men	45	88.2	
	4	15	32,6					
								
N Stage	0	18	39.1	Site	Larynx	5	9.8	
	1	4	8.7		Oral cavity	11	21.7	
	2	23	50		Hypopharynx	8	15.7	
	3	1	2.2		Oropharynx	27	52.8	
								
M Stage	0	46	100	T Stage	1	6	11.8	
	1	0	0		2	12	23.5	
					3	14	27.4	
Grade	1	13	28.3		4	19	37.3	
	2	27	58.7					
	3	6	13	N Stage	0	17	33.2	
					+	34	66.7	
Death	Yes	21	45.7					
	No	25	54.3	M Stage	0	50	1.9	
					1	1	98.1	
Follow-up	Controlled	25	54.3					
	Progression	10	21.7					
	Recurrence	11	23.9					
Qt: quantity

%: percentage

RNA isolation, quality control and cDNA synthesis
To obtain homogeneous and histologically well-characterized samples for RNA analyses, tissue samples were cut with a cryo-microtome into 50-200 slices of 9-mm thickness in RNase-free conditions.",HNSCC,Saliva,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","Conclusion
Preoperative serum IL-6 and CRP levels might be markers of tumor invasion, LN metastasis, and TNM stage.",TNM,serum,-1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","Conclusion
Preoperative serum IL-6 and CRP levels might be markers of tumor invasion, LN metastasis, and TNM stage.",IL-6,serum,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","Conclusion
Preoperative serum IL-6 and CRP levels might be markers of tumor invasion, LN metastasis, and TNM stage.",CRP,serum,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
",For saliva collection both HNSCC patients and control cases followed the same protocole.,HNSCC,saliva,-1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
",The prognostic potential of VEGF-165 levels after chemotherapy has also been described in a study evaluating the role of serum VEGF-165 in patients with complete response after first-line therapy [41].,VEGF-165,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
",The prognostic potential of VEGF-165 levels after chemotherapy has also been described in a study evaluating the role of serum VEGF-165 in patients with complete response after first-line therapy [41].,VEGF-165,serum,-1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Significant correlations were observed between MMP-9 and NGAL serum levels and breast disease severity score (r = 0.229, p &#60; 0.006 and r = 0.206, p &#60; 0.01, respectively), whereas a non-significant correlation was found for their complex.",NGAL,serum,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Significant correlations were observed between MMP-9 and NGAL serum levels and breast disease severity score (r = 0.229, p &#60; 0.006 and r = 0.206, p &#60; 0.01, respectively), whereas a non-significant correlation was found for their complex.",MMP-9,serum,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Evaluation of MMP-9 and MMP-9/NGAL complex in urine of patients with brain tumors revealed significantly higher expression levels compared to controls, which was also confirmed in tumor tissue.",MMP-9,urine,1
"PMC 
BMC_Cancer_2010_Aug_13_10_423.txt
","Factors at initial therapy
The following factors were used in a Cox proportional hazards mode: age at surgery (Age), menstruation state, breast tumor (T) with minor modification (T2 tumors were classed as small (2.1-3.0 cm) or large (3.1-5.0 cm)), clinical and pathological lymph node state (N and pN), histopathology, and estrogen receptor and progesterone receptor status.",T2,lymph,1
"PMC 
BMC_Cancer_2010_Aug_13_10_423.txt
","Factors at initial therapy
The following factors were used in a Cox proportional hazards mode: age at surgery (Age), menstruation state, breast tumor (T) with minor modification (T2 tumors were classed as small (2.1-3.0 cm) or large (3.1-5.0 cm)), clinical and pathological lymph node state (N and pN), histopathology, and estrogen receptor and progesterone receptor status.",T,lymph,1
"PMC 
BMC_Cancer_2010_Apr_28_10_168.txt
","Since the over expression of PI Synthase in NIH3T3 cells increased PI synthesis and the amounts of PIP-2 and PIP-3, it is possible that PI Synthase overexpression also enhances cellular levels of PIP-2 and PIP-3, which, together with serum, cause increased activation of Akt kinase.",PIP-2,serum,1
"PMC 
BMC_Cancer_2010_Apr_28_10_168.txt
","Since the over expression of PI Synthase in NIH3T3 cells increased PI synthesis and the amounts of PIP-2 and PIP-3, it is possible that PI Synthase overexpression also enhances cellular levels of PIP-2 and PIP-3, which, together with serum, cause increased activation of Akt kinase.",NIH3T3,serum,1
"PMC 
BMC_Cancer_2010_Apr_28_10_168.txt
","Since the over expression of PI Synthase in NIH3T3 cells increased PI synthesis and the amounts of PIP-2 and PIP-3, it is possible that PI Synthase overexpression also enhances cellular levels of PIP-2 and PIP-3, which, together with serum, cause increased activation of Akt kinase.",PIP-3,serum,1
"PMC 
BMC_Cancer_2010_Apr_28_10_168.txt
","Since the over expression of PI Synthase in NIH3T3 cells increased PI synthesis and the amounts of PIP-2 and PIP-3, it is possible that PI Synthase overexpression also enhances cellular levels of PIP-2 and PIP-3, which, together with serum, cause increased activation of Akt kinase.",PIP-3,serum,1
"PMC 
BMC_Cancer_2010_Apr_28_10_168.txt
","Since the over expression of PI Synthase in NIH3T3 cells increased PI synthesis and the amounts of PIP-2 and PIP-3, it is possible that PI Synthase overexpression also enhances cellular levels of PIP-2 and PIP-3, which, together with serum, cause increased activation of Akt kinase.",PIP-2,serum,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","A significant positive correlation was observed between MMP-9 serum levels and disease severity score (r = 0.229, p &#60; 0.006).",MMP-9,serum,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","The determination of serum MMP-9 concentrations was performed in duplicates, on the Luminex-100 IS (Integrated System) Luminex Corporation, Austin, TX, US using the MMP-9 assay kit manufactured by R&D Systems, Minneapolis, MN, US.",MMP-9,serum,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","The determination of serum MMP-9 concentrations was performed in duplicates, on the Luminex-100 IS (Integrated System) Luminex Corporation, Austin, TX, US using the MMP-9 assay kit manufactured by R&D Systems, Minneapolis, MN, US.",Luminex-100,serum,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","The determination of serum MMP-9 concentrations was performed in duplicates, on the Luminex-100 IS (Integrated System) Luminex Corporation, Austin, TX, US using the MMP-9 assay kit manufactured by R&D Systems, Minneapolis, MN, US.",MN,serum,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","The determination of serum MMP-9 concentrations was performed in duplicates, on the Luminex-100 IS (Integrated System) Luminex Corporation, Austin, TX, US using the MMP-9 assay kit manufactured by R&D Systems, Minneapolis, MN, US.",TX,serum,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","The determination of serum MMP-9 concentrations was performed in duplicates, on the Luminex-100 IS (Integrated System) Luminex Corporation, Austin, TX, US using the MMP-9 assay kit manufactured by R&D Systems, Minneapolis, MN, US.",MMP-9,serum,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","LNCaP cells were serum-starved for 24 hr, pretreated with DMSO, 10 mM of MP470 or MP470-Erlotinib, and then stimulated by pervanadate for 10 min.",MP470,serum,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","LNCaP cells were serum-starved for 24 hr, pretreated with DMSO, 10 mM of MP470 or MP470-Erlotinib, and then stimulated by pervanadate for 10 min.",DMSO,serum,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Conclusion
These findings suggest that the serum measurement of MMP-9 and NGAL may be useful in non-invasively monitoring breast cancer progression, while supporting their potential role as early biomarkers of breast disease status.
",NGAL,serum,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Conclusion
These findings suggest that the serum measurement of MMP-9 and NGAL may be useful in non-invasively monitoring breast cancer progression, while supporting their potential role as early biomarkers of breast disease status.
",MMP-9,serum,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","NGAL serum levels were similar between women with DCIS, ADH and sclerosing adenosis whereas a marked increase was observed for women with invasive carcinoma (Table 1).",DCIS,serum,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","NGAL serum levels were similar between women with DCIS, ADH and sclerosing adenosis whereas a marked increase was observed for women with invasive carcinoma (Table 1).",ADH,serum,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","NGAL serum levels were similar between women with DCIS, ADH and sclerosing adenosis whereas a marked increase was observed for women with invasive carcinoma (Table 1).",NGAL,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Table 4 Correlations between serum concentration of CA-125, TIMP-1 and VEGF and clinicopathological factors

	Age		Residual Tumor		Ascites		pN		Grading		
		
	p-value	+/-	",VEGF,Ascites,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Table 4 Correlations between serum concentration of CA-125, TIMP-1 and VEGF and clinicopathological factors

	Age		Residual Tumor		Ascites		pN		Grading		
		
	p-value	+/-	",VEGF,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Table 4 Correlations between serum concentration of CA-125, TIMP-1 and VEGF and clinicopathological factors

	Age		Residual Tumor		Ascites		pN		Grading		
		
	p-value	+/-	",TIMP-1,Ascites,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Table 4 Correlations between serum concentration of CA-125, TIMP-1 and VEGF and clinicopathological factors

	Age		Residual Tumor		Ascites		pN		Grading		
		
	p-value	+/-	",TIMP-1,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Table 4 Correlations between serum concentration of CA-125, TIMP-1 and VEGF and clinicopathological factors

	Age		Residual Tumor		Ascites		pN		Grading		
		
	p-value	+/-	",CA-125,Ascites,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Table 4 Correlations between serum concentration of CA-125, TIMP-1 and VEGF and clinicopathological factors

	Age		Residual Tumor		Ascites		pN		Grading		
		
	p-value	+/-	",CA-125,serum,1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","In the present investigation, we focused on the evaluation of IL-1 gene polymorphisms, and did not plan to investigate serum levels of the IL-1 cytokines.",IL-1,serum,1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","In the present investigation, we focused on the evaluation of IL-1 gene polymorphisms, and did not plan to investigate serum levels of the IL-1 cytokines.",IL-1,serum,1
"PMC 
BMC_Cancer_2010_Apr_21_10_155.txt
","Finally, we will include pilot studies to investigate the effects of exercise training on changes in peripheral gene expression (from analysis of whole blood mRNA) using high-density mRNA microarrays.",mRNA,blood,-1
"PMC 
BMC_Cancer_2010_Apr_21_10_155.txt
","Finally, we will include pilot studies to investigate the effects of exercise training on changes in peripheral gene expression (from analysis of whole blood mRNA) using high-density mRNA microarrays.",mRNA,blood,-1
"PMC 
BMC_Cancer_2009_Sep_6_9_315.txt
","Human embryonic kidney cell line 293FT was grown in DMEM supplemented with 10% fetal calf serum (Hyclone, Logan, UT).",DMEM,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","We divided the 100 patients into 2 groups arbitrarily according to the scale of serum TRACP 5b activity, i.e. those with the top 1/3 baseline activities (TRACP 5b >= 5.736 U/L) and the remainders.",TRACP,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","We divided the 100 patients into 2 groups arbitrarily according to the scale of serum TRACP 5b activity, i.e. those with the top 1/3 baseline activities (TRACP 5b >= 5.736 U/L) and the remainders.",TRACP,serum,1
"PMC 
BMC_Cancer_2010_Apr_27_10_161.txt
","Cell Culture and Chemical Compounds
Human cell lines from ATCC, were maintained in Dulbecco's minimal essential medium(Gibco, Grand Island, NY) supplemented with 10% fetal bovine serum, 100 units/mL penicillin, and 100 mg/mL streptomycin at 37degC in a 5% CO2-humidified atmosphere.",ATCC,serum,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",MDR,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",A1S9,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",INPP4B,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",TAP,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",STAT1,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",CKLF,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",BN75,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",RALGPS1,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",SSTK,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",POSTN,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",POR,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",ESR1,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",PTMS,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",GEF,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",P450,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",FARSB,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",KIAA1463,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",PH,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",T,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",RAB5C,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",PPFIA4,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",tRNA,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",SH3,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",MGC4308,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",SSTK,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",HIST2H2BE,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",ID2,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",WSB1,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",LPS,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",FBP1,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",FANCG,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",CALU,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",MYO1C,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",ESR1,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",ST6,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",DNA,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",PSMB10,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",MGC4308,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",MFAP2,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",PTPRF,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",CDCA4,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",TRIM33,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",TUSC3,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",RNA,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",MEF2D,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",RAB21,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",SERPINH1,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",FADS1,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",SELENBP1,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",MADS,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",ACAA2,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",COL6A3,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",DIP2B,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",EXOSC7,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",CYB5A,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",ZNF516,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",RAB5C,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",H2AFV,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",SFTPB,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",IRF4,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",H2A,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",ESR1,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",ST6GAL1,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",PRG2,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",b-5,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",LRBA,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",RAS,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",LPS,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",TM9SF2,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",CLIP4,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",FDPS,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",CAP,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",PTPRF,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",GLY,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",EIF4G1,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",BMI1,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",MMP11,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",FABP3,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",LRBA,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",PRIM2,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",FGFR4,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",H2AFX,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",H2A,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",PLA2R1,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",NUTF2,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",TAP1,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",PPFIA1,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",A2,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",ACAD11,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",X,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",RAB31,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",gamma,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",RAB31,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",ATP,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",UBE1,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",RAB21,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",KDELR3,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",AYTL1,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",ID3,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",DEAD,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",PRIM2,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",RAS,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",SELENBP1,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",RAS,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",SOCS,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",DNA,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",FLJ20481,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",E1,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",IL13RA1,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","P value	Gene symbol	Descriptor	
	
0.0003	FGFR4	Fibroblast growth factor receptor 4	
0.0007	SELENBP1	Selenium binding protein 1	
0.0010	POSTN	Periostin, osteoblast specific factor	
0.0010	CALU	Calumenin	
0.0012	SERPINH1	Serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	
0.0012	KDELR3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	
0.0013	PTMS	Parathymosin	
0.0013	HIST2H2BE	Histone 2, H2be	
0.0015	TUSC3	Tumor suppressor candidate 3	
0.0016	ZNF516	Zinc finger protein 516	
0.0018	BMI1	Polycomb group ring finger 4	
0.0024	ACAD11	Putative acyl-CoA dehydrogenase	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
0.0033	ESR1	Estrogen receptor 1	
0.0037	ACAA2	Myosin VB	
0.005	CYB5A	Cytochrome b-5	
0.005	CLIP4	CAP-GLY domain containing linker protein family, member 4	
0.0051	AYTL1	Hypothetical protein FLJ20481	
0.0056	RALGPS1	Ral GEF with PH domain and SH3 binding motif 1	
0.0062	PSMB10	Proteasome (prosome, macropain) subunit, beta type, 10	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0070	UBE1	Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing)	
0.0084	FBP1	Fructose-1,6-bisphosphatase 1	
0.0087	COL6A3	Collagen, type VI, alpha 3	
0.0087	TM9SF2	Transmembrane 9 superfamily member 2	
0.0090	TAP1	Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	
0.0097	DIP2B	KIAA1463 protein	
0.0100	TncRNA	Trophoblast-derived noncoding RNA	
	
24 genes common with wound healing signature (Chang et al)	
	
0.0038	EIF4G1	Eukaryotic translation initiation factor 4 gamma, 1	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0021	POR	P450 (cytochrome) oxidoreductase	
0.0002	FANCG	Fanconi anemia, complementation group G	
0.0097	EXOSC7	Exosome component 7	
0.0006	FDPS	Farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)	
0.0020	C5orf4	Chromosome 5 open reading frame 4	
0.0055	CDCA4	Cell division cycle associated 4	
0.0099	H2AFV	H2A histone family, member V	
0.0061	FABP3	Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	
0.0027	CKLF	Chemokine-like factor	
0.0014	MGC4308	Hypothetical protein MGC4308	
0.0009	FADS1	Fatty acid desaturase 1	
0.0061	SFTPB	Surfactant, pulmonary-associated protein B	
0.0055	PLA2R1	Phospholipase A2 receptor 1, 180 kDa	
0.0007	SELENBP1	Selenium binding protein 1	
0.006	FARSB	Phenylalanine-tRNA synthetase-like, beta subunit	
0.0054	MEF2D	MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)	
0.0029	NUTF2	Nuclear transport factor 2	
0.0098	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	
0.0087	ID2	Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	
0.0069	PRG2	Proteoglycan 2, bone marrow	
0.0001	H2AFX	H2A histone family, member X	
0.0047	WSB1	WD repeat and SOCS box-containing 1	
	
17 genes common with new intrinsic gene list (Zhiyan et al.)	
	
0.0033	TRIM33	Tripartite motif-containing 33	
0.0003	RAB5C	RAB5C, member RAS oncogene family	
0.0086	PRIM2	primase, polypeptide 2A, 58 kDa	
0.0071	RAB21	RAB21, member RAS oncogene family	
0.0029	SSTK	Serine/threonine protein kinase SSTK	
0.0001	ST6GAL1	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1	
0.0052	IRF4	Interferon regulatory factor 4	
0.0067	LRBA	LPS-responsive vesicle trafficking, beach and anchor containing	
0.0036	IL13RA1	Interleukin 13 receptor, alpha 1	
0.0033	ESR1	Estrogen receptor 1	
0.0017	MFAP2	Microfibrillar-associated protein 2	
0.0031	STAT1	Signal transducer and activator of transcription 1, 91 kDa	
0.0013	PPFIA1	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1	
0.0061	MYO1C	Myosin IC	
0.0082	PPFIA4	Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4	
0.0060	RAB31	RAB31, member RAS oncogene family	
0.0026	INPP4B	Inositol polyphosphate-4-phosphatase, type II, 105 kDa	
	
2 genes common with Recurrence Score genes (Paik et al)	
	
0.0033	ESR1	Estrogen receptor 1	
0.0021	MMP11	Matrix metalloproteinase 11 (stromelysin 3)	
We then assumed that the extent of the impact of tissue handling on the prognostic/predictive reliability of a given gene signature, could be indirectly evaluated looking at its capability to maintain the clustering of individual samples collected at different times.

",INPP4B,bone marrow,1
"PMC 
BMC_Cancer_2009_Mar_24_9_91.txt
","We are aware that this number may be affected by the compliance for biopsy in suspected subject, and additional factors, as the threshold criteria for serum PSA.",PSA,serum,1
"PMC 
BMC_Cancer_2009_Mar_24_9_91.txt
","The occurrence of a high grade PCa with lower PSA levels, confirms the need for a serum marker with a higher sensitivity to diagnose this disease.",PSA,serum,1
"PMC 
BMC_Cancer_2009_Mar_24_9_91.txt
","Gleason Scores	Number of subjects in this range	PCa cases in this range*	Gleason Scores	
0.1 - 4.0	620	1	7	175	0	-	29	0	-	
4.1 - 8.0	53	2	7,8	22	0	-	5	0	-	
8.1-12.0	10	4	7,8,6,9	6	0	-	4	1	8	
&#62; 12.0	14	6	7,9,7,9,9,8	9	1	9	1	0	-	
	
Total	697 *	13	-	212 +	1	-	39	1	-	
* PSA could not be measured for 12 subjects due to insufficient blood sample.

+ PSA could not be measured for 13 subjects due to insufficient blood sample.

*",PSA,blood,1
"PMC 
BMC_Cancer_2009_Mar_24_9_91.txt
","Gleason Scores	Number of subjects in this range	PCa cases in this range*	Gleason Scores	
0.1 - 4.0	620	1	7	175	0	-	29	0	-	
4.1 - 8.0	53	2	7,8	22	0	-	5	0	-	
8.1-12.0	10	4	7,8,6,9	6	0	-	4	1	8	
&#62; 12.0	14	6	7,9,7,9,9,8	9	1	9	1	0	-	
	
Total	697 *	13	-	212 +	1	-	39	1	-	
* PSA could not be measured for 12 subjects due to insufficient blood sample.

+ PSA could not be measured for 13 subjects due to insufficient blood sample.

*",PSA,blood,1
"PMC 
BMC_Cancer_2009_Mar_24_9_91.txt
","Gleason Scores	Number of subjects in this range	PCa cases in this range*	Gleason Scores	
0.1 - 4.0	620	1	7	175	0	-	29	0	-	
4.1 - 8.0	53	2	7,8	22	0	-	5	0	-	
8.1-12.0	10	4	7,8,6,9	6	0	-	4	1	8	
&#62; 12.0	14	6	7,9,7,9,9,8	9	1	9	1	0	-	
	
Total	697 *	13	-	212 +	1	-	39	1	-	
* PSA could not be measured for 12 subjects due to insufficient blood sample.

+ PSA could not be measured for 13 subjects due to insufficient blood sample.

*",PSA,blood,1
"PMC 
BMC_Cancer_2009_Mar_24_9_91.txt
","Gleason Scores	Number of subjects in this range	PCa cases in this range*	Gleason Scores	
0.1 - 4.0	620	1	7	175	0	-	29	0	-	
4.1 - 8.0	53	2	7,8	22	0	-	5	0	-	
8.1-12.0	10	4	7,8,6,9	6	0	-	4	1	8	
&#62; 12.0	14	6	7,9,7,9,9,8	9	1	9	1	0	-	
	
Total	697 *	13	-	212 +	1	-	39	1	-	
* PSA could not be measured for 12 subjects due to insufficient blood sample.

+ PSA could not be measured for 13 subjects due to insufficient blood sample.

*",PSA,blood,1
"PMC 
BMC_Cancer_2009_Sep_2_9_309.txt
",Endogenous peroxidase activities of the sections were quenched with 3% hydrogen peroxide and the sections were blocked using 1% bovine serum albumin (BSA) (w/v in PBS).,BSA,serum,1
"PMC 
BMC_Cancer_2009_Sep_2_9_309.txt
",Endogenous peroxidase activities of the sections were quenched with 3% hydrogen peroxide and the sections were blocked using 1% bovine serum albumin (BSA) (w/v in PBS).,PBS,serum,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
",Patients whose serum NSE level was elevated showed a shorter OS in our study although statistically insignificant (p = .051).,OS,serum,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
",Patients whose serum NSE level was elevated showed a shorter OS in our study although statistically insignificant (p = .051).,NSE,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","As shown in Figure 2, there was an inverse relationship between baseline serum TRACP 5b activity and OS.

",OS,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","As shown in Figure 2, there was an inverse relationship between baseline serum TRACP 5b activity and OS.

",TRACP,serum,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","After two weeks the medium was replaced by HT-medium (DMEM medium (Gibco BRL life technologies) supplemented with 10% bovine calf serum, 100 U/ml penicillin, 100 mg/ml streptomycin, 100 mM hypoxanthine and 160 mM thymidine and another week later cells were cultured in standard DMEM medium (4500 mg/l D-Glucose supplemented with GlutaMax (Gibco BRL life technologies) with 10% bovine calf serum, 100 U/ml penicillin and 100 mg/ml streptomycin.",BRL,serum,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","After two weeks the medium was replaced by HT-medium (DMEM medium (Gibco BRL life technologies) supplemented with 10% bovine calf serum, 100 U/ml penicillin, 100 mg/ml streptomycin, 100 mM hypoxanthine and 160 mM thymidine and another week later cells were cultured in standard DMEM medium (4500 mg/l D-Glucose supplemented with GlutaMax (Gibco BRL life technologies) with 10% bovine calf serum, 100 U/ml penicillin and 100 mg/ml streptomycin.",BRL,serum,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","After two weeks the medium was replaced by HT-medium (DMEM medium (Gibco BRL life technologies) supplemented with 10% bovine calf serum, 100 U/ml penicillin, 100 mg/ml streptomycin, 100 mM hypoxanthine and 160 mM thymidine and another week later cells were cultured in standard DMEM medium (4500 mg/l D-Glucose supplemented with GlutaMax (Gibco BRL life technologies) with 10% bovine calf serum, 100 U/ml penicillin and 100 mg/ml streptomycin.",DMEM,serum,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","After two weeks the medium was replaced by HT-medium (DMEM medium (Gibco BRL life technologies) supplemented with 10% bovine calf serum, 100 U/ml penicillin, 100 mg/ml streptomycin, 100 mM hypoxanthine and 160 mM thymidine and another week later cells were cultured in standard DMEM medium (4500 mg/l D-Glucose supplemented with GlutaMax (Gibco BRL life technologies) with 10% bovine calf serum, 100 U/ml penicillin and 100 mg/ml streptomycin.",DMEM,serum,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","After two weeks the medium was replaced by HT-medium (DMEM medium (Gibco BRL life technologies) supplemented with 10% bovine calf serum, 100 U/ml penicillin, 100 mg/ml streptomycin, 100 mM hypoxanthine and 160 mM thymidine and another week later cells were cultured in standard DMEM medium (4500 mg/l D-Glucose supplemented with GlutaMax (Gibco BRL life technologies) with 10% bovine calf serum, 100 U/ml penicillin and 100 mg/ml streptomycin.",DMEM,serum,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","After two weeks the medium was replaced by HT-medium (DMEM medium (Gibco BRL life technologies) supplemented with 10% bovine calf serum, 100 U/ml penicillin, 100 mg/ml streptomycin, 100 mM hypoxanthine and 160 mM thymidine and another week later cells were cultured in standard DMEM medium (4500 mg/l D-Glucose supplemented with GlutaMax (Gibco BRL life technologies) with 10% bovine calf serum, 100 U/ml penicillin and 100 mg/ml streptomycin.",DMEM,serum,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","After two weeks the medium was replaced by HT-medium (DMEM medium (Gibco BRL life technologies) supplemented with 10% bovine calf serum, 100 U/ml penicillin, 100 mg/ml streptomycin, 100 mM hypoxanthine and 160 mM thymidine and another week later cells were cultured in standard DMEM medium (4500 mg/l D-Glucose supplemented with GlutaMax (Gibco BRL life technologies) with 10% bovine calf serum, 100 U/ml penicillin and 100 mg/ml streptomycin.",BRL,serum,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","After two weeks the medium was replaced by HT-medium (DMEM medium (Gibco BRL life technologies) supplemented with 10% bovine calf serum, 100 U/ml penicillin, 100 mg/ml streptomycin, 100 mM hypoxanthine and 160 mM thymidine and another week later cells were cultured in standard DMEM medium (4500 mg/l D-Glucose supplemented with GlutaMax (Gibco BRL life technologies) with 10% bovine calf serum, 100 U/ml penicillin and 100 mg/ml streptomycin.",BRL,serum,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3221974432210.1186/1471-2407-9-322Research ArticleTumor tissue levels of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and outcome following adjuvant chemotherapy in premenopausal lymph node-positive breast cancer patients: A retrospective study Schrohl Anne-Sofie 1sofie@life.ku.dkLook Maxime P 2m.look@erasmusmc.nlMeijer-van Gelder Marion E 2m.e.meijer@erasmusmc.nlFoekens John A 2j.foekens@erasmusmc.nlBrunner Nils 1nbr@life.ku.dk1 University of Copenhagen, Faculty of Life Sciences, Department of Veterinary Disease Biology, Ridebanevej 9, DK-1870 Frederiksberg C, Denmark2 Erasmus MC, Department of Medical Oncology, Josephine Nefkens Institute and Cancer Genomics Center, Dr. Molewaterplein 50, 3015 GE Rotterdam, the Netherlands2009 10 9 2009 9 322 322 28 4 2009 10 9 2009 Copyright (c)2009 Schrohl et al; licensee BioMed Central Ltd.2009Schrohl et al; licensee BioMed Central Ltd.",TIMP-1,lymph,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3221974432210.1186/1471-2407-9-322Research ArticleTumor tissue levels of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and outcome following adjuvant chemotherapy in premenopausal lymph node-positive breast cancer patients: A retrospective study Schrohl Anne-Sofie 1sofie@life.ku.dkLook Maxime P 2m.look@erasmusmc.nlMeijer-van Gelder Marion E 2m.e.meijer@erasmusmc.nlFoekens John A 2j.foekens@erasmusmc.nlBrunner Nils 1nbr@life.ku.dk1 University of Copenhagen, Faculty of Life Sciences, Department of Veterinary Disease Biology, Ridebanevej 9, DK-1870 Frederiksberg C, Denmark2 Erasmus MC, Department of Medical Oncology, Josephine Nefkens Institute and Cancer Genomics Center, Dr. Molewaterplein 50, 3015 GE Rotterdam, the Netherlands2009 10 9 2009 9 322 322 28 4 2009 10 9 2009 Copyright (c)2009 Schrohl et al; licensee BioMed Central Ltd.2009Schrohl et al; licensee BioMed Central Ltd.",Metalloproteinases-1,lymph,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3221974432210.1186/1471-2407-9-322Research ArticleTumor tissue levels of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and outcome following adjuvant chemotherapy in premenopausal lymph node-positive breast cancer patients: A retrospective study Schrohl Anne-Sofie 1sofie@life.ku.dkLook Maxime P 2m.look@erasmusmc.nlMeijer-van Gelder Marion E 2m.e.meijer@erasmusmc.nlFoekens John A 2j.foekens@erasmusmc.nlBrunner Nils 1nbr@life.ku.dk1 University of Copenhagen, Faculty of Life Sciences, Department of Veterinary Disease Biology, Ridebanevej 9, DK-1870 Frederiksberg C, Denmark2 Erasmus MC, Department of Medical Oncology, Josephine Nefkens Institute and Cancer Genomics Center, Dr. Molewaterplein 50, 3015 GE Rotterdam, the Netherlands2009 10 9 2009 9 322 322 28 4 2009 10 9 2009 Copyright (c)2009 Schrohl et al; licensee BioMed Central Ltd.2009Schrohl et al; licensee BioMed Central Ltd.",DK-1870,lymph,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3221974432210.1186/1471-2407-9-322Research ArticleTumor tissue levels of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and outcome following adjuvant chemotherapy in premenopausal lymph node-positive breast cancer patients: A retrospective study Schrohl Anne-Sofie 1sofie@life.ku.dkLook Maxime P 2m.look@erasmusmc.nlMeijer-van Gelder Marion E 2m.e.meijer@erasmusmc.nlFoekens John A 2j.foekens@erasmusmc.nlBrunner Nils 1nbr@life.ku.dk1 University of Copenhagen, Faculty of Life Sciences, Department of Veterinary Disease Biology, Ridebanevej 9, DK-1870 Frederiksberg C, Denmark2 Erasmus MC, Department of Medical Oncology, Josephine Nefkens Institute and Cancer Genomics Center, Dr. Molewaterplein 50, 3015 GE Rotterdam, the Netherlands2009 10 9 2009 9 322 322 28 4 2009 10 9 2009 Copyright (c)2009 Schrohl et al; licensee BioMed Central Ltd.2009Schrohl et al; licensee BioMed Central Ltd.",BMC,lymph,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3221974432210.1186/1471-2407-9-322Research ArticleTumor tissue levels of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and outcome following adjuvant chemotherapy in premenopausal lymph node-positive breast cancer patients: A retrospective study Schrohl Anne-Sofie 1sofie@life.ku.dkLook Maxime P 2m.look@erasmusmc.nlMeijer-van Gelder Marion E 2m.e.meijer@erasmusmc.nlFoekens John A 2j.foekens@erasmusmc.nlBrunner Nils 1nbr@life.ku.dk1 University of Copenhagen, Faculty of Life Sciences, Department of Veterinary Disease Biology, Ridebanevej 9, DK-1870 Frederiksberg C, Denmark2 Erasmus MC, Department of Medical Oncology, Josephine Nefkens Institute and Cancer Genomics Center, Dr. Molewaterplein 50, 3015 GE Rotterdam, the Netherlands2009 10 9 2009 9 322 322 28 4 2009 10 9 2009 Copyright (c)2009 Schrohl et al; licensee BioMed Central Ltd.2009Schrohl et al; licensee BioMed Central Ltd.",Cancer1471,lymph,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3221974432210.1186/1471-2407-9-322Research ArticleTumor tissue levels of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and outcome following adjuvant chemotherapy in premenopausal lymph node-positive breast cancer patients: A retrospective study Schrohl Anne-Sofie 1sofie@life.ku.dkLook Maxime P 2m.look@erasmusmc.nlMeijer-van Gelder Marion E 2m.e.meijer@erasmusmc.nlFoekens John A 2j.foekens@erasmusmc.nlBrunner Nils 1nbr@life.ku.dk1 University of Copenhagen, Faculty of Life Sciences, Department of Veterinary Disease Biology, Ridebanevej 9, DK-1870 Frederiksberg C, Denmark2 Erasmus MC, Department of Medical Oncology, Josephine Nefkens Institute and Cancer Genomics Center, Dr. Molewaterplein 50, 3015 GE Rotterdam, the Netherlands2009 10 9 2009 9 322 322 28 4 2009 10 9 2009 Copyright (c)2009 Schrohl et al; licensee BioMed Central Ltd.2009Schrohl et al; licensee BioMed Central Ltd.",Netherlands2009,lymph,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3221974432210.1186/1471-2407-9-322Research ArticleTumor tissue levels of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and outcome following adjuvant chemotherapy in premenopausal lymph node-positive breast cancer patients: A retrospective study Schrohl Anne-Sofie 1sofie@life.ku.dkLook Maxime P 2m.look@erasmusmc.nlMeijer-van Gelder Marion E 2m.e.meijer@erasmusmc.nlFoekens John A 2j.foekens@erasmusmc.nlBrunner Nils 1nbr@life.ku.dk1 University of Copenhagen, Faculty of Life Sciences, Department of Veterinary Disease Biology, Ridebanevej 9, DK-1870 Frederiksberg C, Denmark2 Erasmus MC, Department of Medical Oncology, Josephine Nefkens Institute and Cancer Genomics Center, Dr. Molewaterplein 50, 3015 GE Rotterdam, the Netherlands2009 10 9 2009 9 322 322 28 4 2009 10 9 2009 Copyright (c)2009 Schrohl et al; licensee BioMed Central Ltd.2009Schrohl et al; licensee BioMed Central Ltd.",Denmark2,lymph,1
"PMC 
BMC_Cancer_2009_Oct_14_9_364.txt
","In models two to five, HR for each SES group was estimated with additional adjustment for (2) AJCC stage and number of positive lymph nodes, (3) first course treatments, (4) race, (5) rural/urban residence at diagnosis, respectively.",AJCC,lymph,1
"PMC 
BMC_Cancer_2009_Oct_14_9_364.txt
","In models two to five, HR for each SES group was estimated with additional adjustment for (2) AJCC stage and number of positive lymph nodes, (3) first course treatments, (4) race, (5) rural/urban residence at diagnosis, respectively.",HR,lymph,1
"PMC 
BMC_Cancer_2009_Oct_14_9_364.txt
","In models two to five, HR for each SES group was estimated with additional adjustment for (2) AJCC stage and number of positive lymph nodes, (3) first course treatments, (4) race, (5) rural/urban residence at diagnosis, respectively.",SES,lymph,1
"PMC 
BMC_Cancer_2010_Apr_16_10_145.txt
","Second, since the presence of LVI strongly correlates with lymph node metastases, low rates of LVI are likely to result in relatively frequent negative axillary nodal status.",LVI,lymph,1
"PMC 
BMC_Cancer_2010_Apr_16_10_145.txt
","Second, since the presence of LVI strongly correlates with lymph node metastases, low rates of LVI are likely to result in relatively frequent negative axillary nodal status.",LVI,lymph,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","Tumor tissue, normal matched mucosa and saliva were obtained from 74 patients consecutively diagnosed with primary untreated HNSCC between April 2005 and April 2007 in our institution.",HNSCC,saliva,-1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","In addition to salivary detection, MMP1 could be tested at the RNA level for its ability to identify small tumor clusters in diagnostic biopsies, surgical margins or lymph nodes in the setting of primary tumors.",RNA,lymph,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","In addition to salivary detection, MMP1 could be tested at the RNA level for its ability to identify small tumor clusters in diagnostic biopsies, surgical margins or lymph nodes in the setting of primary tumors.",MMP1,lymph,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","One hundred microliters of the standards, diluted control samples and diluted serum samples were dispensed into 96-well plates (coated with an anti-human monoclonal antibody) and incubated for 1.5 hours at 37degC (VEGF-165) or 30 minutes at room temperature (TIMP-1).",VEGF-165,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","One hundred microliters of the standards, diluted control samples and diluted serum samples were dispensed into 96-well plates (coated with an anti-human monoclonal antibody) and incubated for 1.5 hours at 37degC (VEGF-165) or 30 minutes at room temperature (TIMP-1).",TIMP-1,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","We have also demonstrated that serum TRACP 5b activity can be potentially used as a marker to monitor treatment response in BC patients with bone metastasis and as an adjunct to bone scintigraphy for the diagnosis and follow-up of bone metastasis [8,14].",TRACP,serum,1
"PMC 
BMC_Cancer_2010_Apr_27_10_160.txt
","All cells were cultured in RPMI1640 medium containing 10% heat-inactivated fetal bovine serum (FBS) and incubated at 37degC in a humidified incubator containing 5% CO2.

",RPMI1640,serum,1
"PMC 
BMC_Cancer_2010_Apr_27_10_160.txt
","All cells were cultured in RPMI1640 medium containing 10% heat-inactivated fetal bovine serum (FBS) and incubated at 37degC in a humidified incubator containing 5% CO2.

",CO2,serum,1
"PMC 
BMC_Cancer_2010_Apr_27_10_160.txt
","All cells were cultured in RPMI1640 medium containing 10% heat-inactivated fetal bovine serum (FBS) and incubated at 37degC in a humidified incubator containing 5% CO2.

",FBS,serum,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
",Figure 1 Serum levels of MMP-9 depicted as box-plots.,MMP-9,Serum,1
"PMC 
BMC_Cancer_2009_Nov_17_9_400.txt
","The results showed AFB1-DNA adduct levels of the HCC cancerous tissue were positively and linearly related to peripheral blood leukocytes' adduct levels (data not shown), which suggested that the levels of peripheral blood leukocytes' DNA adducts were representative of the tissues' DNA-adduct levels.

",HCC,blood,-1
"PMC 
BMC_Cancer_2009_Nov_17_9_400.txt
","The results showed AFB1-DNA adduct levels of the HCC cancerous tissue were positively and linearly related to peripheral blood leukocytes' adduct levels (data not shown), which suggested that the levels of peripheral blood leukocytes' DNA adducts were representative of the tissues' DNA-adduct levels.

",HCC,blood,-1
"PMC 
BMC_Cancer_2009_Nov_17_9_400.txt
","The results showed AFB1-DNA adduct levels of the HCC cancerous tissue were positively and linearly related to peripheral blood leukocytes' adduct levels (data not shown), which suggested that the levels of peripheral blood leukocytes' DNA adducts were representative of the tissues' DNA-adduct levels.

",AFB1-DNA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_17_9_400.txt
","The results showed AFB1-DNA adduct levels of the HCC cancerous tissue were positively and linearly related to peripheral blood leukocytes' adduct levels (data not shown), which suggested that the levels of peripheral blood leukocytes' DNA adducts were representative of the tissues' DNA-adduct levels.

",AFB1-DNA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_17_9_400.txt
","The results showed AFB1-DNA adduct levels of the HCC cancerous tissue were positively and linearly related to peripheral blood leukocytes' adduct levels (data not shown), which suggested that the levels of peripheral blood leukocytes' DNA adducts were representative of the tissues' DNA-adduct levels.

",DNA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_17_9_400.txt
","The results showed AFB1-DNA adduct levels of the HCC cancerous tissue were positively and linearly related to peripheral blood leukocytes' adduct levels (data not shown), which suggested that the levels of peripheral blood leukocytes' DNA adducts were representative of the tissues' DNA-adduct levels.

",DNA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_17_9_400.txt
","The results showed AFB1-DNA adduct levels of the HCC cancerous tissue were positively and linearly related to peripheral blood leukocytes' adduct levels (data not shown), which suggested that the levels of peripheral blood leukocytes' DNA adducts were representative of the tissues' DNA-adduct levels.

",DNA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_17_9_400.txt
","The results showed AFB1-DNA adduct levels of the HCC cancerous tissue were positively and linearly related to peripheral blood leukocytes' adduct levels (data not shown), which suggested that the levels of peripheral blood leukocytes' DNA adducts were representative of the tissues' DNA-adduct levels.

",DNA,blood,-1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Compared to initial serum levels before surgery, CA-125, TIMP-1 and VEGF-165 during and after chemotherapy also decreased significantly (during chemotherapy: p &#60; 0.001, p = 0.002, p = 0.026 and after Chemotherapy: p &#60; 0.001, p &#60; 0.001, p = 0.001, respectively).",CA-125,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Compared to initial serum levels before surgery, CA-125, TIMP-1 and VEGF-165 during and after chemotherapy also decreased significantly (during chemotherapy: p &#60; 0.001, p = 0.002, p = 0.026 and after Chemotherapy: p &#60; 0.001, p &#60; 0.001, p = 0.001, respectively).",TIMP-1,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Compared to initial serum levels before surgery, CA-125, TIMP-1 and VEGF-165 during and after chemotherapy also decreased significantly (during chemotherapy: p &#60; 0.001, p = 0.002, p = 0.026 and after Chemotherapy: p &#60; 0.001, p &#60; 0.001, p = 0.001, respectively).",VEGF-165,serum,1
"PMC 
BMC_Cancer_2010_Aug_15_10_428.txt
","Methods
Immunohistochemistry was performed using tissue microarrays containing gastric adenocarcinoma specimens from 1,072 Chinese patients with normal adjacent mucosa, primary gastric cancer and lymph node (LN) metastasis and specific antibody against MTSS1.",MTSS1,lymph,-1
"PMC 
BMC_Cancer_2009_Sep_8_9_317.txt
","The cancer stroma contains not only fibromuscular cells but also CD45+ white blood cells, CD31+ endothelial cells of blood vessels, and nerve elements.",CD45,blood,-1
"PMC 
BMC_Cancer_2009_Sep_8_9_317.txt
","The cancer stroma contains not only fibromuscular cells but also CD45+ white blood cells, CD31+ endothelial cells of blood vessels, and nerve elements.",CD45,blood,-1
"PMC 
BMC_Cancer_2009_Sep_8_9_317.txt
","The cancer stroma contains not only fibromuscular cells but also CD45+ white blood cells, CD31+ endothelial cells of blood vessels, and nerve elements.",CD31,blood,-1
"PMC 
BMC_Cancer_2009_Sep_8_9_317.txt
","The cancer stroma contains not only fibromuscular cells but also CD45+ white blood cells, CD31+ endothelial cells of blood vessels, and nerve elements.",CD31,blood,-1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
",All these confounding factors may have weakened the power of serum TRACP 5b activity in reflecting the tumor burden.,TRACP,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","However, 20% of ovarian cancers have low or no expression of CA-125, thus, additional serum markers are required.

",CA-125,serum,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3981991708510.1186/1471-2407-9-398Research ArticleDNA-AP sites generation by Etoposide in whole blood cells Rojas Emilio 1emilior@servidor.unam.mxMussali Patricia 1pmussali@yahoo.com.mxTovar Efrain 2etovar@yahoo.mxValverde Mahara 1mahara@biomedicas.unam.mx1 Departamento de Medicina Genomica y Toxicologia Ambiental Instituto de Investigaciones Biomedicas.",Cancer1471,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3981991708510.1186/1471-2407-9-398Research ArticleDNA-AP sites generation by Etoposide in whole blood cells Rojas Emilio 1emilior@servidor.unam.mxMussali Patricia 1pmussali@yahoo.com.mxTovar Efrain 2etovar@yahoo.mxValverde Mahara 1mahara@biomedicas.unam.mx1 Departamento de Medicina Genomica y Toxicologia Ambiental Instituto de Investigaciones Biomedicas.",BMC,blood,-1
"PMC 
BMC_Cancer_2010_Aug_15_10_428.txt
",Functional analyses of MTSS1 have shown that MTSS1 induced actin-rich protrusions resembling microspikes and lamellipodia at the plasma membrane and promoted disassembly of actin stress fibres [9].,MTSS1,plasma,1
"PMC 
BMC_Cancer_2010_Aug_15_10_428.txt
",Functional analyses of MTSS1 have shown that MTSS1 induced actin-rich protrusions resembling microspikes and lamellipodia at the plasma membrane and promoted disassembly of actin stress fibres [9].,MTSS1,plasma,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Figure 5 Time-to-progression according to presence of liver metastasis

There was a relationship between ORR and the presence of liver metastasis (p = .009) or the elevation of serum NSE (p = .034).",ORR,serum,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Figure 5 Time-to-progression according to presence of liver metastasis

There was a relationship between ORR and the presence of liver metastasis (p = .009) or the elevation of serum NSE (p = .034).",NSE,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","High TIMP-1 concentration after chemotherapy was associated with decreased overall survival (p = 0.007) and patients with large ascites volume had higher TIMP-1 concentrations at this time point (p = 0.032).

",TIMP-1,ascites,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","High TIMP-1 concentration after chemotherapy was associated with decreased overall survival (p = 0.007) and patients with large ascites volume had higher TIMP-1 concentrations at this time point (p = 0.032).

",TIMP-1,ascites,1
"PMC 
BMC_Cancer_2009_Oct_6_9_354.txt
","Several genes (oncogenes, tumor suppressor genes, DNA repair genes and growth control genes) have been shown to have an aberrant methylation profile (promoter hypermethylation) in tumors as compared to normal tissue or blood cells or cells in bodily fluids [4-6].",DNA,blood,-1
"PMC 
BMC_Cancer_2009_Oct_22_9_376.txt
","Fixed cells were blocked in PBS with 1.5% normal horse serum (S-2000; Vector Laboratories, Burlingame, CA) for 30 min at room temperature and were then probed with mouse anti-human CK19 (1:100) antibody for 16 h at 4degC:.",CK19,serum,1
"PMC 
BMC_Cancer_2009_Oct_22_9_376.txt
","Fixed cells were blocked in PBS with 1.5% normal horse serum (S-2000; Vector Laboratories, Burlingame, CA) for 30 min at room temperature and were then probed with mouse anti-human CK19 (1:100) antibody for 16 h at 4degC:.",S-2000,serum,1
"PMC 
BMC_Cancer_2009_Oct_22_9_376.txt
","Fixed cells were blocked in PBS with 1.5% normal horse serum (S-2000; Vector Laboratories, Burlingame, CA) for 30 min at room temperature and were then probed with mouse anti-human CK19 (1:100) antibody for 16 h at 4degC:.",PBS,serum,1
"PMC 
BMC_Cancer_2009_Nov_3_9_389.txt
","21.3	
 IIIA	21.9%	HBsAg Status		
 IIIB	7.5%	 Positive	86.1	
 IV	1.1%	 Negative	13.9	
* Drink and smoking data were self-reported: moderate drinking &#60; = 2 drinks/per day; heavy drinking &#62;2 drinks/per day; moderate smoking &#60; = 1 pack/day; heavy smoking &#62;1 pack/day

Clinicopathological Parameter Measurements
The clinicopathological features of the patients analyzed were sex, age, tumor size, number of tumor nodules, cellular differentiation according to the Edmondson classification, venous infiltration without differentiation into portal or hepatic venules, tumor node metastasis stage (pTNM and AJCC), serum hepatitis B surface antigen (HBsAg) status, and background liver disease in nontumorous liver tissue.",IIIB,serum,1
"PMC 
BMC_Cancer_2009_Nov_3_9_389.txt
","21.3	
 IIIA	21.9%	HBsAg Status		
 IIIB	7.5%	 Positive	86.1	
 IV	1.1%	 Negative	13.9	
* Drink and smoking data were self-reported: moderate drinking &#60; = 2 drinks/per day; heavy drinking &#62;2 drinks/per day; moderate smoking &#60; = 1 pack/day; heavy smoking &#62;1 pack/day

Clinicopathological Parameter Measurements
The clinicopathological features of the patients analyzed were sex, age, tumor size, number of tumor nodules, cellular differentiation according to the Edmondson classification, venous infiltration without differentiation into portal or hepatic venules, tumor node metastasis stage (pTNM and AJCC), serum hepatitis B surface antigen (HBsAg) status, and background liver disease in nontumorous liver tissue.",pTNM,serum,1
"PMC 
BMC_Cancer_2009_Nov_3_9_389.txt
","21.3	
 IIIA	21.9%	HBsAg Status		
 IIIB	7.5%	 Positive	86.1	
 IV	1.1%	 Negative	13.9	
* Drink and smoking data were self-reported: moderate drinking &#60; = 2 drinks/per day; heavy drinking &#62;2 drinks/per day; moderate smoking &#60; = 1 pack/day; heavy smoking &#62;1 pack/day

Clinicopathological Parameter Measurements
The clinicopathological features of the patients analyzed were sex, age, tumor size, number of tumor nodules, cellular differentiation according to the Edmondson classification, venous infiltration without differentiation into portal or hepatic venules, tumor node metastasis stage (pTNM and AJCC), serum hepatitis B surface antigen (HBsAg) status, and background liver disease in nontumorous liver tissue.",IIIA,serum,1
"PMC 
BMC_Cancer_2009_Nov_3_9_389.txt
","21.3	
 IIIA	21.9%	HBsAg Status		
 IIIB	7.5%	 Positive	86.1	
 IV	1.1%	 Negative	13.9	
* Drink and smoking data were self-reported: moderate drinking &#60; = 2 drinks/per day; heavy drinking &#62;2 drinks/per day; moderate smoking &#60; = 1 pack/day; heavy smoking &#62;1 pack/day

Clinicopathological Parameter Measurements
The clinicopathological features of the patients analyzed were sex, age, tumor size, number of tumor nodules, cellular differentiation according to the Edmondson classification, venous infiltration without differentiation into portal or hepatic venules, tumor node metastasis stage (pTNM and AJCC), serum hepatitis B surface antigen (HBsAg) status, and background liver disease in nontumorous liver tissue.",AJCC,serum,1
"PMC 
BMC_Cancer_2009_Nov_13_9_396.txt
","Biospecimens that are collected from over 10607 surgical resections and biopsies, as well as whole blood and DNA samples, are included in the resource.",DNA,blood,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 1 Baseline characteristics of 103 patients

Characteristic	Frequency	%	
	Median (years)	54 (range, 22-78)	
Age	&#60;60	63	61.2	
	>= 60	40	38.8	
	
Sex	Male	58	56.3	
	Female	45	43.7	
	
	Absent	92	89.3	
Carcinoid symptom	Present	5	4.9	
	Unavailable	6	5.8	
	
	Pancreas	26	25.2	
	GI tract	27	26.2	
	 Foregut	11	10.7	
	 Midgut	1	1.0	
Origin	 Hindgut	15	14.6	
	Lung	2	1.9	
	Etc.*	28	27.2	
	Unknown	20	19.4	
	
Initial metastatic site	Liver	50	74.6	
	Bone	12	17.9	
	Lung	12	17.9	
	Brain	3	4.5	
	Lymph node	20	29.9	
	Etc.	10	14.9	
	
Recurrent site	Liver	15	41.7	
	Bone	16	44.4	
	Lung	1	2.8	
	Brain	1	2.8	
	Lymph node	15	41.7	
	Etc.	3	8.3	
	
	Local	21	21.4	
Prior stage	Regional	15	14.6	
	Distant	67	65.0	
	
	1	34	33.0	
	2	1	1.0	
Grade	3	15	14.6	
	Large	9	8.7	
	Small	7	6.8	
	Unclassified	25	24.3	
	Unavailable	12	11.7	
	
		Median (range)	23.0 (2.6-1324.6)	
	24-hour urine 5-HIAA (mmol/day)+	&#60;31.4 (reference range)	15	71.4	
Biomarkers		>= 31.4	6	28.6	
		Median (range)	1.6 (0.4-23.1)	
	Serum NSE (nmol/l)++	&#60;1.0 (reference range)	12	36.4	
		>= 1.0	21	63.6	
GI, gastrointestinal; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase

* The biliary tract (5 cases), thymus (4), uterus (4), mediastinum (3), oral cavity (2), skin (2), trachea (1), liver (1), kidney (1), pelvis (1), prostate (1), bladder (1), nasal cavity (1), and orbit (1)

+ Available data: 21

++",NSE,urine,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 1 Baseline characteristics of 103 patients

Characteristic	Frequency	%	
	Median (years)	54 (range, 22-78)	
Age	&#60;60	63	61.2	
	>= 60	40	38.8	
	
Sex	Male	58	56.3	
	Female	45	43.7	
	
	Absent	92	89.3	
Carcinoid symptom	Present	5	4.9	
	Unavailable	6	5.8	
	
	Pancreas	26	25.2	
	GI tract	27	26.2	
	 Foregut	11	10.7	
	 Midgut	1	1.0	
Origin	 Hindgut	15	14.6	
	Lung	2	1.9	
	Etc.*	28	27.2	
	Unknown	20	19.4	
	
Initial metastatic site	Liver	50	74.6	
	Bone	12	17.9	
	Lung	12	17.9	
	Brain	3	4.5	
	Lymph node	20	29.9	
	Etc.	10	14.9	
	
Recurrent site	Liver	15	41.7	
	Bone	16	44.4	
	Lung	1	2.8	
	Brain	1	2.8	
	Lymph node	15	41.7	
	Etc.	3	8.3	
	
	Local	21	21.4	
Prior stage	Regional	15	14.6	
	Distant	67	65.0	
	
	1	34	33.0	
	2	1	1.0	
Grade	3	15	14.6	
	Large	9	8.7	
	Small	7	6.8	
	Unclassified	25	24.3	
	Unavailable	12	11.7	
	
		Median (range)	23.0 (2.6-1324.6)	
	24-hour urine 5-HIAA (mmol/day)+	&#60;31.4 (reference range)	15	71.4	
Biomarkers		>= 31.4	6	28.6	
		Median (range)	1.6 (0.4-23.1)	
	Serum NSE (nmol/l)++	&#60;1.0 (reference range)	12	36.4	
		>= 1.0	21	63.6	
GI, gastrointestinal; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase

* The biliary tract (5 cases), thymus (4), uterus (4), mediastinum (3), oral cavity (2), skin (2), trachea (1), liver (1), kidney (1), pelvis (1), prostate (1), bladder (1), nasal cavity (1), and orbit (1)

+ Available data: 21

++",NSE,Lymph,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 1 Baseline characteristics of 103 patients

Characteristic	Frequency	%	
	Median (years)	54 (range, 22-78)	
Age	&#60;60	63	61.2	
	>= 60	40	38.8	
	
Sex	Male	58	56.3	
	Female	45	43.7	
	
	Absent	92	89.3	
Carcinoid symptom	Present	5	4.9	
	Unavailable	6	5.8	
	
	Pancreas	26	25.2	
	GI tract	27	26.2	
	 Foregut	11	10.7	
	 Midgut	1	1.0	
Origin	 Hindgut	15	14.6	
	Lung	2	1.9	
	Etc.*	28	27.2	
	Unknown	20	19.4	
	
Initial metastatic site	Liver	50	74.6	
	Bone	12	17.9	
	Lung	12	17.9	
	Brain	3	4.5	
	Lymph node	20	29.9	
	Etc.	10	14.9	
	
Recurrent site	Liver	15	41.7	
	Bone	16	44.4	
	Lung	1	2.8	
	Brain	1	2.8	
	Lymph node	15	41.7	
	Etc.	3	8.3	
	
	Local	21	21.4	
Prior stage	Regional	15	14.6	
	Distant	67	65.0	
	
	1	34	33.0	
	2	1	1.0	
Grade	3	15	14.6	
	Large	9	8.7	
	Small	7	6.8	
	Unclassified	25	24.3	
	Unavailable	12	11.7	
	
		Median (range)	23.0 (2.6-1324.6)	
	24-hour urine 5-HIAA (mmol/day)+	&#60;31.4 (reference range)	15	71.4	
Biomarkers		>= 31.4	6	28.6	
		Median (range)	1.6 (0.4-23.1)	
	Serum NSE (nmol/l)++	&#60;1.0 (reference range)	12	36.4	
		>= 1.0	21	63.6	
GI, gastrointestinal; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase

* The biliary tract (5 cases), thymus (4), uterus (4), mediastinum (3), oral cavity (2), skin (2), trachea (1), liver (1), kidney (1), pelvis (1), prostate (1), bladder (1), nasal cavity (1), and orbit (1)

+ Available data: 21

++",NSE,Serum,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 1 Baseline characteristics of 103 patients

Characteristic	Frequency	%	
	Median (years)	54 (range, 22-78)	
Age	&#60;60	63	61.2	
	>= 60	40	38.8	
	
Sex	Male	58	56.3	
	Female	45	43.7	
	
	Absent	92	89.3	
Carcinoid symptom	Present	5	4.9	
	Unavailable	6	5.8	
	
	Pancreas	26	25.2	
	GI tract	27	26.2	
	 Foregut	11	10.7	
	 Midgut	1	1.0	
Origin	 Hindgut	15	14.6	
	Lung	2	1.9	
	Etc.*	28	27.2	
	Unknown	20	19.4	
	
Initial metastatic site	Liver	50	74.6	
	Bone	12	17.9	
	Lung	12	17.9	
	Brain	3	4.5	
	Lymph node	20	29.9	
	Etc.	10	14.9	
	
Recurrent site	Liver	15	41.7	
	Bone	16	44.4	
	Lung	1	2.8	
	Brain	1	2.8	
	Lymph node	15	41.7	
	Etc.	3	8.3	
	
	Local	21	21.4	
Prior stage	Regional	15	14.6	
	Distant	67	65.0	
	
	1	34	33.0	
	2	1	1.0	
Grade	3	15	14.6	
	Large	9	8.7	
	Small	7	6.8	
	Unclassified	25	24.3	
	Unavailable	12	11.7	
	
		Median (range)	23.0 (2.6-1324.6)	
	24-hour urine 5-HIAA (mmol/day)+	&#60;31.4 (reference range)	15	71.4	
Biomarkers		>= 31.4	6	28.6	
		Median (range)	1.6 (0.4-23.1)	
	Serum NSE (nmol/l)++	&#60;1.0 (reference range)	12	36.4	
		>= 1.0	21	63.6	
GI, gastrointestinal; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase

* The biliary tract (5 cases), thymus (4), uterus (4), mediastinum (3), oral cavity (2), skin (2), trachea (1), liver (1), kidney (1), pelvis (1), prostate (1), bladder (1), nasal cavity (1), and orbit (1)

+ Available data: 21

++",NSE,Lymph,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 1 Baseline characteristics of 103 patients

Characteristic	Frequency	%	
	Median (years)	54 (range, 22-78)	
Age	&#60;60	63	61.2	
	>= 60	40	38.8	
	
Sex	Male	58	56.3	
	Female	45	43.7	
	
	Absent	92	89.3	
Carcinoid symptom	Present	5	4.9	
	Unavailable	6	5.8	
	
	Pancreas	26	25.2	
	GI tract	27	26.2	
	 Foregut	11	10.7	
	 Midgut	1	1.0	
Origin	 Hindgut	15	14.6	
	Lung	2	1.9	
	Etc.*	28	27.2	
	Unknown	20	19.4	
	
Initial metastatic site	Liver	50	74.6	
	Bone	12	17.9	
	Lung	12	17.9	
	Brain	3	4.5	
	Lymph node	20	29.9	
	Etc.	10	14.9	
	
Recurrent site	Liver	15	41.7	
	Bone	16	44.4	
	Lung	1	2.8	
	Brain	1	2.8	
	Lymph node	15	41.7	
	Etc.	3	8.3	
	
	Local	21	21.4	
Prior stage	Regional	15	14.6	
	Distant	67	65.0	
	
	1	34	33.0	
	2	1	1.0	
Grade	3	15	14.6	
	Large	9	8.7	
	Small	7	6.8	
	Unclassified	25	24.3	
	Unavailable	12	11.7	
	
		Median (range)	23.0 (2.6-1324.6)	
	24-hour urine 5-HIAA (mmol/day)+	&#60;31.4 (reference range)	15	71.4	
Biomarkers		>= 31.4	6	28.6	
		Median (range)	1.6 (0.4-23.1)	
	Serum NSE (nmol/l)++	&#60;1.0 (reference range)	12	36.4	
		>= 1.0	21	63.6	
GI, gastrointestinal; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase

* The biliary tract (5 cases), thymus (4), uterus (4), mediastinum (3), oral cavity (2), skin (2), trachea (1), liver (1), kidney (1), pelvis (1), prostate (1), bladder (1), nasal cavity (1), and orbit (1)

+ Available data: 21

++",NSE,urine,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 1 Baseline characteristics of 103 patients

Characteristic	Frequency	%	
	Median (years)	54 (range, 22-78)	
Age	&#60;60	63	61.2	
	>= 60	40	38.8	
	
Sex	Male	58	56.3	
	Female	45	43.7	
	
	Absent	92	89.3	
Carcinoid symptom	Present	5	4.9	
	Unavailable	6	5.8	
	
	Pancreas	26	25.2	
	GI tract	27	26.2	
	 Foregut	11	10.7	
	 Midgut	1	1.0	
Origin	 Hindgut	15	14.6	
	Lung	2	1.9	
	Etc.*	28	27.2	
	Unknown	20	19.4	
	
Initial metastatic site	Liver	50	74.6	
	Bone	12	17.9	
	Lung	12	17.9	
	Brain	3	4.5	
	Lymph node	20	29.9	
	Etc.	10	14.9	
	
Recurrent site	Liver	15	41.7	
	Bone	16	44.4	
	Lung	1	2.8	
	Brain	1	2.8	
	Lymph node	15	41.7	
	Etc.	3	8.3	
	
	Local	21	21.4	
Prior stage	Regional	15	14.6	
	Distant	67	65.0	
	
	1	34	33.0	
	2	1	1.0	
Grade	3	15	14.6	
	Large	9	8.7	
	Small	7	6.8	
	Unclassified	25	24.3	
	Unavailable	12	11.7	
	
		Median (range)	23.0 (2.6-1324.6)	
	24-hour urine 5-HIAA (mmol/day)+	&#60;31.4 (reference range)	15	71.4	
Biomarkers		>= 31.4	6	28.6	
		Median (range)	1.6 (0.4-23.1)	
	Serum NSE (nmol/l)++	&#60;1.0 (reference range)	12	36.4	
		>= 1.0	21	63.6	
GI, gastrointestinal; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase

* The biliary tract (5 cases), thymus (4), uterus (4), mediastinum (3), oral cavity (2), skin (2), trachea (1), liver (1), kidney (1), pelvis (1), prostate (1), bladder (1), nasal cavity (1), and orbit (1)

+ Available data: 21

++",NSE,Lymph,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 1 Baseline characteristics of 103 patients

Characteristic	Frequency	%	
	Median (years)	54 (range, 22-78)	
Age	&#60;60	63	61.2	
	>= 60	40	38.8	
	
Sex	Male	58	56.3	
	Female	45	43.7	
	
	Absent	92	89.3	
Carcinoid symptom	Present	5	4.9	
	Unavailable	6	5.8	
	
	Pancreas	26	25.2	
	GI tract	27	26.2	
	 Foregut	11	10.7	
	 Midgut	1	1.0	
Origin	 Hindgut	15	14.6	
	Lung	2	1.9	
	Etc.*	28	27.2	
	Unknown	20	19.4	
	
Initial metastatic site	Liver	50	74.6	
	Bone	12	17.9	
	Lung	12	17.9	
	Brain	3	4.5	
	Lymph node	20	29.9	
	Etc.	10	14.9	
	
Recurrent site	Liver	15	41.7	
	Bone	16	44.4	
	Lung	1	2.8	
	Brain	1	2.8	
	Lymph node	15	41.7	
	Etc.	3	8.3	
	
	Local	21	21.4	
Prior stage	Regional	15	14.6	
	Distant	67	65.0	
	
	1	34	33.0	
	2	1	1.0	
Grade	3	15	14.6	
	Large	9	8.7	
	Small	7	6.8	
	Unclassified	25	24.3	
	Unavailable	12	11.7	
	
		Median (range)	23.0 (2.6-1324.6)	
	24-hour urine 5-HIAA (mmol/day)+	&#60;31.4 (reference range)	15	71.4	
Biomarkers		>= 31.4	6	28.6	
		Median (range)	1.6 (0.4-23.1)	
	Serum NSE (nmol/l)++	&#60;1.0 (reference range)	12	36.4	
		>= 1.0	21	63.6	
GI, gastrointestinal; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase

* The biliary tract (5 cases), thymus (4), uterus (4), mediastinum (3), oral cavity (2), skin (2), trachea (1), liver (1), kidney (1), pelvis (1), prostate (1), bladder (1), nasal cavity (1), and orbit (1)

+ Available data: 21

++",NSE,Serum,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 1 Baseline characteristics of 103 patients

Characteristic	Frequency	%	
	Median (years)	54 (range, 22-78)	
Age	&#60;60	63	61.2	
	>= 60	40	38.8	
	
Sex	Male	58	56.3	
	Female	45	43.7	
	
	Absent	92	89.3	
Carcinoid symptom	Present	5	4.9	
	Unavailable	6	5.8	
	
	Pancreas	26	25.2	
	GI tract	27	26.2	
	 Foregut	11	10.7	
	 Midgut	1	1.0	
Origin	 Hindgut	15	14.6	
	Lung	2	1.9	
	Etc.*	28	27.2	
	Unknown	20	19.4	
	
Initial metastatic site	Liver	50	74.6	
	Bone	12	17.9	
	Lung	12	17.9	
	Brain	3	4.5	
	Lymph node	20	29.9	
	Etc.	10	14.9	
	
Recurrent site	Liver	15	41.7	
	Bone	16	44.4	
	Lung	1	2.8	
	Brain	1	2.8	
	Lymph node	15	41.7	
	Etc.	3	8.3	
	
	Local	21	21.4	
Prior stage	Regional	15	14.6	
	Distant	67	65.0	
	
	1	34	33.0	
	2	1	1.0	
Grade	3	15	14.6	
	Large	9	8.7	
	Small	7	6.8	
	Unclassified	25	24.3	
	Unavailable	12	11.7	
	
		Median (range)	23.0 (2.6-1324.6)	
	24-hour urine 5-HIAA (mmol/day)+	&#60;31.4 (reference range)	15	71.4	
Biomarkers		>= 31.4	6	28.6	
		Median (range)	1.6 (0.4-23.1)	
	Serum NSE (nmol/l)++	&#60;1.0 (reference range)	12	36.4	
		>= 1.0	21	63.6	
GI, gastrointestinal; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase

* The biliary tract (5 cases), thymus (4), uterus (4), mediastinum (3), oral cavity (2), skin (2), trachea (1), liver (1), kidney (1), pelvis (1), prostate (1), bladder (1), nasal cavity (1), and orbit (1)

+ Available data: 21

++",NSE,Lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","The baseline work-up before neoadjuvant chemotherapy included a complete history and clinical examination, bilateral mammography, bilateral breast and axillary ultrasound, and percutaneous cytology of lymph nodes by fine-needle aspiration (FNA) to assess potential clinically suspicious lymph node involvement.

",FNA,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","The baseline work-up before neoadjuvant chemotherapy included a complete history and clinical examination, bilateral mammography, bilateral breast and axillary ultrasound, and percutaneous cytology of lymph nodes by fine-needle aspiration (FNA) to assess potential clinically suspicious lymph node involvement.

",FNA,lymph,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Moreover, blood d-ALA-D activity seems to be an additional biomarker of oxidative stress in BMT patients.

",BMT,blood,1
"PMC 
BMC_Cancer_2010_Apr_27_10_161.txt
",PBS replaced the murine polyclonal anti-HCCR serum (1:100) as a negative control.,HCCR,serum,1
"PMC 
BMC_Cancer_2010_Apr_27_10_161.txt
",PBS replaced the murine polyclonal anti-HCCR serum (1:100) as a negative control.,PBS,serum,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
",Blood d-ALA-D activity before the CR in both patient groups was similar to that of the control group and chemotherapy or radiochemotherapy (CR) led to a decrease in d-ALA-D activity over time in the patient groups.,CR,Blood,-1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
",Blood d-ALA-D activity before the CR in both patient groups was similar to that of the control group and chemotherapy or radiochemotherapy (CR) led to a decrease in d-ALA-D activity over time in the patient groups.,CR,Blood,-1
"PMC 
BMC_Cancer_2010_Apr_21_10_155.txt
","Heart rate and O2 saturation will be monitored continuously throughout exercise while blood pressure will be assessed prior, during, and immediately following each exercise session.",O2,blood,-1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Finally, d-ALA-D inhibition can result in ALA accumulation, which can have pro-oxidant effects [52] and contribute to oxidative stress caused by the CR and also by the bone marrow transplantation itself.",CR,bone marrow,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Finally, d-ALA-D inhibition can result in ALA accumulation, which can have pro-oxidant effects [52] and contribute to oxidative stress caused by the CR and also by the bone marrow transplantation itself.",ALA,bone marrow,1
"PMC 
BMC_Cancer_2010_Apr_28_10_168.txt
","PI Synthase increased the cellular levels of Akt kinase in serum-stimulated quiescent NIH3T3 cells, decreased doubling time and potentiated colony formation in soft agar [27].",NIH3T3,serum,1
"PMC 
BMC_Cancer_2010_Apr_18_10_148.txt
","Briefly, the sections were: (a) rinsed in a wash buffer; (b) treated with 3% H2O2 in ddH2O for 5 min and rinsed in a wash buffer; (c) blocked with the Universal IHC Blocking/Diluent for 30 min and rinsed in a wash buffer; (d) incubated for 30 min with the rabbit anti-human CA II serum, rabbit-anti human CA XII serum, monoclonal M75 antibody or NRS diluted 1:2000 (rabbit sera) or 1:1000 (M75) in Universal IHC Blocking/Diluent;",IHC,serum,1
"PMC 
BMC_Cancer_2010_Apr_18_10_148.txt
","Briefly, the sections were: (a) rinsed in a wash buffer; (b) treated with 3% H2O2 in ddH2O for 5 min and rinsed in a wash buffer; (c) blocked with the Universal IHC Blocking/Diluent for 30 min and rinsed in a wash buffer; (d) incubated for 30 min with the rabbit anti-human CA II serum, rabbit-anti human CA XII serum, monoclonal M75 antibody or NRS diluted 1:2000 (rabbit sera) or 1:1000 (M75) in Universal IHC Blocking/Diluent;",IHC,sera,1
"PMC 
BMC_Cancer_2010_Apr_18_10_148.txt
","Briefly, the sections were: (a) rinsed in a wash buffer; (b) treated with 3% H2O2 in ddH2O for 5 min and rinsed in a wash buffer; (c) blocked with the Universal IHC Blocking/Diluent for 30 min and rinsed in a wash buffer; (d) incubated for 30 min with the rabbit anti-human CA II serum, rabbit-anti human CA XII serum, monoclonal M75 antibody or NRS diluted 1:2000 (rabbit sera) or 1:1000 (M75) in Universal IHC Blocking/Diluent;",IHC,serum,1
"PMC 
BMC_Cancer_2010_Apr_18_10_148.txt
","Briefly, the sections were: (a) rinsed in a wash buffer; (b) treated with 3% H2O2 in ddH2O for 5 min and rinsed in a wash buffer; (c) blocked with the Universal IHC Blocking/Diluent for 30 min and rinsed in a wash buffer; (d) incubated for 30 min with the rabbit anti-human CA II serum, rabbit-anti human CA XII serum, monoclonal M75 antibody or NRS diluted 1:2000 (rabbit sera) or 1:1000 (M75) in Universal IHC Blocking/Diluent;",NRS,serum,1
"PMC 
BMC_Cancer_2010_Apr_18_10_148.txt
","Briefly, the sections were: (a) rinsed in a wash buffer; (b) treated with 3% H2O2 in ddH2O for 5 min and rinsed in a wash buffer; (c) blocked with the Universal IHC Blocking/Diluent for 30 min and rinsed in a wash buffer; (d) incubated for 30 min with the rabbit anti-human CA II serum, rabbit-anti human CA XII serum, monoclonal M75 antibody or NRS diluted 1:2000 (rabbit sera) or 1:1000 (M75) in Universal IHC Blocking/Diluent;",NRS,sera,1
"PMC 
BMC_Cancer_2010_Apr_18_10_148.txt
","Briefly, the sections were: (a) rinsed in a wash buffer; (b) treated with 3% H2O2 in ddH2O for 5 min and rinsed in a wash buffer; (c) blocked with the Universal IHC Blocking/Diluent for 30 min and rinsed in a wash buffer; (d) incubated for 30 min with the rabbit anti-human CA II serum, rabbit-anti human CA XII serum, monoclonal M75 antibody or NRS diluted 1:2000 (rabbit sera) or 1:1000 (M75) in Universal IHC Blocking/Diluent;",NRS,serum,1
"PMC 
BMC_Cancer_2010_Apr_18_10_148.txt
","Briefly, the sections were: (a) rinsed in a wash buffer; (b) treated with 3% H2O2 in ddH2O for 5 min and rinsed in a wash buffer; (c) blocked with the Universal IHC Blocking/Diluent for 30 min and rinsed in a wash buffer; (d) incubated for 30 min with the rabbit anti-human CA II serum, rabbit-anti human CA XII serum, monoclonal M75 antibody or NRS diluted 1:2000 (rabbit sera) or 1:1000 (M75) in Universal IHC Blocking/Diluent;",XII,serum,1
"PMC 
BMC_Cancer_2010_Apr_18_10_148.txt
","Briefly, the sections were: (a) rinsed in a wash buffer; (b) treated with 3% H2O2 in ddH2O for 5 min and rinsed in a wash buffer; (c) blocked with the Universal IHC Blocking/Diluent for 30 min and rinsed in a wash buffer; (d) incubated for 30 min with the rabbit anti-human CA II serum, rabbit-anti human CA XII serum, monoclonal M75 antibody or NRS diluted 1:2000 (rabbit sera) or 1:1000 (M75) in Universal IHC Blocking/Diluent;",XII,sera,1
"PMC 
BMC_Cancer_2010_Apr_18_10_148.txt
","Briefly, the sections were: (a) rinsed in a wash buffer; (b) treated with 3% H2O2 in ddH2O for 5 min and rinsed in a wash buffer; (c) blocked with the Universal IHC Blocking/Diluent for 30 min and rinsed in a wash buffer; (d) incubated for 30 min with the rabbit anti-human CA II serum, rabbit-anti human CA XII serum, monoclonal M75 antibody or NRS diluted 1:2000 (rabbit sera) or 1:1000 (M75) in Universal IHC Blocking/Diluent;",XII,serum,1
"PMC 
BMC_Cancer_2010_Apr_18_10_148.txt
","Briefly, the sections were: (a) rinsed in a wash buffer; (b) treated with 3% H2O2 in ddH2O for 5 min and rinsed in a wash buffer; (c) blocked with the Universal IHC Blocking/Diluent for 30 min and rinsed in a wash buffer; (d) incubated for 30 min with the rabbit anti-human CA II serum, rabbit-anti human CA XII serum, monoclonal M75 antibody or NRS diluted 1:2000 (rabbit sera) or 1:1000 (M75) in Universal IHC Blocking/Diluent;",M75,serum,1
"PMC 
BMC_Cancer_2010_Apr_18_10_148.txt
","Briefly, the sections were: (a) rinsed in a wash buffer; (b) treated with 3% H2O2 in ddH2O for 5 min and rinsed in a wash buffer; (c) blocked with the Universal IHC Blocking/Diluent for 30 min and rinsed in a wash buffer; (d) incubated for 30 min with the rabbit anti-human CA II serum, rabbit-anti human CA XII serum, monoclonal M75 antibody or NRS diluted 1:2000 (rabbit sera) or 1:1000 (M75) in Universal IHC Blocking/Diluent;",M75,sera,1
"PMC 
BMC_Cancer_2010_Apr_18_10_148.txt
","Briefly, the sections were: (a) rinsed in a wash buffer; (b) treated with 3% H2O2 in ddH2O for 5 min and rinsed in a wash buffer; (c) blocked with the Universal IHC Blocking/Diluent for 30 min and rinsed in a wash buffer; (d) incubated for 30 min with the rabbit anti-human CA II serum, rabbit-anti human CA XII serum, monoclonal M75 antibody or NRS diluted 1:2000 (rabbit sera) or 1:1000 (M75) in Universal IHC Blocking/Diluent;",M75,serum,1
"PMC 
BMC_Cancer_2010_Apr_18_10_148.txt
","Briefly, the sections were: (a) rinsed in a wash buffer; (b) treated with 3% H2O2 in ddH2O for 5 min and rinsed in a wash buffer; (c) blocked with the Universal IHC Blocking/Diluent for 30 min and rinsed in a wash buffer; (d) incubated for 30 min with the rabbit anti-human CA II serum, rabbit-anti human CA XII serum, monoclonal M75 antibody or NRS diluted 1:2000 (rabbit sera) or 1:1000 (M75) in Universal IHC Blocking/Diluent;",IHC,serum,1
"PMC 
BMC_Cancer_2010_Apr_18_10_148.txt
","Briefly, the sections were: (a) rinsed in a wash buffer; (b) treated with 3% H2O2 in ddH2O for 5 min and rinsed in a wash buffer; (c) blocked with the Universal IHC Blocking/Diluent for 30 min and rinsed in a wash buffer; (d) incubated for 30 min with the rabbit anti-human CA II serum, rabbit-anti human CA XII serum, monoclonal M75 antibody or NRS diluted 1:2000 (rabbit sera) or 1:1000 (M75) in Universal IHC Blocking/Diluent;",IHC,sera,1
"PMC 
BMC_Cancer_2010_Apr_18_10_148.txt
","Briefly, the sections were: (a) rinsed in a wash buffer; (b) treated with 3% H2O2 in ddH2O for 5 min and rinsed in a wash buffer; (c) blocked with the Universal IHC Blocking/Diluent for 30 min and rinsed in a wash buffer; (d) incubated for 30 min with the rabbit anti-human CA II serum, rabbit-anti human CA XII serum, monoclonal M75 antibody or NRS diluted 1:2000 (rabbit sera) or 1:1000 (M75) in Universal IHC Blocking/Diluent;",IHC,serum,1
"PMC 
BMC_Cancer_2010_Apr_18_10_148.txt
","Briefly, the sections were: (a) rinsed in a wash buffer; (b) treated with 3% H2O2 in ddH2O for 5 min and rinsed in a wash buffer; (c) blocked with the Universal IHC Blocking/Diluent for 30 min and rinsed in a wash buffer; (d) incubated for 30 min with the rabbit anti-human CA II serum, rabbit-anti human CA XII serum, monoclonal M75 antibody or NRS diluted 1:2000 (rabbit sera) or 1:1000 (M75) in Universal IHC Blocking/Diluent;",M75,serum,1
"PMC 
BMC_Cancer_2010_Apr_18_10_148.txt
","Briefly, the sections were: (a) rinsed in a wash buffer; (b) treated with 3% H2O2 in ddH2O for 5 min and rinsed in a wash buffer; (c) blocked with the Universal IHC Blocking/Diluent for 30 min and rinsed in a wash buffer; (d) incubated for 30 min with the rabbit anti-human CA II serum, rabbit-anti human CA XII serum, monoclonal M75 antibody or NRS diluted 1:2000 (rabbit sera) or 1:1000 (M75) in Universal IHC Blocking/Diluent;",M75,sera,1
"PMC 
BMC_Cancer_2010_Apr_18_10_148.txt
","Briefly, the sections were: (a) rinsed in a wash buffer; (b) treated with 3% H2O2 in ddH2O for 5 min and rinsed in a wash buffer; (c) blocked with the Universal IHC Blocking/Diluent for 30 min and rinsed in a wash buffer; (d) incubated for 30 min with the rabbit anti-human CA II serum, rabbit-anti human CA XII serum, monoclonal M75 antibody or NRS diluted 1:2000 (rabbit sera) or 1:1000 (M75) in Universal IHC Blocking/Diluent;",M75,serum,1
"PMC 
BMC_Cancer_2010_Apr_18_10_148.txt
","Briefly, the sections were: (a) rinsed in a wash buffer; (b) treated with 3% H2O2 in ddH2O for 5 min and rinsed in a wash buffer; (c) blocked with the Universal IHC Blocking/Diluent for 30 min and rinsed in a wash buffer; (d) incubated for 30 min with the rabbit anti-human CA II serum, rabbit-anti human CA XII serum, monoclonal M75 antibody or NRS diluted 1:2000 (rabbit sera) or 1:1000 (M75) in Universal IHC Blocking/Diluent;",H2O2,serum,1
"PMC 
BMC_Cancer_2010_Apr_18_10_148.txt
","Briefly, the sections were: (a) rinsed in a wash buffer; (b) treated with 3% H2O2 in ddH2O for 5 min and rinsed in a wash buffer; (c) blocked with the Universal IHC Blocking/Diluent for 30 min and rinsed in a wash buffer; (d) incubated for 30 min with the rabbit anti-human CA II serum, rabbit-anti human CA XII serum, monoclonal M75 antibody or NRS diluted 1:2000 (rabbit sera) or 1:1000 (M75) in Universal IHC Blocking/Diluent;",H2O2,sera,1
"PMC 
BMC_Cancer_2010_Apr_18_10_148.txt
","Briefly, the sections were: (a) rinsed in a wash buffer; (b) treated with 3% H2O2 in ddH2O for 5 min and rinsed in a wash buffer; (c) blocked with the Universal IHC Blocking/Diluent for 30 min and rinsed in a wash buffer; (d) incubated for 30 min with the rabbit anti-human CA II serum, rabbit-anti human CA XII serum, monoclonal M75 antibody or NRS diluted 1:2000 (rabbit sera) or 1:1000 (M75) in Universal IHC Blocking/Diluent;",H2O2,serum,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","The fused cells were resuspended in DMEM medium (Gibco BRL life technologies) supplemented with 10% bovine calf serum, 100 U/ml penicillin, 100 mg/ml streptomycin, 50 mM hypoxanthine, 160 mM thymidine, and 400 nM aminopterin.",DMEM,serum,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","The fused cells were resuspended in DMEM medium (Gibco BRL life technologies) supplemented with 10% bovine calf serum, 100 U/ml penicillin, 100 mg/ml streptomycin, 50 mM hypoxanthine, 160 mM thymidine, and 400 nM aminopterin.",BRL,serum,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","These findings were recently extended from Wu et al, who reported that serum MMP-9 levels were significantly elevated in patients with breast cancer compared to those with benign breast disease and healthy controls.",MMP-9,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
",It was shown that the serum levels of VEGF are significantly elevated in patients with epithelial ovarian cancer compared to levels in patients with benign disease [33].,VEGF,serum,1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","EDTA-anti-coagulated blood (100 mL) was incubated for 30 min at 4degC with 5 mL phycoerythrin-conjugated anti-Flk-1 (Miltenyi Biotec, Germany), PerCP-conjugated anti-c-Kit, or FITC-conjugated anti-Sca-1 (Beckton Dickinson, Heidelberg, Germany). IgG1-FITC and IgG2a-phycoerythrin antibodies (B&D) served as isotype controls for each procedure.",EDTA,blood,1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","EDTA-anti-coagulated blood (100 mL) was incubated for 30 min at 4degC with 5 mL phycoerythrin-conjugated anti-Flk-1 (Miltenyi Biotec, Germany), PerCP-conjugated anti-c-Kit, or FITC-conjugated anti-Sca-1 (Beckton Dickinson, Heidelberg, Germany). IgG1-FITC and IgG2a-phycoerythrin antibodies (B&D) served as isotype controls for each procedure.",Flk-1,blood,1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","EDTA-anti-coagulated blood (100 mL) was incubated for 30 min at 4degC with 5 mL phycoerythrin-conjugated anti-Flk-1 (Miltenyi Biotec, Germany), PerCP-conjugated anti-c-Kit, or FITC-conjugated anti-Sca-1 (Beckton Dickinson, Heidelberg, Germany). IgG1-FITC and IgG2a-phycoerythrin antibodies (B&D) served as isotype controls for each procedure.",FITC,blood,1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","EDTA-anti-coagulated blood (100 mL) was incubated for 30 min at 4degC with 5 mL phycoerythrin-conjugated anti-Flk-1 (Miltenyi Biotec, Germany), PerCP-conjugated anti-c-Kit, or FITC-conjugated anti-Sca-1 (Beckton Dickinson, Heidelberg, Germany). IgG1-FITC and IgG2a-phycoerythrin antibodies (B&D) served as isotype controls for each procedure.",Sca-1,blood,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
",Figure 4 Percentage of DNA-AP sites relative to controls evidenced by Exo III in non-stimulated blood cells treated for 2-h and PHA-stimulated blood cells treated 24-h with etoposide.,DNA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
",Figure 4 Percentage of DNA-AP sites relative to controls evidenced by Exo III in non-stimulated blood cells treated for 2-h and PHA-stimulated blood cells treated 24-h with etoposide.,DNA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
",Figure 4 Percentage of DNA-AP sites relative to controls evidenced by Exo III in non-stimulated blood cells treated for 2-h and PHA-stimulated blood cells treated 24-h with etoposide.,PHA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
",Figure 4 Percentage of DNA-AP sites relative to controls evidenced by Exo III in non-stimulated blood cells treated for 2-h and PHA-stimulated blood cells treated 24-h with etoposide.,PHA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
",Figure 4 Percentage of DNA-AP sites relative to controls evidenced by Exo III in non-stimulated blood cells treated for 2-h and PHA-stimulated blood cells treated 24-h with etoposide.,III,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
",Figure 4 Percentage of DNA-AP sites relative to controls evidenced by Exo III in non-stimulated blood cells treated for 2-h and PHA-stimulated blood cells treated 24-h with etoposide.,III,blood,-1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","Serum TRACP 5b Activity Assay
Serum from each patient had been collected and processed at diagnosis of bone metastasis and monthly thereafter for 6 months or until death as described in previous studies [12,13].",TRACP,Serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","Serum TRACP 5b Activity Assay
Serum from each patient had been collected and processed at diagnosis of bone metastasis and monthly thereafter for 6 months or until death as described in previous studies [12,13].",TRACP,Serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","Whereas in those patients with lower activities, serum TRACP 5b may not be useful as a prognostic factor.",TRACP,serum,1
"PMC 
BMC_Cancer_2009_Nov_3_9_389.txt
","Results
Our findings based on the training set data reveal 6 common clinicopathologic parameters (tumor size, number of tumor nodules, tumor stage, venous infiltration status, and serum a-fetoprotein and total albumin levels) that were significantly associated with the overall HCC survival and disease-free survival (time to recurrence).",HCC,serum,1
"PMC 
BMC_Cancer_2009_May_6_9_134.txt
","In addition, serum NGAL measurement by ELISA is fairly accurate in distinguishing pancreatic cancer from non-cancer cases and could be investigated as a marker of pancreatic intraepithelial neoplasia (PIN) for early diagnosis of pancreatic cancer[30].",NGAL,serum,1
"PMC 
BMC_Cancer_2009_May_6_9_134.txt
","In addition, serum NGAL measurement by ELISA is fairly accurate in distinguishing pancreatic cancer from non-cancer cases and could be investigated as a marker of pancreatic intraepithelial neoplasia (PIN) for early diagnosis of pancreatic cancer[30].",ELISA,serum,1
"PMC 
BMC_Cancer_2009_May_6_9_134.txt
","In addition, serum NGAL measurement by ELISA is fairly accurate in distinguishing pancreatic cancer from non-cancer cases and could be investigated as a marker of pancreatic intraepithelial neoplasia (PIN) for early diagnosis of pancreatic cancer[30].",PIN,serum,1
"PMC 
BMC_Cancer_2009_May_6_9_134.txt
","This raises the possibility that serum and urine NGAL measurement (or combination with other potential biomarkers such as MMP-9) could also be explored as a utility for detecting disease status, progression, and therapeutic efficacy through noninvasive surveillance in rectal cancers, which deserves our attention.

",NGAL,serum,1
"PMC 
BMC_Cancer_2009_May_6_9_134.txt
","This raises the possibility that serum and urine NGAL measurement (or combination with other potential biomarkers such as MMP-9) could also be explored as a utility for detecting disease status, progression, and therapeutic efficacy through noninvasive surveillance in rectal cancers, which deserves our attention.

",NGAL,urine,1
"PMC 
BMC_Cancer_2009_May_6_9_134.txt
","This raises the possibility that serum and urine NGAL measurement (or combination with other potential biomarkers such as MMP-9) could also be explored as a utility for detecting disease status, progression, and therapeutic efficacy through noninvasive surveillance in rectal cancers, which deserves our attention.

",MMP-9,serum,1
"PMC 
BMC_Cancer_2009_May_6_9_134.txt
","This raises the possibility that serum and urine NGAL measurement (or combination with other potential biomarkers such as MMP-9) could also be explored as a utility for detecting disease status, progression, and therapeutic efficacy through noninvasive surveillance in rectal cancers, which deserves our attention.

",MMP-9,urine,1
"PMC 
BMC_Cancer_2009_May_6_9_134.txt
","Fernandez et al have demonstrated that NGAL and MMP-9 complexes were identified in nearly 86.36% of urine sample from breast cancer patients whereas this molecule is undetectable in the urine of healthy controls, suggesting that urinary NGAL may represent a novel, non-invasive biomarker for tracking disease status and the effectiveness of anticancer therapy in NGAL positive breast carcinomas[12].",MMP-9,urine,1
"PMC 
BMC_Cancer_2009_May_6_9_134.txt
","Fernandez et al have demonstrated that NGAL and MMP-9 complexes were identified in nearly 86.36% of urine sample from breast cancer patients whereas this molecule is undetectable in the urine of healthy controls, suggesting that urinary NGAL may represent a novel, non-invasive biomarker for tracking disease status and the effectiveness of anticancer therapy in NGAL positive breast carcinomas[12].",MMP-9,urine,1
"PMC 
BMC_Cancer_2009_May_6_9_134.txt
","Fernandez et al have demonstrated that NGAL and MMP-9 complexes were identified in nearly 86.36% of urine sample from breast cancer patients whereas this molecule is undetectable in the urine of healthy controls, suggesting that urinary NGAL may represent a novel, non-invasive biomarker for tracking disease status and the effectiveness of anticancer therapy in NGAL positive breast carcinomas[12].",NGAL,urine,1
"PMC 
BMC_Cancer_2009_May_6_9_134.txt
","Fernandez et al have demonstrated that NGAL and MMP-9 complexes were identified in nearly 86.36% of urine sample from breast cancer patients whereas this molecule is undetectable in the urine of healthy controls, suggesting that urinary NGAL may represent a novel, non-invasive biomarker for tracking disease status and the effectiveness of anticancer therapy in NGAL positive breast carcinomas[12].",NGAL,urine,1
"PMC 
BMC_Cancer_2009_May_6_9_134.txt
","Fernandez et al have demonstrated that NGAL and MMP-9 complexes were identified in nearly 86.36% of urine sample from breast cancer patients whereas this molecule is undetectable in the urine of healthy controls, suggesting that urinary NGAL may represent a novel, non-invasive biomarker for tracking disease status and the effectiveness of anticancer therapy in NGAL positive breast carcinomas[12].",NGAL,urine,1
"PMC 
BMC_Cancer_2009_May_6_9_134.txt
","Fernandez et al have demonstrated that NGAL and MMP-9 complexes were identified in nearly 86.36% of urine sample from breast cancer patients whereas this molecule is undetectable in the urine of healthy controls, suggesting that urinary NGAL may represent a novel, non-invasive biomarker for tracking disease status and the effectiveness of anticancer therapy in NGAL positive breast carcinomas[12].",NGAL,urine,1
"PMC 
BMC_Cancer_2009_May_6_9_134.txt
","Fernandez et al have demonstrated that NGAL and MMP-9 complexes were identified in nearly 86.36% of urine sample from breast cancer patients whereas this molecule is undetectable in the urine of healthy controls, suggesting that urinary NGAL may represent a novel, non-invasive biomarker for tracking disease status and the effectiveness of anticancer therapy in NGAL positive breast carcinomas[12].",NGAL,urine,1
"PMC 
BMC_Cancer_2009_May_6_9_134.txt
","Fernandez et al have demonstrated that NGAL and MMP-9 complexes were identified in nearly 86.36% of urine sample from breast cancer patients whereas this molecule is undetectable in the urine of healthy controls, suggesting that urinary NGAL may represent a novel, non-invasive biomarker for tracking disease status and the effectiveness of anticancer therapy in NGAL positive breast carcinomas[12].",NGAL,urine,1
"PMC 
BMC_Cancer_2009_Mar_31_9_100.txt
","Both cells were cultured in high Glucose Dulbecco's modified Eagle's medium (Gibco-BRL, NY, USA) supplemented with 10% fetal calf serum at 37degC in a humidified atmosphere of 95% air and 5% CO2.

RNA interference
HSP27 siRNA duplex (sense:5'-ACGGUCAAGACCAAGGAUGdTdT-3'; antisense: 5'-CAUCCUUGGUCUUGACCGUdTdT-3') were purchased from Cell Signaling Technology.",CO2,serum,1
"PMC 
BMC_Cancer_2009_Mar_31_9_100.txt
","Both cells were cultured in high Glucose Dulbecco's modified Eagle's medium (Gibco-BRL, NY, USA) supplemented with 10% fetal calf serum at 37degC in a humidified atmosphere of 95% air and 5% CO2.

RNA interference
HSP27 siRNA duplex (sense:5'-ACGGUCAAGACCAAGGAUGdTdT-3'; antisense: 5'-CAUCCUUGGUCUUGACCGUdTdT-3') were purchased from Cell Signaling Technology.",RNA,serum,1
"PMC 
BMC_Cancer_2009_Mar_31_9_100.txt
","Both cells were cultured in high Glucose Dulbecco's modified Eagle's medium (Gibco-BRL, NY, USA) supplemented with 10% fetal calf serum at 37degC in a humidified atmosphere of 95% air and 5% CO2.

RNA interference
HSP27 siRNA duplex (sense:5'-ACGGUCAAGACCAAGGAUGdTdT-3'; antisense: 5'-CAUCCUUGGUCUUGACCGUdTdT-3') were purchased from Cell Signaling Technology.",HSP27,serum,1
"PMC 
BMC_Cancer_2009_Mar_31_9_100.txt
","Both cells were cultured in high Glucose Dulbecco's modified Eagle's medium (Gibco-BRL, NY, USA) supplemented with 10% fetal calf serum at 37degC in a humidified atmosphere of 95% air and 5% CO2.

RNA interference
HSP27 siRNA duplex (sense:5'-ACGGUCAAGACCAAGGAUGdTdT-3'; antisense: 5'-CAUCCUUGGUCUUGACCGUdTdT-3') were purchased from Cell Signaling Technology.",BRL,serum,1
"PMC 
BMC_Cancer_2009_Mar_31_9_100.txt
","Both cells were cultured in high Glucose Dulbecco's modified Eagle's medium (Gibco-BRL, NY, USA) supplemented with 10% fetal calf serum at 37degC in a humidified atmosphere of 95% air and 5% CO2.

RNA interference
HSP27 siRNA duplex (sense:5'-ACGGUCAAGACCAAGGAUGdTdT-3'; antisense: 5'-CAUCCUUGGUCUUGACCGUdTdT-3') were purchased from Cell Signaling Technology.",USA,serum,1
"PMC 
BMC_Cancer_2009_Mar_31_9_100.txt
","Methods
Cell culture
Hep3B cells were maintained in RPMI1640 medium (Gibco-BRL, NY, USA) supplemented with 10% fetal bovine serum (FBS).",RPMI1640,serum,1
"PMC 
BMC_Cancer_2009_Mar_31_9_100.txt
","Methods
Cell culture
Hep3B cells were maintained in RPMI1640 medium (Gibco-BRL, NY, USA) supplemented with 10% fetal bovine serum (FBS).",BRL,serum,1
"PMC 
BMC_Cancer_2009_Mar_31_9_100.txt
","Methods
Cell culture
Hep3B cells were maintained in RPMI1640 medium (Gibco-BRL, NY, USA) supplemented with 10% fetal bovine serum (FBS).",USA,serum,1
"PMC 
BMC_Cancer_2009_Mar_31_9_100.txt
","Methods
Cell culture
Hep3B cells were maintained in RPMI1640 medium (Gibco-BRL, NY, USA) supplemented with 10% fetal bovine serum (FBS).",FBS,serum,1
"PMC 
BMC_Cancer_2009_Oct_14_9_364.txt
","This is likely because women living in the lowest SES areas had highest percent of advanced stages (III, IV) and >= 4 lymph nodes positive (Table 1) and much worse survival for those with advanced stage disease.",III,lymph,1
"PMC 
BMC_Cancer_2009_Oct_14_9_364.txt
","This is likely because women living in the lowest SES areas had highest percent of advanced stages (III, IV) and >= 4 lymph nodes positive (Table 1) and much worse survival for those with advanced stage disease.",SES,lymph,1
"PMC 
BMC_Cancer_2010_Apr_27_10_161.txt
",Then the cells stably transfected with HCCR siRNA plasmid and vector plasmid were harvested and 4 x 105 cells in 200 ml of 0.1% bovine serum albumin were placed in the upper chamber.,HCCR,serum,1
"PMC 
BMC_Cancer_2009_Oct_6_9_353.txt
","The miRNA hsa-miR-22 that showed a high MI value and up-regulation in our study, was recently also reported to be up-regulated in blood cells of lung cancer patients [10].",MI,blood,-1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","We and other investigators have found that serum TRACP 5b activity could become elevated in BC patients with bone metastasis because 80% of the bone metastasis lesions caused by BC are osteolytic in nature [12,13].",TRACP,serum,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","We evaluated the impact of clinical (age, clinical stage before NC, clinical ALNs status before and after surgery, clinical response), pathological (histological grade, tumor size, pathology, axillary lymph node status, and pathological response) and immunohistochemical (ER, PR, Ki-67 and HER-2 protein expression before and after surgery) features on disease free survival (DFS) and overall survival (OS).

",ER,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","We evaluated the impact of clinical (age, clinical stage before NC, clinical ALNs status before and after surgery, clinical response), pathological (histological grade, tumor size, pathology, axillary lymph node status, and pathological response) and immunohistochemical (ER, PR, Ki-67 and HER-2 protein expression before and after surgery) features on disease free survival (DFS) and overall survival (OS).

",OS,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","We evaluated the impact of clinical (age, clinical stage before NC, clinical ALNs status before and after surgery, clinical response), pathological (histological grade, tumor size, pathology, axillary lymph node status, and pathological response) and immunohistochemical (ER, PR, Ki-67 and HER-2 protein expression before and after surgery) features on disease free survival (DFS) and overall survival (OS).

",HER-2,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","We evaluated the impact of clinical (age, clinical stage before NC, clinical ALNs status before and after surgery, clinical response), pathological (histological grade, tumor size, pathology, axillary lymph node status, and pathological response) and immunohistochemical (ER, PR, Ki-67 and HER-2 protein expression before and after surgery) features on disease free survival (DFS) and overall survival (OS).

",PR,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","We evaluated the impact of clinical (age, clinical stage before NC, clinical ALNs status before and after surgery, clinical response), pathological (histological grade, tumor size, pathology, axillary lymph node status, and pathological response) and immunohistochemical (ER, PR, Ki-67 and HER-2 protein expression before and after surgery) features on disease free survival (DFS) and overall survival (OS).

",DFS,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","We evaluated the impact of clinical (age, clinical stage before NC, clinical ALNs status before and after surgery, clinical response), pathological (histological grade, tumor size, pathology, axillary lymph node status, and pathological response) and immunohistochemical (ER, PR, Ki-67 and HER-2 protein expression before and after surgery) features on disease free survival (DFS) and overall survival (OS).

",Ki-67,lymph,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Non-specific binding was blocked using normal rabbit serum (NRS, Biosera) diluted 1:4 in TBS containing 5% BSA (NRS/TBS/BSA) [ERa, ERb2] or normal goat serum (NGS, Biosera) diluted 1:4 in TBS containing 5% BSA (NGS/TBS/BSA) [ERb1, ERb5].",NGS,serum,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Non-specific binding was blocked using normal rabbit serum (NRS, Biosera) diluted 1:4 in TBS containing 5% BSA (NRS/TBS/BSA) [ERa, ERb2] or normal goat serum (NGS, Biosera) diluted 1:4 in TBS containing 5% BSA (NGS/TBS/BSA) [ERb1, ERb5].",NGS,serum,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Non-specific binding was blocked using normal rabbit serum (NRS, Biosera) diluted 1:4 in TBS containing 5% BSA (NRS/TBS/BSA) [ERa, ERb2] or normal goat serum (NGS, Biosera) diluted 1:4 in TBS containing 5% BSA (NGS/TBS/BSA) [ERb1, ERb5].",TBS,serum,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Non-specific binding was blocked using normal rabbit serum (NRS, Biosera) diluted 1:4 in TBS containing 5% BSA (NRS/TBS/BSA) [ERa, ERb2] or normal goat serum (NGS, Biosera) diluted 1:4 in TBS containing 5% BSA (NGS/TBS/BSA) [ERb1, ERb5].",TBS,serum,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Non-specific binding was blocked using normal rabbit serum (NRS, Biosera) diluted 1:4 in TBS containing 5% BSA (NRS/TBS/BSA) [ERa, ERb2] or normal goat serum (NGS, Biosera) diluted 1:4 in TBS containing 5% BSA (NGS/TBS/BSA) [ERb1, ERb5].",TBS,serum,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Non-specific binding was blocked using normal rabbit serum (NRS, Biosera) diluted 1:4 in TBS containing 5% BSA (NRS/TBS/BSA) [ERa, ERb2] or normal goat serum (NGS, Biosera) diluted 1:4 in TBS containing 5% BSA (NGS/TBS/BSA) [ERb1, ERb5].",TBS,serum,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Non-specific binding was blocked using normal rabbit serum (NRS, Biosera) diluted 1:4 in TBS containing 5% BSA (NRS/TBS/BSA) [ERa, ERb2] or normal goat serum (NGS, Biosera) diluted 1:4 in TBS containing 5% BSA (NGS/TBS/BSA) [ERb1, ERb5].",TBS,serum,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Non-specific binding was blocked using normal rabbit serum (NRS, Biosera) diluted 1:4 in TBS containing 5% BSA (NRS/TBS/BSA) [ERa, ERb2] or normal goat serum (NGS, Biosera) diluted 1:4 in TBS containing 5% BSA (NGS/TBS/BSA) [ERb1, ERb5].",TBS,serum,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Non-specific binding was blocked using normal rabbit serum (NRS, Biosera) diluted 1:4 in TBS containing 5% BSA (NRS/TBS/BSA) [ERa, ERb2] or normal goat serum (NGS, Biosera) diluted 1:4 in TBS containing 5% BSA (NGS/TBS/BSA) [ERb1, ERb5].",BSA,serum,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Non-specific binding was blocked using normal rabbit serum (NRS, Biosera) diluted 1:4 in TBS containing 5% BSA (NRS/TBS/BSA) [ERa, ERb2] or normal goat serum (NGS, Biosera) diluted 1:4 in TBS containing 5% BSA (NGS/TBS/BSA) [ERb1, ERb5].",BSA,serum,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Non-specific binding was blocked using normal rabbit serum (NRS, Biosera) diluted 1:4 in TBS containing 5% BSA (NRS/TBS/BSA) [ERa, ERb2] or normal goat serum (NGS, Biosera) diluted 1:4 in TBS containing 5% BSA (NGS/TBS/BSA) [ERb1, ERb5].",BSA,serum,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Non-specific binding was blocked using normal rabbit serum (NRS, Biosera) diluted 1:4 in TBS containing 5% BSA (NRS/TBS/BSA) [ERa, ERb2] or normal goat serum (NGS, Biosera) diluted 1:4 in TBS containing 5% BSA (NGS/TBS/BSA) [ERb1, ERb5].",BSA,serum,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Non-specific binding was blocked using normal rabbit serum (NRS, Biosera) diluted 1:4 in TBS containing 5% BSA (NRS/TBS/BSA) [ERa, ERb2] or normal goat serum (NGS, Biosera) diluted 1:4 in TBS containing 5% BSA (NGS/TBS/BSA) [ERb1, ERb5].",TBS,serum,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Non-specific binding was blocked using normal rabbit serum (NRS, Biosera) diluted 1:4 in TBS containing 5% BSA (NRS/TBS/BSA) [ERa, ERb2] or normal goat serum (NGS, Biosera) diluted 1:4 in TBS containing 5% BSA (NGS/TBS/BSA) [ERb1, ERb5].",TBS,serum,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Non-specific binding was blocked using normal rabbit serum (NRS, Biosera) diluted 1:4 in TBS containing 5% BSA (NRS/TBS/BSA) [ERa, ERb2] or normal goat serum (NGS, Biosera) diluted 1:4 in TBS containing 5% BSA (NGS/TBS/BSA) [ERb1, ERb5].",BSA,serum,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Non-specific binding was blocked using normal rabbit serum (NRS, Biosera) diluted 1:4 in TBS containing 5% BSA (NRS/TBS/BSA) [ERa, ERb2] or normal goat serum (NGS, Biosera) diluted 1:4 in TBS containing 5% BSA (NGS/TBS/BSA) [ERb1, ERb5].",BSA,serum,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Non-specific binding was blocked using normal rabbit serum (NRS, Biosera) diluted 1:4 in TBS containing 5% BSA (NRS/TBS/BSA) [ERa, ERb2] or normal goat serum (NGS, Biosera) diluted 1:4 in TBS containing 5% BSA (NGS/TBS/BSA) [ERb1, ERb5].",NRS,serum,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Non-specific binding was blocked using normal rabbit serum (NRS, Biosera) diluted 1:4 in TBS containing 5% BSA (NRS/TBS/BSA) [ERa, ERb2] or normal goat serum (NGS, Biosera) diluted 1:4 in TBS containing 5% BSA (NGS/TBS/BSA) [ERb1, ERb5].",NRS,serum,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Non-specific binding was blocked using normal rabbit serum (NRS, Biosera) diluted 1:4 in TBS containing 5% BSA (NRS/TBS/BSA) [ERa, ERb2] or normal goat serum (NGS, Biosera) diluted 1:4 in TBS containing 5% BSA (NGS/TBS/BSA) [ERb1, ERb5].",BSA,serum,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Non-specific binding was blocked using normal rabbit serum (NRS, Biosera) diluted 1:4 in TBS containing 5% BSA (NRS/TBS/BSA) [ERa, ERb2] or normal goat serum (NGS, Biosera) diluted 1:4 in TBS containing 5% BSA (NGS/TBS/BSA) [ERb1, ERb5].",BSA,serum,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Non-specific binding was blocked using normal rabbit serum (NRS, Biosera) diluted 1:4 in TBS containing 5% BSA (NRS/TBS/BSA) [ERa, ERb2] or normal goat serum (NGS, Biosera) diluted 1:4 in TBS containing 5% BSA (NGS/TBS/BSA) [ERb1, ERb5].",NGS,serum,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Non-specific binding was blocked using normal rabbit serum (NRS, Biosera) diluted 1:4 in TBS containing 5% BSA (NRS/TBS/BSA) [ERa, ERb2] or normal goat serum (NGS, Biosera) diluted 1:4 in TBS containing 5% BSA (NGS/TBS/BSA) [ERb1, ERb5].",NGS,serum,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Non-specific binding was blocked using normal rabbit serum (NRS, Biosera) diluted 1:4 in TBS containing 5% BSA (NRS/TBS/BSA) [ERa, ERb2] or normal goat serum (NGS, Biosera) diluted 1:4 in TBS containing 5% BSA (NGS/TBS/BSA) [ERb1, ERb5].",NRS,serum,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
","Non-specific binding was blocked using normal rabbit serum (NRS, Biosera) diluted 1:4 in TBS containing 5% BSA (NRS/TBS/BSA) [ERa, ERb2] or normal goat serum (NGS, Biosera) diluted 1:4 in TBS containing 5% BSA (NGS/TBS/BSA) [ERb1, ERb5].",NRS,serum,1
"PMC 
BMC_Cancer_2010_Apr_22_10_156.txt
","Antigens were retrieved by a high-temperature heating method (slides were immersed in target retrieval solution at pH 6 [Dako Cytomation], in a steamer (90-95degC) with a 20-minute incubation for all antigens except for Her-2 neu, for which slides were kept in a water bath for 40 min at 97degC. Tissues were then blocked for endogenous peroxidase in 3% hydrogen peroxide in water, and for nonspecific binding in PBS containing 0.25% casein, stabilizing protein and 0.015 mol/L sodium azide (Protein Block Serum-Free, DakoCytomation).",Her-2,Serum,1
"PMC 
BMC_Cancer_2010_Apr_22_10_156.txt
","Antigens were retrieved by a high-temperature heating method (slides were immersed in target retrieval solution at pH 6 [Dako Cytomation], in a steamer (90-95degC) with a 20-minute incubation for all antigens except for Her-2 neu, for which slides were kept in a water bath for 40 min at 97degC. Tissues were then blocked for endogenous peroxidase in 3% hydrogen peroxide in water, and for nonspecific binding in PBS containing 0.25% casein, stabilizing protein and 0.015 mol/L sodium azide (Protein Block Serum-Free, DakoCytomation).",mol,Serum,1
"PMC 
BMC_Cancer_2010_Apr_22_10_156.txt
","Antigens were retrieved by a high-temperature heating method (slides were immersed in target retrieval solution at pH 6 [Dako Cytomation], in a steamer (90-95degC) with a 20-minute incubation for all antigens except for Her-2 neu, for which slides were kept in a water bath for 40 min at 97degC. Tissues were then blocked for endogenous peroxidase in 3% hydrogen peroxide in water, and for nonspecific binding in PBS containing 0.25% casein, stabilizing protein and 0.015 mol/L sodium azide (Protein Block Serum-Free, DakoCytomation).",PBS,Serum,1
"PMC 
BMC_Cancer_2010_Aug_10_10_415.txt
","Immunofluorescence
U87-MG and U251-MG cells were grown on coverslips, after washing with serum free-DMEM, the cells were fixed for 10 min with 4% paraformaldehyde in PBS, permeabilized with 0.5% Triton X-100 in PBS and blocked 1 h in PBS supplemented with 5% FBS.",PBS,serum,1
"PMC 
BMC_Cancer_2010_Aug_10_10_415.txt
","Immunofluorescence
U87-MG and U251-MG cells were grown on coverslips, after washing with serum free-DMEM, the cells were fixed for 10 min with 4% paraformaldehyde in PBS, permeabilized with 0.5% Triton X-100 in PBS and blocked 1 h in PBS supplemented with 5% FBS.",X-100,serum,1
"PMC 
BMC_Cancer_2010_Aug_10_10_415.txt
","Immunofluorescence
U87-MG and U251-MG cells were grown on coverslips, after washing with serum free-DMEM, the cells were fixed for 10 min with 4% paraformaldehyde in PBS, permeabilized with 0.5% Triton X-100 in PBS and blocked 1 h in PBS supplemented with 5% FBS.",U251-MG,serum,1
"PMC 
BMC_Cancer_2010_Aug_10_10_415.txt
","Immunofluorescence
U87-MG and U251-MG cells were grown on coverslips, after washing with serum free-DMEM, the cells were fixed for 10 min with 4% paraformaldehyde in PBS, permeabilized with 0.5% Triton X-100 in PBS and blocked 1 h in PBS supplemented with 5% FBS.",DMEM,serum,1
"PMC 
BMC_Cancer_2010_Aug_10_10_415.txt
","Immunofluorescence
U87-MG and U251-MG cells were grown on coverslips, after washing with serum free-DMEM, the cells were fixed for 10 min with 4% paraformaldehyde in PBS, permeabilized with 0.5% Triton X-100 in PBS and blocked 1 h in PBS supplemented with 5% FBS.",PBS,serum,1
"PMC 
BMC_Cancer_2010_Aug_10_10_415.txt
","Immunofluorescence
U87-MG and U251-MG cells were grown on coverslips, after washing with serum free-DMEM, the cells were fixed for 10 min with 4% paraformaldehyde in PBS, permeabilized with 0.5% Triton X-100 in PBS and blocked 1 h in PBS supplemented with 5% FBS.",U87-MG,serum,1
"PMC 
BMC_Cancer_2010_Aug_10_10_415.txt
","Immunofluorescence
U87-MG and U251-MG cells were grown on coverslips, after washing with serum free-DMEM, the cells were fixed for 10 min with 4% paraformaldehyde in PBS, permeabilized with 0.5% Triton X-100 in PBS and blocked 1 h in PBS supplemented with 5% FBS.",PBS,serum,1
"PMC 
BMC_Cancer_2010_Aug_10_10_415.txt
","Immunofluorescence
U87-MG and U251-MG cells were grown on coverslips, after washing with serum free-DMEM, the cells were fixed for 10 min with 4% paraformaldehyde in PBS, permeabilized with 0.5% Triton X-100 in PBS and blocked 1 h in PBS supplemented with 5% FBS.",FBS,serum,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
",CR: conditioning regimen; BMT: bone marrow transplantation.,BMT,bone marrow,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
",CR: conditioning regimen; BMT: bone marrow transplantation.,CR,bone marrow,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","13.08(9.96/16.66)a	8.09(4.63/10.50)ac	7.50(6.48/12.50)ac	9.10(4.37/12.40)ac	
CR: conditioning regimen; BMT: bone marrow transplantation; Units - vitamin C: mg/mL plasma.

",CR,plasma,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","13.08(9.96/16.66)a	8.09(4.63/10.50)ac	7.50(6.48/12.50)ac	9.10(4.37/12.40)ac	
CR: conditioning regimen; BMT: bone marrow transplantation; Units - vitamin C: mg/mL plasma.

",CR,bone marrow,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","13.08(9.96/16.66)a	8.09(4.63/10.50)ac	7.50(6.48/12.50)ac	9.10(4.37/12.40)ac	
CR: conditioning regimen; BMT: bone marrow transplantation; Units - vitamin C: mg/mL plasma.

",BMT,plasma,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","13.08(9.96/16.66)a	8.09(4.63/10.50)ac	7.50(6.48/12.50)ac	9.10(4.37/12.40)ac	
CR: conditioning regimen; BMT: bone marrow transplantation; Units - vitamin C: mg/mL plasma.

",BMT,bone marrow,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Although there is abundant evidence that VEGF plays a central role in the development and growth of ovarian cancer, information regarding the clinical utility of serum VEGF levels is limited and inconclusive.",VEGF,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Although there is abundant evidence that VEGF plays a central role in the development and growth of ovarian cancer, information regarding the clinical utility of serum VEGF levels is limited and inconclusive.",VEGF,serum,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","From our initial cohort of 74 HNSCC patients, 46 matched pairs of tumor tissue and normal mucosa as well as 51 saliva samples were useful.",HNSCC,saliva,-1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Healthy Controls
(N = 30)	Sclerosing Adenosis
(N = 35)	ADH
(N = 18)	DCIS
(N = 32)	IDC
(N = 28)	
NGAL (ng/ml)	70.7 +- 17.4	78.3 +- 28.8	79.1 +- 30.6	80.0 +- 22.5	87.4 +- 28.1*	
MMP-9 (ng/ml)	264.2 +- 128.3	402.0 +- 284.8	326.0 +- 171.8	330.7 +- 165.7	392.6 +- 181.7**	
MMP-9/NGAL (ng/ml)	39.9 +- 20.9	54.9 +- 41.0	53.9 +- 36.7	49.5 +- 34.1	60.7 +- 42.3***	
Serum levels of NGAL, MMP-9 and MMP-9/NGAL complex in healthy controls and patients with Sclerosing adenosis, Atypical ductal hyperplasia (ADH), Ductal carcinoma in situ (DCIS) and Invasive ductal carcinoma (IDC).",MMP-9,Serum,-1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Healthy Controls
(N = 30)	Sclerosing Adenosis
(N = 35)	ADH
(N = 18)	DCIS
(N = 32)	IDC
(N = 28)	
NGAL (ng/ml)	70.7 +- 17.4	78.3 +- 28.8	79.1 +- 30.6	80.0 +- 22.5	87.4 +- 28.1*	
MMP-9 (ng/ml)	264.2 +- 128.3	402.0 +- 284.8	326.0 +- 171.8	330.7 +- 165.7	392.6 +- 181.7**	
MMP-9/NGAL (ng/ml)	39.9 +- 20.9	54.9 +- 41.0	53.9 +- 36.7	49.5 +- 34.1	60.7 +- 42.3***	
Serum levels of NGAL, MMP-9 and MMP-9/NGAL complex in healthy controls and patients with Sclerosing adenosis, Atypical ductal hyperplasia (ADH), Ductal carcinoma in situ (DCIS) and Invasive ductal carcinoma (IDC).",NGAL,Serum,-1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Healthy Controls
(N = 30)	Sclerosing Adenosis
(N = 35)	ADH
(N = 18)	DCIS
(N = 32)	IDC
(N = 28)	
NGAL (ng/ml)	70.7 +- 17.4	78.3 +- 28.8	79.1 +- 30.6	80.0 +- 22.5	87.4 +- 28.1*	
MMP-9 (ng/ml)	264.2 +- 128.3	402.0 +- 284.8	326.0 +- 171.8	330.7 +- 165.7	392.6 +- 181.7**	
MMP-9/NGAL (ng/ml)	39.9 +- 20.9	54.9 +- 41.0	53.9 +- 36.7	49.5 +- 34.1	60.7 +- 42.3***	
Serum levels of NGAL, MMP-9 and MMP-9/NGAL complex in healthy controls and patients with Sclerosing adenosis, Atypical ductal hyperplasia (ADH), Ductal carcinoma in situ (DCIS) and Invasive ductal carcinoma (IDC).",IDC,Serum,-1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Healthy Controls
(N = 30)	Sclerosing Adenosis
(N = 35)	ADH
(N = 18)	DCIS
(N = 32)	IDC
(N = 28)	
NGAL (ng/ml)	70.7 +- 17.4	78.3 +- 28.8	79.1 +- 30.6	80.0 +- 22.5	87.4 +- 28.1*	
MMP-9 (ng/ml)	264.2 +- 128.3	402.0 +- 284.8	326.0 +- 171.8	330.7 +- 165.7	392.6 +- 181.7**	
MMP-9/NGAL (ng/ml)	39.9 +- 20.9	54.9 +- 41.0	53.9 +- 36.7	49.5 +- 34.1	60.7 +- 42.3***	
Serum levels of NGAL, MMP-9 and MMP-9/NGAL complex in healthy controls and patients with Sclerosing adenosis, Atypical ductal hyperplasia (ADH), Ductal carcinoma in situ (DCIS) and Invasive ductal carcinoma (IDC).",DCIS,Serum,-1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Healthy Controls
(N = 30)	Sclerosing Adenosis
(N = 35)	ADH
(N = 18)	DCIS
(N = 32)	IDC
(N = 28)	
NGAL (ng/ml)	70.7 +- 17.4	78.3 +- 28.8	79.1 +- 30.6	80.0 +- 22.5	87.4 +- 28.1*	
MMP-9 (ng/ml)	264.2 +- 128.3	402.0 +- 284.8	326.0 +- 171.8	330.7 +- 165.7	392.6 +- 181.7**	
MMP-9/NGAL (ng/ml)	39.9 +- 20.9	54.9 +- 41.0	53.9 +- 36.7	49.5 +- 34.1	60.7 +- 42.3***	
Serum levels of NGAL, MMP-9 and MMP-9/NGAL complex in healthy controls and patients with Sclerosing adenosis, Atypical ductal hyperplasia (ADH), Ductal carcinoma in situ (DCIS) and Invasive ductal carcinoma (IDC).",IDC,Serum,-1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Healthy Controls
(N = 30)	Sclerosing Adenosis
(N = 35)	ADH
(N = 18)	DCIS
(N = 32)	IDC
(N = 28)	
NGAL (ng/ml)	70.7 +- 17.4	78.3 +- 28.8	79.1 +- 30.6	80.0 +- 22.5	87.4 +- 28.1*	
MMP-9 (ng/ml)	264.2 +- 128.3	402.0 +- 284.8	326.0 +- 171.8	330.7 +- 165.7	392.6 +- 181.7**	
MMP-9/NGAL (ng/ml)	39.9 +- 20.9	54.9 +- 41.0	53.9 +- 36.7	49.5 +- 34.1	60.7 +- 42.3***	
Serum levels of NGAL, MMP-9 and MMP-9/NGAL complex in healthy controls and patients with Sclerosing adenosis, Atypical ductal hyperplasia (ADH), Ductal carcinoma in situ (DCIS) and Invasive ductal carcinoma (IDC).",NGAL,Serum,-1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Healthy Controls
(N = 30)	Sclerosing Adenosis
(N = 35)	ADH
(N = 18)	DCIS
(N = 32)	IDC
(N = 28)	
NGAL (ng/ml)	70.7 +- 17.4	78.3 +- 28.8	79.1 +- 30.6	80.0 +- 22.5	87.4 +- 28.1*	
MMP-9 (ng/ml)	264.2 +- 128.3	402.0 +- 284.8	326.0 +- 171.8	330.7 +- 165.7	392.6 +- 181.7**	
MMP-9/NGAL (ng/ml)	39.9 +- 20.9	54.9 +- 41.0	53.9 +- 36.7	49.5 +- 34.1	60.7 +- 42.3***	
Serum levels of NGAL, MMP-9 and MMP-9/NGAL complex in healthy controls and patients with Sclerosing adenosis, Atypical ductal hyperplasia (ADH), Ductal carcinoma in situ (DCIS) and Invasive ductal carcinoma (IDC).",ADH,Serum,-1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Healthy Controls
(N = 30)	Sclerosing Adenosis
(N = 35)	ADH
(N = 18)	DCIS
(N = 32)	IDC
(N = 28)	
NGAL (ng/ml)	70.7 +- 17.4	78.3 +- 28.8	79.1 +- 30.6	80.0 +- 22.5	87.4 +- 28.1*	
MMP-9 (ng/ml)	264.2 +- 128.3	402.0 +- 284.8	326.0 +- 171.8	330.7 +- 165.7	392.6 +- 181.7**	
MMP-9/NGAL (ng/ml)	39.9 +- 20.9	54.9 +- 41.0	53.9 +- 36.7	49.5 +- 34.1	60.7 +- 42.3***	
Serum levels of NGAL, MMP-9 and MMP-9/NGAL complex in healthy controls and patients with Sclerosing adenosis, Atypical ductal hyperplasia (ADH), Ductal carcinoma in situ (DCIS) and Invasive ductal carcinoma (IDC).",ADH,Serum,-1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Healthy Controls
(N = 30)	Sclerosing Adenosis
(N = 35)	ADH
(N = 18)	DCIS
(N = 32)	IDC
(N = 28)	
NGAL (ng/ml)	70.7 +- 17.4	78.3 +- 28.8	79.1 +- 30.6	80.0 +- 22.5	87.4 +- 28.1*	
MMP-9 (ng/ml)	264.2 +- 128.3	402.0 +- 284.8	326.0 +- 171.8	330.7 +- 165.7	392.6 +- 181.7**	
MMP-9/NGAL (ng/ml)	39.9 +- 20.9	54.9 +- 41.0	53.9 +- 36.7	49.5 +- 34.1	60.7 +- 42.3***	
Serum levels of NGAL, MMP-9 and MMP-9/NGAL complex in healthy controls and patients with Sclerosing adenosis, Atypical ductal hyperplasia (ADH), Ductal carcinoma in situ (DCIS) and Invasive ductal carcinoma (IDC).",DCIS,Serum,-1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Healthy Controls
(N = 30)	Sclerosing Adenosis
(N = 35)	ADH
(N = 18)	DCIS
(N = 32)	IDC
(N = 28)	
NGAL (ng/ml)	70.7 +- 17.4	78.3 +- 28.8	79.1 +- 30.6	80.0 +- 22.5	87.4 +- 28.1*	
MMP-9 (ng/ml)	264.2 +- 128.3	402.0 +- 284.8	326.0 +- 171.8	330.7 +- 165.7	392.6 +- 181.7**	
MMP-9/NGAL (ng/ml)	39.9 +- 20.9	54.9 +- 41.0	53.9 +- 36.7	49.5 +- 34.1	60.7 +- 42.3***	
Serum levels of NGAL, MMP-9 and MMP-9/NGAL complex in healthy controls and patients with Sclerosing adenosis, Atypical ductal hyperplasia (ADH), Ductal carcinoma in situ (DCIS) and Invasive ductal carcinoma (IDC).",MMP-9,Serum,-1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","There was no relationship between clinical response (p = 0.284, p = 0.651, respectively) and pathological axillary lymph node status (p = 0.456, p = 0.425, respectively) with DFS and OS.

",OS,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","There was no relationship between clinical response (p = 0.284, p = 0.651, respectively) and pathological axillary lymph node status (p = 0.456, p = 0.425, respectively) with DFS and OS.

",DFS,lymph,1
"PMC 
BMC_Cancer_2009_Oct_20_9_374.txt
","Signaling	2.24E-02	2.24E-05	
GM-CSF",GM,CSF,-1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","If the lesions were primarily osteoblastic, serum TRACP 5b activity might be lower than those with osteolytic or mixed lesions (Personal observations by TYC).",TRACP,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","If the lesions were primarily osteoblastic, serum TRACP 5b activity might be lower than those with osteolytic or mixed lesions (Personal observations by TYC).",TYC,serum,1
"PMC 
BMC_Cancer_2010_Aug_16_10_431.txt
","Genotyping
Genomic DNA was extracted from the buffy coat fraction of each blood sample by using a Blood Mini Kit (Qiagen, Valencia, CA) according to the manufacturer's instructions.",DNA,blood,-1
"PMC 
BMC_Cancer_2010_Aug_16_10_431.txt
","Genotyping
Genomic DNA was extracted from the buffy coat fraction of each blood sample by using a Blood Mini Kit (Qiagen, Valencia, CA) according to the manufacturer's instructions.",DNA,Blood,-1
"PMC 
BMC_Cancer_2009_May_29_9_165.txt
","HER2 gene amplification has been reported in 10-35% of invasive breast carcinomas, and it is associated with an aggressive disease course, increased disease recurrence, and decreased disease-free and overall survival in lymph node-positive patients [2-5].",HER2,lymph,-1
"PMC 
BMC_Cancer_2009_Mar_5_9_77.txt
","Two AML patients outside this gene expression analysis demonstrated unaltered white blood cell (WBC) and lymphocyte counts or a 50% reduction in WBC and 20% reduction in lymphocytes at 24 h, respectively.",WBC,blood,-1
"PMC 
BMC_Cancer_2009_Mar_5_9_77.txt
","Two AML patients outside this gene expression analysis demonstrated unaltered white blood cell (WBC) and lymphocyte counts or a 50% reduction in WBC and 20% reduction in lymphocytes at 24 h, respectively.",WBC,blood,-1
"PMC 
BMC_Cancer_2009_Mar_5_9_77.txt
","Two AML patients outside this gene expression analysis demonstrated unaltered white blood cell (WBC) and lymphocyte counts or a 50% reduction in WBC and 20% reduction in lymphocytes at 24 h, respectively.",AML,blood,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_434.txt
","Additional clinico-pathological data refer to the differentiation status of the tumour, the state of histiocytes and pleural invasion, the presence of metastasis in lymph nodes (LNs) and the tumour-to-node metastasis (TNM) index.",TNM,lymph,1
"PMC 
BMC_Cancer_2010_Aug_15_10_428.txt
","The high frequency of down regulation of MTSS1 expression in primary gastric tumors and lost MTSS1 expression in metastases and their direct association with poor outcome of gastric cancer indicated that MTSS1 could suppress tumor invasion and metastasis, and might be a candidate prognostic factor for lymph node metastasis and tumor progression.",MTSS1,lymph,1
"PMC 
BMC_Cancer_2010_Aug_15_10_428.txt
","The high frequency of down regulation of MTSS1 expression in primary gastric tumors and lost MTSS1 expression in metastases and their direct association with poor outcome of gastric cancer indicated that MTSS1 could suppress tumor invasion and metastasis, and might be a candidate prognostic factor for lymph node metastasis and tumor progression.",MTSS1,lymph,1
"PMC 
BMC_Cancer_2010_Aug_15_10_428.txt
","The high frequency of down regulation of MTSS1 expression in primary gastric tumors and lost MTSS1 expression in metastases and their direct association with poor outcome of gastric cancer indicated that MTSS1 could suppress tumor invasion and metastasis, and might be a candidate prognostic factor for lymph node metastasis and tumor progression.",MTSS1,lymph,1
"PMC 
BMC_Cancer_2009_Mar_26_9_93.txt
",QPRT has been described in the nucleus and cytoplasma [21] of cells of the human central nervous system and the liver [22] and in blood cells (platelets and erythrocytes) [23].,QPRT,blood,-1
"PMC 
BMC_Cancer_2009_Mar_5_9_77.txt
","It has previously been reported that apoptotic cells are absent in bone marrow and peripheral blood during intensive chemotherapy of AML for at least 24 h, even if the cell numbers in peripheral circulation start to decline [27,28].",AML,bone marrow,-1
"PMC 
BMC_Cancer_2009_Mar_5_9_77.txt
","It has previously been reported that apoptotic cells are absent in bone marrow and peripheral blood during intensive chemotherapy of AML for at least 24 h, even if the cell numbers in peripheral circulation start to decline [27,28].",AML,blood,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Methods
Cells and reagents
LNCaP, PC-3 and DU145 prostate cancer cell lines used in this study were purchased from American Type Culture Collection (Rockville, MD) and maintained in RPMI 1640 medium (Mediatech, VA) supplemented with 10% fetal bovine serum, 2 mM sodium pyruvate and 100 units/ml penicillin/streptomycin at 37degC in a humidified atmosphere containing 5% CO2.",RPMI,serum,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Methods
Cells and reagents
LNCaP, PC-3 and DU145 prostate cancer cell lines used in this study were purchased from American Type Culture Collection (Rockville, MD) and maintained in RPMI 1640 medium (Mediatech, VA) supplemented with 10% fetal bovine serum, 2 mM sodium pyruvate and 100 units/ml penicillin/streptomycin at 37degC in a humidified atmosphere containing 5% CO2.",CO2,serum,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Methods
Cells and reagents
LNCaP, PC-3 and DU145 prostate cancer cell lines used in this study were purchased from American Type Culture Collection (Rockville, MD) and maintained in RPMI 1640 medium (Mediatech, VA) supplemented with 10% fetal bovine serum, 2 mM sodium pyruvate and 100 units/ml penicillin/streptomycin at 37degC in a humidified atmosphere containing 5% CO2.",PC-3,serum,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","Methods
Cells and reagents
LNCaP, PC-3 and DU145 prostate cancer cell lines used in this study were purchased from American Type Culture Collection (Rockville, MD) and maintained in RPMI 1640 medium (Mediatech, VA) supplemented with 10% fetal bovine serum, 2 mM sodium pyruvate and 100 units/ml penicillin/streptomycin at 37degC in a humidified atmosphere containing 5% CO2.",DU145,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","However, the variation of serum VEGF values in the course of treatment has not been studied since many of these studies used 'pre-treatment' samples and did not separate between pre- and postoperative serum samples or clearly define time points of serum collection.

",VEGF,serum,-1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","However, the variation of serum VEGF values in the course of treatment has not been studied since many of these studies used 'pre-treatment' samples and did not separate between pre- and postoperative serum samples or clearly define time points of serum collection.

",VEGF,serum,-1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","However, the variation of serum VEGF values in the course of treatment has not been studied since many of these studies used 'pre-treatment' samples and did not separate between pre- and postoperative serum samples or clearly define time points of serum collection.

",VEGF,serum,-1
"PMC 
BMC_Cancer_2010_Aug_15_10_428.txt
","Risk factors for gastric cancers have been explored in a number of studies, including status of lymph nodes, depth of tumor invasion, age at diagnosis, TNM stage and some molecular markers [5,7,19-23].",TNM,lymph,-1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","There was also a decrease in plasma P-SH levels after the CR and BMT, demonstrating that the protein thiol groups were oxidized by cytostatic drugs utilized in the CR preceding BMT.",BMT,plasma,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","There was also a decrease in plasma P-SH levels after the CR and BMT, demonstrating that the protein thiol groups were oxidized by cytostatic drugs utilized in the CR preceding BMT.",CR,plasma,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","There was also a decrease in plasma P-SH levels after the CR and BMT, demonstrating that the protein thiol groups were oxidized by cytostatic drugs utilized in the CR preceding BMT.",CR,plasma,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","There was also a decrease in plasma P-SH levels after the CR and BMT, demonstrating that the protein thiol groups were oxidized by cytostatic drugs utilized in the CR preceding BMT.",BMT,plasma,1
"PMC 
BMC_Cancer_2010_Aug_18_10_439.txt
","Methods
In the current study we elucidate the association between plasma levels of 8-OHdG and the OGG1 repair capacity.",OGG1,plasma,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
",Figure 1 DNA damage in non-stimulated and PHA-stimulated blood cells caused by 2-h and 24-h etoposide treatment at the indicated doses detected by Comet Assay at pH &#62; 13.,DNA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
",Figure 1 DNA damage in non-stimulated and PHA-stimulated blood cells caused by 2-h and 24-h etoposide treatment at the indicated doses detected by Comet Assay at pH &#62; 13.,PHA,blood,-1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","In our study, autologous and allogeneic patients presented plasma P-SH levels lower than those of healthy volunteers and also a negative correlation with TBARS, at all time points analyzed.",TBARS,plasma,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Higher serum levels of MMP-9/NGAL were observed in IDC, DCIS, ADH and sclerosing adenosis patients compared to healthy women (Figure 3).",DCIS,serum,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Higher serum levels of MMP-9/NGAL were observed in IDC, DCIS, ADH and sclerosing adenosis patients compared to healthy women (Figure 3).",ADH,serum,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Higher serum levels of MMP-9/NGAL were observed in IDC, DCIS, ADH and sclerosing adenosis patients compared to healthy women (Figure 3).",IDC,serum,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","However, in group II (autol.), this increase was already present before CR and there was no further increase in lipid peroxidation, probably because of the disease itself and procedures carried out previously, such as chemotherapy that precedes the collection of the patient's own bone marrow for posterior use in BMT.",CR,bone marrow,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","However, in group II (autol.), this increase was already present before CR and there was no further increase in lipid peroxidation, probably because of the disease itself and procedures carried out previously, such as chemotherapy that precedes the collection of the patient's own bone marrow for posterior use in BMT.",BMT,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_3_9_389.txt
","Among these predictors, the serum albumin level may reflect the conditions of patients liver physiology, while the rest of other factors hint to the biology or characteristics of the HCC tumor per se.",HCC,serum,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
",VIT C levels were lower in the plasma of patients from groups II (autol.) and III (allog.),VIT,plasma,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
",VIT C levels were lower in the plasma of patients from groups II (autol.) and III (allog.),III,plasma,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","During first-line chemotherapy the serum concentrations of CA-125, TIMP-1 and VEGF-165 decreased significantly compared to the previous time-point.",TIMP-1,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","During first-line chemotherapy the serum concentrations of CA-125, TIMP-1 and VEGF-165 decreased significantly compared to the previous time-point.",CA-125,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","During first-line chemotherapy the serum concentrations of CA-125, TIMP-1 and VEGF-165 decreased significantly compared to the previous time-point.",VEGF-165,serum,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","==== Body
Background
Bone marrow transplantation (BMT) is a therapeutic method used in various malignant, hematologic, immunologic, and genetic diseases [1].",BMT,Bone marrow,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Thus, patients who received CMF more often had only 1-3 involved lymph nodes and also had smaller tumors (pT1) when compared with untreated patients and with patients who received anthracycline-based chemotherapy.",pT1,lymph,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Thus, patients who received CMF more often had only 1-3 involved lymph nodes and also had smaller tumors (pT1) when compared with untreated patients and with patients who received anthracycline-based chemotherapy.",CMF,lymph,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Correlation between serum concentration of CA-125, TIMP-1 and VEGF-165 and clinicopathological factors, response, progression and survival
The serum values of each marker were divided in two groups (high and low) at each time-point using the median as cut-off value.",CA-125,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Correlation between serum concentration of CA-125, TIMP-1 and VEGF-165 and clinicopathological factors, response, progression and survival
The serum values of each marker were divided in two groups (high and low) at each time-point using the median as cut-off value.",CA-125,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Correlation between serum concentration of CA-125, TIMP-1 and VEGF-165 and clinicopathological factors, response, progression and survival
The serum values of each marker were divided in two groups (high and low) at each time-point using the median as cut-off value.",TIMP-1,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Correlation between serum concentration of CA-125, TIMP-1 and VEGF-165 and clinicopathological factors, response, progression and survival
The serum values of each marker were divided in two groups (high and low) at each time-point using the median as cut-off value.",TIMP-1,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Correlation between serum concentration of CA-125, TIMP-1 and VEGF-165 and clinicopathological factors, response, progression and survival
The serum values of each marker were divided in two groups (high and low) at each time-point using the median as cut-off value.",VEGF-165,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Correlation between serum concentration of CA-125, TIMP-1 and VEGF-165 and clinicopathological factors, response, progression and survival
The serum values of each marker were divided in two groups (high and low) at each time-point using the median as cut-off value.",VEGF-165,serum,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","Trizol, RPMI 1640, fetal bovine serum (FBS), and lipofectamine 2000 were purchased from Invitrogen (Carlsbad, CA).",FBS,serum,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","Trizol, RPMI 1640, fetal bovine serum (FBS), and lipofectamine 2000 were purchased from Invitrogen (Carlsbad, CA).",RPMI,serum,1
"PMC 
BMC_Cancer_2009_Mar_4_9_75.txt
","Cells (1 x 105 cells/well) were washed with 1 x PBS twice, re-suspended in 200 ml of serum-free medium and then transferred into the upper chamber.",PBS,serum,1
"PMC 
BMC_Cancer_2010_Aug_10_10_418.txt
","The expression of survivin increases gradually from normal prostate tissue, to primary low-grade prostate carcinoma, and to primary high-grade carcinoma, with the highest expression observed in foci of prostate cancer metastasized to the lymph nodes [5].",survivin,lymph,-1
"PMC 
BMC_Cancer_2009_Mar_5_9_77.txt
","AML cell number in peripheral blood was rapidly declining after chemotherapy and partly followed by a decrease in lymphocytes, not sufficient to explain the increase in T-cell receptor related genes.",AML,blood,-1
"PMC 
BMC_Cancer_2009_Mar_5_9_77.txt
","AML cell number in peripheral blood was rapidly declining after chemotherapy and partly followed by a decrease in lymphocytes, not sufficient to explain the increase in T-cell receptor related genes.",T,blood,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 3 Cross-validation classification errors, normal versus cancer

Model	FN	FP	
BMA of linear models	19	8	
	
BMA of logistic models	15	12	
	
BMA of probit models	18	7	
	
SVM with RFS	18	12	
	
LAR	24	5	
Figure 1 ROC curves showing the classification performance of statistical models using the serum protein levels.",BMA,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 3 Cross-validation classification errors, normal versus cancer

Model	FN	FP	
BMA of linear models	19	8	
	
BMA of logistic models	15	12	
	
BMA of probit models	18	7	
	
SVM with RFS	18	12	
	
LAR	24	5	
Figure 1 ROC curves showing the classification performance of statistical models using the serum protein levels.",SVM,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 3 Cross-validation classification errors, normal versus cancer

Model	FN	FP	
BMA of linear models	19	8	
	
BMA of logistic models	15	12	
	
BMA of probit models	18	7	
	
SVM with RFS	18	12	
	
LAR	24	5	
Figure 1 ROC curves showing the classification performance of statistical models using the serum protein levels.",LAR,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 3 Cross-validation classification errors, normal versus cancer

Model	FN	FP	
BMA of linear models	19	8	
	
BMA of logistic models	15	12	
	
BMA of probit models	18	7	
	
SVM with RFS	18	12	
	
LAR	24	5	
Figure 1 ROC curves showing the classification performance of statistical models using the serum protein levels.",FP,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 3 Cross-validation classification errors, normal versus cancer

Model	FN	FP	
BMA of linear models	19	8	
	
BMA of logistic models	15	12	
	
BMA of probit models	18	7	
	
SVM with RFS	18	12	
	
LAR	24	5	
Figure 1 ROC curves showing the classification performance of statistical models using the serum protein levels.",BMA,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 3 Cross-validation classification errors, normal versus cancer

Model	FN	FP	
BMA of linear models	19	8	
	
BMA of logistic models	15	12	
	
BMA of probit models	18	7	
	
SVM with RFS	18	12	
	
LAR	24	5	
Figure 1 ROC curves showing the classification performance of statistical models using the serum protein levels.",ROC,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 3 Cross-validation classification errors, normal versus cancer

Model	FN	FP	
BMA of linear models	19	8	
	
BMA of logistic models	15	12	
	
BMA of probit models	18	7	
	
SVM with RFS	18	12	
	
LAR	24	5	
Figure 1 ROC curves showing the classification performance of statistical models using the serum protein levels.",BMA,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 3 Cross-validation classification errors, normal versus cancer

Model	FN	FP	
BMA of linear models	19	8	
	
BMA of logistic models	15	12	
	
BMA of probit models	18	7	
	
SVM with RFS	18	12	
	
LAR	24	5	
Figure 1 ROC curves showing the classification performance of statistical models using the serum protein levels.",RFS,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","Furthermore elevated serum TRACP 5b activity in BC patients is positively correlated with the extent of bone metastasis [8,14].",TRACP,serum,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
",The dual cell-stain assay described by Hartman and Speit [32] was employed to determine the viability of the PHA-stimulated and the non stimulated whole blood cells after etoposide treatments.,PHA,blood,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","Pro-angiogenic factors such as the VEGF-A, bFGF, and MCP-1 are involved in the activation, mobilization and recruitment of EPCs from the bone marrow and in promoting the differentiation of EPCs into ECs in some ischemic diseases and during tumor growth [24,25].",VEGF,bone marrow,1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","Pro-angiogenic factors such as the VEGF-A, bFGF, and MCP-1 are involved in the activation, mobilization and recruitment of EPCs from the bone marrow and in promoting the differentiation of EPCs into ECs in some ischemic diseases and during tumor growth [24,25].",bFGF,bone marrow,1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","Pro-angiogenic factors such as the VEGF-A, bFGF, and MCP-1 are involved in the activation, mobilization and recruitment of EPCs from the bone marrow and in promoting the differentiation of EPCs into ECs in some ischemic diseases and during tumor growth [24,25].",MCP-1,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","As shown in Figure 3, non-stimulated whole blood cells had higher ALS index values than PHA-stimulated cells treated with etoposide.",PHA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","As shown in Figure 3, non-stimulated whole blood cells had higher ALS index values than PHA-stimulated cells treated with etoposide.",ALS,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Etoposide	2 h treatment non-stimulated blood cells	2 h treatment PHA-stimulated blood cells	
0 mM	100 +- 5.5	100 +- 5.6	
2.07 mM	95.5 +- 8.5	88.6 +- 3.9	
20.7 mM	99.2 +- 2.2	83.2 +- 8.2	
207 mM	91.1 +- 8.2	75.6 +- 7.6	
	
Etoposide	24 h treatment non-stimulated blood cells	24 h treatment PHA-stimulated blood cells	
	
0 mM	100 +- 2.3	100 +- 3.9	
2.07 mM	100 +- 3.7	96.7 +- 3.4	
20.7 mM	100 +- 8.0	96.7 +- 3.4	
207 mM	93.8 +- 8.2	81.4 +- 9.9	
Viability % +- SD.",SD,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Etoposide	2 h treatment non-stimulated blood cells	2 h treatment PHA-stimulated blood cells	
0 mM	100 +- 5.5	100 +- 5.6	
2.07 mM	95.5 +- 8.5	88.6 +- 3.9	
20.7 mM	99.2 +- 2.2	83.2 +- 8.2	
207 mM	91.1 +- 8.2	75.6 +- 7.6	
	
Etoposide	24 h treatment non-stimulated blood cells	24 h treatment PHA-stimulated blood cells	
	
0 mM	100 +- 2.3	100 +- 3.9	
2.07 mM	100 +- 3.7	96.7 +- 3.4	
20.7 mM	100 +- 8.0	96.7 +- 3.4	
207 mM	93.8 +- 8.2	81.4 +- 9.9	
Viability % +- SD.",SD,blood,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Etoposide	2 h treatment non-stimulated blood cells	2 h treatment PHA-stimulated blood cells	
0 mM	100 +- 5.5	100 +- 5.6	
2.07 mM	95.5 +- 8.5	88.6 +- 3.9	
20.7 mM	99.2 +- 2.2	83.2 +- 8.2	
207 mM	91.1 +- 8.2	75.6 +- 7.6	
	
Etoposide	24 h treatment non-stimulated blood cells	24 h treatment PHA-stimulated blood cells	
	
0 mM	100 +- 2.3	100 +- 3.9	
2.07 mM	100 +- 3.7	96.7 +- 3.4	
20.7 mM	100 +- 8.0	96.7 +- 3.4	
207 mM	93.8 +- 8.2	81.4 +- 9.9	
Viability % +- SD.",SD,blood,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Etoposide	2 h treatment non-stimulated blood cells	2 h treatment PHA-stimulated blood cells	
0 mM	100 +- 5.5	100 +- 5.6	
2.07 mM	95.5 +- 8.5	88.6 +- 3.9	
20.7 mM	99.2 +- 2.2	83.2 +- 8.2	
207 mM	91.1 +- 8.2	75.6 +- 7.6	
	
Etoposide	24 h treatment non-stimulated blood cells	24 h treatment PHA-stimulated blood cells	
	
0 mM	100 +- 2.3	100 +- 3.9	
2.07 mM	100 +- 3.7	96.7 +- 3.4	
20.7 mM	100 +- 8.0	96.7 +- 3.4	
207 mM	93.8 +- 8.2	81.4 +- 9.9	
Viability % +- SD.",SD,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Etoposide	2 h treatment non-stimulated blood cells	2 h treatment PHA-stimulated blood cells	
0 mM	100 +- 5.5	100 +- 5.6	
2.07 mM	95.5 +- 8.5	88.6 +- 3.9	
20.7 mM	99.2 +- 2.2	83.2 +- 8.2	
207 mM	91.1 +- 8.2	75.6 +- 7.6	
	
Etoposide	24 h treatment non-stimulated blood cells	24 h treatment PHA-stimulated blood cells	
	
0 mM	100 +- 2.3	100 +- 3.9	
2.07 mM	100 +- 3.7	96.7 +- 3.4	
20.7 mM	100 +- 8.0	96.7 +- 3.4	
207 mM	93.8 +- 8.2	81.4 +- 9.9	
Viability % +- SD.",PHA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Etoposide	2 h treatment non-stimulated blood cells	2 h treatment PHA-stimulated blood cells	
0 mM	100 +- 5.5	100 +- 5.6	
2.07 mM	95.5 +- 8.5	88.6 +- 3.9	
20.7 mM	99.2 +- 2.2	83.2 +- 8.2	
207 mM	91.1 +- 8.2	75.6 +- 7.6	
	
Etoposide	24 h treatment non-stimulated blood cells	24 h treatment PHA-stimulated blood cells	
	
0 mM	100 +- 2.3	100 +- 3.9	
2.07 mM	100 +- 3.7	96.7 +- 3.4	
20.7 mM	100 +- 8.0	96.7 +- 3.4	
207 mM	93.8 +- 8.2	81.4 +- 9.9	
Viability % +- SD.",PHA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Etoposide	2 h treatment non-stimulated blood cells	2 h treatment PHA-stimulated blood cells	
0 mM	100 +- 5.5	100 +- 5.6	
2.07 mM	95.5 +- 8.5	88.6 +- 3.9	
20.7 mM	99.2 +- 2.2	83.2 +- 8.2	
207 mM	91.1 +- 8.2	75.6 +- 7.6	
	
Etoposide	24 h treatment non-stimulated blood cells	24 h treatment PHA-stimulated blood cells	
	
0 mM	100 +- 2.3	100 +- 3.9	
2.07 mM	100 +- 3.7	96.7 +- 3.4	
20.7 mM	100 +- 8.0	96.7 +- 3.4	
207 mM	93.8 +- 8.2	81.4 +- 9.9	
Viability % +- SD.",PHA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Etoposide	2 h treatment non-stimulated blood cells	2 h treatment PHA-stimulated blood cells	
0 mM	100 +- 5.5	100 +- 5.6	
2.07 mM	95.5 +- 8.5	88.6 +- 3.9	
20.7 mM	99.2 +- 2.2	83.2 +- 8.2	
207 mM	91.1 +- 8.2	75.6 +- 7.6	
	
Etoposide	24 h treatment non-stimulated blood cells	24 h treatment PHA-stimulated blood cells	
	
0 mM	100 +- 2.3	100 +- 3.9	
2.07 mM	100 +- 3.7	96.7 +- 3.4	
20.7 mM	100 +- 8.0	96.7 +- 3.4	
207 mM	93.8 +- 8.2	81.4 +- 9.9	
Viability % +- SD.",PHA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Etoposide	2 h treatment non-stimulated blood cells	2 h treatment PHA-stimulated blood cells	
0 mM	100 +- 5.5	100 +- 5.6	
2.07 mM	95.5 +- 8.5	88.6 +- 3.9	
20.7 mM	99.2 +- 2.2	83.2 +- 8.2	
207 mM	91.1 +- 8.2	75.6 +- 7.6	
	
Etoposide	24 h treatment non-stimulated blood cells	24 h treatment PHA-stimulated blood cells	
	
0 mM	100 +- 2.3	100 +- 3.9	
2.07 mM	100 +- 3.7	96.7 +- 3.4	
20.7 mM	100 +- 8.0	96.7 +- 3.4	
207 mM	93.8 +- 8.2	81.4 +- 9.9	
Viability % +- SD.",PHA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Etoposide	2 h treatment non-stimulated blood cells	2 h treatment PHA-stimulated blood cells	
0 mM	100 +- 5.5	100 +- 5.6	
2.07 mM	95.5 +- 8.5	88.6 +- 3.9	
20.7 mM	99.2 +- 2.2	83.2 +- 8.2	
207 mM	91.1 +- 8.2	75.6 +- 7.6	
	
Etoposide	24 h treatment non-stimulated blood cells	24 h treatment PHA-stimulated blood cells	
	
0 mM	100 +- 2.3	100 +- 3.9	
2.07 mM	100 +- 3.7	96.7 +- 3.4	
20.7 mM	100 +- 8.0	96.7 +- 3.4	
207 mM	93.8 +- 8.2	81.4 +- 9.9	
Viability % +- SD.",PHA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Etoposide	2 h treatment non-stimulated blood cells	2 h treatment PHA-stimulated blood cells	
0 mM	100 +- 5.5	100 +- 5.6	
2.07 mM	95.5 +- 8.5	88.6 +- 3.9	
20.7 mM	99.2 +- 2.2	83.2 +- 8.2	
207 mM	91.1 +- 8.2	75.6 +- 7.6	
	
Etoposide	24 h treatment non-stimulated blood cells	24 h treatment PHA-stimulated blood cells	
	
0 mM	100 +- 2.3	100 +- 3.9	
2.07 mM	100 +- 3.7	96.7 +- 3.4	
20.7 mM	100 +- 8.0	96.7 +- 3.4	
207 mM	93.8 +- 8.2	81.4 +- 9.9	
Viability % +- SD.",PHA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Etoposide	2 h treatment non-stimulated blood cells	2 h treatment PHA-stimulated blood cells	
0 mM	100 +- 5.5	100 +- 5.6	
2.07 mM	95.5 +- 8.5	88.6 +- 3.9	
20.7 mM	99.2 +- 2.2	83.2 +- 8.2	
207 mM	91.1 +- 8.2	75.6 +- 7.6	
	
Etoposide	24 h treatment non-stimulated blood cells	24 h treatment PHA-stimulated blood cells	
	
0 mM	100 +- 2.3	100 +- 3.9	
2.07 mM	100 +- 3.7	96.7 +- 3.4	
20.7 mM	100 +- 8.0	96.7 +- 3.4	
207 mM	93.8 +- 8.2	81.4 +- 9.9	
Viability % +- SD.",PHA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_3_9_389.txt
","Preoperative investigation of the patients included blood biochemistry, alpha-fetoprotein assay, chest x-ray, percutaneous ultrasonography, computed tomography (CT), and hepatic angiography in selected patients.",CT,blood,1
"PMC 
BMC_Cancer_2009_May_11_9_140.txt
","DNA extractions for all samples were made with QIAmp 96 DNA blood kit (Qiagen, Hilden, Germany) by SWEGENE resource centre for Profiling Polygenic Diseases in Malmo University hospital, Sweden, apart from the blood samples from the breast control group, which were extracted for DNA with Wizard Genomic DNA Purification Kit (Promega, Madison, WI, USA).",USA,blood,-1
"PMC 
BMC_Cancer_2009_May_11_9_140.txt
","DNA extractions for all samples were made with QIAmp 96 DNA blood kit (Qiagen, Hilden, Germany) by SWEGENE resource centre for Profiling Polygenic Diseases in Malmo University hospital, Sweden, apart from the blood samples from the breast control group, which were extracted for DNA with Wizard Genomic DNA Purification Kit (Promega, Madison, WI, USA).",USA,blood,-1
"PMC 
BMC_Cancer_2009_May_11_9_140.txt
","DNA extractions for all samples were made with QIAmp 96 DNA blood kit (Qiagen, Hilden, Germany) by SWEGENE resource centre for Profiling Polygenic Diseases in Malmo University hospital, Sweden, apart from the blood samples from the breast control group, which were extracted for DNA with Wizard Genomic DNA Purification Kit (Promega, Madison, WI, USA).",DNA,blood,-1
"PMC 
BMC_Cancer_2009_May_11_9_140.txt
","DNA extractions for all samples were made with QIAmp 96 DNA blood kit (Qiagen, Hilden, Germany) by SWEGENE resource centre for Profiling Polygenic Diseases in Malmo University hospital, Sweden, apart from the blood samples from the breast control group, which were extracted for DNA with Wizard Genomic DNA Purification Kit (Promega, Madison, WI, USA).",DNA,blood,-1
"PMC 
BMC_Cancer_2009_May_11_9_140.txt
","DNA extractions for all samples were made with QIAmp 96 DNA blood kit (Qiagen, Hilden, Germany) by SWEGENE resource centre for Profiling Polygenic Diseases in Malmo University hospital, Sweden, apart from the blood samples from the breast control group, which were extracted for DNA with Wizard Genomic DNA Purification Kit (Promega, Madison, WI, USA).",DNA,blood,-1
"PMC 
BMC_Cancer_2009_May_11_9_140.txt
","DNA extractions for all samples were made with QIAmp 96 DNA blood kit (Qiagen, Hilden, Germany) by SWEGENE resource centre for Profiling Polygenic Diseases in Malmo University hospital, Sweden, apart from the blood samples from the breast control group, which were extracted for DNA with Wizard Genomic DNA Purification Kit (Promega, Madison, WI, USA).",DNA,blood,-1
"PMC 
BMC_Cancer_2009_May_11_9_140.txt
","DNA extractions for all samples were made with QIAmp 96 DNA blood kit (Qiagen, Hilden, Germany) by SWEGENE resource centre for Profiling Polygenic Diseases in Malmo University hospital, Sweden, apart from the blood samples from the breast control group, which were extracted for DNA with Wizard Genomic DNA Purification Kit (Promega, Madison, WI, USA).",SWEGENE,blood,-1
"PMC 
BMC_Cancer_2009_May_11_9_140.txt
","DNA extractions for all samples were made with QIAmp 96 DNA blood kit (Qiagen, Hilden, Germany) by SWEGENE resource centre for Profiling Polygenic Diseases in Malmo University hospital, Sweden, apart from the blood samples from the breast control group, which were extracted for DNA with Wizard Genomic DNA Purification Kit (Promega, Madison, WI, USA).",SWEGENE,blood,-1
"PMC 
BMC_Cancer_2009_May_11_9_140.txt
","DNA extractions for all samples were made with QIAmp 96 DNA blood kit (Qiagen, Hilden, Germany) by SWEGENE resource centre for Profiling Polygenic Diseases in Malmo University hospital, Sweden, apart from the blood samples from the breast control group, which were extracted for DNA with Wizard Genomic DNA Purification Kit (Promega, Madison, WI, USA).",DNA,blood,-1
"PMC 
BMC_Cancer_2009_May_11_9_140.txt
","DNA extractions for all samples were made with QIAmp 96 DNA blood kit (Qiagen, Hilden, Germany) by SWEGENE resource centre for Profiling Polygenic Diseases in Malmo University hospital, Sweden, apart from the blood samples from the breast control group, which were extracted for DNA with Wizard Genomic DNA Purification Kit (Promega, Madison, WI, USA).",DNA,blood,-1
"PMC 
BMC_Cancer_2009_May_11_9_140.txt
","DNA extractions for all samples were made with QIAmp 96 DNA blood kit (Qiagen, Hilden, Germany) by SWEGENE resource centre for Profiling Polygenic Diseases in Malmo University hospital, Sweden, apart from the blood samples from the breast control group, which were extracted for DNA with Wizard Genomic DNA Purification Kit (Promega, Madison, WI, USA).",DNA,blood,-1
"PMC 
BMC_Cancer_2009_May_11_9_140.txt
","DNA extractions for all samples were made with QIAmp 96 DNA blood kit (Qiagen, Hilden, Germany) by SWEGENE resource centre for Profiling Polygenic Diseases in Malmo University hospital, Sweden, apart from the blood samples from the breast control group, which were extracted for DNA with Wizard Genomic DNA Purification Kit (Promega, Madison, WI, USA).",DNA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Mean serum levels of MMP-9, NGAL and MMP-9/NGAL complex in healthy women and patients with sclerosing adenosis, ADH, DCIS and IDC are presented in Table 1.",NGAL,serum,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Mean serum levels of MMP-9, NGAL and MMP-9/NGAL complex in healthy women and patients with sclerosing adenosis, ADH, DCIS and IDC are presented in Table 1.",DCIS,serum,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Mean serum levels of MMP-9, NGAL and MMP-9/NGAL complex in healthy women and patients with sclerosing adenosis, ADH, DCIS and IDC are presented in Table 1.",MMP-9,serum,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Mean serum levels of MMP-9, NGAL and MMP-9/NGAL complex in healthy women and patients with sclerosing adenosis, ADH, DCIS and IDC are presented in Table 1.",IDC,serum,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Mean serum levels of MMP-9, NGAL and MMP-9/NGAL complex in healthy women and patients with sclerosing adenosis, ADH, DCIS and IDC are presented in Table 1.",ADH,serum,1
"PMC 
BMC_Cancer_2009_Mar_5_9_77.txt
","Methods
The gene expression was examined by whole genome 44 k oligo microarrays and 12 k cDNA microarrays in peripheral blood leukocytes collected from seven leukemia patients before treatment, 2-4 h and 18-24 h after start of chemotherapy and validated by real-time quantitative PCR.",PCR,blood,-1
"PMC 
BMC_Cancer_2009_Mar_5_9_77.txt
","Methods
The gene expression was examined by whole genome 44 k oligo microarrays and 12 k cDNA microarrays in peripheral blood leukocytes collected from seven leukemia patients before treatment, 2-4 h and 18-24 h after start of chemotherapy and validated by real-time quantitative PCR.",cDNA,blood,-1
"PMC 
BMC_Cancer_2009_Mar_30_9_99.txt
","Overall, fifty ""drug-likeness"" parameters have been calculated, covering molecular weight, polarity, solubility, cell permeability, blood brain barrier, HERG K+ blockage, HSA binding and metabolic stability, etc.",HSA,blood,-1
"PMC 
BMC_Cancer_2009_Mar_30_9_99.txt
","Overall, fifty ""drug-likeness"" parameters have been calculated, covering molecular weight, polarity, solubility, cell permeability, blood brain barrier, HERG K+ blockage, HSA binding and metabolic stability, etc.",HERG,blood,-1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","Elevated serum IL-6 levels have been implicated in many different conditions characterized by chronic inflammation, including viral and bacterial infections, autoimmune disease, ischemia, diabetes mellitus, severe exercise, and malignancy [6,32].",IL-6,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","According to a decrease in CA-125 serum concentrations, all patients responded to first-line treatment except for one (median decrease in CA-125 was 95% (range 54%-100%).",CA-125,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","According to a decrease in CA-125 serum concentrations, all patients responded to first-line treatment except for one (median decrease in CA-125 was 95% (range 54%-100%).",CA-125,serum,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","A significant positive correlation between NGAL serum levels and disease severity score was found (r = 0.206, p &#60; 0.02).",NGAL,serum,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
",We also noted significant differences in serum CRP levels between patients with lymph node metastasis and those without lymph node metastasis (P = 0.024).,CRP,lymph,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
",We also noted significant differences in serum CRP levels between patients with lymph node metastasis and those without lymph node metastasis (P = 0.024).,CRP,serum,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
",We also noted significant differences in serum CRP levels between patients with lymph node metastasis and those without lymph node metastasis (P = 0.024).,CRP,lymph,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","Association between IL-6 and CRP
Serum IL-6 levels were positively correlated with CRP levels (r2 = 0.049, P = 0.018) (Figure 5).

",CRP,Serum,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","Association between IL-6 and CRP
Serum IL-6 levels were positively correlated with CRP levels (r2 = 0.049, P = 0.018) (Figure 5).

",IL-6,Serum,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","Association between IL-6 and CRP
Serum IL-6 levels were positively correlated with CRP levels (r2 = 0.049, P = 0.018) (Figure 5).

",IL-6,Serum,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","Association between IL-6 and CRP
Serum IL-6 levels were positively correlated with CRP levels (r2 = 0.049, P = 0.018) (Figure 5).

",CRP,Serum,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","Discussion
In this study, the serum levels of both IL-6 and CRP evidenced statistically significant differences in tumor size, tumor invasion depth, and LN metastasis.",IL-6,serum,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","Discussion
In this study, the serum levels of both IL-6 and CRP evidenced statistically significant differences in tumor size, tumor invasion depth, and LN metastasis.",CRP,serum,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","The median level of IL-6 increased proportionally with the stage of the cancer (the median level of IL-6 in stage I 7.36 +- 5.52 pg/ml, stage II 7.66 +- 2.24 pg/ml, stage III 11.87 +- 14.90 pg/ml and stage IV 13.92 +- 10.76 pg/ml), and this difference was statistically significant (P &#60; 0.001). Additionally, serum IL-6 levels were significantly higher in patients with peritoneal metastasis (23.70 +- 14.55",IL-6,serum,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","The median level of IL-6 increased proportionally with the stage of the cancer (the median level of IL-6 in stage I 7.36 +- 5.52 pg/ml, stage II 7.66 +- 2.24 pg/ml, stage III 11.87 +- 14.90 pg/ml and stage IV 13.92 +- 10.76 pg/ml), and this difference was statistically significant (P &#60; 0.001). Additionally, serum IL-6 levels were significantly higher in patients with peritoneal metastasis (23.70 +- 14.55",IL-6,serum,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","The median level of IL-6 increased proportionally with the stage of the cancer (the median level of IL-6 in stage I 7.36 +- 5.52 pg/ml, stage II 7.66 +- 2.24 pg/ml, stage III 11.87 +- 14.90 pg/ml and stage IV 13.92 +- 10.76 pg/ml), and this difference was statistically significant (P &#60; 0.001). Additionally, serum IL-6 levels were significantly higher in patients with peritoneal metastasis (23.70 +- 14.55",IL-6,serum,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","The median level of IL-6 increased proportionally with the stage of the cancer (the median level of IL-6 in stage I 7.36 +- 5.52 pg/ml, stage II 7.66 +- 2.24 pg/ml, stage III 11.87 +- 14.90 pg/ml and stage IV 13.92 +- 10.76 pg/ml), and this difference was statistically significant (P &#60; 0.001). Additionally, serum IL-6 levels were significantly higher in patients with peritoneal metastasis (23.70 +- 14.55",III,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","The best protein for distinguishing malignant from benign tumors was cancer antigen 125 (CA-125), which is a prominent serum marker for ovarian cancer [12,81,83].",CA-125,serum,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","The principal objective of this study was to determine the preoperative serum levels of IL-6 and CRP in gastric carcinoma, and to correlate them with disease status and prognosis.

",IL-6,serum,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","The principal objective of this study was to determine the preoperative serum levels of IL-6 and CRP in gastric carcinoma, and to correlate them with disease status and prognosis.

",CRP,serum,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","Assay of serum IL-6 and CRP
Venous blood sampling was conducted within 7 days before the patients underwent operations.",IL-6,blood,-1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","Assay of serum IL-6 and CRP
Venous blood sampling was conducted within 7 days before the patients underwent operations.",IL-6,serum,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","Assay of serum IL-6 and CRP
Venous blood sampling was conducted within 7 days before the patients underwent operations.",CRP,blood,-1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","Assay of serum IL-6 and CRP
Venous blood sampling was conducted within 7 days before the patients underwent operations.",CRP,serum,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-1551945723110.1186/1471-2407-9-155Research ArticleClinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer Kim Do-Kyong 1dinkum1211@naver.comOh Sung Yong 1drosy@freechal.comKwon Hyuk-Chan 1hckwon@dau.ac.krLee Suee 1suee97@hanmail.netKwon Kyung A 1kkinga78@naver.comKim Byung Geun 1ebk10@hanmail.netKim Seong-Geun 1patheny@nate.comKim Sung-Hyun 1kshmoon@dau.ac.krJang Jin Seok 1jsjang@dau.ac.krKim Min Chan 2mckim@dau.ac.krKim Kyeong Hee 3progreen@dau.ac.krHan Jin-Yeong 3jyhan@dau.ac.krKim Hyo-Jin 1kimhj@dau.ac.kr1 Departments of Internal Medicine, Dong-A university College of Medicine, Busan, Korea2 Departments of Surgery, Dong-A university College of Medicine, Busan, Korea3 Departments of Laboratory Medicine, Dong-A university College of Medicine, Busan, Korea2009 20 5 2009 9 155 155 1 1 2009 20 5 2009 Copyright (c)2009 Kim et al; licensee BioMed Central Ltd.2009Kim et al; licensee BioMed Central Ltd.",Korea2,serum,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-1551945723110.1186/1471-2407-9-155Research ArticleClinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer Kim Do-Kyong 1dinkum1211@naver.comOh Sung Yong 1drosy@freechal.comKwon Hyuk-Chan 1hckwon@dau.ac.krLee Suee 1suee97@hanmail.netKwon Kyung A 1kkinga78@naver.comKim Byung Geun 1ebk10@hanmail.netKim Seong-Geun 1patheny@nate.comKim Sung-Hyun 1kshmoon@dau.ac.krJang Jin Seok 1jsjang@dau.ac.krKim Min Chan 2mckim@dau.ac.krKim Kyeong Hee 3progreen@dau.ac.krHan Jin-Yeong 3jyhan@dau.ac.krKim Hyo-Jin 1kimhj@dau.ac.kr1 Departments of Internal Medicine, Dong-A university College of Medicine, Busan, Korea2 Departments of Surgery, Dong-A university College of Medicine, Busan, Korea3 Departments of Laboratory Medicine, Dong-A university College of Medicine, Busan, Korea2009 20 5 2009 9 155 155 1 1 2009 20 5 2009 Copyright (c)2009 Kim et al; licensee BioMed Central Ltd.2009Kim et al; licensee BioMed Central Ltd.",BMC,serum,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-1551945723110.1186/1471-2407-9-155Research ArticleClinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer Kim Do-Kyong 1dinkum1211@naver.comOh Sung Yong 1drosy@freechal.comKwon Hyuk-Chan 1hckwon@dau.ac.krLee Suee 1suee97@hanmail.netKwon Kyung A 1kkinga78@naver.comKim Byung Geun 1ebk10@hanmail.netKim Seong-Geun 1patheny@nate.comKim Sung-Hyun 1kshmoon@dau.ac.krJang Jin Seok 1jsjang@dau.ac.krKim Min Chan 2mckim@dau.ac.krKim Kyeong Hee 3progreen@dau.ac.krHan Jin-Yeong 3jyhan@dau.ac.krKim Hyo-Jin 1kimhj@dau.ac.kr1 Departments of Internal Medicine, Dong-A university College of Medicine, Busan, Korea2 Departments of Surgery, Dong-A university College of Medicine, Busan, Korea3 Departments of Laboratory Medicine, Dong-A university College of Medicine, Busan, Korea2009 20 5 2009 9 155 155 1 1 2009 20 5 2009 Copyright (c)2009 Kim et al; licensee BioMed Central Ltd.2009Kim et al; licensee BioMed Central Ltd.",Korea3,serum,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-1551945723110.1186/1471-2407-9-155Research ArticleClinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer Kim Do-Kyong 1dinkum1211@naver.comOh Sung Yong 1drosy@freechal.comKwon Hyuk-Chan 1hckwon@dau.ac.krLee Suee 1suee97@hanmail.netKwon Kyung A 1kkinga78@naver.comKim Byung Geun 1ebk10@hanmail.netKim Seong-Geun 1patheny@nate.comKim Sung-Hyun 1kshmoon@dau.ac.krJang Jin Seok 1jsjang@dau.ac.krKim Min Chan 2mckim@dau.ac.krKim Kyeong Hee 3progreen@dau.ac.krHan Jin-Yeong 3jyhan@dau.ac.krKim Hyo-Jin 1kimhj@dau.ac.kr1 Departments of Internal Medicine, Dong-A university College of Medicine, Busan, Korea2 Departments of Surgery, Dong-A university College of Medicine, Busan, Korea3 Departments of Laboratory Medicine, Dong-A university College of Medicine, Busan, Korea2009 20 5 2009 9 155 155 1 1 2009 20 5 2009 Copyright (c)2009 Kim et al; licensee BioMed Central Ltd.2009Kim et al; licensee BioMed Central Ltd.",Cancer1471,serum,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-1551945723110.1186/1471-2407-9-155Research ArticleClinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer Kim Do-Kyong 1dinkum1211@naver.comOh Sung Yong 1drosy@freechal.comKwon Hyuk-Chan 1hckwon@dau.ac.krLee Suee 1suee97@hanmail.netKwon Kyung A 1kkinga78@naver.comKim Byung Geun 1ebk10@hanmail.netKim Seong-Geun 1patheny@nate.comKim Sung-Hyun 1kshmoon@dau.ac.krJang Jin Seok 1jsjang@dau.ac.krKim Min Chan 2mckim@dau.ac.krKim Kyeong Hee 3progreen@dau.ac.krHan Jin-Yeong 3jyhan@dau.ac.krKim Hyo-Jin 1kimhj@dau.ac.kr1 Departments of Internal Medicine, Dong-A university College of Medicine, Busan, Korea2 Departments of Surgery, Dong-A university College of Medicine, Busan, Korea3 Departments of Laboratory Medicine, Dong-A university College of Medicine, Busan, Korea2009 20 5 2009 9 155 155 1 1 2009 20 5 2009 Copyright (c)2009 Kim et al; licensee BioMed Central Ltd.2009Kim et al; licensee BioMed Central Ltd.",Korea2009,serum,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","PHA-stimulated whole blood was first incubated for 6 h at 37degC under 5% CO2 conditions in 1 ml of RPMI-1640 culture medium with 71 ml of PHA, and then treated with etoposide as described above.",CO2,blood,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","PHA-stimulated whole blood was first incubated for 6 h at 37degC under 5% CO2 conditions in 1 ml of RPMI-1640 culture medium with 71 ml of PHA, and then treated with etoposide as described above.",PHA,blood,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","PHA-stimulated whole blood was first incubated for 6 h at 37degC under 5% CO2 conditions in 1 ml of RPMI-1640 culture medium with 71 ml of PHA, and then treated with etoposide as described above.",RPMI-1640,blood,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","PHA-stimulated whole blood was first incubated for 6 h at 37degC under 5% CO2 conditions in 1 ml of RPMI-1640 culture medium with 71 ml of PHA, and then treated with etoposide as described above.",PHA,blood,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","Serum IL-6 levels were correlated positively with CRP levels (r2 = 0.049, P = 0.018).

",CRP,Serum,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","Serum IL-6 levels were correlated positively with CRP levels (r2 = 0.049, P = 0.018).

",IL-6,Serum,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","Statistical analysis
Serum levels of IL-6 and CRP were expressed as the means +- SD.",SD,Serum,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","Statistical analysis
Serum levels of IL-6 and CRP were expressed as the means +- SD.",IL-6,Serum,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","Statistical analysis
Serum levels of IL-6 and CRP were expressed as the means +- SD.",CRP,Serum,1
"PMC 
BMC_Cancer_2010_Aug_19_10_444.txt
","Tumour interstitial fluid (TIF) analysis
TIFs were produced by cutting the tumours into smaller 1 mm-sized pieces followed by 2 h incubation at 37degC in phosphate-buffered saline (PBS; 1:20 w/v ratio) as originally described by Celis et al., 2004 [22].",TIF,interstitial fluid,1
"PMC 
BMC_Cancer_2010_Aug_19_10_444.txt
","Tumour interstitial fluid (TIF) analysis
TIFs were produced by cutting the tumours into smaller 1 mm-sized pieces followed by 2 h incubation at 37degC in phosphate-buffered saline (PBS; 1:20 w/v ratio) as originally described by Celis et al., 2004 [22].",PBS,interstitial fluid,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","In cases of LN metastasis, we also noted a significant difference between the serum level of IL-6 and LN metastasis (P &#60; 0.001).",IL-6,serum,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","+- 0.69			
r, P: Spearman rho correlation, IL-6: interleukin-6, CRP: C-reactive protein, LN: lymph node, TNM (6th AJCC Stage Groupings: The staging systems; Primary tumor, regional LN, metastasis)

We noted that IL-6 levels were significantly correlated with IL-6 levels, and tumor size with higher IL-6 levels was detected in tumors sized >= 5 cm (P = 0.0012).",TNM,lymph,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","+- 0.69			
r, P: Spearman rho correlation, IL-6: interleukin-6, CRP: C-reactive protein, LN: lymph node, TNM (6th AJCC Stage Groupings: The staging systems; Primary tumor, regional LN, metastasis)

We noted that IL-6 levels were significantly correlated with IL-6 levels, and tumor size with higher IL-6 levels was detected in tumors sized >= 5 cm (P = 0.0012).",IL-6,lymph,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","+- 0.69			
r, P: Spearman rho correlation, IL-6: interleukin-6, CRP: C-reactive protein, LN: lymph node, TNM (6th AJCC Stage Groupings: The staging systems; Primary tumor, regional LN, metastasis)

We noted that IL-6 levels were significantly correlated with IL-6 levels, and tumor size with higher IL-6 levels was detected in tumors sized >= 5 cm (P = 0.0012).",IL-6,lymph,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","+- 0.69			
r, P: Spearman rho correlation, IL-6: interleukin-6, CRP: C-reactive protein, LN: lymph node, TNM (6th AJCC Stage Groupings: The staging systems; Primary tumor, regional LN, metastasis)

We noted that IL-6 levels were significantly correlated with IL-6 levels, and tumor size with higher IL-6 levels was detected in tumors sized >= 5 cm (P = 0.0012).",CRP,lymph,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","+- 0.69			
r, P: Spearman rho correlation, IL-6: interleukin-6, CRP: C-reactive protein, LN: lymph node, TNM (6th AJCC Stage Groupings: The staging systems; Primary tumor, regional LN, metastasis)

We noted that IL-6 levels were significantly correlated with IL-6 levels, and tumor size with higher IL-6 levels was detected in tumors sized >= 5 cm (P = 0.0012).",AJCC,lymph,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","+- 0.69			
r, P: Spearman rho correlation, IL-6: interleukin-6, CRP: C-reactive protein, LN: lymph node, TNM (6th AJCC Stage Groupings: The staging systems; Primary tumor, regional LN, metastasis)

We noted that IL-6 levels were significantly correlated with IL-6 levels, and tumor size with higher IL-6 levels was detected in tumors sized >= 5 cm (P = 0.0012).",IL-6,lymph,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","+- 0.69			
r, P: Spearman rho correlation, IL-6: interleukin-6, CRP: C-reactive protein, LN: lymph node, TNM (6th AJCC Stage Groupings: The staging systems; Primary tumor, regional LN, metastasis)

We noted that IL-6 levels were significantly correlated with IL-6 levels, and tumor size with higher IL-6 levels was detected in tumors sized >= 5 cm (P = 0.0012).",IL-6,lymph,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","Results
Patients' characteristics
The patients were classified by their pathologic characteristics, including tumor size, depth of tumor invasion, status of lymph node metastasis, TNM staging, and peritoneal metastasis.",TNM,lymph,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Figure 3 Kaplan-Meier plots of progression-free survival (left) and overall survival (right) for serum concentrations of CA-125 after chemotherapy, TIMP-1 after chemotherapy, VEGF-165 before chemotherapy and VEGF-165 after chemotherapy.",CA-125,serum,-1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Figure 3 Kaplan-Meier plots of progression-free survival (left) and overall survival (right) for serum concentrations of CA-125 after chemotherapy, TIMP-1 after chemotherapy, VEGF-165 before chemotherapy and VEGF-165 after chemotherapy.",VEGF-165,serum,-1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Figure 3 Kaplan-Meier plots of progression-free survival (left) and overall survival (right) for serum concentrations of CA-125 after chemotherapy, TIMP-1 after chemotherapy, VEGF-165 before chemotherapy and VEGF-165 after chemotherapy.",VEGF-165,serum,-1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Figure 3 Kaplan-Meier plots of progression-free survival (left) and overall survival (right) for serum concentrations of CA-125 after chemotherapy, TIMP-1 after chemotherapy, VEGF-165 before chemotherapy and VEGF-165 after chemotherapy.",TIMP-1,serum,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","PHA-stimulated and non-stimulated whole blood cells were treated for 2 or 24 h with different etoposide concentrations (0, 2.07, 20.7 and 207 mM), in the presence of RPMI-1640 culture medium and maintained at 37degC under 5% CO2 conditions.

",RPMI-1640,blood,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","PHA-stimulated and non-stimulated whole blood cells were treated for 2 or 24 h with different etoposide concentrations (0, 2.07, 20.7 and 207 mM), in the presence of RPMI-1640 culture medium and maintained at 37degC under 5% CO2 conditions.

",CO2,blood,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","PHA-stimulated and non-stimulated whole blood cells were treated for 2 or 24 h with different etoposide concentrations (0, 2.07, 20.7 and 207 mM), in the presence of RPMI-1640 culture medium and maintained at 37degC under 5% CO2 conditions.

",PHA,blood,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","358.37
(303.10/386.70)a	345.00
(308.48/383.40)ac	
CR: conditioning regimen; BMT: bone marrow transplantation; Units - P-SH: nmol P-SH/mL plasma.

",BMT,plasma,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","358.37
(303.10/386.70)a	345.00
(308.48/383.40)ac	
CR: conditioning regimen; BMT: bone marrow transplantation; Units - P-SH: nmol P-SH/mL plasma.

",BMT,bone marrow,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","358.37
(303.10/386.70)a	345.00
(308.48/383.40)ac	
CR: conditioning regimen; BMT: bone marrow transplantation; Units - P-SH: nmol P-SH/mL plasma.

",CR,plasma,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","358.37
(303.10/386.70)a	345.00
(308.48/383.40)ac	
CR: conditioning regimen; BMT: bone marrow transplantation; Units - P-SH: nmol P-SH/mL plasma.

",CR,bone marrow,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
",The enzyme reaction was initiated after 10 min of pre-incubation of blood with 1 mM ZnCl2.,ZnCl2,blood,-1
"PMC 
BMC_Cancer_2010_Apr_16_10_145.txt
","For the determination of LVI status we used criteria for identification as postulated by Rosen: ""Evaluation is limited to tissue peripheral to the carcinoma, intralymphatic tumor emboli usually do not conform exactly to the space in which they lie, endothelial nuclei should be present and coexistent blood vessels are confirmatory evidence.""[40]

Since many of the hereditary cases and some of the sporadic cases were referrals for which only one slide with tumor was available, we selected for each matched pair (case and control) the same number of slides to end up with a comparable number of slides assessed for LVI in both groups.",LVI,blood,1
"PMC 
BMC_Cancer_2010_Apr_16_10_145.txt
","For the determination of LVI status we used criteria for identification as postulated by Rosen: ""Evaluation is limited to tissue peripheral to the carcinoma, intralymphatic tumor emboli usually do not conform exactly to the space in which they lie, endothelial nuclei should be present and coexistent blood vessels are confirmatory evidence.""[40]

Since many of the hereditary cases and some of the sporadic cases were referrals for which only one slide with tumor was available, we selected for each matched pair (case and control) the same number of slides to end up with a comparable number of slides assessed for LVI in both groups.",LVI,blood,-1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Not graded	24(33.3%)	0.624	28(32.2%)	0.827	
 pathological response in tumor site				
  pCR	21(29.2%)		22(25.3%)		
  non-pCR	51(70.8%)	&#60;0.001	65(74.7%)	0.003	
Abbreviations: DFS, disease free survival, OS, overall survival; OR, odds ratio; 95%CI, 95% confidence interval; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; pCR, pathological complete response.

",OS,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Not graded	24(33.3%)	0.624	28(32.2%)	0.827	
 pathological response in tumor site				
  pCR	21(29.2%)		22(25.3%)		
  non-pCR	51(70.8%)	&#60;0.001	65(74.7%)	0.003	
Abbreviations: DFS, disease free survival, OS, overall survival; OR, odds ratio; 95%CI, 95% confidence interval; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; pCR, pathological complete response.

",OS,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Not graded	24(33.3%)	0.624	28(32.2%)	0.827	
 pathological response in tumor site				
  pCR	21(29.2%)		22(25.3%)		
  non-pCR	51(70.8%)	&#60;0.001	65(74.7%)	0.003	
Abbreviations: DFS, disease free survival, OS, overall survival; OR, odds ratio; 95%CI, 95% confidence interval; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; pCR, pathological complete response.

",IDC,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Not graded	24(33.3%)	0.624	28(32.2%)	0.827	
 pathological response in tumor site				
  pCR	21(29.2%)		22(25.3%)		
  non-pCR	51(70.8%)	&#60;0.001	65(74.7%)	0.003	
Abbreviations: DFS, disease free survival, OS, overall survival; OR, odds ratio; 95%CI, 95% confidence interval; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; pCR, pathological complete response.

",IDC,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Not graded	24(33.3%)	0.624	28(32.2%)	0.827	
 pathological response in tumor site				
  pCR	21(29.2%)		22(25.3%)		
  non-pCR	51(70.8%)	&#60;0.001	65(74.7%)	0.003	
Abbreviations: DFS, disease free survival, OS, overall survival; OR, odds ratio; 95%CI, 95% confidence interval; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; pCR, pathological complete response.

",PR,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Not graded	24(33.3%)	0.624	28(32.2%)	0.827	
 pathological response in tumor site				
  pCR	21(29.2%)		22(25.3%)		
  non-pCR	51(70.8%)	&#60;0.001	65(74.7%)	0.003	
Abbreviations: DFS, disease free survival, OS, overall survival; OR, odds ratio; 95%CI, 95% confidence interval; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; pCR, pathological complete response.

",PR,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Not graded	24(33.3%)	0.624	28(32.2%)	0.827	
 pathological response in tumor site				
  pCR	21(29.2%)		22(25.3%)		
  non-pCR	51(70.8%)	&#60;0.001	65(74.7%)	0.003	
Abbreviations: DFS, disease free survival, OS, overall survival; OR, odds ratio; 95%CI, 95% confidence interval; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; pCR, pathological complete response.

",DFS,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Not graded	24(33.3%)	0.624	28(32.2%)	0.827	
 pathological response in tumor site				
  pCR	21(29.2%)		22(25.3%)		
  non-pCR	51(70.8%)	&#60;0.001	65(74.7%)	0.003	
Abbreviations: DFS, disease free survival, OS, overall survival; OR, odds ratio; 95%CI, 95% confidence interval; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; pCR, pathological complete response.

",DFS,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Not graded	24(33.3%)	0.624	28(32.2%)	0.827	
 pathological response in tumor site				
  pCR	21(29.2%)		22(25.3%)		
  non-pCR	51(70.8%)	&#60;0.001	65(74.7%)	0.003	
Abbreviations: DFS, disease free survival, OS, overall survival; OR, odds ratio; 95%CI, 95% confidence interval; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; pCR, pathological complete response.

",cALN,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Not graded	24(33.3%)	0.624	28(32.2%)	0.827	
 pathological response in tumor site				
  pCR	21(29.2%)		22(25.3%)		
  non-pCR	51(70.8%)	&#60;0.001	65(74.7%)	0.003	
Abbreviations: DFS, disease free survival, OS, overall survival; OR, odds ratio; 95%CI, 95% confidence interval; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; pCR, pathological complete response.

",cALN,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Not graded	24(33.3%)	0.624	28(32.2%)	0.827	
 pathological response in tumor site				
  pCR	21(29.2%)		22(25.3%)		
  non-pCR	51(70.8%)	&#60;0.001	65(74.7%)	0.003	
Abbreviations: DFS, disease free survival, OS, overall survival; OR, odds ratio; 95%CI, 95% confidence interval; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; pCR, pathological complete response.

",pCR,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Not graded	24(33.3%)	0.624	28(32.2%)	0.827	
 pathological response in tumor site				
  pCR	21(29.2%)		22(25.3%)		
  non-pCR	51(70.8%)	&#60;0.001	65(74.7%)	0.003	
Abbreviations: DFS, disease free survival, OS, overall survival; OR, odds ratio; 95%CI, 95% confidence interval; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; pCR, pathological complete response.

",pCR,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Not graded	24(33.3%)	0.624	28(32.2%)	0.827	
 pathological response in tumor site				
  pCR	21(29.2%)		22(25.3%)		
  non-pCR	51(70.8%)	&#60;0.001	65(74.7%)	0.003	
Abbreviations: DFS, disease free survival, OS, overall survival; OR, odds ratio; 95%CI, 95% confidence interval; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; pCR, pathological complete response.

",SD,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Not graded	24(33.3%)	0.624	28(32.2%)	0.827	
 pathological response in tumor site				
  pCR	21(29.2%)		22(25.3%)		
  non-pCR	51(70.8%)	&#60;0.001	65(74.7%)	0.003	
Abbreviations: DFS, disease free survival, OS, overall survival; OR, odds ratio; 95%CI, 95% confidence interval; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; pCR, pathological complete response.

",SD,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Not graded	24(33.3%)	0.624	28(32.2%)	0.827	
 pathological response in tumor site				
  pCR	21(29.2%)		22(25.3%)		
  non-pCR	51(70.8%)	&#60;0.001	65(74.7%)	0.003	
Abbreviations: DFS, disease free survival, OS, overall survival; OR, odds ratio; 95%CI, 95% confidence interval; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; pCR, pathological complete response.

",pCR,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Not graded	24(33.3%)	0.624	28(32.2%)	0.827	
 pathological response in tumor site				
  pCR	21(29.2%)		22(25.3%)		
  non-pCR	51(70.8%)	&#60;0.001	65(74.7%)	0.003	
Abbreviations: DFS, disease free survival, OS, overall survival; OR, odds ratio; 95%CI, 95% confidence interval; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; pCR, pathological complete response.

",pCR,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Not graded	24(33.3%)	0.624	28(32.2%)	0.827	
 pathological response in tumor site				
  pCR	21(29.2%)		22(25.3%)		
  non-pCR	51(70.8%)	&#60;0.001	65(74.7%)	0.003	
Abbreviations: DFS, disease free survival, OS, overall survival; OR, odds ratio; 95%CI, 95% confidence interval; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; pCR, pathological complete response.

",pALN,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Not graded	24(33.3%)	0.624	28(32.2%)	0.827	
 pathological response in tumor site				
  pCR	21(29.2%)		22(25.3%)		
  non-pCR	51(70.8%)	&#60;0.001	65(74.7%)	0.003	
Abbreviations: DFS, disease free survival, OS, overall survival; OR, odds ratio; 95%CI, 95% confidence interval; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; pCR, pathological complete response.

",pALN,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Not graded	24(33.3%)	0.624	28(32.2%)	0.827	
 pathological response in tumor site				
  pCR	21(29.2%)		22(25.3%)		
  non-pCR	51(70.8%)	&#60;0.001	65(74.7%)	0.003	
Abbreviations: DFS, disease free survival, OS, overall survival; OR, odds ratio; 95%CI, 95% confidence interval; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; pCR, pathological complete response.

",pCR,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Not graded	24(33.3%)	0.624	28(32.2%)	0.827	
 pathological response in tumor site				
  pCR	21(29.2%)		22(25.3%)		
  non-pCR	51(70.8%)	&#60;0.001	65(74.7%)	0.003	
Abbreviations: DFS, disease free survival, OS, overall survival; OR, odds ratio; 95%CI, 95% confidence interval; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; pCR, pathological complete response.

",pCR,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Not graded	24(33.3%)	0.624	28(32.2%)	0.827	
 pathological response in tumor site				
  pCR	21(29.2%)		22(25.3%)		
  non-pCR	51(70.8%)	&#60;0.001	65(74.7%)	0.003	
Abbreviations: DFS, disease free survival, OS, overall survival; OR, odds ratio; 95%CI, 95% confidence interval; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; pCR, pathological complete response.

",CR,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Not graded	24(33.3%)	0.624	28(32.2%)	0.827	
 pathological response in tumor site				
  pCR	21(29.2%)		22(25.3%)		
  non-pCR	51(70.8%)	&#60;0.001	65(74.7%)	0.003	
Abbreviations: DFS, disease free survival, OS, overall survival; OR, odds ratio; 95%CI, 95% confidence interval; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; pCR, pathological complete response.

",CR,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Not graded	24(33.3%)	0.624	28(32.2%)	0.827	
 pathological response in tumor site				
  pCR	21(29.2%)		22(25.3%)		
  non-pCR	51(70.8%)	&#60;0.001	65(74.7%)	0.003	
Abbreviations: DFS, disease free survival, OS, overall survival; OR, odds ratio; 95%CI, 95% confidence interval; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; pCR, pathological complete response.

",ILC,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Not graded	24(33.3%)	0.624	28(32.2%)	0.827	
 pathological response in tumor site				
  pCR	21(29.2%)		22(25.3%)		
  non-pCR	51(70.8%)	&#60;0.001	65(74.7%)	0.003	
Abbreviations: DFS, disease free survival, OS, overall survival; OR, odds ratio; 95%CI, 95% confidence interval; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; pCR, pathological complete response.

",ILC,lymph,1
"PMC 
BMC_Cancer_2009_May_27_9_162.txt
","Methods
Cell culture
The human melanoma cell lines, A375 (American Type Culture Collection, Manassas, VA), WM266-4 (Wistar Special Collection), Lox (established from a lymph node metastasis of a patient at the Norwegian Radium Hospital) [10] and C8161.9 (a highly metastatic, amelanotic melanoma cell line derived from an abdominal wall metastasis) [11] were grown in monolayer culture in RPMI 1640 with glutamine supplemented with 10% fetal bovine serum at 37degC in a humidified atmosphere consisting of 5% CO2 and 95% air.",A375,lymph,1
"PMC 
BMC_Cancer_2009_May_27_9_162.txt
","Methods
Cell culture
The human melanoma cell lines, A375 (American Type Culture Collection, Manassas, VA), WM266-4 (Wistar Special Collection), Lox (established from a lymph node metastasis of a patient at the Norwegian Radium Hospital) [10] and C8161.9 (a highly metastatic, amelanotic melanoma cell line derived from an abdominal wall metastasis) [11] were grown in monolayer culture in RPMI 1640 with glutamine supplemented with 10% fetal bovine serum at 37degC in a humidified atmosphere consisting of 5% CO2 and 95% air.",A375,serum,1
"PMC 
BMC_Cancer_2009_May_27_9_162.txt
","Methods
Cell culture
The human melanoma cell lines, A375 (American Type Culture Collection, Manassas, VA), WM266-4 (Wistar Special Collection), Lox (established from a lymph node metastasis of a patient at the Norwegian Radium Hospital) [10] and C8161.9 (a highly metastatic, amelanotic melanoma cell line derived from an abdominal wall metastasis) [11] were grown in monolayer culture in RPMI 1640 with glutamine supplemented with 10% fetal bovine serum at 37degC in a humidified atmosphere consisting of 5% CO2 and 95% air.",RPMI,lymph,1
"PMC 
BMC_Cancer_2009_May_27_9_162.txt
","Methods
Cell culture
The human melanoma cell lines, A375 (American Type Culture Collection, Manassas, VA), WM266-4 (Wistar Special Collection), Lox (established from a lymph node metastasis of a patient at the Norwegian Radium Hospital) [10] and C8161.9 (a highly metastatic, amelanotic melanoma cell line derived from an abdominal wall metastasis) [11] were grown in monolayer culture in RPMI 1640 with glutamine supplemented with 10% fetal bovine serum at 37degC in a humidified atmosphere consisting of 5% CO2 and 95% air.",RPMI,serum,1
"PMC 
BMC_Cancer_2009_May_27_9_162.txt
","Methods
Cell culture
The human melanoma cell lines, A375 (American Type Culture Collection, Manassas, VA), WM266-4 (Wistar Special Collection), Lox (established from a lymph node metastasis of a patient at the Norwegian Radium Hospital) [10] and C8161.9 (a highly metastatic, amelanotic melanoma cell line derived from an abdominal wall metastasis) [11] were grown in monolayer culture in RPMI 1640 with glutamine supplemented with 10% fetal bovine serum at 37degC in a humidified atmosphere consisting of 5% CO2 and 95% air.",CO2,lymph,1
"PMC 
BMC_Cancer_2009_May_27_9_162.txt
","Methods
Cell culture
The human melanoma cell lines, A375 (American Type Culture Collection, Manassas, VA), WM266-4 (Wistar Special Collection), Lox (established from a lymph node metastasis of a patient at the Norwegian Radium Hospital) [10] and C8161.9 (a highly metastatic, amelanotic melanoma cell line derived from an abdominal wall metastasis) [11] were grown in monolayer culture in RPMI 1640 with glutamine supplemented with 10% fetal bovine serum at 37degC in a humidified atmosphere consisting of 5% CO2 and 95% air.",CO2,serum,1
"PMC 
BMC_Cancer_2009_May_27_9_162.txt
","Methods
Cell culture
The human melanoma cell lines, A375 (American Type Culture Collection, Manassas, VA), WM266-4 (Wistar Special Collection), Lox (established from a lymph node metastasis of a patient at the Norwegian Radium Hospital) [10] and C8161.9 (a highly metastatic, amelanotic melanoma cell line derived from an abdominal wall metastasis) [11] were grown in monolayer culture in RPMI 1640 with glutamine supplemented with 10% fetal bovine serum at 37degC in a humidified atmosphere consisting of 5% CO2 and 95% air.",WM266,lymph,1
"PMC 
BMC_Cancer_2009_May_27_9_162.txt
","Methods
Cell culture
The human melanoma cell lines, A375 (American Type Culture Collection, Manassas, VA), WM266-4 (Wistar Special Collection), Lox (established from a lymph node metastasis of a patient at the Norwegian Radium Hospital) [10] and C8161.9 (a highly metastatic, amelanotic melanoma cell line derived from an abdominal wall metastasis) [11] were grown in monolayer culture in RPMI 1640 with glutamine supplemented with 10% fetal bovine serum at 37degC in a humidified atmosphere consisting of 5% CO2 and 95% air.",WM266,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Patients with low serum CA-125 at the end of first-line therapy had a favourable progression-free (p &#60; 0.001) and overall survival (p = 0.002, Figure 3).",CA-125,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_138.txt
","In line with our data on p16 methylation in normal tissue, Hibi et al presented one case of p16 methylation in the normal tissue in addition to WBCs of peripheral blood.",p16,blood,-1
"PMC 
BMC_Cancer_2010_Apr_13_10_138.txt
","In line with our data on p16 methylation in normal tissue, Hibi et al presented one case of p16 methylation in the normal tissue in addition to WBCs of peripheral blood.",p16,blood,-1
"PMC 
BMC_Cancer_2009_May_6_9_134.txt
","In rectal cancer, NGAL mRNA overexpression was significantly associated with depth of invasion (p = 0.028), lymph node metastasis (p = 0.009), venous involvement (p = 0.023) and advanced pTNM stage (p = 0.011).

",NGAL,lymph,1
"PMC 
BMC_Cancer_2009_May_6_9_134.txt
","In rectal cancer, NGAL mRNA overexpression was significantly associated with depth of invasion (p = 0.028), lymph node metastasis (p = 0.009), venous involvement (p = 0.023) and advanced pTNM stage (p = 0.011).

",mRNA,lymph,1
"PMC 
BMC_Cancer_2009_May_6_9_134.txt
","In rectal cancer, NGAL mRNA overexpression was significantly associated with depth of invasion (p = 0.028), lymph node metastasis (p = 0.009), venous involvement (p = 0.023) and advanced pTNM stage (p = 0.011).

",pTNM,lymph,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","There were no significant differences among untreated TIMP-1 high and low patients with respect to clinicopathological parameters (type of surgery, age, number of tumor-positive lymph nodes, tumor size, hormone receptor status, tumor grade, RT; data not shown).

",TIMP-1,lymph,1
"PMC 
BMC_Cancer_2010_Apr_28_10_168.txt
","High PI Synthase activity has been observed in src- and erbB2-transformed cells regulated by tyrosine kinase [25]; moreover, PI synthesis could be stimulated by addition of mitogenic growth factors and serum in quiescent normal rat kidney (NRK) cells.",NRK,serum,1
"PMC 
BMC_Cancer_2009_Nov_24_9_409.txt
","Notwithstanding the relatively limited RNA degradation, a time-dependent modulation of genes was observed in the different serial aliquots, likely expected as a cellular reaction to stress conditions following the surgical resection of blood vessels and the suboptimal pre-analytical conditions.",RNA,blood,-1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
",CR: conditioning regimen; BMT: bone marrow transplantation.,CR,bone marrow,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
",CR: conditioning regimen; BMT: bone marrow transplantation.,BMT,bone marrow,1
"PMC 
BMC_Cancer_2010_Aug_19_10_444.txt
","It has been shown that elevated serum levels of IL-6 and MMP-2 in breast cancer patients correlates with the stage and the severity of the disease [63,64].",IL-6,serum,1
"PMC 
BMC_Cancer_2010_Aug_19_10_444.txt
","It has been shown that elevated serum levels of IL-6 and MMP-2 in breast cancer patients correlates with the stage and the severity of the disease [63,64].",MMP-2,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
",CA-125 decreased significantly after surgery whereas the serum concentrations of TIMP-1 and VEGF-165 increased (Figure 1).,TIMP-1,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
",CA-125 decreased significantly after surgery whereas the serum concentrations of TIMP-1 and VEGF-165 increased (Figure 1).,VEGF-165,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
",CA-125 decreased significantly after surgery whereas the serum concentrations of TIMP-1 and VEGF-165 increased (Figure 1).,CA-125,serum,1
"PMC 
BMC_Cancer_2009_May_27_9_162.txt
","We analyzed 4 thick PM's (&#62;4 mm) and 16 MM samples composed of 12 bulky, macroscopic (replaced) lymph node metastases and 4 subcutaneous metastases.

",PM,lymph,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Serum NGAL levels were higher in patients with IDC (p &#60; 0.008) while moderate in patients with DCIS, ADH and sclerosing adenosis compared to healthy controls.",NGAL,Serum,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Serum NGAL levels were higher in patients with IDC (p &#60; 0.008) while moderate in patients with DCIS, ADH and sclerosing adenosis compared to healthy controls.",IDC,Serum,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Serum NGAL levels were higher in patients with IDC (p &#60; 0.008) while moderate in patients with DCIS, ADH and sclerosing adenosis compared to healthy controls.",DCIS,Serum,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Serum NGAL levels were higher in patients with IDC (p &#60; 0.008) while moderate in patients with DCIS, ADH and sclerosing adenosis compared to healthy controls.",ADH,Serum,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","The authors also reported similar findings for NGAL expression in serum, with levels being significantly higher in patients with benign and grade 1 tumors compared to healthy controls.",NGAL,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Table 5 Correlations between serum concentrations of VEGF-165 and TIMP-1 and response to first-line treatment according to decrease of CA-125.

	",CA-125,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Table 5 Correlations between serum concentrations of VEGF-165 and TIMP-1 and response to first-line treatment according to decrease of CA-125.

	",TIMP-1,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Table 5 Correlations between serum concentrations of VEGF-165 and TIMP-1 and response to first-line treatment according to decrease of CA-125.

	",VEGF-165,serum,1
"PMC 
BMC_Cancer_2010_Aug_19_10_444.txt
","The formed cell aggregates were manually transferred to a layer of polymerized Matrigel(tm) (growth factor-reduced, BD) mixed 1:1 with serum-free DMEM prior to use.",DMEM,serum,1
"PMC 
BMC_Cancer_2010_Aug_16_10_431.txt
",An increased serum VEGF expression was also observed in ovarian cancer patients carrying -634 C allele [22].,VEGF,serum,1
"PMC 
BMC_Cancer_2009_Sep_6_9_315.txt
","Methods
Cell lines
The human NPC cell lines C666-1, CNE-1, CNE-2, HNE-1, SUNE-1, and HONE-1 were grown in RPMI-1640 medium (Hyclone, Logan, UT) supplemented with 10% fetal calf serum (ExCell, Shanghai, China) and 1% L-glutamine.",C666,serum,1
"PMC 
BMC_Cancer_2009_Sep_6_9_315.txt
","Methods
Cell lines
The human NPC cell lines C666-1, CNE-1, CNE-2, HNE-1, SUNE-1, and HONE-1 were grown in RPMI-1640 medium (Hyclone, Logan, UT) supplemented with 10% fetal calf serum (ExCell, Shanghai, China) and 1% L-glutamine.",NPC,serum,1
"PMC 
BMC_Cancer_2009_Sep_6_9_315.txt
","Methods
Cell lines
The human NPC cell lines C666-1, CNE-1, CNE-2, HNE-1, SUNE-1, and HONE-1 were grown in RPMI-1640 medium (Hyclone, Logan, UT) supplemented with 10% fetal calf serum (ExCell, Shanghai, China) and 1% L-glutamine.",RPMI-1640,serum,1
"PMC 
BMC_Cancer_2009_Sep_6_9_315.txt
","Methods
Cell lines
The human NPC cell lines C666-1, CNE-1, CNE-2, HNE-1, SUNE-1, and HONE-1 were grown in RPMI-1640 medium (Hyclone, Logan, UT) supplemented with 10% fetal calf serum (ExCell, Shanghai, China) and 1% L-glutamine.",HNE-1,serum,1
"PMC 
BMC_Cancer_2009_Sep_6_9_315.txt
","Methods
Cell lines
The human NPC cell lines C666-1, CNE-1, CNE-2, HNE-1, SUNE-1, and HONE-1 were grown in RPMI-1640 medium (Hyclone, Logan, UT) supplemented with 10% fetal calf serum (ExCell, Shanghai, China) and 1% L-glutamine.",CNE-1,serum,1
"PMC 
BMC_Cancer_2009_Sep_6_9_315.txt
","Methods
Cell lines
The human NPC cell lines C666-1, CNE-1, CNE-2, HNE-1, SUNE-1, and HONE-1 were grown in RPMI-1640 medium (Hyclone, Logan, UT) supplemented with 10% fetal calf serum (ExCell, Shanghai, China) and 1% L-glutamine.",HONE-1,serum,1
"PMC 
BMC_Cancer_2009_Sep_6_9_315.txt
","Methods
Cell lines
The human NPC cell lines C666-1, CNE-1, CNE-2, HNE-1, SUNE-1, and HONE-1 were grown in RPMI-1640 medium (Hyclone, Logan, UT) supplemented with 10% fetal calf serum (ExCell, Shanghai, China) and 1% L-glutamine.",SUNE-1,serum,1
"PMC 
BMC_Cancer_2009_Sep_6_9_315.txt
","Methods
Cell lines
The human NPC cell lines C666-1, CNE-1, CNE-2, HNE-1, SUNE-1, and HONE-1 were grown in RPMI-1640 medium (Hyclone, Logan, UT) supplemented with 10% fetal calf serum (ExCell, Shanghai, China) and 1% L-glutamine.",CNE-2,serum,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","The three subgroups differed significantly with respect to the number of tumor-positive lymph nodes, tumor size, and primary treatment (Pearson X2 test, P &#60; 0.001, Table 1).",X2,lymph,1
"PMC 
BMC_Cancer_2009_Sep_6_9_315.txt
","Furthermore, the Cripto-1 expression level was increased in lymph node metastases compared with their primary tumours[23].",Cripto-1,lymph,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Correlations between serum VEGF-165 and TIMP-1 concentrations and treatment response according to CA-125 decrease were evaluated by pair wise Pearson-correlations, assessing the coherence of continuous serum values of VEGF-165 and TIMP-1 and the relative decrease of CA-125 during therapy.

",VEGF-165,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Correlations between serum VEGF-165 and TIMP-1 concentrations and treatment response according to CA-125 decrease were evaluated by pair wise Pearson-correlations, assessing the coherence of continuous serum values of VEGF-165 and TIMP-1 and the relative decrease of CA-125 during therapy.

",VEGF-165,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Correlations between serum VEGF-165 and TIMP-1 concentrations and treatment response according to CA-125 decrease were evaluated by pair wise Pearson-correlations, assessing the coherence of continuous serum values of VEGF-165 and TIMP-1 and the relative decrease of CA-125 during therapy.

",CA-125,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Correlations between serum VEGF-165 and TIMP-1 concentrations and treatment response according to CA-125 decrease were evaluated by pair wise Pearson-correlations, assessing the coherence of continuous serum values of VEGF-165 and TIMP-1 and the relative decrease of CA-125 during therapy.

",CA-125,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Correlations between serum VEGF-165 and TIMP-1 concentrations and treatment response according to CA-125 decrease were evaluated by pair wise Pearson-correlations, assessing the coherence of continuous serum values of VEGF-165 and TIMP-1 and the relative decrease of CA-125 during therapy.

",VEGF-165,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Correlations between serum VEGF-165 and TIMP-1 concentrations and treatment response according to CA-125 decrease were evaluated by pair wise Pearson-correlations, assessing the coherence of continuous serum values of VEGF-165 and TIMP-1 and the relative decrease of CA-125 during therapy.

",VEGF-165,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Correlations between serum VEGF-165 and TIMP-1 concentrations and treatment response according to CA-125 decrease were evaluated by pair wise Pearson-correlations, assessing the coherence of continuous serum values of VEGF-165 and TIMP-1 and the relative decrease of CA-125 during therapy.

",CA-125,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Correlations between serum VEGF-165 and TIMP-1 concentrations and treatment response according to CA-125 decrease were evaluated by pair wise Pearson-correlations, assessing the coherence of continuous serum values of VEGF-165 and TIMP-1 and the relative decrease of CA-125 during therapy.

",CA-125,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Correlations between serum VEGF-165 and TIMP-1 concentrations and treatment response according to CA-125 decrease were evaluated by pair wise Pearson-correlations, assessing the coherence of continuous serum values of VEGF-165 and TIMP-1 and the relative decrease of CA-125 during therapy.

",TIMP-1,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Correlations between serum VEGF-165 and TIMP-1 concentrations and treatment response according to CA-125 decrease were evaluated by pair wise Pearson-correlations, assessing the coherence of continuous serum values of VEGF-165 and TIMP-1 and the relative decrease of CA-125 during therapy.

",TIMP-1,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Correlations between serum VEGF-165 and TIMP-1 concentrations and treatment response according to CA-125 decrease were evaluated by pair wise Pearson-correlations, assessing the coherence of continuous serum values of VEGF-165 and TIMP-1 and the relative decrease of CA-125 during therapy.

",TIMP-1,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Correlations between serum VEGF-165 and TIMP-1 concentrations and treatment response according to CA-125 decrease were evaluated by pair wise Pearson-correlations, assessing the coherence of continuous serum values of VEGF-165 and TIMP-1 and the relative decrease of CA-125 during therapy.

",TIMP-1,serum,1
"PMC 
BMC_Cancer_2009_Oct_6_9_353.txt
","PL developed the protocol for miRNA extraction, extracted the miRNAs from blood cells, and contributed in paper writing.",PL,blood,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
",And elevation of serum NSE (p = .034) was related to a higher ORR.,ORR,serum,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
",And elevation of serum NSE (p = .034) was related to a higher ORR.,NSE,serum,1
"PMC 
BMC_Cancer_2009_Oct_22_9_376.txt
","We previously reported that the upregulation of CK19 in feces predicted the presence of metastasis [20].

",CK19,feces,1
"PMC 
BMC_Cancer_2009_Nov_30_9_414.txt
","Se speciation analysis by HPLC/ICP-MS
Se speciation was measured using high-performance liquid chromatography (HPLC) coupled to inductively coupled plasma mass spectrometry (ICP-MS).",HPLC,plasma,1
"PMC 
BMC_Cancer_2009_Nov_30_9_414.txt
","Se speciation analysis by HPLC/ICP-MS
Se speciation was measured using high-performance liquid chromatography (HPLC) coupled to inductively coupled plasma mass spectrometry (ICP-MS).",ICP,plasma,1
"PMC 
BMC_Cancer_2009_Nov_30_9_414.txt
","Se speciation analysis by HPLC/ICP-MS
Se speciation was measured using high-performance liquid chromatography (HPLC) coupled to inductively coupled plasma mass spectrometry (ICP-MS).",HPLC,plasma,1
"PMC 
BMC_Cancer_2009_Nov_30_9_414.txt
","Se speciation analysis by HPLC/ICP-MS
Se speciation was measured using high-performance liquid chromatography (HPLC) coupled to inductively coupled plasma mass spectrometry (ICP-MS).",ICP,plasma,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
",Lim et al reported that tissue expression of NGAL in ovarian tumors changes with disease grade and this is also reflected in serum levels [17].,NGAL,serum,1
"PMC 
BMC_Cancer_2009_Oct_22_9_376.txt
","In addition, serum levels of the CK19 protein fragment CYFRA 21-1 were also evaluated in many cancers, and could represent a useful circulating tumor marker [12-14].

",CK19,serum,1
"PMC 
BMC_Cancer_2009_Oct_22_9_376.txt
","In addition, serum levels of the CK19 protein fragment CYFRA 21-1 were also evaluated in many cancers, and could represent a useful circulating tumor marker [12-14].

",CYFRA,serum,1
"PMC 
BMC_Cancer_2009_Oct_22_9_376.txt
","In the present study, we used quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) [21] to specifically quantify the CK19 transcript, which is considered to be relatively specific for epithelial cells in the feces of CRC patients.",PCR,feces,1
"PMC 
BMC_Cancer_2009_Oct_22_9_376.txt
","In the present study, we used quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) [21] to specifically quantify the CK19 transcript, which is considered to be relatively specific for epithelial cells in the feces of CRC patients.",CRC,feces,1
"PMC 
BMC_Cancer_2009_Oct_22_9_376.txt
","In the present study, we used quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) [21] to specifically quantify the CK19 transcript, which is considered to be relatively specific for epithelial cells in the feces of CRC patients.",CK19,feces,1
"PMC 
BMC_Cancer_2009_Oct_22_9_376.txt
","In the present study, we used quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) [21] to specifically quantify the CK19 transcript, which is considered to be relatively specific for epithelial cells in the feces of CRC patients.",qRT,feces,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","HEK293T cells were cultured in DME-medium containing 10% fetal bovine serum, 100 U/ml penicillin, 100 mg/ml streptomycin and 2 mM L-glutamine.",T,serum,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","HEK293T cells were cultured in DME-medium containing 10% fetal bovine serum, 100 U/ml penicillin, 100 mg/ml streptomycin and 2 mM L-glutamine.",HEK293,serum,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","HEK293T cells were cultured in DME-medium containing 10% fetal bovine serum, 100 U/ml penicillin, 100 mg/ml streptomycin and 2 mM L-glutamine.",DME,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","It is reasonable to hypothesize that a higher tumor burden in the marrow could be associated with higher cytokine levels, which could further result in increased numbers of mature osteoclasts and elevated serum TRACP 5b activity.

",TRACP,serum,1
"PMC 
BMC_Cancer_2010_Aug_11_10_419.txt
","(Nanjing, China), and were cultured in RPMI 1640 supplemented with 10% fetal bovine serum, at 37degC in a humid incubator with 5% CO2.",RPMI,serum,1
"PMC 
BMC_Cancer_2010_Aug_11_10_419.txt
","(Nanjing, China), and were cultured in RPMI 1640 supplemented with 10% fetal bovine serum, at 37degC in a humid incubator with 5% CO2.",CO2,serum,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
","Methods
Specimens
The serum samples for SELDI-TOF mass spectrometry analysis were collected from 27 OS patients (age 8 - 26 years) prior to chemotherapeutics.",SELDI,serum,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
","Methods
Specimens
The serum samples for SELDI-TOF mass spectrometry analysis were collected from 27 OS patients (age 8 - 26 years) prior to chemotherapeutics.",TOF,serum,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
","Methods
Specimens
The serum samples for SELDI-TOF mass spectrometry analysis were collected from 27 OS patients (age 8 - 26 years) prior to chemotherapeutics.",OS,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Measuring serum protein levels with ELISA
Blood sera were collected under the HIPAA-compliant protocol ""Blood and Tissue Bank for the Discovery and Validation of Circulating Breast Cancer Markers.",ELISA,sera,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Measuring serum protein levels with ELISA
Blood sera were collected under the HIPAA-compliant protocol ""Blood and Tissue Bank for the Discovery and Validation of Circulating Breast Cancer Markers.",ELISA,Blood,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Measuring serum protein levels with ELISA
Blood sera were collected under the HIPAA-compliant protocol ""Blood and Tissue Bank for the Discovery and Validation of Circulating Breast Cancer Markers.",ELISA,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Measuring serum protein levels with ELISA
Blood sera were collected under the HIPAA-compliant protocol ""Blood and Tissue Bank for the Discovery and Validation of Circulating Breast Cancer Markers.",ELISA,Blood,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Measuring serum protein levels with ELISA
Blood sera were collected under the HIPAA-compliant protocol ""Blood and Tissue Bank for the Discovery and Validation of Circulating Breast Cancer Markers.",HIPAA,sera,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Measuring serum protein levels with ELISA
Blood sera were collected under the HIPAA-compliant protocol ""Blood and Tissue Bank for the Discovery and Validation of Circulating Breast Cancer Markers.",HIPAA,Blood,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Measuring serum protein levels with ELISA
Blood sera were collected under the HIPAA-compliant protocol ""Blood and Tissue Bank for the Discovery and Validation of Circulating Breast Cancer Markers.",HIPAA,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Measuring serum protein levels with ELISA
Blood sera were collected under the HIPAA-compliant protocol ""Blood and Tissue Bank for the Discovery and Validation of Circulating Breast Cancer Markers.",HIPAA,Blood,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IL-7,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IL-7,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IL-7,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MCP-2,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MCP-2,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MCP-2,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",CD40L,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",CD40L,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",CD40L,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",RII,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",RII,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",RII,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",A2,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",A2,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",A2,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IL-17,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IL-17,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IL-17,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IL-8,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IL-8,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IL-8,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",sIL-6R,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",sIL-6R,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",sIL-6R,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",TTR,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",TTR,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",TTR,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MCP-3,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MCP-3,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MCP-3,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",C3,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",C3,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",C3,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",ULBP-3,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",ULBP-3,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",ULBP-3,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",TRAP,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",TRAP,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",TRAP,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MPO,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MPO,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MPO,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",HGF,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",HGF,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",HGF,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MMP-13,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MMP-13,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MMP-13,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IFN,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IFN,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IFN,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",CEA,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",CEA,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",CEA,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",TSH,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",TSH,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",TSH,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",FGF,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",FGF,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",FGF,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",PROLACTIN,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",PROLACTIN,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",PROLACTIN,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IFN,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IFN,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IFN,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",tPAI-1,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",tPAI-1,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",tPAI-1,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MMP-2,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MMP-2,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MMP-2,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MCP-1,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MCP-1,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MCP-1,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IL-4,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IL-4,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IL-4,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IL-2R,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IL-2R,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IL-2R,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",sICAM-1,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",sICAM-1,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",sICAM-1,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",AFP,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",AFP,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",AFP,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MIG,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MIG,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MIG,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",RANTES,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",RANTES,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",RANTES,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",ULBP-1,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",ULBP-1,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",ULBP-1,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MIF,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MIF,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MIF,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MICA,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MICA,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MICA,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",ELISA,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",ELISA,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",ELISA,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",VEGF,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",VEGF,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",VEGF,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IGFBP-1,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IGFBP-1,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IGFBP-1,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IL-2,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IL-2,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IL-2,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MMP-7,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MMP-7,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MMP-7,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",ULBP-2,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",ULBP-2,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",ULBP-2,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",FSH,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",FSH,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",FSH,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",SCC,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",SCC,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",SCC,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",DR5,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",DR5,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",DR5,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MMP-3,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MMP-3,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MMP-3,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IL-10,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IL-10,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IL-10,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",sVCAM-1,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",sVCAM-1,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",sVCAM-1,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MMP-8,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MMP-8,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MMP-8,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",CSF,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",CSF,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",S-100,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",S-100,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",S-100,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",GH,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",GH,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",GH,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",TNF,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",TNF,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",TNF,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",EGFR,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",EGFR,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",EGFR,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MMP-9,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MMP-9,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MMP-9,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",A1,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",A1,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",A1,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",SAA,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",SAA,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",SAA,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",C2,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",C2,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",C2,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MMP-12,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MMP-12,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MMP-12,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",PAI,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",PAI,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",PAI,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",GM,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",GM,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",GM,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",TNF,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",TNF,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",TNF,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IL-5,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IL-5,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IL-5,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",EGF,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",EGF,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",EGF,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",CA-125,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",CA-125,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",CA-125,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",CSF,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",EOTAXIN,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",EOTAXIN,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",EOTAXIN,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MMP-1,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MMP-1,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",MMP-1,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IL-6,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IL-6,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IL-6,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IL-13,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IL-13,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IL-13,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",NGF,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",NGF,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",NGF,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",GROa,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",GROa,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",GROa,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",CA72,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",CA72,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",CA72,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",TNF,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",TNF,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",TNF,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",ErbB2,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",ErbB2,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",ErbB2,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",ACTH,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",ACTH,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",ACTH,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IL-15,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IL-15,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IL-15,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IP-10,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IP-10,CSF,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Table 2 List of the 98 serum proteins measured by ELISA assay (Luminex platform)

ACTH	Adiponectin	AFP	Angiostatin	
Apolipoprotein A1	Apolipoprotein Apo A2	Apolipoprotein Apo B	Apolipoprotein Apo C2	
	
Apolipoprotein Apo C3	Apolipoprotein Apo E	CA 15-3	CA 19-9	
	
CA-125	CA72-4	CD40L (TRAP)	CEA	
	
Cytokeratin 19	DR5	EGF	EGFR	
	
EOTAXIN	ErbB2	FGF-b	Fibrinogen	
	
Fractalkine	FSH	G-CSF	GH	
	
GM-CSF	GROa	Haptoglobin	HGF	
	
IFN-a	IFN-g	IGFBP-1	IL-10	
	
IL-12p40	IL-13	IL-15	IL-17	
	
IL-1a	IL-1b	IL-1Ra	IL-2	
	
IL-2R	IL-4	IL-5	IL-6	
	
IL-7	IL-8	IP-10	Kallikrein 10	
	
Kallikrein 8	Leptin	LH	MCP-1	
	
MCP-2	MCP-3	Mesothelin(IgY)	MICA	
	
MIF	MIG	MIP-1a	MIP-1b	
	
MMP-1	MMP-12	MMP-13	MMP-2	
	
MMP-3	MMP-7	MMP-8	MMP-9	
	
MPO	NGF	PAI-I(active)	PROLACTIN	
	
RANTES	Resistin	S-100	SAA	
	
SCC	sE-Selectin	sFas	sFasL	
	
sICAM-1	sIL-6R	sVCAM-1	TGFa	
	
TNF-a	TNF-RI	TNF-RII	tPAI-1	
	
TSH	TTR	ULBP-1	ULBP-2	
	
ULBP-3	VEGF			
Regression with variable selection
In order to incorporate these proteins into a breast cancer screening tool, we built statistical models linking the protein levels to the probability of malignancy.",IP-10,serum,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
","At the same time, 47 serum samples of healthy individuals (age 7 - 29 years) were also collected as a normal control for SELDI-TOF-MS detection.",SELDI,serum,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
","At the same time, 47 serum samples of healthy individuals (age 7 - 29 years) were also collected as a normal control for SELDI-TOF-MS detection.",TOF,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","Conclusions
We found that TRACP 5b activity and its interval change after treatment bore a prognostic role in BC patients with bone metastasis and a high baseline serum TRACP 5b activity.",TRACP,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","Conclusions
We found that TRACP 5b activity and its interval change after treatment bore a prognostic role in BC patients with bone metastasis and a high baseline serum TRACP 5b activity.",TRACP,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","This file is a comma-delimited file of blood serum ELISA data intended for computational analysis in the R scripts of Additional file 1.

",ELISA,blood,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","This file is a comma-delimited file of blood serum ELISA data intended for computational analysis in the R scripts of Additional file 1.

",ELISA,serum,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","The PCR cycle conditions were set as follow: a preincubation step for 10 minutes at 95degC followed by 40 cycles for tissue cDNA and 53 cycles for saliva cell cDNA; each cycle included 15 seconds at 95degC, 15 seconds at 60degC, and 15 seconds at 72degC.",cDNA,saliva,-1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","The PCR cycle conditions were set as follow: a preincubation step for 10 minutes at 95degC followed by 40 cycles for tissue cDNA and 53 cycles for saliva cell cDNA; each cycle included 15 seconds at 95degC, 15 seconds at 60degC, and 15 seconds at 72degC.",PCR,saliva,-1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","The PCR cycle conditions were set as follow: a preincubation step for 10 minutes at 95degC followed by 40 cycles for tissue cDNA and 53 cycles for saliva cell cDNA; each cycle included 15 seconds at 95degC, 15 seconds at 60degC, and 15 seconds at 72degC.",cDNA,saliva,-1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","Accordingly, we proposed that only in those patients with higher serum activity can TRACP 5b genuinely reflected higher tumor burden.",TRACP,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
",VEGF has been detected in tissue and serum of patients with ovarian cancer [27-33].,VEGF,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","These data show sample information with the serum protein levels measured by ELISA.

",ELISA,serum,1
"PMC 
BMC_Cancer_2010_Aug_15_10_428.txt
","The sections were placed in 3% H2O2 for 10 min to inhibit the endogenous peroxide activity, washed three times with phosphate-buffered saline (PBS) buffer for 5 min and placed in normal goat serum as blocking antibody at room temperature for 10 min.",PBS,serum,-1
"PMC 
BMC_Cancer_2010_Aug_15_10_428.txt
","The sections were placed in 3% H2O2 for 10 min to inhibit the endogenous peroxide activity, washed three times with phosphate-buffered saline (PBS) buffer for 5 min and placed in normal goat serum as blocking antibody at room temperature for 10 min.",H2O2,serum,-1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","The resulting cDNA were diluted 1:10 for tissue samples and 1:4 for saliva samples before being used as PCR template.

",cDNA,saliva,-1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","The resulting cDNA were diluted 1:10 for tissue samples and 1:4 for saliva samples before being used as PCR template.

",PCR,saliva,-1
"PMC 
BMC_Cancer_2010_Apr_1_10_123.txt
",Sections were incubated with normal goat serum diluted 1:5 in PBS containing 10% of BSA for 20 min.,PBS,serum,1
"PMC 
BMC_Cancer_2010_Apr_1_10_123.txt
",Sections were incubated with normal goat serum diluted 1:5 in PBS containing 10% of BSA for 20 min.,BSA,serum,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Among anthracycline-treated patients there were no significant differences in clinicopathological characteristics between TIMP-1 high and low patients; among CMF-treated patients there were significantly more patients younger than 40 years in the TIMP-1 low subgroup and significantly more patients with more than 3 tumor-positive lymph nodes in the TIMP-1 high subgroup (data not shown).

",TIMP-1,lymph,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Among anthracycline-treated patients there were no significant differences in clinicopathological characteristics between TIMP-1 high and low patients; among CMF-treated patients there were significantly more patients younger than 40 years in the TIMP-1 low subgroup and significantly more patients with more than 3 tumor-positive lymph nodes in the TIMP-1 high subgroup (data not shown).

",TIMP-1,lymph,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Among anthracycline-treated patients there were no significant differences in clinicopathological characteristics between TIMP-1 high and low patients; among CMF-treated patients there were significantly more patients younger than 40 years in the TIMP-1 low subgroup and significantly more patients with more than 3 tumor-positive lymph nodes in the TIMP-1 high subgroup (data not shown).

",TIMP-1,lymph,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Among anthracycline-treated patients there were no significant differences in clinicopathological characteristics between TIMP-1 high and low patients; among CMF-treated patients there were significantly more patients younger than 40 years in the TIMP-1 low subgroup and significantly more patients with more than 3 tumor-positive lymph nodes in the TIMP-1 high subgroup (data not shown).

",CMF,lymph,1
"PMC 
BMC_Cancer_2009_Nov_30_9_414.txt
","The cell lines were cultured in RPMI-1640 medium (Sigma, MO, USA) supplemented with 10% fetal bovine serum and antibiotics (100 U/ml penicillin and 100 mg/ml streptomycin).

",RPMI-1640,serum,1
"PMC 
BMC_Cancer_2009_Nov_30_9_414.txt
","The cell lines were cultured in RPMI-1640 medium (Sigma, MO, USA) supplemented with 10% fetal bovine serum and antibiotics (100 U/ml penicillin and 100 mg/ml streptomycin).

",USA,serum,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
",and saliva samples with total RNA concentration &#62;40 ng/ml and RIN value &#62;4.,RIN,saliva,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
",and saliva samples with total RNA concentration &#62;40 ng/ml and RIN value &#62;4.,RNA,saliva,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","In the largest published analysis of 314 patients with ovarian cancer, high preoperative VEGF serum concentrations were associated with decreased overall survival by multivariate analysis [31].",VEGF,serum,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Besides the predictive information, which can apparently be gained from TIMP-1, several publications demonstrate that high levels of TIMP-1 protein in breast cancer tissue [11-14], plasma and serum [12,15-17] are associated with a poor prognosis.",TIMP-1,plasma,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Besides the predictive information, which can apparently be gained from TIMP-1, several publications demonstrate that high levels of TIMP-1 protein in breast cancer tissue [11-14], plasma and serum [12,15-17] are associated with a poor prognosis.",TIMP-1,serum,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Besides the predictive information, which can apparently be gained from TIMP-1, several publications demonstrate that high levels of TIMP-1 protein in breast cancer tissue [11-14], plasma and serum [12,15-17] are associated with a poor prognosis.",TIMP-1,plasma,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Besides the predictive information, which can apparently be gained from TIMP-1, several publications demonstrate that high levels of TIMP-1 protein in breast cancer tissue [11-14], plasma and serum [12,15-17] are associated with a poor prognosis.",TIMP-1,serum,-1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","Fourthly, the cut-off value of 5.736 U/L was arbitrarily determined by dividing patients into top 1/3 and bottom 2/3 according to the scale of serum TRACP 5b activity.",TRACP,serum,1
"PMC 
BMC_Cancer_2010_Apr_18_10_148.txt
","Normal rabbit serum (NRS) was used for control staining.

",NRS,serum,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","After quality control of tissues and saliva of the initial cohort of 74 HNSCC patients, 46 matched pairs of tumor tissue and normal mucosa and 51 saliva samples were useful.",HNSCC,saliva,-1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","After quality control of tissues and saliva of the initial cohort of 74 HNSCC patients, 46 matched pairs of tumor tissue and normal mucosa and 51 saliva samples were useful.",HNSCC,saliva,-1
"PMC 
BMC_Cancer_2009_Oct_20_9_374.txt
","Rapid soft agar assay
2x Iscove's Modified Dulbecco's Medium (IMDM) (Gibco) was supplemented with 0.6% Sodium Bicarbonate, 20% fetal bovine serum (JRH Biosciences), 4 mM L-glutamine (Gibco), 2x Non Essential Amino Acid Solution (Gibco), 2% Sodium Pyruvate (Gibco) and Penicillin-Streptomycin solution (0.1 U/mL penicillin and 0.1 mg/mL streptomycin) (Gibco).",IMDM,serum,1
"PMC 
BMC_Cancer_2009_Oct_20_9_374.txt
","Rapid soft agar assay
2x Iscove's Modified Dulbecco's Medium (IMDM) (Gibco) was supplemented with 0.6% Sodium Bicarbonate, 20% fetal bovine serum (JRH Biosciences), 4 mM L-glutamine (Gibco), 2x Non Essential Amino Acid Solution (Gibco), 2% Sodium Pyruvate (Gibco) and Penicillin-Streptomycin solution (0.1 U/mL penicillin and 0.1 mg/mL streptomycin) (Gibco).",JRH,serum,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
","Results
Mass markers from SELDI-TOF-MS
The ""case"" dataset consists of 27 serum samples from OS patients, and the ""control"" dataset consists of 47 serum samples from healthy volunteers.",SELDI,serum,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
","Results
Mass markers from SELDI-TOF-MS
The ""case"" dataset consists of 27 serum samples from OS patients, and the ""control"" dataset consists of 47 serum samples from healthy volunteers.",SELDI,serum,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
","Results
Mass markers from SELDI-TOF-MS
The ""case"" dataset consists of 27 serum samples from OS patients, and the ""control"" dataset consists of 47 serum samples from healthy volunteers.",OS,serum,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
","Results
Mass markers from SELDI-TOF-MS
The ""case"" dataset consists of 27 serum samples from OS patients, and the ""control"" dataset consists of 47 serum samples from healthy volunteers.",OS,serum,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
","Results
Mass markers from SELDI-TOF-MS
The ""case"" dataset consists of 27 serum samples from OS patients, and the ""control"" dataset consists of 47 serum samples from healthy volunteers.",TOF,serum,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
","Results
Mass markers from SELDI-TOF-MS
The ""case"" dataset consists of 27 serum samples from OS patients, and the ""control"" dataset consists of 47 serum samples from healthy volunteers.",TOF,serum,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
","Among them, four peaks (m/z values were 4476.07, 8769.12, 13761.73 and 4258.54) represented up-regulation of corresponding proteins in samples from patients with OS, while the other two peaks (m/z values were 4820.49 and 5909.03) represented down-regulation of corresponding proteins in patients' serum.",OS,serum,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
","Immuno-blot analysis
Serum samples from eight OS patients and eight healthy individuals were subjected to SDS-PAGE, transferred to nitrocellulose, and blotted with the rabbit anti-human CYC-1 antibody, which was purchased from Protein Tech Group (Chicago, IL, USA).",SDS,Serum,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
","Immuno-blot analysis
Serum samples from eight OS patients and eight healthy individuals were subjected to SDS-PAGE, transferred to nitrocellulose, and blotted with the rabbit anti-human CYC-1 antibody, which was purchased from Protein Tech Group (Chicago, IL, USA).",CYC-1,Serum,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
","Immuno-blot analysis
Serum samples from eight OS patients and eight healthy individuals were subjected to SDS-PAGE, transferred to nitrocellulose, and blotted with the rabbit anti-human CYC-1 antibody, which was purchased from Protein Tech Group (Chicago, IL, USA).",Tech,Serum,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
","Immuno-blot analysis
Serum samples from eight OS patients and eight healthy individuals were subjected to SDS-PAGE, transferred to nitrocellulose, and blotted with the rabbit anti-human CYC-1 antibody, which was purchased from Protein Tech Group (Chicago, IL, USA).",OS,Serum,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
","Immuno-blot analysis
Serum samples from eight OS patients and eight healthy individuals were subjected to SDS-PAGE, transferred to nitrocellulose, and blotted with the rabbit anti-human CYC-1 antibody, which was purchased from Protein Tech Group (Chicago, IL, USA).",PAGE,Serum,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
","Immuno-blot analysis
Serum samples from eight OS patients and eight healthy individuals were subjected to SDS-PAGE, transferred to nitrocellulose, and blotted with the rabbit anti-human CYC-1 antibody, which was purchased from Protein Tech Group (Chicago, IL, USA).",USA,Serum,1
"PMC 
BMC_Cancer_2009_May_21_9_157.txt
","In brief, 20 mL 5x Moloney murine leukemia virus (MMLV) buffer (containing 250 mmol/L Tris-HCl [pH 8.3], 375 mmol/L KCl, and 15 mmol/L MgCl2; Life Technologies, Gaithersburg, Md.), 10 mL dithiothreitol (100 mmol/L; Life Technologies), 10 mL dNTP (each type 10 mmol/L; Amersham Pharmacia Biotech), 0.5 mL random hexamers (50 OD dissolved in 550 mL of 10 mmol/L Tris-HCl [pH 7.5], and 1 mmol/L EDTA; Amersham Pharmacia Biotech), 2.5 mL bovine serum albumin (3 mg/ml in 10 mmol/L Tris-HCl [pH 7.5], Amersham Pharmacia Biotech), 2.5 mL RNAse inhibitor (5x 1000 units; Amersham Pharmacia Biotech), and 5 mL MMLV reverse transcriptase (200 U/mL; Life Technologies), added to a total volume of 50.5 mL. Reaction temperatures were first at 26degC for 8 min, then at 42degC for 45 min,, finally at 95degC for 5 min",MMLV,serum,1
"PMC 
BMC_Cancer_2009_May_21_9_157.txt
","In brief, 20 mL 5x Moloney murine leukemia virus (MMLV) buffer (containing 250 mmol/L Tris-HCl [pH 8.3], 375 mmol/L KCl, and 15 mmol/L MgCl2; Life Technologies, Gaithersburg, Md.), 10 mL dithiothreitol (100 mmol/L; Life Technologies), 10 mL dNTP (each type 10 mmol/L; Amersham Pharmacia Biotech), 0.5 mL random hexamers (50 OD dissolved in 550 mL of 10 mmol/L Tris-HCl [pH 7.5], and 1 mmol/L EDTA; Amersham Pharmacia Biotech), 2.5 mL bovine serum albumin (3 mg/ml in 10 mmol/L Tris-HCl [pH 7.5], Amersham Pharmacia Biotech), 2.5 mL RNAse inhibitor (5x 1000 units; Amersham Pharmacia Biotech), and 5 mL MMLV reverse transcriptase (200 U/mL; Life Technologies), added to a total volume of 50.5 mL. Reaction temperatures were first at 26degC for 8 min, then at 42degC for 45 min,, finally at 95degC for 5 min",MMLV,serum,1
"PMC 
BMC_Cancer_2009_May_21_9_157.txt
","In brief, 20 mL 5x Moloney murine leukemia virus (MMLV) buffer (containing 250 mmol/L Tris-HCl [pH 8.3], 375 mmol/L KCl, and 15 mmol/L MgCl2; Life Technologies, Gaithersburg, Md.), 10 mL dithiothreitol (100 mmol/L; Life Technologies), 10 mL dNTP (each type 10 mmol/L; Amersham Pharmacia Biotech), 0.5 mL random hexamers (50 OD dissolved in 550 mL of 10 mmol/L Tris-HCl [pH 7.5], and 1 mmol/L EDTA; Amersham Pharmacia Biotech), 2.5 mL bovine serum albumin (3 mg/ml in 10 mmol/L Tris-HCl [pH 7.5], Amersham Pharmacia Biotech), 2.5 mL RNAse inhibitor (5x 1000 units; Amersham Pharmacia Biotech), and 5 mL MMLV reverse transcriptase (200 U/mL; Life Technologies), added to a total volume of 50.5 mL. Reaction temperatures were first at 26degC for 8 min, then at 42degC for 45 min,, finally at 95degC for 5 min",MgCl2,serum,1
"PMC 
BMC_Cancer_2009_May_21_9_157.txt
","In brief, 20 mL 5x Moloney murine leukemia virus (MMLV) buffer (containing 250 mmol/L Tris-HCl [pH 8.3], 375 mmol/L KCl, and 15 mmol/L MgCl2; Life Technologies, Gaithersburg, Md.), 10 mL dithiothreitol (100 mmol/L; Life Technologies), 10 mL dNTP (each type 10 mmol/L; Amersham Pharmacia Biotech), 0.5 mL random hexamers (50 OD dissolved in 550 mL of 10 mmol/L Tris-HCl [pH 7.5], and 1 mmol/L EDTA; Amersham Pharmacia Biotech), 2.5 mL bovine serum albumin (3 mg/ml in 10 mmol/L Tris-HCl [pH 7.5], Amersham Pharmacia Biotech), 2.5 mL RNAse inhibitor (5x 1000 units; Amersham Pharmacia Biotech), and 5 mL MMLV reverse transcriptase (200 U/mL; Life Technologies), added to a total volume of 50.5 mL. Reaction temperatures were first at 26degC for 8 min, then at 42degC for 45 min,, finally at 95degC for 5 min",EDTA,serum,1
"PMC 
BMC_Cancer_2009_May_21_9_157.txt
","In brief, 20 mL 5x Moloney murine leukemia virus (MMLV) buffer (containing 250 mmol/L Tris-HCl [pH 8.3], 375 mmol/L KCl, and 15 mmol/L MgCl2; Life Technologies, Gaithersburg, Md.), 10 mL dithiothreitol (100 mmol/L; Life Technologies), 10 mL dNTP (each type 10 mmol/L; Amersham Pharmacia Biotech), 0.5 mL random hexamers (50 OD dissolved in 550 mL of 10 mmol/L Tris-HCl [pH 7.5], and 1 mmol/L EDTA; Amersham Pharmacia Biotech), 2.5 mL bovine serum albumin (3 mg/ml in 10 mmol/L Tris-HCl [pH 7.5], Amersham Pharmacia Biotech), 2.5 mL RNAse inhibitor (5x 1000 units; Amersham Pharmacia Biotech), and 5 mL MMLV reverse transcriptase (200 U/mL; Life Technologies), added to a total volume of 50.5 mL. Reaction temperatures were first at 26degC for 8 min, then at 42degC for 45 min,, finally at 95degC for 5 min",dNTP,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","In our study, the LSC for serum TRACP 5b activity was 38.59% determined from 15 early BC patients.",TRACP,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","In our study, the LSC for serum TRACP 5b activity was 38.59% determined from 15 early BC patients.",LSC,serum,1
"PMC 
BMC_Cancer_2010_Apr_16_10_145.txt
",In ER-negative breast cancer it has been shown that the presence of pushing margins correlates with the absence of LVI and lymph node negative status[25].,ER,lymph,1
"PMC 
BMC_Cancer_2010_Apr_16_10_145.txt
",In ER-negative breast cancer it has been shown that the presence of pushing margins correlates with the absence of LVI and lymph node negative status[25].,LVI,lymph,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Based on their findings that NGAL in human tissue and urine samples were consistently associated with invasive breast cancer, Yang et al suggested that NGAL may be a potential noninvasive biomarker of breast disease [39].",NGAL,urine,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Based on their findings that NGAL in human tissue and urine samples were consistently associated with invasive breast cancer, Yang et al suggested that NGAL may be a potential noninvasive biomarker of breast disease [39].",NGAL,urine,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Expression levels of MMP-9, NGAL and their complex MMP-9/NGAL were determined in peripheral blood samples with immunoenzymatic assays.

",NGAL,blood,-1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Expression levels of MMP-9, NGAL and their complex MMP-9/NGAL were determined in peripheral blood samples with immunoenzymatic assays.

",MMP-9,blood,-1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","In this study, we retrieved data from 15 randomly selected early breast cancer patients from previous studies to calculate the LSC of serum TRACP 5b from monthly samples taken over a 4-month period.",TRACP,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","In this study, we retrieved data from 15 randomly selected early breast cancer patients from previous studies to calculate the LSC of serum TRACP 5b from monthly samples taken over a 4-month period.",LSC,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
",We have already shown that serum TRACP 5b activity correlates with extent of bone metastasis in BC patients [13].,TRACP,serum,1
"PMC 
BMC_Cancer_2009_Oct_20_9_374.txt
","Cell proliferation assay
SW620 cells (3 x 103 cells/well) were seeded in 96-well plates in serum-containing media.",SW620,serum,1
"PMC 
BMC_Cancer_2010_Apr_16_10_145.txt
","LVI correlates with the presence of lymph node metastases[20,21] and is, not unexpectedly, a poor prognostic sign [22-24].",LVI,lymph,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Small	33.3		100.0		
	
	24-hour urine 5-HIAA (mmol/day)
	&#60;31.4

>= 31.4	0.0

33.3	
.455
	20.0

66.7	
.242
	
Biomarkers		
	
Serum NSE (nmol/l)
	&#60;1.0

>= 1.0	0.0

55.6	.034	28.6

77.8	.126	
	
	IFN	23.1		53.8		
Regimen	Somatostatin-analogue*	0.0	.400	0.0	.079	
	Chemotherapy	39.5		71.1		
ORR, overall response rate; DCR, disease-control rate; GI, gastrointestinal; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase; IFN, interferon

*Somatostatin-analogue was given to only 2 patients.

",NSE,Serum,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Small	33.3		100.0		
	
	24-hour urine 5-HIAA (mmol/day)
	&#60;31.4

>= 31.4	0.0

33.3	
.455
	20.0

66.7	
.242
	
Biomarkers		
	
Serum NSE (nmol/l)
	&#60;1.0

>= 1.0	0.0

55.6	.034	28.6

77.8	.126	
	
	IFN	23.1		53.8		
Regimen	Somatostatin-analogue*	0.0	.400	0.0	.079	
	Chemotherapy	39.5		71.1		
ORR, overall response rate; DCR, disease-control rate; GI, gastrointestinal; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase; IFN, interferon

*Somatostatin-analogue was given to only 2 patients.

",NSE,urine,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Small	33.3		100.0		
	
	24-hour urine 5-HIAA (mmol/day)
	&#60;31.4

>= 31.4	0.0

33.3	
.455
	20.0

66.7	
.242
	
Biomarkers		
	
Serum NSE (nmol/l)
	&#60;1.0

>= 1.0	0.0

55.6	.034	28.6

77.8	.126	
	
	IFN	23.1		53.8		
Regimen	Somatostatin-analogue*	0.0	.400	0.0	.079	
	Chemotherapy	39.5		71.1		
ORR, overall response rate; DCR, disease-control rate; GI, gastrointestinal; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase; IFN, interferon

*Somatostatin-analogue was given to only 2 patients.

",DCR,Serum,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Small	33.3		100.0		
	
	24-hour urine 5-HIAA (mmol/day)
	&#60;31.4

>= 31.4	0.0

33.3	
.455
	20.0

66.7	
.242
	
Biomarkers		
	
Serum NSE (nmol/l)
	&#60;1.0

>= 1.0	0.0

55.6	.034	28.6

77.8	.126	
	
	IFN	23.1		53.8		
Regimen	Somatostatin-analogue*	0.0	.400	0.0	.079	
	Chemotherapy	39.5		71.1		
ORR, overall response rate; DCR, disease-control rate; GI, gastrointestinal; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase; IFN, interferon

*Somatostatin-analogue was given to only 2 patients.

",DCR,urine,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Small	33.3		100.0		
	
	24-hour urine 5-HIAA (mmol/day)
	&#60;31.4

>= 31.4	0.0

33.3	
.455
	20.0

66.7	
.242
	
Biomarkers		
	
Serum NSE (nmol/l)
	&#60;1.0

>= 1.0	0.0

55.6	.034	28.6

77.8	.126	
	
	IFN	23.1		53.8		
Regimen	Somatostatin-analogue*	0.0	.400	0.0	.079	
	Chemotherapy	39.5		71.1		
ORR, overall response rate; DCR, disease-control rate; GI, gastrointestinal; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase; IFN, interferon

*Somatostatin-analogue was given to only 2 patients.

",IFN,Serum,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Small	33.3		100.0		
	
	24-hour urine 5-HIAA (mmol/day)
	&#60;31.4

>= 31.4	0.0

33.3	
.455
	20.0

66.7	
.242
	
Biomarkers		
	
Serum NSE (nmol/l)
	&#60;1.0

>= 1.0	0.0

55.6	.034	28.6

77.8	.126	
	
	IFN	23.1		53.8		
Regimen	Somatostatin-analogue*	0.0	.400	0.0	.079	
	Chemotherapy	39.5		71.1		
ORR, overall response rate; DCR, disease-control rate; GI, gastrointestinal; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase; IFN, interferon

*Somatostatin-analogue was given to only 2 patients.

",IFN,urine,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Small	33.3		100.0		
	
	24-hour urine 5-HIAA (mmol/day)
	&#60;31.4

>= 31.4	0.0

33.3	
.455
	20.0

66.7	
.242
	
Biomarkers		
	
Serum NSE (nmol/l)
	&#60;1.0

>= 1.0	0.0

55.6	.034	28.6

77.8	.126	
	
	IFN	23.1		53.8		
Regimen	Somatostatin-analogue*	0.0	.400	0.0	.079	
	Chemotherapy	39.5		71.1		
ORR, overall response rate; DCR, disease-control rate; GI, gastrointestinal; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase; IFN, interferon

*Somatostatin-analogue was given to only 2 patients.

",ORR,Serum,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Small	33.3		100.0		
	
	24-hour urine 5-HIAA (mmol/day)
	&#60;31.4

>= 31.4	0.0

33.3	
.455
	20.0

66.7	
.242
	
Biomarkers		
	
Serum NSE (nmol/l)
	&#60;1.0

>= 1.0	0.0

55.6	.034	28.6

77.8	.126	
	
	IFN	23.1		53.8		
Regimen	Somatostatin-analogue*	0.0	.400	0.0	.079	
	Chemotherapy	39.5		71.1		
ORR, overall response rate; DCR, disease-control rate; GI, gastrointestinal; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase; IFN, interferon

*Somatostatin-analogue was given to only 2 patients.

",ORR,urine,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Small	33.3		100.0		
	
	24-hour urine 5-HIAA (mmol/day)
	&#60;31.4

>= 31.4	0.0

33.3	
.455
	20.0

66.7	
.242
	
Biomarkers		
	
Serum NSE (nmol/l)
	&#60;1.0

>= 1.0	0.0

55.6	.034	28.6

77.8	.126	
	
	IFN	23.1		53.8		
Regimen	Somatostatin-analogue*	0.0	.400	0.0	.079	
	Chemotherapy	39.5		71.1		
ORR, overall response rate; DCR, disease-control rate; GI, gastrointestinal; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase; IFN, interferon

*Somatostatin-analogue was given to only 2 patients.

",NSE,Serum,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Small	33.3		100.0		
	
	24-hour urine 5-HIAA (mmol/day)
	&#60;31.4

>= 31.4	0.0

33.3	
.455
	20.0

66.7	
.242
	
Biomarkers		
	
Serum NSE (nmol/l)
	&#60;1.0

>= 1.0	0.0

55.6	.034	28.6

77.8	.126	
	
	IFN	23.1		53.8		
Regimen	Somatostatin-analogue*	0.0	.400	0.0	.079	
	Chemotherapy	39.5		71.1		
ORR, overall response rate; DCR, disease-control rate; GI, gastrointestinal; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase; IFN, interferon

*Somatostatin-analogue was given to only 2 patients.

",NSE,urine,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Small	33.3		100.0		
	
	24-hour urine 5-HIAA (mmol/day)
	&#60;31.4

>= 31.4	0.0

33.3	
.455
	20.0

66.7	
.242
	
Biomarkers		
	
Serum NSE (nmol/l)
	&#60;1.0

>= 1.0	0.0

55.6	.034	28.6

77.8	.126	
	
	IFN	23.1		53.8		
Regimen	Somatostatin-analogue*	0.0	.400	0.0	.079	
	Chemotherapy	39.5		71.1		
ORR, overall response rate; DCR, disease-control rate; GI, gastrointestinal; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase; IFN, interferon

*Somatostatin-analogue was given to only 2 patients.

",IFN,Serum,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Small	33.3		100.0		
	
	24-hour urine 5-HIAA (mmol/day)
	&#60;31.4

>= 31.4	0.0

33.3	
.455
	20.0

66.7	
.242
	
Biomarkers		
	
Serum NSE (nmol/l)
	&#60;1.0

>= 1.0	0.0

55.6	.034	28.6

77.8	.126	
	
	IFN	23.1		53.8		
Regimen	Somatostatin-analogue*	0.0	.400	0.0	.079	
	Chemotherapy	39.5		71.1		
ORR, overall response rate; DCR, disease-control rate; GI, gastrointestinal; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase; IFN, interferon

*Somatostatin-analogue was given to only 2 patients.

",IFN,urine,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","Serum levels of IL-6 were assessed via Enzyme-Linked Immuno-Sorbent Assay (ELISA), and CRP was measured via immunoturbidimetry.",CRP,Serum,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","Serum levels of IL-6 were assessed via Enzyme-Linked Immuno-Sorbent Assay (ELISA), and CRP was measured via immunoturbidimetry.",ELISA,Serum,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","Serum levels of IL-6 were assessed via Enzyme-Linked Immuno-Sorbent Assay (ELISA), and CRP was measured via immunoturbidimetry.",IL-6,Serum,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Chemotherapy and radiotherapy are associated with the generation of large amounts of reactive oxygen/nitrogen species and depletion of antioxidants (vitamins A, C and E, reduced glutathione-GSH) and with an increase in plasma lipid hydroperoxides and TBARS [9-16].",GSH,plasma,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Chemotherapy and radiotherapy are associated with the generation of large amounts of reactive oxygen/nitrogen species and depletion of antioxidants (vitamins A, C and E, reduced glutathione-GSH) and with an increase in plasma lipid hydroperoxides and TBARS [9-16].",TBARS,plasma,1
"PMC 
BMC_Cancer_2009_Sep_6_9_315.txt
","Human MCF-7 breast cancer cells that overexpress Cripto-1 proliferate at higher rates in serum-free medium, form increased numbers of colonies in soft agar, are more resistant to apoptosis when grown under anchorage independent conditions, and show increased propensity to invade and migrate in vitro[21].",MCF-7,serum,1
"PMC 
BMC_Cancer_2009_Sep_6_9_315.txt
","Human MCF-7 breast cancer cells that overexpress Cripto-1 proliferate at higher rates in serum-free medium, form increased numbers of colonies in soft agar, are more resistant to apoptosis when grown under anchorage independent conditions, and show increased propensity to invade and migrate in vitro[21].",Cripto-1,serum,1
"PMC 
BMC_Cancer_2010_Aug_17_10_434.txt
","Nonetheless, hnRNP B1 expression is seen from the early stages of malignant transformation (in occult cancer, bronchial dysplasia and sputum) and is currently considered to be a more specific and sensitive biomarker than hnRNP A2/B1 for the early detection of lung cancer [24,25,27].

",B1,sputum,1
"PMC 
BMC_Cancer_2010_Aug_17_10_434.txt
","Nonetheless, hnRNP B1 expression is seen from the early stages of malignant transformation (in occult cancer, bronchial dysplasia and sputum) and is currently considered to be a more specific and sensitive biomarker than hnRNP A2/B1 for the early detection of lung cancer [24,25,27].

",B1,sputum,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","In the TNM stage, as the stage of the disease increased, serum IL-6 and CRP levels were significantly higher.",TNM,serum,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","In the TNM stage, as the stage of the disease increased, serum IL-6 and CRP levels were significantly higher.",IL-6,serum,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","In the TNM stage, as the stage of the disease increased, serum IL-6 and CRP levels were significantly higher.",CRP,serum,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Peripheral blood samples were obtained from patients before preoperative histological diagnosis of non-palpable lesions by vacuum-assisted breast biopsy (VABB), after overnight fasting.",VABB,blood,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","Furthermore, these factors activate MMPs, particularly MMP-9, leading to the release of soluble Kit ligand which, in turn, promotes cell proliferation and motility within the bone marrow [17,26].",MMP-9,bone marrow,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","60.0	.114	1.0	-	-	.045	
		>= 31.4	40.0	-	62.5		12.0	0.0-29.6	44.4		

Biomarkers
		
	Serum NSE (nmol/l)
	&#60;1.0

>= 1.0	25.0

6.0	18.0-32.0

0.0-18.0	75.0

46.4	
.170
	2.0

4.0	0.9-3.1

1.2-6.8	0.0

22.2	
.381
	
	
	IFN	36.0	22.6-49.4	86.7	.169	10.0	0.0-25.6	22.9		
Regimen	Somatostatin-analogue+	3.0	.	50.0		0.0	-	-	.057	
	Chemotherapy	20.0	13.3-26.7	64.5		6.0	3.6-8.4	34.2		
	

Treatment modality
	Systemic treatment only

Systemic+local treatment	23.0

29.0	0.4-45.6

23.6-34.4	57.9

86.1	
.350					
OS, overall survival; TTP, time-to-progression; CI, confidence interval; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase; IFN, interferon

*OS was estimated after initiation of systemic treatment except in treatment modality where OS was calculated after diagnosis of metastasis.

",NSE,Serum,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","60.0	.114	1.0	-	-	.045	
		>= 31.4	40.0	-	62.5		12.0	0.0-29.6	44.4		

Biomarkers
		
	Serum NSE (nmol/l)
	&#60;1.0

>= 1.0	25.0

6.0	18.0-32.0

0.0-18.0	75.0

46.4	
.170
	2.0

4.0	0.9-3.1

1.2-6.8	0.0

22.2	
.381
	
	
	IFN	36.0	22.6-49.4	86.7	.169	10.0	0.0-25.6	22.9		
Regimen	Somatostatin-analogue+	3.0	.	50.0		0.0	-	-	.057	
	Chemotherapy	20.0	13.3-26.7	64.5		6.0	3.6-8.4	34.2		
	

Treatment modality
	Systemic treatment only

Systemic+local treatment	23.0

29.0	0.4-45.6

23.6-34.4	57.9

86.1	
.350					
OS, overall survival; TTP, time-to-progression; CI, confidence interval; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase; IFN, interferon

*OS was estimated after initiation of systemic treatment except in treatment modality where OS was calculated after diagnosis of metastasis.

",TTP,Serum,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","60.0	.114	1.0	-	-	.045	
		>= 31.4	40.0	-	62.5		12.0	0.0-29.6	44.4		

Biomarkers
		
	Serum NSE (nmol/l)
	&#60;1.0

>= 1.0	25.0

6.0	18.0-32.0

0.0-18.0	75.0

46.4	
.170
	2.0

4.0	0.9-3.1

1.2-6.8	0.0

22.2	
.381
	
	
	IFN	36.0	22.6-49.4	86.7	.169	10.0	0.0-25.6	22.9		
Regimen	Somatostatin-analogue+	3.0	.	50.0		0.0	-	-	.057	
	Chemotherapy	20.0	13.3-26.7	64.5		6.0	3.6-8.4	34.2		
	

Treatment modality
	Systemic treatment only

Systemic+local treatment	23.0

29.0	0.4-45.6

23.6-34.4	57.9

86.1	
.350					
OS, overall survival; TTP, time-to-progression; CI, confidence interval; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase; IFN, interferon

*OS was estimated after initiation of systemic treatment except in treatment modality where OS was calculated after diagnosis of metastasis.

",OS,Serum,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","60.0	.114	1.0	-	-	.045	
		>= 31.4	40.0	-	62.5		12.0	0.0-29.6	44.4		

Biomarkers
		
	Serum NSE (nmol/l)
	&#60;1.0

>= 1.0	25.0

6.0	18.0-32.0

0.0-18.0	75.0

46.4	
.170
	2.0

4.0	0.9-3.1

1.2-6.8	0.0

22.2	
.381
	
	
	IFN	36.0	22.6-49.4	86.7	.169	10.0	0.0-25.6	22.9		
Regimen	Somatostatin-analogue+	3.0	.	50.0		0.0	-	-	.057	
	Chemotherapy	20.0	13.3-26.7	64.5		6.0	3.6-8.4	34.2		
	

Treatment modality
	Systemic treatment only

Systemic+local treatment	23.0

29.0	0.4-45.6

23.6-34.4	57.9

86.1	
.350					
OS, overall survival; TTP, time-to-progression; CI, confidence interval; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase; IFN, interferon

*OS was estimated after initiation of systemic treatment except in treatment modality where OS was calculated after diagnosis of metastasis.

",CI,Serum,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","60.0	.114	1.0	-	-	.045	
		>= 31.4	40.0	-	62.5		12.0	0.0-29.6	44.4		

Biomarkers
		
	Serum NSE (nmol/l)
	&#60;1.0

>= 1.0	25.0

6.0	18.0-32.0

0.0-18.0	75.0

46.4	
.170
	2.0

4.0	0.9-3.1

1.2-6.8	0.0

22.2	
.381
	
	
	IFN	36.0	22.6-49.4	86.7	.169	10.0	0.0-25.6	22.9		
Regimen	Somatostatin-analogue+	3.0	.	50.0		0.0	-	-	.057	
	Chemotherapy	20.0	13.3-26.7	64.5		6.0	3.6-8.4	34.2		
	

Treatment modality
	Systemic treatment only

Systemic+local treatment	23.0

29.0	0.4-45.6

23.6-34.4	57.9

86.1	
.350					
OS, overall survival; TTP, time-to-progression; CI, confidence interval; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase; IFN, interferon

*OS was estimated after initiation of systemic treatment except in treatment modality where OS was calculated after diagnosis of metastasis.

",IFN,Serum,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","60.0	.114	1.0	-	-	.045	
		>= 31.4	40.0	-	62.5		12.0	0.0-29.6	44.4		

Biomarkers
		
	Serum NSE (nmol/l)
	&#60;1.0

>= 1.0	25.0

6.0	18.0-32.0

0.0-18.0	75.0

46.4	
.170
	2.0

4.0	0.9-3.1

1.2-6.8	0.0

22.2	
.381
	
	
	IFN	36.0	22.6-49.4	86.7	.169	10.0	0.0-25.6	22.9		
Regimen	Somatostatin-analogue+	3.0	.	50.0		0.0	-	-	.057	
	Chemotherapy	20.0	13.3-26.7	64.5		6.0	3.6-8.4	34.2		
	

Treatment modality
	Systemic treatment only

Systemic+local treatment	23.0

29.0	0.4-45.6

23.6-34.4	57.9

86.1	
.350					
OS, overall survival; TTP, time-to-progression; CI, confidence interval; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase; IFN, interferon

*OS was estimated after initiation of systemic treatment except in treatment modality where OS was calculated after diagnosis of metastasis.

",OS,Serum,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","60.0	.114	1.0	-	-	.045	
		>= 31.4	40.0	-	62.5		12.0	0.0-29.6	44.4		

Biomarkers
		
	Serum NSE (nmol/l)
	&#60;1.0

>= 1.0	25.0

6.0	18.0-32.0

0.0-18.0	75.0

46.4	
.170
	2.0

4.0	0.9-3.1

1.2-6.8	0.0

22.2	
.381
	
	
	IFN	36.0	22.6-49.4	86.7	.169	10.0	0.0-25.6	22.9		
Regimen	Somatostatin-analogue+	3.0	.	50.0		0.0	-	-	.057	
	Chemotherapy	20.0	13.3-26.7	64.5		6.0	3.6-8.4	34.2		
	

Treatment modality
	Systemic treatment only

Systemic+local treatment	23.0

29.0	0.4-45.6

23.6-34.4	57.9

86.1	
.350					
OS, overall survival; TTP, time-to-progression; CI, confidence interval; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase; IFN, interferon

*OS was estimated after initiation of systemic treatment except in treatment modality where OS was calculated after diagnosis of metastasis.

",NSE,Serum,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","60.0	.114	1.0	-	-	.045	
		>= 31.4	40.0	-	62.5		12.0	0.0-29.6	44.4		

Biomarkers
		
	Serum NSE (nmol/l)
	&#60;1.0

>= 1.0	25.0

6.0	18.0-32.0

0.0-18.0	75.0

46.4	
.170
	2.0

4.0	0.9-3.1

1.2-6.8	0.0

22.2	
.381
	
	
	IFN	36.0	22.6-49.4	86.7	.169	10.0	0.0-25.6	22.9		
Regimen	Somatostatin-analogue+	3.0	.	50.0		0.0	-	-	.057	
	Chemotherapy	20.0	13.3-26.7	64.5		6.0	3.6-8.4	34.2		
	

Treatment modality
	Systemic treatment only

Systemic+local treatment	23.0

29.0	0.4-45.6

23.6-34.4	57.9

86.1	
.350					
OS, overall survival; TTP, time-to-progression; CI, confidence interval; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase; IFN, interferon

*OS was estimated after initiation of systemic treatment except in treatment modality where OS was calculated after diagnosis of metastasis.

",OS,Serum,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","60.0	.114	1.0	-	-	.045	
		>= 31.4	40.0	-	62.5		12.0	0.0-29.6	44.4		

Biomarkers
		
	Serum NSE (nmol/l)
	&#60;1.0

>= 1.0	25.0

6.0	18.0-32.0

0.0-18.0	75.0

46.4	
.170
	2.0

4.0	0.9-3.1

1.2-6.8	0.0

22.2	
.381
	
	
	IFN	36.0	22.6-49.4	86.7	.169	10.0	0.0-25.6	22.9		
Regimen	Somatostatin-analogue+	3.0	.	50.0		0.0	-	-	.057	
	Chemotherapy	20.0	13.3-26.7	64.5		6.0	3.6-8.4	34.2		
	

Treatment modality
	Systemic treatment only

Systemic+local treatment	23.0

29.0	0.4-45.6

23.6-34.4	57.9

86.1	
.350					
OS, overall survival; TTP, time-to-progression; CI, confidence interval; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase; IFN, interferon

*OS was estimated after initiation of systemic treatment except in treatment modality where OS was calculated after diagnosis of metastasis.

",IFN,Serum,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
","To validate the specificity and sensitivity of the potential biomarkers in the early diagnosis, serum samples from eight patients with OS and eight healthy individuals were examined by immuno-blot analysis using antibodies specific for the selected proteins.",OS,serum,1
"PMC 
BMC_Cancer_2009_May_13_9_146.txt
","Table 3 Frequency and distribution of the systemic events occurred at each dose level

Systemic Events	Group I
(14 mg)	Group II
(70 mg)	Group III
(245 mg)	Group IV
(490 mg)		
Itching	8 (14.6%)	18 (25.0%)	29 (25.9%)	29 (32.3%)	84	
Hot flashes	12 (21.8%)	14 (11.7%)	8 (7.1%)	8 (8.9%)	42	
Localized rash	3 (5.4%)	21 (17.5%)	6 (5.4%)	8 (8.9%)	38	
Localized facial edema	9 (16.4%)	6 (5.0%)	8 (7.1%)	13 (14.4%)	36	
Bumps	0	12 (10.0%)	17 (15.2%)	6 (6.7%)	35	
Extensive rash	2 (3.6%)	0	21 (18.8%)	5 (5.6%)	28	
Cramps	3 (5.4%)	2 (1.7%)	11 (9.0%)	6 (6.7%)	22	
Headache	3 (5.4%)	2 (1.7%)	4 (3.6%)	2 (2.2%)	11	
Metallic flavor	4 (7.3%)	6 (5.0%)	1 (0.9%)	0	11	
Tickling or tingling	5 (9.1%)	6 (5.0%)	0	0	11	
Tachycardia	0	7 (5.8%)	3 (2.7%)	0	10	
Tinnitus	0	7 (5.8%)	0	0	7	
Nausea	0	3 (2.5%)	1 (0.9%)	3 (3.3%)	7	
Facial erythema	0	7 (5.8%)	0	0	7	
Palpitations	0	2 (1.7%)	1 (0.9%)	2 (2.2%)	5	
Hypertension	3 (5.4%)	1 (0.8%)	0	1 (1.1%)	5	
Vasovagal syndrome	0	g2: 2 (1.7%)		g3: 2 (2.2%)	4	
Dizziness	1 (1.8%)	2 (1.7%)	0	0	3	
Tremors	0	0	0	3 (3.3%)	3	
Vomiting	0	2 (1.7%)	0	0	2	
Fast breathing	1 (1.8%)	0	0	0	1	
Abdominal pain	1 (1.8%)	0	0	0	1	
Arrhythmia	0	0	0	1 (1.1%)	1	
Hypotension	0	0	1 (0.9%)	0	1	
Posture-related tremor in lower limbs	0	0	0	1 (1.1%)	1	
Red eyes	0	0	1 (0.9%)	0	1	
	
Total	55	120	112	90		
There were no differences between baseline and post-treatment blood counts, serum chemistry results, coagulation parameters and electrocardiograms (data not shown).

Efficacy analysis
Individual efficacy results are shown in Table 1 and summarized in Table 4.",III,blood,1
"PMC 
BMC_Cancer_2009_May_13_9_146.txt
","Table 3 Frequency and distribution of the systemic events occurred at each dose level

Systemic Events	Group I
(14 mg)	Group II
(70 mg)	Group III
(245 mg)	Group IV
(490 mg)		
Itching	8 (14.6%)	18 (25.0%)	29 (25.9%)	29 (32.3%)	84	
Hot flashes	12 (21.8%)	14 (11.7%)	8 (7.1%)	8 (8.9%)	42	
Localized rash	3 (5.4%)	21 (17.5%)	6 (5.4%)	8 (8.9%)	38	
Localized facial edema	9 (16.4%)	6 (5.0%)	8 (7.1%)	13 (14.4%)	36	
Bumps	0	12 (10.0%)	17 (15.2%)	6 (6.7%)	35	
Extensive rash	2 (3.6%)	0	21 (18.8%)	5 (5.6%)	28	
Cramps	3 (5.4%)	2 (1.7%)	11 (9.0%)	6 (6.7%)	22	
Headache	3 (5.4%)	2 (1.7%)	4 (3.6%)	2 (2.2%)	11	
Metallic flavor	4 (7.3%)	6 (5.0%)	1 (0.9%)	0	11	
Tickling or tingling	5 (9.1%)	6 (5.0%)	0	0	11	
Tachycardia	0	7 (5.8%)	3 (2.7%)	0	10	
Tinnitus	0	7 (5.8%)	0	0	7	
Nausea	0	3 (2.5%)	1 (0.9%)	3 (3.3%)	7	
Facial erythema	0	7 (5.8%)	0	0	7	
Palpitations	0	2 (1.7%)	1 (0.9%)	2 (2.2%)	5	
Hypertension	3 (5.4%)	1 (0.8%)	0	1 (1.1%)	5	
Vasovagal syndrome	0	g2: 2 (1.7%)		g3: 2 (2.2%)	4	
Dizziness	1 (1.8%)	2 (1.7%)	0	0	3	
Tremors	0	0	0	3 (3.3%)	3	
Vomiting	0	2 (1.7%)	0	0	2	
Fast breathing	1 (1.8%)	0	0	0	1	
Abdominal pain	1 (1.8%)	0	0	0	1	
Arrhythmia	0	0	0	1 (1.1%)	1	
Hypotension	0	0	1 (0.9%)	0	1	
Posture-related tremor in lower limbs	0	0	0	1 (1.1%)	1	
Red eyes	0	0	1 (0.9%)	0	1	
	
Total	55	120	112	90		
There were no differences between baseline and post-treatment blood counts, serum chemistry results, coagulation parameters and electrocardiograms (data not shown).

Efficacy analysis
Individual efficacy results are shown in Table 1 and summarized in Table 4.",III,serum,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","The pCR in the breast was achieved in 22 patients (18.5%) and in the axillary lymph nodes in 39 patients (32.8%), while absence of tumors in the breast occurred in 10 patients (8.4%).",pCR,lymph,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
",The expression of the 35 kDa CYC-1 protein in serum from the 'case' and 'control' samples was shown in Figure 5a.,CYC-1,serum,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","In this study, we assessed the capacity of MMP1, one of the most relevant markers, to detect HNSCC tumor cells in saliva cells; this provided information on its utility as a non invasive diagnostic marker.

",HNSCC,saliva,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","In this study, we assessed the capacity of MMP1, one of the most relevant markers, to detect HNSCC tumor cells in saliva cells; this provided information on its utility as a non invasive diagnostic marker.

",MMP1,saliva,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
",CR: conditioning regimen; BMT: bone marrow transplantation; TBARS: thiobarbituric acid-reactive substances; VIT C: vitamin C; CAT: catalase; SOD: superoxide dismutase; P-SH: protein thiol groups; NP-SH: non protein thiol groups; d-ALA-D: d-aminolevulinate dehydratase; n.s.: no significant.,SOD,bone marrow,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
",CR: conditioning regimen; BMT: bone marrow transplantation; TBARS: thiobarbituric acid-reactive substances; VIT C: vitamin C; CAT: catalase; SOD: superoxide dismutase; P-SH: protein thiol groups; NP-SH: non protein thiol groups; d-ALA-D: d-aminolevulinate dehydratase; n.s.: no significant.,BMT,bone marrow,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
",CR: conditioning regimen; BMT: bone marrow transplantation; TBARS: thiobarbituric acid-reactive substances; VIT C: vitamin C; CAT: catalase; SOD: superoxide dismutase; P-SH: protein thiol groups; NP-SH: non protein thiol groups; d-ALA-D: d-aminolevulinate dehydratase; n.s.: no significant.,VIT,bone marrow,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
",CR: conditioning regimen; BMT: bone marrow transplantation; TBARS: thiobarbituric acid-reactive substances; VIT C: vitamin C; CAT: catalase; SOD: superoxide dismutase; P-SH: protein thiol groups; NP-SH: non protein thiol groups; d-ALA-D: d-aminolevulinate dehydratase; n.s.: no significant.,TBARS,bone marrow,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
",CR: conditioning regimen; BMT: bone marrow transplantation; TBARS: thiobarbituric acid-reactive substances; VIT C: vitamin C; CAT: catalase; SOD: superoxide dismutase; P-SH: protein thiol groups; NP-SH: non protein thiol groups; d-ALA-D: d-aminolevulinate dehydratase; n.s.: no significant.,CAT,bone marrow,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
",CR: conditioning regimen; BMT: bone marrow transplantation; TBARS: thiobarbituric acid-reactive substances; VIT C: vitamin C; CAT: catalase; SOD: superoxide dismutase; P-SH: protein thiol groups; NP-SH: non protein thiol groups; d-ALA-D: d-aminolevulinate dehydratase; n.s.: no significant.,CR,bone marrow,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
",CR: conditioning regimen; BMT: bone marrow transplantation; TBARS: thiobarbituric acid-reactive substances; VIT C: vitamin C; CAT: catalase; SOD: superoxide dismutase; P-SH: protein thiol groups; NP-SH: non protein thiol groups; d-ALA-D: d-aminolevulinate dehydratase; n.s.: no significant.,NP,bone marrow,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","d-Aminolevulinate dehydratase
Blood d-ALA-D activity was significantly lower in groups II (autol.) and III (allog.)",III,Blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","The damage observed in the PHA-stimulated whole blood cells could be explained by the classical events ascribed to topoisomerase II poisons [12].

",PHA,blood,-1
"PMC 
BMC_Cancer_2010_Apr_27_10_161.txt
","Total protein were extracted from serum starved PANC-1 cells treated with EGF at different concentration, and subjected to Western blotting.",PANC-1,serum,-1
"PMC 
BMC_Cancer_2010_Apr_27_10_161.txt
","Total protein were extracted from serum starved PANC-1 cells treated with EGF at different concentration, and subjected to Western blotting.",EGF,serum,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","To asses the molecular processes involved in the etoposide treatment-induced breaks, we compared the non-stimulated whole blood cells genotoxicity data generated by the SCGE assay under both highly basic (= 12.3) and extremely basic (&#62; 13) pH conditions and thus generated the ALS index values (see results section).",ALS,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","To asses the molecular processes involved in the etoposide treatment-induced breaks, we compared the non-stimulated whole blood cells genotoxicity data generated by the SCGE assay under both highly basic (= 12.3) and extremely basic (&#62; 13) pH conditions and thus generated the ALS index values (see results section).",SCGE,blood,-1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Sera were assayed using the Enzyme-Linked ImmunoSorbent Assay (ELISA, Luminex platform) and reagents in the Luminex Core Facility of University of Pittsburgh Cancer Institute.",ELISA,Sera,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Regarding NGAL, increased serum expression was observed for patients with breast disease compared to healthy controls (Figure 2).",NGAL,serum,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Bauer et al recently extended these findings to show that immunohistochemical NGAL expression strongly correlated with negative steroid receptor status, Her-2/neu overexpression, poor histologic grade, the presence of lymph node metastasis and high proliferation index.",NGAL,lymph,1
"PMC 
BMC_Cancer_2009_May_27_9_162.txt
","Nucleic acid isolation and bisulfite modification
Genomic DNA (gDNA) was isolated from tumor tissue and cultured cell lines, using Qiagen Blood and Cell Culture DNA Kit (Qiagen, Inc., Valencia, VA) and stored at -20degC before use.",DNA,Blood,-1
"PMC 
BMC_Cancer_2009_May_27_9_162.txt
","Nucleic acid isolation and bisulfite modification
Genomic DNA (gDNA) was isolated from tumor tissue and cultured cell lines, using Qiagen Blood and Cell Culture DNA Kit (Qiagen, Inc., Valencia, VA) and stored at -20degC before use.",DNA,Blood,-1
"PMC 
BMC_Cancer_2009_May_27_9_162.txt
","Nucleic acid isolation and bisulfite modification
Genomic DNA (gDNA) was isolated from tumor tissue and cultured cell lines, using Qiagen Blood and Cell Culture DNA Kit (Qiagen, Inc., Valencia, VA) and stored at -20degC before use.",gDNA,Blood,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","The DFS analysis of the untreated group is particularly interesting as this analysis describes only the prognostic impact of TIMP-1 with no interference from systemic treatment; currently, this is rarely feasible as most patients, certainly among lymph node-positive patients, receive systemic adjuvant treatment.",TIMP-1,lymph,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","The DFS analysis of the untreated group is particularly interesting as this analysis describes only the prognostic impact of TIMP-1 with no interference from systemic treatment; currently, this is rarely feasible as most patients, certainly among lymph node-positive patients, receive systemic adjuvant treatment.",DFS,lymph,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
",Saliva is an easily accessible diagnostic fluid for screening HNSCC [29].,HNSCC,Saliva,-1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Table 1 Serum levels of MMP-9, NGAL and MMP-9/NGAL complex.

	",MMP-9,Serum,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Table 1 Serum levels of MMP-9, NGAL and MMP-9/NGAL complex.

	",NGAL,Serum,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","The whole RT-qPCR procedure was carried out with and without RT enzyme, confirming the absence of contamination by genomic DNA during the automated saliva rinse RNA extraction process (data not shown).

",RNA,saliva,-1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","The whole RT-qPCR procedure was carried out with and without RT enzyme, confirming the absence of contamination by genomic DNA during the automated saliva rinse RNA extraction process (data not shown).

",qPCR,saliva,-1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","The whole RT-qPCR procedure was carried out with and without RT enzyme, confirming the absence of contamination by genomic DNA during the automated saliva rinse RNA extraction process (data not shown).

",DNA,saliva,-1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
",Increased MMP-9 serum levels were observed for all patients compared to healthy subjects (Figure 1).,MMP-9,serum,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Peripheral blood stem cell transplantation (PBSCT) with collection by apheresis has replaced bone marrow as a source of hematopoietic stem cells for autologous transplantation, because this type of collection results in a more rapid hematopoietic recovery [5,6].",PBSCT,blood,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Peripheral blood stem cell transplantation (PBSCT) with collection by apheresis has replaced bone marrow as a source of hematopoietic stem cells for autologous transplantation, because this type of collection results in a more rapid hematopoietic recovery [5,6].",PBSCT,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Additionally, increased MMP-9 levels were associated with lymph node metastasis, higher tumor stage, lower relapse-free and overall survival [36].",MMP-9,lymph,1
"PMC 
BMC_Cancer_2009_Oct_20_9_374.txt
","Over-expression of miR-145 in the presence of sense control RNA resulted in increased cell proliferation in serum, and more markedly in serum-free medium (Fig.",RNA,serum,1
"PMC 
BMC_Cancer_2009_Oct_20_9_374.txt
","Over-expression of miR-145 in the presence of sense control RNA resulted in increased cell proliferation in serum, and more markedly in serum-free medium (Fig.",RNA,serum,1
"PMC 
BMC_Cancer_2010_Aug_12_10_422.txt
",Genomic DNA was extracted from the buffy coats using QIA Gen Blood Kit according to the manufacture's instructions (Qiagen).,QIA,Blood,-1
"PMC 
BMC_Cancer_2010_Aug_12_10_422.txt
",Genomic DNA was extracted from the buffy coats using QIA Gen Blood Kit according to the manufacture's instructions (Qiagen).,Gen,Blood,-1
"PMC 
BMC_Cancer_2010_Aug_12_10_422.txt
",Genomic DNA was extracted from the buffy coats using QIA Gen Blood Kit according to the manufacture's instructions (Qiagen).,DNA,Blood,-1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
",DNA was extracted from patients' blood.,DNA,blood,-1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","Among the 51 HNSCC patients, only 10 (20%) exhibited MMP1 mRNA at a measurable concentration in their saliva rinse.",MMP1,saliva,-1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","Among the 51 HNSCC patients, only 10 (20%) exhibited MMP1 mRNA at a measurable concentration in their saliva rinse.",HNSCC,saliva,-1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","Among the 51 HNSCC patients, only 10 (20%) exhibited MMP1 mRNA at a measurable concentration in their saliva rinse.",mRNA,saliva,-1
"PMC 
BMC_Cancer_2010_Apr_21_10_155.txt
","Mean cell Hb (amount of Hb/red blood cell) and platelet count (number of platelets in blood volume) will also be calculated, and (3) Arterial O2 Saturation will be assessed at rest and continuously during exercise using pulse oximetry (Biox 3700, Ohmeda Medical, Boulder, CO), which provides the most accurate noninvasive assessment of blood arterial O2 saturation levels.",O2,blood,-1
"PMC 
BMC_Cancer_2010_Apr_21_10_155.txt
","Mean cell Hb (amount of Hb/red blood cell) and platelet count (number of platelets in blood volume) will also be calculated, and (3) Arterial O2 Saturation will be assessed at rest and continuously during exercise using pulse oximetry (Biox 3700, Ohmeda Medical, Boulder, CO), which provides the most accurate noninvasive assessment of blood arterial O2 saturation levels.",O2,blood,-1
"PMC 
BMC_Cancer_2010_Apr_21_10_155.txt
","Mean cell Hb (amount of Hb/red blood cell) and platelet count (number of platelets in blood volume) will also be calculated, and (3) Arterial O2 Saturation will be assessed at rest and continuously during exercise using pulse oximetry (Biox 3700, Ohmeda Medical, Boulder, CO), which provides the most accurate noninvasive assessment of blood arterial O2 saturation levels.",O2,blood,-1
"PMC 
BMC_Cancer_2010_Apr_21_10_155.txt
","Mean cell Hb (amount of Hb/red blood cell) and platelet count (number of platelets in blood volume) will also be calculated, and (3) Arterial O2 Saturation will be assessed at rest and continuously during exercise using pulse oximetry (Biox 3700, Ohmeda Medical, Boulder, CO), which provides the most accurate noninvasive assessment of blood arterial O2 saturation levels.",O2,blood,-1
"PMC 
BMC_Cancer_2010_Apr_21_10_155.txt
","Mean cell Hb (amount of Hb/red blood cell) and platelet count (number of platelets in blood volume) will also be calculated, and (3) Arterial O2 Saturation will be assessed at rest and continuously during exercise using pulse oximetry (Biox 3700, Ohmeda Medical, Boulder, CO), which provides the most accurate noninvasive assessment of blood arterial O2 saturation levels.",O2,blood,-1
"PMC 
BMC_Cancer_2010_Apr_21_10_155.txt
","Mean cell Hb (amount of Hb/red blood cell) and platelet count (number of platelets in blood volume) will also be calculated, and (3) Arterial O2 Saturation will be assessed at rest and continuously during exercise using pulse oximetry (Biox 3700, Ohmeda Medical, Boulder, CO), which provides the most accurate noninvasive assessment of blood arterial O2 saturation levels.",O2,blood,-1
"PMC 
BMC_Cancer_2010_Aug_15_10_428.txt
","Positive associations between MTSS1 expression and other clinicopathologic features, such as tumor size, depth of tumor invasion, status of lymph nodes, TNM stage, differentiation and Lauren's classification were indicated.",TNM,lymph,1
"PMC 
BMC_Cancer_2010_Aug_15_10_428.txt
","Positive associations between MTSS1 expression and other clinicopathologic features, such as tumor size, depth of tumor invasion, status of lymph nodes, TNM stage, differentiation and Lauren's classification were indicated.",MTSS1,lymph,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","Serum TRACP 5b and Overall Survival Time
Table 2 summarizes the results of Cox proportion regression models assessing the OS as a function of baseline variables including age, ER status, CEA, CA15.3, HER2 status and visceral metastasis in addition to baseline serum TRACP 5b activity.",TRACP,Serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","Serum TRACP 5b and Overall Survival Time
Table 2 summarizes the results of Cox proportion regression models assessing the OS as a function of baseline variables including age, ER status, CEA, CA15.3, HER2 status and visceral metastasis in addition to baseline serum TRACP 5b activity.",TRACP,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","Serum TRACP 5b and Overall Survival Time
Table 2 summarizes the results of Cox proportion regression models assessing the OS as a function of baseline variables including age, ER status, CEA, CA15.3, HER2 status and visceral metastasis in addition to baseline serum TRACP 5b activity.",HER2,Serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","Serum TRACP 5b and Overall Survival Time
Table 2 summarizes the results of Cox proportion regression models assessing the OS as a function of baseline variables including age, ER status, CEA, CA15.3, HER2 status and visceral metastasis in addition to baseline serum TRACP 5b activity.",HER2,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","Serum TRACP 5b and Overall Survival Time
Table 2 summarizes the results of Cox proportion regression models assessing the OS as a function of baseline variables including age, ER status, CEA, CA15.3, HER2 status and visceral metastasis in addition to baseline serum TRACP 5b activity.",OS,Serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","Serum TRACP 5b and Overall Survival Time
Table 2 summarizes the results of Cox proportion regression models assessing the OS as a function of baseline variables including age, ER status, CEA, CA15.3, HER2 status and visceral metastasis in addition to baseline serum TRACP 5b activity.",OS,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","Serum TRACP 5b and Overall Survival Time
Table 2 summarizes the results of Cox proportion regression models assessing the OS as a function of baseline variables including age, ER status, CEA, CA15.3, HER2 status and visceral metastasis in addition to baseline serum TRACP 5b activity.",TRACP,Serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","Serum TRACP 5b and Overall Survival Time
Table 2 summarizes the results of Cox proportion regression models assessing the OS as a function of baseline variables including age, ER status, CEA, CA15.3, HER2 status and visceral metastasis in addition to baseline serum TRACP 5b activity.",TRACP,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","Serum TRACP 5b and Overall Survival Time
Table 2 summarizes the results of Cox proportion regression models assessing the OS as a function of baseline variables including age, ER status, CEA, CA15.3, HER2 status and visceral metastasis in addition to baseline serum TRACP 5b activity.",CEA,Serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","Serum TRACP 5b and Overall Survival Time
Table 2 summarizes the results of Cox proportion regression models assessing the OS as a function of baseline variables including age, ER status, CEA, CA15.3, HER2 status and visceral metastasis in addition to baseline serum TRACP 5b activity.",CEA,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","Serum TRACP 5b and Overall Survival Time
Table 2 summarizes the results of Cox proportion regression models assessing the OS as a function of baseline variables including age, ER status, CEA, CA15.3, HER2 status and visceral metastasis in addition to baseline serum TRACP 5b activity.",ER,Serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","Serum TRACP 5b and Overall Survival Time
Table 2 summarizes the results of Cox proportion regression models assessing the OS as a function of baseline variables including age, ER status, CEA, CA15.3, HER2 status and visceral metastasis in addition to baseline serum TRACP 5b activity.",ER,serum,1
"PMC 
BMC_Cancer_2009_Oct_6_9_354.txt
","The comparison of the findings in the tumor tissue and in the peripheral blood from the same patient showed no RASSF1 or CDKN2A methylation in any of the peripheral blood samples, and only one sample positive for MGMT methylation; a T4N0 M0 (stage IVa) squamous cancer of the oral cavity.",CDKN2A,blood,-1
"PMC 
BMC_Cancer_2009_Oct_6_9_354.txt
","The comparison of the findings in the tumor tissue and in the peripheral blood from the same patient showed no RASSF1 or CDKN2A methylation in any of the peripheral blood samples, and only one sample positive for MGMT methylation; a T4N0 M0 (stage IVa) squamous cancer of the oral cavity.",CDKN2A,blood,-1
"PMC 
BMC_Cancer_2009_Oct_6_9_354.txt
","The comparison of the findings in the tumor tissue and in the peripheral blood from the same patient showed no RASSF1 or CDKN2A methylation in any of the peripheral blood samples, and only one sample positive for MGMT methylation; a T4N0 M0 (stage IVa) squamous cancer of the oral cavity.",RASSF1,blood,-1
"PMC 
BMC_Cancer_2009_Oct_6_9_354.txt
","The comparison of the findings in the tumor tissue and in the peripheral blood from the same patient showed no RASSF1 or CDKN2A methylation in any of the peripheral blood samples, and only one sample positive for MGMT methylation; a T4N0 M0 (stage IVa) squamous cancer of the oral cavity.",RASSF1,blood,-1
"PMC 
BMC_Cancer_2009_Oct_6_9_354.txt
","The comparison of the findings in the tumor tissue and in the peripheral blood from the same patient showed no RASSF1 or CDKN2A methylation in any of the peripheral blood samples, and only one sample positive for MGMT methylation; a T4N0 M0 (stage IVa) squamous cancer of the oral cavity.",M0,blood,-1
"PMC 
BMC_Cancer_2009_Oct_6_9_354.txt
","The comparison of the findings in the tumor tissue and in the peripheral blood from the same patient showed no RASSF1 or CDKN2A methylation in any of the peripheral blood samples, and only one sample positive for MGMT methylation; a T4N0 M0 (stage IVa) squamous cancer of the oral cavity.",M0,blood,-1
"PMC 
BMC_Cancer_2009_Oct_6_9_354.txt
","The comparison of the findings in the tumor tissue and in the peripheral blood from the same patient showed no RASSF1 or CDKN2A methylation in any of the peripheral blood samples, and only one sample positive for MGMT methylation; a T4N0 M0 (stage IVa) squamous cancer of the oral cavity.",MGMT,blood,-1
"PMC 
BMC_Cancer_2009_Oct_6_9_354.txt
","The comparison of the findings in the tumor tissue and in the peripheral blood from the same patient showed no RASSF1 or CDKN2A methylation in any of the peripheral blood samples, and only one sample positive for MGMT methylation; a T4N0 M0 (stage IVa) squamous cancer of the oral cavity.",MGMT,blood,-1
"PMC 
BMC_Cancer_2009_Mar_27_9_96.txt
","Reagents
MCF-7 cells and cell culturing reagents [Eagle's Minimum Essential Medium (EMEM), fetal bovine serum (FBS), insulin, trypsin/EDTA for cell detachment] were purchased from ATCC (Manassas, VA USA).",FBS,serum,1
"PMC 
BMC_Cancer_2009_Mar_27_9_96.txt
","Reagents
MCF-7 cells and cell culturing reagents [Eagle's Minimum Essential Medium (EMEM), fetal bovine serum (FBS), insulin, trypsin/EDTA for cell detachment] were purchased from ATCC (Manassas, VA USA).",EMEM,serum,1
"PMC 
BMC_Cancer_2009_Mar_27_9_96.txt
","Reagents
MCF-7 cells and cell culturing reagents [Eagle's Minimum Essential Medium (EMEM), fetal bovine serum (FBS), insulin, trypsin/EDTA for cell detachment] were purchased from ATCC (Manassas, VA USA).",EDTA,serum,1
"PMC 
BMC_Cancer_2009_Mar_27_9_96.txt
","Reagents
MCF-7 cells and cell culturing reagents [Eagle's Minimum Essential Medium (EMEM), fetal bovine serum (FBS), insulin, trypsin/EDTA for cell detachment] were purchased from ATCC (Manassas, VA USA).",USA,serum,1
"PMC 
BMC_Cancer_2009_Mar_27_9_96.txt
","Reagents
MCF-7 cells and cell culturing reagents [Eagle's Minimum Essential Medium (EMEM), fetal bovine serum (FBS), insulin, trypsin/EDTA for cell detachment] were purchased from ATCC (Manassas, VA USA).",ATCC,serum,1
"PMC 
BMC_Cancer_2009_Mar_27_9_96.txt
","Reagents
MCF-7 cells and cell culturing reagents [Eagle's Minimum Essential Medium (EMEM), fetal bovine serum (FBS), insulin, trypsin/EDTA for cell detachment] were purchased from ATCC (Manassas, VA USA).",MCF-7,serum,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","Table 5 Characteristics of patients with positive MMP1 salivary test

Patient	Tumor site	T stage	N stage	M stage	
1	Oral cavity	1	0	0	
2	Oral cavity	4a	2b	0	
3	Oral cavity	4a	2c	0	
4	Oropharynx	2	0	0	
5	Oropharynx	2	2b	0	
6	Oropharynx	3	2b	0	
7	Oropharynx	4a	0	0	
8	Oropharynx	4a	2c	0	
9	Oropharynx	4a	2c	1	
10	Hypopharynx	3	2b	0	
Tumor sites and TNM stages of the 10 patients with detectable levels of MMP1 in their saliva rinse.

",MMP1,saliva,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","Table 5 Characteristics of patients with positive MMP1 salivary test

Patient	Tumor site	T stage	N stage	M stage	
1	Oral cavity	1	0	0	
2	Oral cavity	4a	2b	0	
3	Oral cavity	4a	2c	0	
4	Oropharynx	2	0	0	
5	Oropharynx	2	2b	0	
6	Oropharynx	3	2b	0	
7	Oropharynx	4a	0	0	
8	Oropharynx	4a	2c	0	
9	Oropharynx	4a	2c	1	
10	Hypopharynx	3	2b	0	
Tumor sites and TNM stages of the 10 patients with detectable levels of MMP1 in their saliva rinse.

",TNM,saliva,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","Table 5 Characteristics of patients with positive MMP1 salivary test

Patient	Tumor site	T stage	N stage	M stage	
1	Oral cavity	1	0	0	
2	Oral cavity	4a	2b	0	
3	Oral cavity	4a	2c	0	
4	Oropharynx	2	0	0	
5	Oropharynx	2	2b	0	
6	Oropharynx	3	2b	0	
7	Oropharynx	4a	0	0	
8	Oropharynx	4a	2c	0	
9	Oropharynx	4a	2c	1	
10	Hypopharynx	3	2b	0	
Tumor sites and TNM stages of the 10 patients with detectable levels of MMP1 in their saliva rinse.

",MMP1,saliva,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","Table 5 Characteristics of patients with positive MMP1 salivary test

Patient	Tumor site	T stage	N stage	M stage	
1	Oral cavity	1	0	0	
2	Oral cavity	4a	2b	0	
3	Oral cavity	4a	2c	0	
4	Oropharynx	2	0	0	
5	Oropharynx	2	2b	0	
6	Oropharynx	3	2b	0	
7	Oropharynx	4a	0	0	
8	Oropharynx	4a	2c	0	
9	Oropharynx	4a	2c	1	
10	Hypopharynx	3	2b	0	
Tumor sites and TNM stages of the 10 patients with detectable levels of MMP1 in their saliva rinse.

",T,saliva,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","29.8	.001	
	Large	15.0	2.8-27.2	13.9		
	Small	18.0	7.1-28.9	17.9		
	
	24-hour urine 5-HIAA (mmol/day)	&#60;31.4	31.0	24.3-37.7	42.8	.653	
		>= 31.4	46.0	-	66,7		
Biomarkers							
	Serum NSE (nmol/l)	&#60;1.0	31.0	-	47.7	.051	
		>= 1.0	7.0	4.3-9.7	26.8		
	
	Local treatment only	43.0	23.1-62.9	53.0		
Treatment modality	Systemic treatment only	23.0	0.4-45.6	38.0	.245	
	Both treatments	29.0	23.6-34.4	43.0		
OS, overall survival; CI, confidence interval; GI, gastrointestinal; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase

Figure 2 Overall survival by treatment modality

OS was significantly influenced by grade (p = .001) (Figure 3).",NSE,urine,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","29.8	.001	
	Large	15.0	2.8-27.2	13.9		
	Small	18.0	7.1-28.9	17.9		
	
	24-hour urine 5-HIAA (mmol/day)	&#60;31.4	31.0	24.3-37.7	42.8	.653	
		>= 31.4	46.0	-	66,7		
Biomarkers							
	Serum NSE (nmol/l)	&#60;1.0	31.0	-	47.7	.051	
		>= 1.0	7.0	4.3-9.7	26.8		
	
	Local treatment only	43.0	23.1-62.9	53.0		
Treatment modality	Systemic treatment only	23.0	0.4-45.6	38.0	.245	
	Both treatments	29.0	23.6-34.4	43.0		
OS, overall survival; CI, confidence interval; GI, gastrointestinal; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase

Figure 2 Overall survival by treatment modality

OS was significantly influenced by grade (p = .001) (Figure 3).",NSE,Serum,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","29.8	.001	
	Large	15.0	2.8-27.2	13.9		
	Small	18.0	7.1-28.9	17.9		
	
	24-hour urine 5-HIAA (mmol/day)	&#60;31.4	31.0	24.3-37.7	42.8	.653	
		>= 31.4	46.0	-	66,7		
Biomarkers							
	Serum NSE (nmol/l)	&#60;1.0	31.0	-	47.7	.051	
		>= 1.0	7.0	4.3-9.7	26.8		
	
	Local treatment only	43.0	23.1-62.9	53.0		
Treatment modality	Systemic treatment only	23.0	0.4-45.6	38.0	.245	
	Both treatments	29.0	23.6-34.4	43.0		
OS, overall survival; CI, confidence interval; GI, gastrointestinal; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase

Figure 2 Overall survival by treatment modality

OS was significantly influenced by grade (p = .001) (Figure 3).",CI,urine,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","29.8	.001	
	Large	15.0	2.8-27.2	13.9		
	Small	18.0	7.1-28.9	17.9		
	
	24-hour urine 5-HIAA (mmol/day)	&#60;31.4	31.0	24.3-37.7	42.8	.653	
		>= 31.4	46.0	-	66,7		
Biomarkers							
	Serum NSE (nmol/l)	&#60;1.0	31.0	-	47.7	.051	
		>= 1.0	7.0	4.3-9.7	26.8		
	
	Local treatment only	43.0	23.1-62.9	53.0		
Treatment modality	Systemic treatment only	23.0	0.4-45.6	38.0	.245	
	Both treatments	29.0	23.6-34.4	43.0		
OS, overall survival; CI, confidence interval; GI, gastrointestinal; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase

Figure 2 Overall survival by treatment modality

OS was significantly influenced by grade (p = .001) (Figure 3).",CI,Serum,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","29.8	.001	
	Large	15.0	2.8-27.2	13.9		
	Small	18.0	7.1-28.9	17.9		
	
	24-hour urine 5-HIAA (mmol/day)	&#60;31.4	31.0	24.3-37.7	42.8	.653	
		>= 31.4	46.0	-	66,7		
Biomarkers							
	Serum NSE (nmol/l)	&#60;1.0	31.0	-	47.7	.051	
		>= 1.0	7.0	4.3-9.7	26.8		
	
	Local treatment only	43.0	23.1-62.9	53.0		
Treatment modality	Systemic treatment only	23.0	0.4-45.6	38.0	.245	
	Both treatments	29.0	23.6-34.4	43.0		
OS, overall survival; CI, confidence interval; GI, gastrointestinal; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase

Figure 2 Overall survival by treatment modality

OS was significantly influenced by grade (p = .001) (Figure 3).",OS,urine,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","29.8	.001	
	Large	15.0	2.8-27.2	13.9		
	Small	18.0	7.1-28.9	17.9		
	
	24-hour urine 5-HIAA (mmol/day)	&#60;31.4	31.0	24.3-37.7	42.8	.653	
		>= 31.4	46.0	-	66,7		
Biomarkers							
	Serum NSE (nmol/l)	&#60;1.0	31.0	-	47.7	.051	
		>= 1.0	7.0	4.3-9.7	26.8		
	
	Local treatment only	43.0	23.1-62.9	53.0		
Treatment modality	Systemic treatment only	23.0	0.4-45.6	38.0	.245	
	Both treatments	29.0	23.6-34.4	43.0		
OS, overall survival; CI, confidence interval; GI, gastrointestinal; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase

Figure 2 Overall survival by treatment modality

OS was significantly influenced by grade (p = .001) (Figure 3).",OS,Serum,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","29.8	.001	
	Large	15.0	2.8-27.2	13.9		
	Small	18.0	7.1-28.9	17.9		
	
	24-hour urine 5-HIAA (mmol/day)	&#60;31.4	31.0	24.3-37.7	42.8	.653	
		>= 31.4	46.0	-	66,7		
Biomarkers							
	Serum NSE (nmol/l)	&#60;1.0	31.0	-	47.7	.051	
		>= 1.0	7.0	4.3-9.7	26.8		
	
	Local treatment only	43.0	23.1-62.9	53.0		
Treatment modality	Systemic treatment only	23.0	0.4-45.6	38.0	.245	
	Both treatments	29.0	23.6-34.4	43.0		
OS, overall survival; CI, confidence interval; GI, gastrointestinal; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase

Figure 2 Overall survival by treatment modality

OS was significantly influenced by grade (p = .001) (Figure 3).",OS,urine,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","29.8	.001	
	Large	15.0	2.8-27.2	13.9		
	Small	18.0	7.1-28.9	17.9		
	
	24-hour urine 5-HIAA (mmol/day)	&#60;31.4	31.0	24.3-37.7	42.8	.653	
		>= 31.4	46.0	-	66,7		
Biomarkers							
	Serum NSE (nmol/l)	&#60;1.0	31.0	-	47.7	.051	
		>= 1.0	7.0	4.3-9.7	26.8		
	
	Local treatment only	43.0	23.1-62.9	53.0		
Treatment modality	Systemic treatment only	23.0	0.4-45.6	38.0	.245	
	Both treatments	29.0	23.6-34.4	43.0		
OS, overall survival; CI, confidence interval; GI, gastrointestinal; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase

Figure 2 Overall survival by treatment modality

OS was significantly influenced by grade (p = .001) (Figure 3).",OS,Serum,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","29.8	.001	
	Large	15.0	2.8-27.2	13.9		
	Small	18.0	7.1-28.9	17.9		
	
	24-hour urine 5-HIAA (mmol/day)	&#60;31.4	31.0	24.3-37.7	42.8	.653	
		>= 31.4	46.0	-	66,7		
Biomarkers							
	Serum NSE (nmol/l)	&#60;1.0	31.0	-	47.7	.051	
		>= 1.0	7.0	4.3-9.7	26.8		
	
	Local treatment only	43.0	23.1-62.9	53.0		
Treatment modality	Systemic treatment only	23.0	0.4-45.6	38.0	.245	
	Both treatments	29.0	23.6-34.4	43.0		
OS, overall survival; CI, confidence interval; GI, gastrointestinal; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase

Figure 2 Overall survival by treatment modality

OS was significantly influenced by grade (p = .001) (Figure 3).",NSE,urine,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","29.8	.001	
	Large	15.0	2.8-27.2	13.9		
	Small	18.0	7.1-28.9	17.9		
	
	24-hour urine 5-HIAA (mmol/day)	&#60;31.4	31.0	24.3-37.7	42.8	.653	
		>= 31.4	46.0	-	66,7		
Biomarkers							
	Serum NSE (nmol/l)	&#60;1.0	31.0	-	47.7	.051	
		>= 1.0	7.0	4.3-9.7	26.8		
	
	Local treatment only	43.0	23.1-62.9	53.0		
Treatment modality	Systemic treatment only	23.0	0.4-45.6	38.0	.245	
	Both treatments	29.0	23.6-34.4	43.0		
OS, overall survival; CI, confidence interval; GI, gastrointestinal; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase

Figure 2 Overall survival by treatment modality

OS was significantly influenced by grade (p = .001) (Figure 3).",NSE,Serum,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
",We thus hypothesized that it could be detected in the saliva rinses of patients with HNSCC for diagnosis or screening purposes.,HNSCC,saliva,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","Histological findings included tumor size, depth of tumor invasion, lymph node (LN) metastasis, and TNM stage (6th AJCC Stage Groupings: The staging systems; Primary tumor, regional LN, metastasis).

",AJCC,lymph,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","Histological findings included tumor size, depth of tumor invasion, lymph node (LN) metastasis, and TNM stage (6th AJCC Stage Groupings: The staging systems; Primary tumor, regional LN, metastasis).

",TNM,lymph,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","The results were expressed as nmol P-SH/mL plasma [39,38].

Non protein thiol groups
Erythrocyte non protein thiol groups (NP-SH) were determined as described by Boyne and Ellman (1972) modified by Jacques-Silva et al.",NP,plasma,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","25	56.1%^^	
*p &#60; 0.05, **p &#60; 0.01, AT versus HC; #p &#60; 0.05, ##p &#60; 0.01, HCC versus AT, ^p &#60; 0.05; ^^p &#60; 0.01, HCC versus HC

Bone marrow EPCs are mobilized and recruited into cirrhotic liver
",HCC,Bone marrow,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","25	56.1%^^	
*p &#60; 0.05, **p &#60; 0.01, AT versus HC; #p &#60; 0.05, ##p &#60; 0.01, HCC versus AT, ^p &#60; 0.05; ^^p &#60; 0.01, HCC versus HC

Bone marrow EPCs are mobilized and recruited into cirrhotic liver
",HCC,Bone marrow,-1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Pathology		Pathological tumor size		
 IDC	92 (77.3%)	 <= 2 cm	28 (23.5%)	
 ILC	4 (3.4%)	 &#62; 2 cm	59 (49.6%)	
 other	23 (19.3%)	 unmeasured	32 (26.9%)	
Clinical response		pALN		
 CR	27 (22.7%)	 N 0	39 (32.8%)	
 PR	78 (65.6%)	 N 1-3	24 (20.2%)	
 SD	13 (10.9%)	 N 4-9	35 (29.4%)	
 PD	1 (0.8%)	 N &#62;9	21 (17.6%)	
Pathological response in tumor site				
 T-A	22 (18.5%)			
 T-B	75 (63.0%)			
 T-C	22 (18.5%)			
Abbreviations: pre-, before chemotherapy; post-, after chemotherapy; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, Complete response; PR, Partial response; SD, Stable disease; PD, Progressive disease; T-A: no tumor cell or presence of in situ carcinoma, no invasive tumor; T-B: presence of invasive carcinoma without special involvement (such as skin, vessel, more than one quadrant); T-C: presence of invasive carcinoma with special involvement.

",pALN,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Pathology		Pathological tumor size		
 IDC	92 (77.3%)	 <= 2 cm	28 (23.5%)	
 ILC	4 (3.4%)	 &#62; 2 cm	59 (49.6%)	
 other	23 (19.3%)	 unmeasured	32 (26.9%)	
Clinical response		pALN		
 CR	27 (22.7%)	 N 0	39 (32.8%)	
 PR	78 (65.6%)	 N 1-3	24 (20.2%)	
 SD	13 (10.9%)	 N 4-9	35 (29.4%)	
 PD	1 (0.8%)	 N &#62;9	21 (17.6%)	
Pathological response in tumor site				
 T-A	22 (18.5%)			
 T-B	75 (63.0%)			
 T-C	22 (18.5%)			
Abbreviations: pre-, before chemotherapy; post-, after chemotherapy; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, Complete response; PR, Partial response; SD, Stable disease; PD, Progressive disease; T-A: no tumor cell or presence of in situ carcinoma, no invasive tumor; T-B: presence of invasive carcinoma without special involvement (such as skin, vessel, more than one quadrant); T-C: presence of invasive carcinoma with special involvement.

",pALN,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Pathology		Pathological tumor size		
 IDC	92 (77.3%)	 <= 2 cm	28 (23.5%)	
 ILC	4 (3.4%)	 &#62; 2 cm	59 (49.6%)	
 other	23 (19.3%)	 unmeasured	32 (26.9%)	
Clinical response		pALN		
 CR	27 (22.7%)	 N 0	39 (32.8%)	
 PR	78 (65.6%)	 N 1-3	24 (20.2%)	
 SD	13 (10.9%)	 N 4-9	35 (29.4%)	
 PD	1 (0.8%)	 N &#62;9	21 (17.6%)	
Pathological response in tumor site				
 T-A	22 (18.5%)			
 T-B	75 (63.0%)			
 T-C	22 (18.5%)			
Abbreviations: pre-, before chemotherapy; post-, after chemotherapy; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, Complete response; PR, Partial response; SD, Stable disease; PD, Progressive disease; T-A: no tumor cell or presence of in situ carcinoma, no invasive tumor; T-B: presence of invasive carcinoma without special involvement (such as skin, vessel, more than one quadrant); T-C: presence of invasive carcinoma with special involvement.

",PR,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Pathology		Pathological tumor size		
 IDC	92 (77.3%)	 <= 2 cm	28 (23.5%)	
 ILC	4 (3.4%)	 &#62; 2 cm	59 (49.6%)	
 other	23 (19.3%)	 unmeasured	32 (26.9%)	
Clinical response		pALN		
 CR	27 (22.7%)	 N 0	39 (32.8%)	
 PR	78 (65.6%)	 N 1-3	24 (20.2%)	
 SD	13 (10.9%)	 N 4-9	35 (29.4%)	
 PD	1 (0.8%)	 N &#62;9	21 (17.6%)	
Pathological response in tumor site				
 T-A	22 (18.5%)			
 T-B	75 (63.0%)			
 T-C	22 (18.5%)			
Abbreviations: pre-, before chemotherapy; post-, after chemotherapy; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, Complete response; PR, Partial response; SD, Stable disease; PD, Progressive disease; T-A: no tumor cell or presence of in situ carcinoma, no invasive tumor; T-B: presence of invasive carcinoma without special involvement (such as skin, vessel, more than one quadrant); T-C: presence of invasive carcinoma with special involvement.

",PR,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Pathology		Pathological tumor size		
 IDC	92 (77.3%)	 <= 2 cm	28 (23.5%)	
 ILC	4 (3.4%)	 &#62; 2 cm	59 (49.6%)	
 other	23 (19.3%)	 unmeasured	32 (26.9%)	
Clinical response		pALN		
 CR	27 (22.7%)	 N 0	39 (32.8%)	
 PR	78 (65.6%)	 N 1-3	24 (20.2%)	
 SD	13 (10.9%)	 N 4-9	35 (29.4%)	
 PD	1 (0.8%)	 N &#62;9	21 (17.6%)	
Pathological response in tumor site				
 T-A	22 (18.5%)			
 T-B	75 (63.0%)			
 T-C	22 (18.5%)			
Abbreviations: pre-, before chemotherapy; post-, after chemotherapy; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, Complete response; PR, Partial response; SD, Stable disease; PD, Progressive disease; T-A: no tumor cell or presence of in situ carcinoma, no invasive tumor; T-B: presence of invasive carcinoma without special involvement (such as skin, vessel, more than one quadrant); T-C: presence of invasive carcinoma with special involvement.

",T,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Pathology		Pathological tumor size		
 IDC	92 (77.3%)	 <= 2 cm	28 (23.5%)	
 ILC	4 (3.4%)	 &#62; 2 cm	59 (49.6%)	
 other	23 (19.3%)	 unmeasured	32 (26.9%)	
Clinical response		pALN		
 CR	27 (22.7%)	 N 0	39 (32.8%)	
 PR	78 (65.6%)	 N 1-3	24 (20.2%)	
 SD	13 (10.9%)	 N 4-9	35 (29.4%)	
 PD	1 (0.8%)	 N &#62;9	21 (17.6%)	
Pathological response in tumor site				
 T-A	22 (18.5%)			
 T-B	75 (63.0%)			
 T-C	22 (18.5%)			
Abbreviations: pre-, before chemotherapy; post-, after chemotherapy; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, Complete response; PR, Partial response; SD, Stable disease; PD, Progressive disease; T-A: no tumor cell or presence of in situ carcinoma, no invasive tumor; T-B: presence of invasive carcinoma without special involvement (such as skin, vessel, more than one quadrant); T-C: presence of invasive carcinoma with special involvement.

",T,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Pathology		Pathological tumor size		
 IDC	92 (77.3%)	 <= 2 cm	28 (23.5%)	
 ILC	4 (3.4%)	 &#62; 2 cm	59 (49.6%)	
 other	23 (19.3%)	 unmeasured	32 (26.9%)	
Clinical response		pALN		
 CR	27 (22.7%)	 N 0	39 (32.8%)	
 PR	78 (65.6%)	 N 1-3	24 (20.2%)	
 SD	13 (10.9%)	 N 4-9	35 (29.4%)	
 PD	1 (0.8%)	 N &#62;9	21 (17.6%)	
Pathological response in tumor site				
 T-A	22 (18.5%)			
 T-B	75 (63.0%)			
 T-C	22 (18.5%)			
Abbreviations: pre-, before chemotherapy; post-, after chemotherapy; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, Complete response; PR, Partial response; SD, Stable disease; PD, Progressive disease; T-A: no tumor cell or presence of in situ carcinoma, no invasive tumor; T-B: presence of invasive carcinoma without special involvement (such as skin, vessel, more than one quadrant); T-C: presence of invasive carcinoma with special involvement.

",T,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Pathology		Pathological tumor size		
 IDC	92 (77.3%)	 <= 2 cm	28 (23.5%)	
 ILC	4 (3.4%)	 &#62; 2 cm	59 (49.6%)	
 other	23 (19.3%)	 unmeasured	32 (26.9%)	
Clinical response		pALN		
 CR	27 (22.7%)	 N 0	39 (32.8%)	
 PR	78 (65.6%)	 N 1-3	24 (20.2%)	
 SD	13 (10.9%)	 N 4-9	35 (29.4%)	
 PD	1 (0.8%)	 N &#62;9	21 (17.6%)	
Pathological response in tumor site				
 T-A	22 (18.5%)			
 T-B	75 (63.0%)			
 T-C	22 (18.5%)			
Abbreviations: pre-, before chemotherapy; post-, after chemotherapy; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, Complete response; PR, Partial response; SD, Stable disease; PD, Progressive disease; T-A: no tumor cell or presence of in situ carcinoma, no invasive tumor; T-B: presence of invasive carcinoma without special involvement (such as skin, vessel, more than one quadrant); T-C: presence of invasive carcinoma with special involvement.

",T,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Pathology		Pathological tumor size		
 IDC	92 (77.3%)	 <= 2 cm	28 (23.5%)	
 ILC	4 (3.4%)	 &#62; 2 cm	59 (49.6%)	
 other	23 (19.3%)	 unmeasured	32 (26.9%)	
Clinical response		pALN		
 CR	27 (22.7%)	 N 0	39 (32.8%)	
 PR	78 (65.6%)	 N 1-3	24 (20.2%)	
 SD	13 (10.9%)	 N 4-9	35 (29.4%)	
 PD	1 (0.8%)	 N &#62;9	21 (17.6%)	
Pathological response in tumor site				
 T-A	22 (18.5%)			
 T-B	75 (63.0%)			
 T-C	22 (18.5%)			
Abbreviations: pre-, before chemotherapy; post-, after chemotherapy; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, Complete response; PR, Partial response; SD, Stable disease; PD, Progressive disease; T-A: no tumor cell or presence of in situ carcinoma, no invasive tumor; T-B: presence of invasive carcinoma without special involvement (such as skin, vessel, more than one quadrant); T-C: presence of invasive carcinoma with special involvement.

",cALN,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Pathology		Pathological tumor size		
 IDC	92 (77.3%)	 <= 2 cm	28 (23.5%)	
 ILC	4 (3.4%)	 &#62; 2 cm	59 (49.6%)	
 other	23 (19.3%)	 unmeasured	32 (26.9%)	
Clinical response		pALN		
 CR	27 (22.7%)	 N 0	39 (32.8%)	
 PR	78 (65.6%)	 N 1-3	24 (20.2%)	
 SD	13 (10.9%)	 N 4-9	35 (29.4%)	
 PD	1 (0.8%)	 N &#62;9	21 (17.6%)	
Pathological response in tumor site				
 T-A	22 (18.5%)			
 T-B	75 (63.0%)			
 T-C	22 (18.5%)			
Abbreviations: pre-, before chemotherapy; post-, after chemotherapy; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, Complete response; PR, Partial response; SD, Stable disease; PD, Progressive disease; T-A: no tumor cell or presence of in situ carcinoma, no invasive tumor; T-B: presence of invasive carcinoma without special involvement (such as skin, vessel, more than one quadrant); T-C: presence of invasive carcinoma with special involvement.

",cALN,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Pathology		Pathological tumor size		
 IDC	92 (77.3%)	 <= 2 cm	28 (23.5%)	
 ILC	4 (3.4%)	 &#62; 2 cm	59 (49.6%)	
 other	23 (19.3%)	 unmeasured	32 (26.9%)	
Clinical response		pALN		
 CR	27 (22.7%)	 N 0	39 (32.8%)	
 PR	78 (65.6%)	 N 1-3	24 (20.2%)	
 SD	13 (10.9%)	 N 4-9	35 (29.4%)	
 PD	1 (0.8%)	 N &#62;9	21 (17.6%)	
Pathological response in tumor site				
 T-A	22 (18.5%)			
 T-B	75 (63.0%)			
 T-C	22 (18.5%)			
Abbreviations: pre-, before chemotherapy; post-, after chemotherapy; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, Complete response; PR, Partial response; SD, Stable disease; PD, Progressive disease; T-A: no tumor cell or presence of in situ carcinoma, no invasive tumor; T-B: presence of invasive carcinoma without special involvement (such as skin, vessel, more than one quadrant); T-C: presence of invasive carcinoma with special involvement.

",T,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Pathology		Pathological tumor size		
 IDC	92 (77.3%)	 <= 2 cm	28 (23.5%)	
 ILC	4 (3.4%)	 &#62; 2 cm	59 (49.6%)	
 other	23 (19.3%)	 unmeasured	32 (26.9%)	
Clinical response		pALN		
 CR	27 (22.7%)	 N 0	39 (32.8%)	
 PR	78 (65.6%)	 N 1-3	24 (20.2%)	
 SD	13 (10.9%)	 N 4-9	35 (29.4%)	
 PD	1 (0.8%)	 N &#62;9	21 (17.6%)	
Pathological response in tumor site				
 T-A	22 (18.5%)			
 T-B	75 (63.0%)			
 T-C	22 (18.5%)			
Abbreviations: pre-, before chemotherapy; post-, after chemotherapy; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, Complete response; PR, Partial response; SD, Stable disease; PD, Progressive disease; T-A: no tumor cell or presence of in situ carcinoma, no invasive tumor; T-B: presence of invasive carcinoma without special involvement (such as skin, vessel, more than one quadrant); T-C: presence of invasive carcinoma with special involvement.

",T,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Pathology		Pathological tumor size		
 IDC	92 (77.3%)	 <= 2 cm	28 (23.5%)	
 ILC	4 (3.4%)	 &#62; 2 cm	59 (49.6%)	
 other	23 (19.3%)	 unmeasured	32 (26.9%)	
Clinical response		pALN		
 CR	27 (22.7%)	 N 0	39 (32.8%)	
 PR	78 (65.6%)	 N 1-3	24 (20.2%)	
 SD	13 (10.9%)	 N 4-9	35 (29.4%)	
 PD	1 (0.8%)	 N &#62;9	21 (17.6%)	
Pathological response in tumor site				
 T-A	22 (18.5%)			
 T-B	75 (63.0%)			
 T-C	22 (18.5%)			
Abbreviations: pre-, before chemotherapy; post-, after chemotherapy; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, Complete response; PR, Partial response; SD, Stable disease; PD, Progressive disease; T-A: no tumor cell or presence of in situ carcinoma, no invasive tumor; T-B: presence of invasive carcinoma without special involvement (such as skin, vessel, more than one quadrant); T-C: presence of invasive carcinoma with special involvement.

",PR,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Pathology		Pathological tumor size		
 IDC	92 (77.3%)	 <= 2 cm	28 (23.5%)	
 ILC	4 (3.4%)	 &#62; 2 cm	59 (49.6%)	
 other	23 (19.3%)	 unmeasured	32 (26.9%)	
Clinical response		pALN		
 CR	27 (22.7%)	 N 0	39 (32.8%)	
 PR	78 (65.6%)	 N 1-3	24 (20.2%)	
 SD	13 (10.9%)	 N 4-9	35 (29.4%)	
 PD	1 (0.8%)	 N &#62;9	21 (17.6%)	
Pathological response in tumor site				
 T-A	22 (18.5%)			
 T-B	75 (63.0%)			
 T-C	22 (18.5%)			
Abbreviations: pre-, before chemotherapy; post-, after chemotherapy; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, Complete response; PR, Partial response; SD, Stable disease; PD, Progressive disease; T-A: no tumor cell or presence of in situ carcinoma, no invasive tumor; T-B: presence of invasive carcinoma without special involvement (such as skin, vessel, more than one quadrant); T-C: presence of invasive carcinoma with special involvement.

",PR,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Pathology		Pathological tumor size		
 IDC	92 (77.3%)	 <= 2 cm	28 (23.5%)	
 ILC	4 (3.4%)	 &#62; 2 cm	59 (49.6%)	
 other	23 (19.3%)	 unmeasured	32 (26.9%)	
Clinical response		pALN		
 CR	27 (22.7%)	 N 0	39 (32.8%)	
 PR	78 (65.6%)	 N 1-3	24 (20.2%)	
 SD	13 (10.9%)	 N 4-9	35 (29.4%)	
 PD	1 (0.8%)	 N &#62;9	21 (17.6%)	
Pathological response in tumor site				
 T-A	22 (18.5%)			
 T-B	75 (63.0%)			
 T-C	22 (18.5%)			
Abbreviations: pre-, before chemotherapy; post-, after chemotherapy; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, Complete response; PR, Partial response; SD, Stable disease; PD, Progressive disease; T-A: no tumor cell or presence of in situ carcinoma, no invasive tumor; T-B: presence of invasive carcinoma without special involvement (such as skin, vessel, more than one quadrant); T-C: presence of invasive carcinoma with special involvement.

",pALN,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Pathology		Pathological tumor size		
 IDC	92 (77.3%)	 <= 2 cm	28 (23.5%)	
 ILC	4 (3.4%)	 &#62; 2 cm	59 (49.6%)	
 other	23 (19.3%)	 unmeasured	32 (26.9%)	
Clinical response		pALN		
 CR	27 (22.7%)	 N 0	39 (32.8%)	
 PR	78 (65.6%)	 N 1-3	24 (20.2%)	
 SD	13 (10.9%)	 N 4-9	35 (29.4%)	
 PD	1 (0.8%)	 N &#62;9	21 (17.6%)	
Pathological response in tumor site				
 T-A	22 (18.5%)			
 T-B	75 (63.0%)			
 T-C	22 (18.5%)			
Abbreviations: pre-, before chemotherapy; post-, after chemotherapy; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, Complete response; PR, Partial response; SD, Stable disease; PD, Progressive disease; T-A: no tumor cell or presence of in situ carcinoma, no invasive tumor; T-B: presence of invasive carcinoma without special involvement (such as skin, vessel, more than one quadrant); T-C: presence of invasive carcinoma with special involvement.

",pALN,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Pathology		Pathological tumor size		
 IDC	92 (77.3%)	 <= 2 cm	28 (23.5%)	
 ILC	4 (3.4%)	 &#62; 2 cm	59 (49.6%)	
 other	23 (19.3%)	 unmeasured	32 (26.9%)	
Clinical response		pALN		
 CR	27 (22.7%)	 N 0	39 (32.8%)	
 PR	78 (65.6%)	 N 1-3	24 (20.2%)	
 SD	13 (10.9%)	 N 4-9	35 (29.4%)	
 PD	1 (0.8%)	 N &#62;9	21 (17.6%)	
Pathological response in tumor site				
 T-A	22 (18.5%)			
 T-B	75 (63.0%)			
 T-C	22 (18.5%)			
Abbreviations: pre-, before chemotherapy; post-, after chemotherapy; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, Complete response; PR, Partial response; SD, Stable disease; PD, Progressive disease; T-A: no tumor cell or presence of in situ carcinoma, no invasive tumor; T-B: presence of invasive carcinoma without special involvement (such as skin, vessel, more than one quadrant); T-C: presence of invasive carcinoma with special involvement.

",T,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Pathology		Pathological tumor size		
 IDC	92 (77.3%)	 <= 2 cm	28 (23.5%)	
 ILC	4 (3.4%)	 &#62; 2 cm	59 (49.6%)	
 other	23 (19.3%)	 unmeasured	32 (26.9%)	
Clinical response		pALN		
 CR	27 (22.7%)	 N 0	39 (32.8%)	
 PR	78 (65.6%)	 N 1-3	24 (20.2%)	
 SD	13 (10.9%)	 N 4-9	35 (29.4%)	
 PD	1 (0.8%)	 N &#62;9	21 (17.6%)	
Pathological response in tumor site				
 T-A	22 (18.5%)			
 T-B	75 (63.0%)			
 T-C	22 (18.5%)			
Abbreviations: pre-, before chemotherapy; post-, after chemotherapy; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, Complete response; PR, Partial response; SD, Stable disease; PD, Progressive disease; T-A: no tumor cell or presence of in situ carcinoma, no invasive tumor; T-B: presence of invasive carcinoma without special involvement (such as skin, vessel, more than one quadrant); T-C: presence of invasive carcinoma with special involvement.

",T,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Pathology		Pathological tumor size		
 IDC	92 (77.3%)	 <= 2 cm	28 (23.5%)	
 ILC	4 (3.4%)	 &#62; 2 cm	59 (49.6%)	
 other	23 (19.3%)	 unmeasured	32 (26.9%)	
Clinical response		pALN		
 CR	27 (22.7%)	 N 0	39 (32.8%)	
 PR	78 (65.6%)	 N 1-3	24 (20.2%)	
 SD	13 (10.9%)	 N 4-9	35 (29.4%)	
 PD	1 (0.8%)	 N &#62;9	21 (17.6%)	
Pathological response in tumor site				
 T-A	22 (18.5%)			
 T-B	75 (63.0%)			
 T-C	22 (18.5%)			
Abbreviations: pre-, before chemotherapy; post-, after chemotherapy; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, Complete response; PR, Partial response; SD, Stable disease; PD, Progressive disease; T-A: no tumor cell or presence of in situ carcinoma, no invasive tumor; T-B: presence of invasive carcinoma without special involvement (such as skin, vessel, more than one quadrant); T-C: presence of invasive carcinoma with special involvement.

",SD,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Pathology		Pathological tumor size		
 IDC	92 (77.3%)	 <= 2 cm	28 (23.5%)	
 ILC	4 (3.4%)	 &#62; 2 cm	59 (49.6%)	
 other	23 (19.3%)	 unmeasured	32 (26.9%)	
Clinical response		pALN		
 CR	27 (22.7%)	 N 0	39 (32.8%)	
 PR	78 (65.6%)	 N 1-3	24 (20.2%)	
 SD	13 (10.9%)	 N 4-9	35 (29.4%)	
 PD	1 (0.8%)	 N &#62;9	21 (17.6%)	
Pathological response in tumor site				
 T-A	22 (18.5%)			
 T-B	75 (63.0%)			
 T-C	22 (18.5%)			
Abbreviations: pre-, before chemotherapy; post-, after chemotherapy; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, Complete response; PR, Partial response; SD, Stable disease; PD, Progressive disease; T-A: no tumor cell or presence of in situ carcinoma, no invasive tumor; T-B: presence of invasive carcinoma without special involvement (such as skin, vessel, more than one quadrant); T-C: presence of invasive carcinoma with special involvement.

",SD,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Pathology		Pathological tumor size		
 IDC	92 (77.3%)	 <= 2 cm	28 (23.5%)	
 ILC	4 (3.4%)	 &#62; 2 cm	59 (49.6%)	
 other	23 (19.3%)	 unmeasured	32 (26.9%)	
Clinical response		pALN		
 CR	27 (22.7%)	 N 0	39 (32.8%)	
 PR	78 (65.6%)	 N 1-3	24 (20.2%)	
 SD	13 (10.9%)	 N 4-9	35 (29.4%)	
 PD	1 (0.8%)	 N &#62;9	21 (17.6%)	
Pathological response in tumor site				
 T-A	22 (18.5%)			
 T-B	75 (63.0%)			
 T-C	22 (18.5%)			
Abbreviations: pre-, before chemotherapy; post-, after chemotherapy; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, Complete response; PR, Partial response; SD, Stable disease; PD, Progressive disease; T-A: no tumor cell or presence of in situ carcinoma, no invasive tumor; T-B: presence of invasive carcinoma without special involvement (such as skin, vessel, more than one quadrant); T-C: presence of invasive carcinoma with special involvement.

",IDC,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Pathology		Pathological tumor size		
 IDC	92 (77.3%)	 <= 2 cm	28 (23.5%)	
 ILC	4 (3.4%)	 &#62; 2 cm	59 (49.6%)	
 other	23 (19.3%)	 unmeasured	32 (26.9%)	
Clinical response		pALN		
 CR	27 (22.7%)	 N 0	39 (32.8%)	
 PR	78 (65.6%)	 N 1-3	24 (20.2%)	
 SD	13 (10.9%)	 N 4-9	35 (29.4%)	
 PD	1 (0.8%)	 N &#62;9	21 (17.6%)	
Pathological response in tumor site				
 T-A	22 (18.5%)			
 T-B	75 (63.0%)			
 T-C	22 (18.5%)			
Abbreviations: pre-, before chemotherapy; post-, after chemotherapy; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, Complete response; PR, Partial response; SD, Stable disease; PD, Progressive disease; T-A: no tumor cell or presence of in situ carcinoma, no invasive tumor; T-B: presence of invasive carcinoma without special involvement (such as skin, vessel, more than one quadrant); T-C: presence of invasive carcinoma with special involvement.

",IDC,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Pathology		Pathological tumor size		
 IDC	92 (77.3%)	 <= 2 cm	28 (23.5%)	
 ILC	4 (3.4%)	 &#62; 2 cm	59 (49.6%)	
 other	23 (19.3%)	 unmeasured	32 (26.9%)	
Clinical response		pALN		
 CR	27 (22.7%)	 N 0	39 (32.8%)	
 PR	78 (65.6%)	 N 1-3	24 (20.2%)	
 SD	13 (10.9%)	 N 4-9	35 (29.4%)	
 PD	1 (0.8%)	 N &#62;9	21 (17.6%)	
Pathological response in tumor site				
 T-A	22 (18.5%)			
 T-B	75 (63.0%)			
 T-C	22 (18.5%)			
Abbreviations: pre-, before chemotherapy; post-, after chemotherapy; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, Complete response; PR, Partial response; SD, Stable disease; PD, Progressive disease; T-A: no tumor cell or presence of in situ carcinoma, no invasive tumor; T-B: presence of invasive carcinoma without special involvement (such as skin, vessel, more than one quadrant); T-C: presence of invasive carcinoma with special involvement.

",CR,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Pathology		Pathological tumor size		
 IDC	92 (77.3%)	 <= 2 cm	28 (23.5%)	
 ILC	4 (3.4%)	 &#62; 2 cm	59 (49.6%)	
 other	23 (19.3%)	 unmeasured	32 (26.9%)	
Clinical response		pALN		
 CR	27 (22.7%)	 N 0	39 (32.8%)	
 PR	78 (65.6%)	 N 1-3	24 (20.2%)	
 SD	13 (10.9%)	 N 4-9	35 (29.4%)	
 PD	1 (0.8%)	 N &#62;9	21 (17.6%)	
Pathological response in tumor site				
 T-A	22 (18.5%)			
 T-B	75 (63.0%)			
 T-C	22 (18.5%)			
Abbreviations: pre-, before chemotherapy; post-, after chemotherapy; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, Complete response; PR, Partial response; SD, Stable disease; PD, Progressive disease; T-A: no tumor cell or presence of in situ carcinoma, no invasive tumor; T-B: presence of invasive carcinoma without special involvement (such as skin, vessel, more than one quadrant); T-C: presence of invasive carcinoma with special involvement.

",CR,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Pathology		Pathological tumor size		
 IDC	92 (77.3%)	 <= 2 cm	28 (23.5%)	
 ILC	4 (3.4%)	 &#62; 2 cm	59 (49.6%)	
 other	23 (19.3%)	 unmeasured	32 (26.9%)	
Clinical response		pALN		
 CR	27 (22.7%)	 N 0	39 (32.8%)	
 PR	78 (65.6%)	 N 1-3	24 (20.2%)	
 SD	13 (10.9%)	 N 4-9	35 (29.4%)	
 PD	1 (0.8%)	 N &#62;9	21 (17.6%)	
Pathological response in tumor site				
 T-A	22 (18.5%)			
 T-B	75 (63.0%)			
 T-C	22 (18.5%)			
Abbreviations: pre-, before chemotherapy; post-, after chemotherapy; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, Complete response; PR, Partial response; SD, Stable disease; PD, Progressive disease; T-A: no tumor cell or presence of in situ carcinoma, no invasive tumor; T-B: presence of invasive carcinoma without special involvement (such as skin, vessel, more than one quadrant); T-C: presence of invasive carcinoma with special involvement.

",CR,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Pathology		Pathological tumor size		
 IDC	92 (77.3%)	 <= 2 cm	28 (23.5%)	
 ILC	4 (3.4%)	 &#62; 2 cm	59 (49.6%)	
 other	23 (19.3%)	 unmeasured	32 (26.9%)	
Clinical response		pALN		
 CR	27 (22.7%)	 N 0	39 (32.8%)	
 PR	78 (65.6%)	 N 1-3	24 (20.2%)	
 SD	13 (10.9%)	 N 4-9	35 (29.4%)	
 PD	1 (0.8%)	 N &#62;9	21 (17.6%)	
Pathological response in tumor site				
 T-A	22 (18.5%)			
 T-B	75 (63.0%)			
 T-C	22 (18.5%)			
Abbreviations: pre-, before chemotherapy; post-, after chemotherapy; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, Complete response; PR, Partial response; SD, Stable disease; PD, Progressive disease; T-A: no tumor cell or presence of in situ carcinoma, no invasive tumor; T-B: presence of invasive carcinoma without special involvement (such as skin, vessel, more than one quadrant); T-C: presence of invasive carcinoma with special involvement.

",CR,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Pathology		Pathological tumor size		
 IDC	92 (77.3%)	 <= 2 cm	28 (23.5%)	
 ILC	4 (3.4%)	 &#62; 2 cm	59 (49.6%)	
 other	23 (19.3%)	 unmeasured	32 (26.9%)	
Clinical response		pALN		
 CR	27 (22.7%)	 N 0	39 (32.8%)	
 PR	78 (65.6%)	 N 1-3	24 (20.2%)	
 SD	13 (10.9%)	 N 4-9	35 (29.4%)	
 PD	1 (0.8%)	 N &#62;9	21 (17.6%)	
Pathological response in tumor site				
 T-A	22 (18.5%)			
 T-B	75 (63.0%)			
 T-C	22 (18.5%)			
Abbreviations: pre-, before chemotherapy; post-, after chemotherapy; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, Complete response; PR, Partial response; SD, Stable disease; PD, Progressive disease; T-A: no tumor cell or presence of in situ carcinoma, no invasive tumor; T-B: presence of invasive carcinoma without special involvement (such as skin, vessel, more than one quadrant); T-C: presence of invasive carcinoma with special involvement.

",T,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Pathology		Pathological tumor size		
 IDC	92 (77.3%)	 <= 2 cm	28 (23.5%)	
 ILC	4 (3.4%)	 &#62; 2 cm	59 (49.6%)	
 other	23 (19.3%)	 unmeasured	32 (26.9%)	
Clinical response		pALN		
 CR	27 (22.7%)	 N 0	39 (32.8%)	
 PR	78 (65.6%)	 N 1-3	24 (20.2%)	
 SD	13 (10.9%)	 N 4-9	35 (29.4%)	
 PD	1 (0.8%)	 N &#62;9	21 (17.6%)	
Pathological response in tumor site				
 T-A	22 (18.5%)			
 T-B	75 (63.0%)			
 T-C	22 (18.5%)			
Abbreviations: pre-, before chemotherapy; post-, after chemotherapy; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, Complete response; PR, Partial response; SD, Stable disease; PD, Progressive disease; T-A: no tumor cell or presence of in situ carcinoma, no invasive tumor; T-B: presence of invasive carcinoma without special involvement (such as skin, vessel, more than one quadrant); T-C: presence of invasive carcinoma with special involvement.

",T,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Pathology		Pathological tumor size		
 IDC	92 (77.3%)	 <= 2 cm	28 (23.5%)	
 ILC	4 (3.4%)	 &#62; 2 cm	59 (49.6%)	
 other	23 (19.3%)	 unmeasured	32 (26.9%)	
Clinical response		pALN		
 CR	27 (22.7%)	 N 0	39 (32.8%)	
 PR	78 (65.6%)	 N 1-3	24 (20.2%)	
 SD	13 (10.9%)	 N 4-9	35 (29.4%)	
 PD	1 (0.8%)	 N &#62;9	21 (17.6%)	
Pathological response in tumor site				
 T-A	22 (18.5%)			
 T-B	75 (63.0%)			
 T-C	22 (18.5%)			
Abbreviations: pre-, before chemotherapy; post-, after chemotherapy; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, Complete response; PR, Partial response; SD, Stable disease; PD, Progressive disease; T-A: no tumor cell or presence of in situ carcinoma, no invasive tumor; T-B: presence of invasive carcinoma without special involvement (such as skin, vessel, more than one quadrant); T-C: presence of invasive carcinoma with special involvement.

",ILC,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Pathology		Pathological tumor size		
 IDC	92 (77.3%)	 <= 2 cm	28 (23.5%)	
 ILC	4 (3.4%)	 &#62; 2 cm	59 (49.6%)	
 other	23 (19.3%)	 unmeasured	32 (26.9%)	
Clinical response		pALN		
 CR	27 (22.7%)	 N 0	39 (32.8%)	
 PR	78 (65.6%)	 N 1-3	24 (20.2%)	
 SD	13 (10.9%)	 N 4-9	35 (29.4%)	
 PD	1 (0.8%)	 N &#62;9	21 (17.6%)	
Pathological response in tumor site				
 T-A	22 (18.5%)			
 T-B	75 (63.0%)			
 T-C	22 (18.5%)			
Abbreviations: pre-, before chemotherapy; post-, after chemotherapy; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, Complete response; PR, Partial response; SD, Stable disease; PD, Progressive disease; T-A: no tumor cell or presence of in situ carcinoma, no invasive tumor; T-B: presence of invasive carcinoma without special involvement (such as skin, vessel, more than one quadrant); T-C: presence of invasive carcinoma with special involvement.

",ILC,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Pathology		Pathological tumor size		
 IDC	92 (77.3%)	 <= 2 cm	28 (23.5%)	
 ILC	4 (3.4%)	 &#62; 2 cm	59 (49.6%)	
 other	23 (19.3%)	 unmeasured	32 (26.9%)	
Clinical response		pALN		
 CR	27 (22.7%)	 N 0	39 (32.8%)	
 PR	78 (65.6%)	 N 1-3	24 (20.2%)	
 SD	13 (10.9%)	 N 4-9	35 (29.4%)	
 PD	1 (0.8%)	 N &#62;9	21 (17.6%)	
Pathological response in tumor site				
 T-A	22 (18.5%)			
 T-B	75 (63.0%)			
 T-C	22 (18.5%)			
Abbreviations: pre-, before chemotherapy; post-, after chemotherapy; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, Complete response; PR, Partial response; SD, Stable disease; PD, Progressive disease; T-A: no tumor cell or presence of in situ carcinoma, no invasive tumor; T-B: presence of invasive carcinoma without special involvement (such as skin, vessel, more than one quadrant); T-C: presence of invasive carcinoma with special involvement.

",ILC,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Pathology		Pathological tumor size		
 IDC	92 (77.3%)	 <= 2 cm	28 (23.5%)	
 ILC	4 (3.4%)	 &#62; 2 cm	59 (49.6%)	
 other	23 (19.3%)	 unmeasured	32 (26.9%)	
Clinical response		pALN		
 CR	27 (22.7%)	 N 0	39 (32.8%)	
 PR	78 (65.6%)	 N 1-3	24 (20.2%)	
 SD	13 (10.9%)	 N 4-9	35 (29.4%)	
 PD	1 (0.8%)	 N &#62;9	21 (17.6%)	
Pathological response in tumor site				
 T-A	22 (18.5%)			
 T-B	75 (63.0%)			
 T-C	22 (18.5%)			
Abbreviations: pre-, before chemotherapy; post-, after chemotherapy; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, Complete response; PR, Partial response; SD, Stable disease; PD, Progressive disease; T-A: no tumor cell or presence of in situ carcinoma, no invasive tumor; T-B: presence of invasive carcinoma without special involvement (such as skin, vessel, more than one quadrant); T-C: presence of invasive carcinoma with special involvement.

",ILC,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Pathology		Pathological tumor size		
 IDC	92 (77.3%)	 <= 2 cm	28 (23.5%)	
 ILC	4 (3.4%)	 &#62; 2 cm	59 (49.6%)	
 other	23 (19.3%)	 unmeasured	32 (26.9%)	
Clinical response		pALN		
 CR	27 (22.7%)	 N 0	39 (32.8%)	
 PR	78 (65.6%)	 N 1-3	24 (20.2%)	
 SD	13 (10.9%)	 N 4-9	35 (29.4%)	
 PD	1 (0.8%)	 N &#62;9	21 (17.6%)	
Pathological response in tumor site				
 T-A	22 (18.5%)			
 T-B	75 (63.0%)			
 T-C	22 (18.5%)			
Abbreviations: pre-, before chemotherapy; post-, after chemotherapy; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, Complete response; PR, Partial response; SD, Stable disease; PD, Progressive disease; T-A: no tumor cell or presence of in situ carcinoma, no invasive tumor; T-B: presence of invasive carcinoma without special involvement (such as skin, vessel, more than one quadrant); T-C: presence of invasive carcinoma with special involvement.

",SD,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Pathology		Pathological tumor size		
 IDC	92 (77.3%)	 <= 2 cm	28 (23.5%)	
 ILC	4 (3.4%)	 &#62; 2 cm	59 (49.6%)	
 other	23 (19.3%)	 unmeasured	32 (26.9%)	
Clinical response		pALN		
 CR	27 (22.7%)	 N 0	39 (32.8%)	
 PR	78 (65.6%)	 N 1-3	24 (20.2%)	
 SD	13 (10.9%)	 N 4-9	35 (29.4%)	
 PD	1 (0.8%)	 N &#62;9	21 (17.6%)	
Pathological response in tumor site				
 T-A	22 (18.5%)			
 T-B	75 (63.0%)			
 T-C	22 (18.5%)			
Abbreviations: pre-, before chemotherapy; post-, after chemotherapy; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, Complete response; PR, Partial response; SD, Stable disease; PD, Progressive disease; T-A: no tumor cell or presence of in situ carcinoma, no invasive tumor; T-B: presence of invasive carcinoma without special involvement (such as skin, vessel, more than one quadrant); T-C: presence of invasive carcinoma with special involvement.

",SD,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Pathology		Pathological tumor size		
 IDC	92 (77.3%)	 <= 2 cm	28 (23.5%)	
 ILC	4 (3.4%)	 &#62; 2 cm	59 (49.6%)	
 other	23 (19.3%)	 unmeasured	32 (26.9%)	
Clinical response		pALN		
 CR	27 (22.7%)	 N 0	39 (32.8%)	
 PR	78 (65.6%)	 N 1-3	24 (20.2%)	
 SD	13 (10.9%)	 N 4-9	35 (29.4%)	
 PD	1 (0.8%)	 N &#62;9	21 (17.6%)	
Pathological response in tumor site				
 T-A	22 (18.5%)			
 T-B	75 (63.0%)			
 T-C	22 (18.5%)			
Abbreviations: pre-, before chemotherapy; post-, after chemotherapy; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, Complete response; PR, Partial response; SD, Stable disease; PD, Progressive disease; T-A: no tumor cell or presence of in situ carcinoma, no invasive tumor; T-B: presence of invasive carcinoma without special involvement (such as skin, vessel, more than one quadrant); T-C: presence of invasive carcinoma with special involvement.

",T,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Pathology		Pathological tumor size		
 IDC	92 (77.3%)	 <= 2 cm	28 (23.5%)	
 ILC	4 (3.4%)	 &#62; 2 cm	59 (49.6%)	
 other	23 (19.3%)	 unmeasured	32 (26.9%)	
Clinical response		pALN		
 CR	27 (22.7%)	 N 0	39 (32.8%)	
 PR	78 (65.6%)	 N 1-3	24 (20.2%)	
 SD	13 (10.9%)	 N 4-9	35 (29.4%)	
 PD	1 (0.8%)	 N &#62;9	21 (17.6%)	
Pathological response in tumor site				
 T-A	22 (18.5%)			
 T-B	75 (63.0%)			
 T-C	22 (18.5%)			
Abbreviations: pre-, before chemotherapy; post-, after chemotherapy; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, Complete response; PR, Partial response; SD, Stable disease; PD, Progressive disease; T-A: no tumor cell or presence of in situ carcinoma, no invasive tumor; T-B: presence of invasive carcinoma without special involvement (such as skin, vessel, more than one quadrant); T-C: presence of invasive carcinoma with special involvement.

",T,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Pathology		Pathological tumor size		
 IDC	92 (77.3%)	 <= 2 cm	28 (23.5%)	
 ILC	4 (3.4%)	 &#62; 2 cm	59 (49.6%)	
 other	23 (19.3%)	 unmeasured	32 (26.9%)	
Clinical response		pALN		
 CR	27 (22.7%)	 N 0	39 (32.8%)	
 PR	78 (65.6%)	 N 1-3	24 (20.2%)	
 SD	13 (10.9%)	 N 4-9	35 (29.4%)	
 PD	1 (0.8%)	 N &#62;9	21 (17.6%)	
Pathological response in tumor site				
 T-A	22 (18.5%)			
 T-B	75 (63.0%)			
 T-C	22 (18.5%)			
Abbreviations: pre-, before chemotherapy; post-, after chemotherapy; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, Complete response; PR, Partial response; SD, Stable disease; PD, Progressive disease; T-A: no tumor cell or presence of in situ carcinoma, no invasive tumor; T-B: presence of invasive carcinoma without special involvement (such as skin, vessel, more than one quadrant); T-C: presence of invasive carcinoma with special involvement.

",IDC,lymph,1
"PMC 
BMC_Cancer_2009_Oct_21_9_375.txt
","Pathology		Pathological tumor size		
 IDC	92 (77.3%)	 <= 2 cm	28 (23.5%)	
 ILC	4 (3.4%)	 &#62; 2 cm	59 (49.6%)	
 other	23 (19.3%)	 unmeasured	32 (26.9%)	
Clinical response		pALN		
 CR	27 (22.7%)	 N 0	39 (32.8%)	
 PR	78 (65.6%)	 N 1-3	24 (20.2%)	
 SD	13 (10.9%)	 N 4-9	35 (29.4%)	
 PD	1 (0.8%)	 N &#62;9	21 (17.6%)	
Pathological response in tumor site				
 T-A	22 (18.5%)			
 T-B	75 (63.0%)			
 T-C	22 (18.5%)			
Abbreviations: pre-, before chemotherapy; post-, after chemotherapy; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, Complete response; PR, Partial response; SD, Stable disease; PD, Progressive disease; T-A: no tumor cell or presence of in situ carcinoma, no invasive tumor; T-B: presence of invasive carcinoma without special involvement (such as skin, vessel, more than one quadrant); T-C: presence of invasive carcinoma with special involvement.

",IDC,lymph,1
"PMC 
BMC_Cancer_2009_Oct_22_9_376.txt
","Because of the deregulation of apoptosis in CRC cells, cancer cells in feces are thought to be more stable than other cells sloughed from normal mucosa [23] and could even represent a target for the molecular diagnosis of CRC [24]; therefore, fecal molecules from exfoliated colonic cells are currently being developed as potential markers for colonic neoplasia [20].

",CRC,feces,-1
"PMC 
BMC_Cancer_2009_Oct_22_9_376.txt
","Because of the deregulation of apoptosis in CRC cells, cancer cells in feces are thought to be more stable than other cells sloughed from normal mucosa [23] and could even represent a target for the molecular diagnosis of CRC [24]; therefore, fecal molecules from exfoliated colonic cells are currently being developed as potential markers for colonic neoplasia [20].

",CRC,feces,-1
"PMC 
BMC_Cancer_2010_Aug_18_10_439.txt
","To test these hypotheses, we quantified the levels of 8-OHdG and measured ROS-induced DNA damage and repair in peripheral blood lymphocytes of lung cancer cases and controls.",ROS,blood,-1
"PMC 
BMC_Cancer_2010_Aug_18_10_439.txt
","To test these hypotheses, we quantified the levels of 8-OHdG and measured ROS-induced DNA damage and repair in peripheral blood lymphocytes of lung cancer cases and controls.",DNA,blood,-1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","If this change was a decline in serum TRACP 5b activity, it was considered to be a positive treatment response and clinical improvement.

",TRACP,serum,1
"PMC 
BMC_Cancer_2009_Oct_20_9_374.txt
",(C) The miR-145-expressing SW620 cell population showed a two-fold increase in anchorage-independent growth when grown in the presence of serum and a greater than 50% increase in cell proliferation/metabolic activity when grown in the presence (solid bars) or absence (open bars) of serum. *** p &#60; 0.001.,SW620,serum,1
"PMC 
BMC_Cancer_2009_Oct_20_9_374.txt
",(C) The miR-145-expressing SW620 cell population showed a two-fold increase in anchorage-independent growth when grown in the presence of serum and a greater than 50% increase in cell proliferation/metabolic activity when grown in the presence (solid bars) or absence (open bars) of serum. *** p &#60; 0.001.,SW620,serum,1
"PMC 
BMC_Cancer_2010_Aug_18_10_439.txt
","We used the commercially available 8-OHdG ELISA (enzyme-linked immunosorbent assay) to measure the levels of 8-OHdG in plasma and the Comet assay and hOGG1 FLARE (Fragment Length Analysis by Repair Enzymes) assay to measure the constitutive, induced and unrepaired residual damage by measuring DNA strand breaks and abasic sites.",ELISA,plasma,1
"PMC 
BMC_Cancer_2010_Aug_18_10_439.txt
","We used the commercially available 8-OHdG ELISA (enzyme-linked immunosorbent assay) to measure the levels of 8-OHdG in plasma and the Comet assay and hOGG1 FLARE (Fragment Length Analysis by Repair Enzymes) assay to measure the constitutive, induced and unrepaired residual damage by measuring DNA strand breaks and abasic sites.",DNA,plasma,1
"PMC 
BMC_Cancer_2010_Aug_18_10_439.txt
","We used the commercially available 8-OHdG ELISA (enzyme-linked immunosorbent assay) to measure the levels of 8-OHdG in plasma and the Comet assay and hOGG1 FLARE (Fragment Length Analysis by Repair Enzymes) assay to measure the constitutive, induced and unrepaired residual damage by measuring DNA strand breaks and abasic sites.",FLARE,plasma,1
"PMC 
BMC_Cancer_2010_Aug_18_10_439.txt
","We used the commercially available 8-OHdG ELISA (enzyme-linked immunosorbent assay) to measure the levels of 8-OHdG in plasma and the Comet assay and hOGG1 FLARE (Fragment Length Analysis by Repair Enzymes) assay to measure the constitutive, induced and unrepaired residual damage by measuring DNA strand breaks and abasic sites.",hOGG1,plasma,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","p*	n	events	p+	n	events	p+	
Clinico-pathological data:												
Age at diagnosis											
	&#60;50 years	51	43	8	0.036	51	9	0.0064	51	16	0.1895	
	>= 50 years	108	74	34		108	45		102	42		
Tumor stage											
	pT1	40	35	5	0.004	40	4	&#60;0.0001	39	5	0.0001	
	pT2	83	63	20		83	28		81	34		
	pT3	10	4	6		10	4		9	4		
	pT4	26	15	11		26	18		24	15		
Lymph node status											
	pN0	75	60	15	0.101	75	11	&#60;0.0001	74	13	&#60;0.0001	
	pN1-3	80	54	26		80	41		76	42		
Histologic grade											
	G1	17	16	1	0.011	17	4	0.0047	17	4	&#60;0.0001	
	G2	69	55	14		69	17		65	16		
	G3	73	46	27		73	33		71	38		
Multifocality											
	unifocal tumor	141	104	37	1.000	141	45	0.0903	136	49	0.0683	
	multifocal tumor	18	13	5		18	9		17	9		
Histologic type											
	ductal	125	93	32	0.710	125	43	0.9302	123	49	0.5730	
	lobular	16	11	5		16	5		14	4		
	other	15	10	5		15	5		13	4		
												
Immunohistochemistry (IHC):											
Estrogen receptor status											
	negative	42	30	12	1.000	42	19	0.0129	42	24	0.0026	
	positive	96	69	27		96	25		92	27		
Progesterone receptor status											
	negative	98	63	35	0.002	98	40	0.0045	93	44	0.0019	
	positive	46	41	5		46	8		46	9		
Cytokeratin 5/6 IHC											
	negative (0)	118	85	33	0.540	118	34	0.0100	114	38	0.0349	
	positive (1+-3+)	41	32	9		41	20		39	20		
TP53 IHC											
	&#60;10%	85	62	23	1.000	85	28	0.3823	82	28	0.4422	
	>= 10%	48	31	17		48	18		46	19		
HER2 IHC											
	negative (0-1+)	108	83	25	1.000	108	28	0.0081	102	31	0.0008	
	positive (2+-3+)	35	21	14		35	18		35	20		
* Fisher's exact test (two-sided), bold face representing significant data.

+ Log rank test (two-sided), bold face representing significant data.

",G3,Lymph,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","p*	n	events	p+	n	events	p+	
Clinico-pathological data:												
Age at diagnosis											
	&#60;50 years	51	43	8	0.036	51	9	0.0064	51	16	0.1895	
	>= 50 years	108	74	34		108	45		102	42		
Tumor stage											
	pT1	40	35	5	0.004	40	4	&#60;0.0001	39	5	0.0001	
	pT2	83	63	20		83	28		81	34		
	pT3	10	4	6		10	4		9	4		
	pT4	26	15	11		26	18		24	15		
Lymph node status											
	pN0	75	60	15	0.101	75	11	&#60;0.0001	74	13	&#60;0.0001	
	pN1-3	80	54	26		80	41		76	42		
Histologic grade											
	G1	17	16	1	0.011	17	4	0.0047	17	4	&#60;0.0001	
	G2	69	55	14		69	17		65	16		
	G3	73	46	27		73	33		71	38		
Multifocality											
	unifocal tumor	141	104	37	1.000	141	45	0.0903	136	49	0.0683	
	multifocal tumor	18	13	5		18	9		17	9		
Histologic type											
	ductal	125	93	32	0.710	125	43	0.9302	123	49	0.5730	
	lobular	16	11	5		16	5		14	4		
	other	15	10	5		15	5		13	4		
												
Immunohistochemistry (IHC):											
Estrogen receptor status											
	negative	42	30	12	1.000	42	19	0.0129	42	24	0.0026	
	positive	96	69	27		96	25		92	27		
Progesterone receptor status											
	negative	98	63	35	0.002	98	40	0.0045	93	44	0.0019	
	positive	46	41	5		46	8		46	9		
Cytokeratin 5/6 IHC											
	negative (0)	118	85	33	0.540	118	34	0.0100	114	38	0.0349	
	positive (1+-3+)	41	32	9		41	20		39	20		
TP53 IHC											
	&#60;10%	85	62	23	1.000	85	28	0.3823	82	28	0.4422	
	>= 10%	48	31	17		48	18		46	19		
HER2 IHC											
	negative (0-1+)	108	83	25	1.000	108	28	0.0081	102	31	0.0008	
	positive (2+-3+)	35	21	14		35	18		35	20		
* Fisher's exact test (two-sided), bold face representing significant data.

+ Log rank test (two-sided), bold face representing significant data.

",IHC,Lymph,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","p*	n	events	p+	n	events	p+	
Clinico-pathological data:												
Age at diagnosis											
	&#60;50 years	51	43	8	0.036	51	9	0.0064	51	16	0.1895	
	>= 50 years	108	74	34		108	45		102	42		
Tumor stage											
	pT1	40	35	5	0.004	40	4	&#60;0.0001	39	5	0.0001	
	pT2	83	63	20		83	28		81	34		
	pT3	10	4	6		10	4		9	4		
	pT4	26	15	11		26	18		24	15		
Lymph node status											
	pN0	75	60	15	0.101	75	11	&#60;0.0001	74	13	&#60;0.0001	
	pN1-3	80	54	26		80	41		76	42		
Histologic grade											
	G1	17	16	1	0.011	17	4	0.0047	17	4	&#60;0.0001	
	G2	69	55	14		69	17		65	16		
	G3	73	46	27		73	33		71	38		
Multifocality											
	unifocal tumor	141	104	37	1.000	141	45	0.0903	136	49	0.0683	
	multifocal tumor	18	13	5		18	9		17	9		
Histologic type											
	ductal	125	93	32	0.710	125	43	0.9302	123	49	0.5730	
	lobular	16	11	5		16	5		14	4		
	other	15	10	5		15	5		13	4		
												
Immunohistochemistry (IHC):											
Estrogen receptor status											
	negative	42	30	12	1.000	42	19	0.0129	42	24	0.0026	
	positive	96	69	27		96	25		92	27		
Progesterone receptor status											
	negative	98	63	35	0.002	98	40	0.0045	93	44	0.0019	
	positive	46	41	5		46	8		46	9		
Cytokeratin 5/6 IHC											
	negative (0)	118	85	33	0.540	118	34	0.0100	114	38	0.0349	
	positive (1+-3+)	41	32	9		41	20		39	20		
TP53 IHC											
	&#60;10%	85	62	23	1.000	85	28	0.3823	82	28	0.4422	
	>= 10%	48	31	17		48	18		46	19		
HER2 IHC											
	negative (0-1+)	108	83	25	1.000	108	28	0.0081	102	31	0.0008	
	positive (2+-3+)	35	21	14		35	18		35	20		
* Fisher's exact test (two-sided), bold face representing significant data.

+ Log rank test (two-sided), bold face representing significant data.

",G2,Lymph,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","p*	n	events	p+	n	events	p+	
Clinico-pathological data:												
Age at diagnosis											
	&#60;50 years	51	43	8	0.036	51	9	0.0064	51	16	0.1895	
	>= 50 years	108	74	34		108	45		102	42		
Tumor stage											
	pT1	40	35	5	0.004	40	4	&#60;0.0001	39	5	0.0001	
	pT2	83	63	20		83	28		81	34		
	pT3	10	4	6		10	4		9	4		
	pT4	26	15	11		26	18		24	15		
Lymph node status											
	pN0	75	60	15	0.101	75	11	&#60;0.0001	74	13	&#60;0.0001	
	pN1-3	80	54	26		80	41		76	42		
Histologic grade											
	G1	17	16	1	0.011	17	4	0.0047	17	4	&#60;0.0001	
	G2	69	55	14		69	17		65	16		
	G3	73	46	27		73	33		71	38		
Multifocality											
	unifocal tumor	141	104	37	1.000	141	45	0.0903	136	49	0.0683	
	multifocal tumor	18	13	5		18	9		17	9		
Histologic type											
	ductal	125	93	32	0.710	125	43	0.9302	123	49	0.5730	
	lobular	16	11	5		16	5		14	4		
	other	15	10	5		15	5		13	4		
												
Immunohistochemistry (IHC):											
Estrogen receptor status											
	negative	42	30	12	1.000	42	19	0.0129	42	24	0.0026	
	positive	96	69	27		96	25		92	27		
Progesterone receptor status											
	negative	98	63	35	0.002	98	40	0.0045	93	44	0.0019	
	positive	46	41	5		46	8		46	9		
Cytokeratin 5/6 IHC											
	negative (0)	118	85	33	0.540	118	34	0.0100	114	38	0.0349	
	positive (1+-3+)	41	32	9		41	20		39	20		
TP53 IHC											
	&#60;10%	85	62	23	1.000	85	28	0.3823	82	28	0.4422	
	>= 10%	48	31	17		48	18		46	19		
HER2 IHC											
	negative (0-1+)	108	83	25	1.000	108	28	0.0081	102	31	0.0008	
	positive (2+-3+)	35	21	14		35	18		35	20		
* Fisher's exact test (two-sided), bold face representing significant data.

+ Log rank test (two-sided), bold face representing significant data.

",G1,Lymph,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","p*	n	events	p+	n	events	p+	
Clinico-pathological data:												
Age at diagnosis											
	&#60;50 years	51	43	8	0.036	51	9	0.0064	51	16	0.1895	
	>= 50 years	108	74	34		108	45		102	42		
Tumor stage											
	pT1	40	35	5	0.004	40	4	&#60;0.0001	39	5	0.0001	
	pT2	83	63	20		83	28		81	34		
	pT3	10	4	6		10	4		9	4		
	pT4	26	15	11		26	18		24	15		
Lymph node status											
	pN0	75	60	15	0.101	75	11	&#60;0.0001	74	13	&#60;0.0001	
	pN1-3	80	54	26		80	41		76	42		
Histologic grade											
	G1	17	16	1	0.011	17	4	0.0047	17	4	&#60;0.0001	
	G2	69	55	14		69	17		65	16		
	G3	73	46	27		73	33		71	38		
Multifocality											
	unifocal tumor	141	104	37	1.000	141	45	0.0903	136	49	0.0683	
	multifocal tumor	18	13	5		18	9		17	9		
Histologic type											
	ductal	125	93	32	0.710	125	43	0.9302	123	49	0.5730	
	lobular	16	11	5		16	5		14	4		
	other	15	10	5		15	5		13	4		
												
Immunohistochemistry (IHC):											
Estrogen receptor status											
	negative	42	30	12	1.000	42	19	0.0129	42	24	0.0026	
	positive	96	69	27		96	25		92	27		
Progesterone receptor status											
	negative	98	63	35	0.002	98	40	0.0045	93	44	0.0019	
	positive	46	41	5		46	8		46	9		
Cytokeratin 5/6 IHC											
	negative (0)	118	85	33	0.540	118	34	0.0100	114	38	0.0349	
	positive (1+-3+)	41	32	9		41	20		39	20		
TP53 IHC											
	&#60;10%	85	62	23	1.000	85	28	0.3823	82	28	0.4422	
	>= 10%	48	31	17		48	18		46	19		
HER2 IHC											
	negative (0-1+)	108	83	25	1.000	108	28	0.0081	102	31	0.0008	
	positive (2+-3+)	35	21	14		35	18		35	20		
* Fisher's exact test (two-sided), bold face representing significant data.

+ Log rank test (two-sided), bold face representing significant data.

",pT4,Lymph,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","p*	n	events	p+	n	events	p+	
Clinico-pathological data:												
Age at diagnosis											
	&#60;50 years	51	43	8	0.036	51	9	0.0064	51	16	0.1895	
	>= 50 years	108	74	34		108	45		102	42		
Tumor stage											
	pT1	40	35	5	0.004	40	4	&#60;0.0001	39	5	0.0001	
	pT2	83	63	20		83	28		81	34		
	pT3	10	4	6		10	4		9	4		
	pT4	26	15	11		26	18		24	15		
Lymph node status											
	pN0	75	60	15	0.101	75	11	&#60;0.0001	74	13	&#60;0.0001	
	pN1-3	80	54	26		80	41		76	42		
Histologic grade											
	G1	17	16	1	0.011	17	4	0.0047	17	4	&#60;0.0001	
	G2	69	55	14		69	17		65	16		
	G3	73	46	27		73	33		71	38		
Multifocality											
	unifocal tumor	141	104	37	1.000	141	45	0.0903	136	49	0.0683	
	multifocal tumor	18	13	5		18	9		17	9		
Histologic type											
	ductal	125	93	32	0.710	125	43	0.9302	123	49	0.5730	
	lobular	16	11	5		16	5		14	4		
	other	15	10	5		15	5		13	4		
												
Immunohistochemistry (IHC):											
Estrogen receptor status											
	negative	42	30	12	1.000	42	19	0.0129	42	24	0.0026	
	positive	96	69	27		96	25		92	27		
Progesterone receptor status											
	negative	98	63	35	0.002	98	40	0.0045	93	44	0.0019	
	positive	46	41	5		46	8		46	9		
Cytokeratin 5/6 IHC											
	negative (0)	118	85	33	0.540	118	34	0.0100	114	38	0.0349	
	positive (1+-3+)	41	32	9		41	20		39	20		
TP53 IHC											
	&#60;10%	85	62	23	1.000	85	28	0.3823	82	28	0.4422	
	>= 10%	48	31	17		48	18		46	19		
HER2 IHC											
	negative (0-1+)	108	83	25	1.000	108	28	0.0081	102	31	0.0008	
	positive (2+-3+)	35	21	14		35	18		35	20		
* Fisher's exact test (two-sided), bold face representing significant data.

+ Log rank test (two-sided), bold face representing significant data.

",IHC,Lymph,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","p*	n	events	p+	n	events	p+	
Clinico-pathological data:												
Age at diagnosis											
	&#60;50 years	51	43	8	0.036	51	9	0.0064	51	16	0.1895	
	>= 50 years	108	74	34		108	45		102	42		
Tumor stage											
	pT1	40	35	5	0.004	40	4	&#60;0.0001	39	5	0.0001	
	pT2	83	63	20		83	28		81	34		
	pT3	10	4	6		10	4		9	4		
	pT4	26	15	11		26	18		24	15		
Lymph node status											
	pN0	75	60	15	0.101	75	11	&#60;0.0001	74	13	&#60;0.0001	
	pN1-3	80	54	26		80	41		76	42		
Histologic grade											
	G1	17	16	1	0.011	17	4	0.0047	17	4	&#60;0.0001	
	G2	69	55	14		69	17		65	16		
	G3	73	46	27		73	33		71	38		
Multifocality											
	unifocal tumor	141	104	37	1.000	141	45	0.0903	136	49	0.0683	
	multifocal tumor	18	13	5		18	9		17	9		
Histologic type											
	ductal	125	93	32	0.710	125	43	0.9302	123	49	0.5730	
	lobular	16	11	5		16	5		14	4		
	other	15	10	5		15	5		13	4		
												
Immunohistochemistry (IHC):											
Estrogen receptor status											
	negative	42	30	12	1.000	42	19	0.0129	42	24	0.0026	
	positive	96	69	27		96	25		92	27		
Progesterone receptor status											
	negative	98	63	35	0.002	98	40	0.0045	93	44	0.0019	
	positive	46	41	5		46	8		46	9		
Cytokeratin 5/6 IHC											
	negative (0)	118	85	33	0.540	118	34	0.0100	114	38	0.0349	
	positive (1+-3+)	41	32	9		41	20		39	20		
TP53 IHC											
	&#60;10%	85	62	23	1.000	85	28	0.3823	82	28	0.4422	
	>= 10%	48	31	17		48	18		46	19		
HER2 IHC											
	negative (0-1+)	108	83	25	1.000	108	28	0.0081	102	31	0.0008	
	positive (2+-3+)	35	21	14		35	18		35	20		
* Fisher's exact test (two-sided), bold face representing significant data.

+ Log rank test (two-sided), bold face representing significant data.

",IHC,Lymph,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","p*	n	events	p+	n	events	p+	
Clinico-pathological data:												
Age at diagnosis											
	&#60;50 years	51	43	8	0.036	51	9	0.0064	51	16	0.1895	
	>= 50 years	108	74	34		108	45		102	42		
Tumor stage											
	pT1	40	35	5	0.004	40	4	&#60;0.0001	39	5	0.0001	
	pT2	83	63	20		83	28		81	34		
	pT3	10	4	6		10	4		9	4		
	pT4	26	15	11		26	18		24	15		
Lymph node status											
	pN0	75	60	15	0.101	75	11	&#60;0.0001	74	13	&#60;0.0001	
	pN1-3	80	54	26		80	41		76	42		
Histologic grade											
	G1	17	16	1	0.011	17	4	0.0047	17	4	&#60;0.0001	
	G2	69	55	14		69	17		65	16		
	G3	73	46	27		73	33		71	38		
Multifocality											
	unifocal tumor	141	104	37	1.000	141	45	0.0903	136	49	0.0683	
	multifocal tumor	18	13	5		18	9		17	9		
Histologic type											
	ductal	125	93	32	0.710	125	43	0.9302	123	49	0.5730	
	lobular	16	11	5		16	5		14	4		
	other	15	10	5		15	5		13	4		
												
Immunohistochemistry (IHC):											
Estrogen receptor status											
	negative	42	30	12	1.000	42	19	0.0129	42	24	0.0026	
	positive	96	69	27		96	25		92	27		
Progesterone receptor status											
	negative	98	63	35	0.002	98	40	0.0045	93	44	0.0019	
	positive	46	41	5		46	8		46	9		
Cytokeratin 5/6 IHC											
	negative (0)	118	85	33	0.540	118	34	0.0100	114	38	0.0349	
	positive (1+-3+)	41	32	9		41	20		39	20		
TP53 IHC											
	&#60;10%	85	62	23	1.000	85	28	0.3823	82	28	0.4422	
	>= 10%	48	31	17		48	18		46	19		
HER2 IHC											
	negative (0-1+)	108	83	25	1.000	108	28	0.0081	102	31	0.0008	
	positive (2+-3+)	35	21	14		35	18		35	20		
* Fisher's exact test (two-sided), bold face representing significant data.

+ Log rank test (two-sided), bold face representing significant data.

",TP53,Lymph,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","p*	n	events	p+	n	events	p+	
Clinico-pathological data:												
Age at diagnosis											
	&#60;50 years	51	43	8	0.036	51	9	0.0064	51	16	0.1895	
	>= 50 years	108	74	34		108	45		102	42		
Tumor stage											
	pT1	40	35	5	0.004	40	4	&#60;0.0001	39	5	0.0001	
	pT2	83	63	20		83	28		81	34		
	pT3	10	4	6		10	4		9	4		
	pT4	26	15	11		26	18		24	15		
Lymph node status											
	pN0	75	60	15	0.101	75	11	&#60;0.0001	74	13	&#60;0.0001	
	pN1-3	80	54	26		80	41		76	42		
Histologic grade											
	G1	17	16	1	0.011	17	4	0.0047	17	4	&#60;0.0001	
	G2	69	55	14		69	17		65	16		
	G3	73	46	27		73	33		71	38		
Multifocality											
	unifocal tumor	141	104	37	1.000	141	45	0.0903	136	49	0.0683	
	multifocal tumor	18	13	5		18	9		17	9		
Histologic type											
	ductal	125	93	32	0.710	125	43	0.9302	123	49	0.5730	
	lobular	16	11	5		16	5		14	4		
	other	15	10	5		15	5		13	4		
												
Immunohistochemistry (IHC):											
Estrogen receptor status											
	negative	42	30	12	1.000	42	19	0.0129	42	24	0.0026	
	positive	96	69	27		96	25		92	27		
Progesterone receptor status											
	negative	98	63	35	0.002	98	40	0.0045	93	44	0.0019	
	positive	46	41	5		46	8		46	9		
Cytokeratin 5/6 IHC											
	negative (0)	118	85	33	0.540	118	34	0.0100	114	38	0.0349	
	positive (1+-3+)	41	32	9		41	20		39	20		
TP53 IHC											
	&#60;10%	85	62	23	1.000	85	28	0.3823	82	28	0.4422	
	>= 10%	48	31	17		48	18		46	19		
HER2 IHC											
	negative (0-1+)	108	83	25	1.000	108	28	0.0081	102	31	0.0008	
	positive (2+-3+)	35	21	14		35	18		35	20		
* Fisher's exact test (two-sided), bold face representing significant data.

+ Log rank test (two-sided), bold face representing significant data.

",pN1,Lymph,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","p*	n	events	p+	n	events	p+	
Clinico-pathological data:												
Age at diagnosis											
	&#60;50 years	51	43	8	0.036	51	9	0.0064	51	16	0.1895	
	>= 50 years	108	74	34		108	45		102	42		
Tumor stage											
	pT1	40	35	5	0.004	40	4	&#60;0.0001	39	5	0.0001	
	pT2	83	63	20		83	28		81	34		
	pT3	10	4	6		10	4		9	4		
	pT4	26	15	11		26	18		24	15		
Lymph node status											
	pN0	75	60	15	0.101	75	11	&#60;0.0001	74	13	&#60;0.0001	
	pN1-3	80	54	26		80	41		76	42		
Histologic grade											
	G1	17	16	1	0.011	17	4	0.0047	17	4	&#60;0.0001	
	G2	69	55	14		69	17		65	16		
	G3	73	46	27		73	33		71	38		
Multifocality											
	unifocal tumor	141	104	37	1.000	141	45	0.0903	136	49	0.0683	
	multifocal tumor	18	13	5		18	9		17	9		
Histologic type											
	ductal	125	93	32	0.710	125	43	0.9302	123	49	0.5730	
	lobular	16	11	5		16	5		14	4		
	other	15	10	5		15	5		13	4		
												
Immunohistochemistry (IHC):											
Estrogen receptor status											
	negative	42	30	12	1.000	42	19	0.0129	42	24	0.0026	
	positive	96	69	27		96	25		92	27		
Progesterone receptor status											
	negative	98	63	35	0.002	98	40	0.0045	93	44	0.0019	
	positive	46	41	5		46	8		46	9		
Cytokeratin 5/6 IHC											
	negative (0)	118	85	33	0.540	118	34	0.0100	114	38	0.0349	
	positive (1+-3+)	41	32	9		41	20		39	20		
TP53 IHC											
	&#60;10%	85	62	23	1.000	85	28	0.3823	82	28	0.4422	
	>= 10%	48	31	17		48	18		46	19		
HER2 IHC											
	negative (0-1+)	108	83	25	1.000	108	28	0.0081	102	31	0.0008	
	positive (2+-3+)	35	21	14		35	18		35	20		
* Fisher's exact test (two-sided), bold face representing significant data.

+ Log rank test (two-sided), bold face representing significant data.

",pT3,Lymph,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","p*	n	events	p+	n	events	p+	
Clinico-pathological data:												
Age at diagnosis											
	&#60;50 years	51	43	8	0.036	51	9	0.0064	51	16	0.1895	
	>= 50 years	108	74	34		108	45		102	42		
Tumor stage											
	pT1	40	35	5	0.004	40	4	&#60;0.0001	39	5	0.0001	
	pT2	83	63	20		83	28		81	34		
	pT3	10	4	6		10	4		9	4		
	pT4	26	15	11		26	18		24	15		
Lymph node status											
	pN0	75	60	15	0.101	75	11	&#60;0.0001	74	13	&#60;0.0001	
	pN1-3	80	54	26		80	41		76	42		
Histologic grade											
	G1	17	16	1	0.011	17	4	0.0047	17	4	&#60;0.0001	
	G2	69	55	14		69	17		65	16		
	G3	73	46	27		73	33		71	38		
Multifocality											
	unifocal tumor	141	104	37	1.000	141	45	0.0903	136	49	0.0683	
	multifocal tumor	18	13	5		18	9		17	9		
Histologic type											
	ductal	125	93	32	0.710	125	43	0.9302	123	49	0.5730	
	lobular	16	11	5		16	5		14	4		
	other	15	10	5		15	5		13	4		
												
Immunohistochemistry (IHC):											
Estrogen receptor status											
	negative	42	30	12	1.000	42	19	0.0129	42	24	0.0026	
	positive	96	69	27		96	25		92	27		
Progesterone receptor status											
	negative	98	63	35	0.002	98	40	0.0045	93	44	0.0019	
	positive	46	41	5		46	8		46	9		
Cytokeratin 5/6 IHC											
	negative (0)	118	85	33	0.540	118	34	0.0100	114	38	0.0349	
	positive (1+-3+)	41	32	9		41	20		39	20		
TP53 IHC											
	&#60;10%	85	62	23	1.000	85	28	0.3823	82	28	0.4422	
	>= 10%	48	31	17		48	18		46	19		
HER2 IHC											
	negative (0-1+)	108	83	25	1.000	108	28	0.0081	102	31	0.0008	
	positive (2+-3+)	35	21	14		35	18		35	20		
* Fisher's exact test (two-sided), bold face representing significant data.

+ Log rank test (two-sided), bold face representing significant data.

",pT1,Lymph,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","p*	n	events	p+	n	events	p+	
Clinico-pathological data:												
Age at diagnosis											
	&#60;50 years	51	43	8	0.036	51	9	0.0064	51	16	0.1895	
	>= 50 years	108	74	34		108	45		102	42		
Tumor stage											
	pT1	40	35	5	0.004	40	4	&#60;0.0001	39	5	0.0001	
	pT2	83	63	20		83	28		81	34		
	pT3	10	4	6		10	4		9	4		
	pT4	26	15	11		26	18		24	15		
Lymph node status											
	pN0	75	60	15	0.101	75	11	&#60;0.0001	74	13	&#60;0.0001	
	pN1-3	80	54	26		80	41		76	42		
Histologic grade											
	G1	17	16	1	0.011	17	4	0.0047	17	4	&#60;0.0001	
	G2	69	55	14		69	17		65	16		
	G3	73	46	27		73	33		71	38		
Multifocality											
	unifocal tumor	141	104	37	1.000	141	45	0.0903	136	49	0.0683	
	multifocal tumor	18	13	5		18	9		17	9		
Histologic type											
	ductal	125	93	32	0.710	125	43	0.9302	123	49	0.5730	
	lobular	16	11	5		16	5		14	4		
	other	15	10	5		15	5		13	4		
												
Immunohistochemistry (IHC):											
Estrogen receptor status											
	negative	42	30	12	1.000	42	19	0.0129	42	24	0.0026	
	positive	96	69	27		96	25		92	27		
Progesterone receptor status											
	negative	98	63	35	0.002	98	40	0.0045	93	44	0.0019	
	positive	46	41	5		46	8		46	9		
Cytokeratin 5/6 IHC											
	negative (0)	118	85	33	0.540	118	34	0.0100	114	38	0.0349	
	positive (1+-3+)	41	32	9		41	20		39	20		
TP53 IHC											
	&#60;10%	85	62	23	1.000	85	28	0.3823	82	28	0.4422	
	>= 10%	48	31	17		48	18		46	19		
HER2 IHC											
	negative (0-1+)	108	83	25	1.000	108	28	0.0081	102	31	0.0008	
	positive (2+-3+)	35	21	14		35	18		35	20		
* Fisher's exact test (two-sided), bold face representing significant data.

+ Log rank test (two-sided), bold face representing significant data.

",pT2,Lymph,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","p*	n	events	p+	n	events	p+	
Clinico-pathological data:												
Age at diagnosis											
	&#60;50 years	51	43	8	0.036	51	9	0.0064	51	16	0.1895	
	>= 50 years	108	74	34		108	45		102	42		
Tumor stage											
	pT1	40	35	5	0.004	40	4	&#60;0.0001	39	5	0.0001	
	pT2	83	63	20		83	28		81	34		
	pT3	10	4	6		10	4		9	4		
	pT4	26	15	11		26	18		24	15		
Lymph node status											
	pN0	75	60	15	0.101	75	11	&#60;0.0001	74	13	&#60;0.0001	
	pN1-3	80	54	26		80	41		76	42		
Histologic grade											
	G1	17	16	1	0.011	17	4	0.0047	17	4	&#60;0.0001	
	G2	69	55	14		69	17		65	16		
	G3	73	46	27		73	33		71	38		
Multifocality											
	unifocal tumor	141	104	37	1.000	141	45	0.0903	136	49	0.0683	
	multifocal tumor	18	13	5		18	9		17	9		
Histologic type											
	ductal	125	93	32	0.710	125	43	0.9302	123	49	0.5730	
	lobular	16	11	5		16	5		14	4		
	other	15	10	5		15	5		13	4		
												
Immunohistochemistry (IHC):											
Estrogen receptor status											
	negative	42	30	12	1.000	42	19	0.0129	42	24	0.0026	
	positive	96	69	27		96	25		92	27		
Progesterone receptor status											
	negative	98	63	35	0.002	98	40	0.0045	93	44	0.0019	
	positive	46	41	5		46	8		46	9		
Cytokeratin 5/6 IHC											
	negative (0)	118	85	33	0.540	118	34	0.0100	114	38	0.0349	
	positive (1+-3+)	41	32	9		41	20		39	20		
TP53 IHC											
	&#60;10%	85	62	23	1.000	85	28	0.3823	82	28	0.4422	
	>= 10%	48	31	17		48	18		46	19		
HER2 IHC											
	negative (0-1+)	108	83	25	1.000	108	28	0.0081	102	31	0.0008	
	positive (2+-3+)	35	21	14		35	18		35	20		
* Fisher's exact test (two-sided), bold face representing significant data.

+ Log rank test (two-sided), bold face representing significant data.

",HER2,Lymph,1
"PMC 
BMC_Cancer_2009_Nov_24_9_410.txt
","p*	n	events	p+	n	events	p+	
Clinico-pathological data:												
Age at diagnosis											
	&#60;50 years	51	43	8	0.036	51	9	0.0064	51	16	0.1895	
	>= 50 years	108	74	34		108	45		102	42		
Tumor stage											
	pT1	40	35	5	0.004	40	4	&#60;0.0001	39	5	0.0001	
	pT2	83	63	20		83	28		81	34		
	pT3	10	4	6		10	4		9	4		
	pT4	26	15	11		26	18		24	15		
Lymph node status											
	pN0	75	60	15	0.101	75	11	&#60;0.0001	74	13	&#60;0.0001	
	pN1-3	80	54	26		80	41		76	42		
Histologic grade											
	G1	17	16	1	0.011	17	4	0.0047	17	4	&#60;0.0001	
	G2	69	55	14		69	17		65	16		
	G3	73	46	27		73	33		71	38		
Multifocality											
	unifocal tumor	141	104	37	1.000	141	45	0.0903	136	49	0.0683	
	multifocal tumor	18	13	5		18	9		17	9		
Histologic type											
	ductal	125	93	32	0.710	125	43	0.9302	123	49	0.5730	
	lobular	16	11	5		16	5		14	4		
	other	15	10	5		15	5		13	4		
												
Immunohistochemistry (IHC):											
Estrogen receptor status											
	negative	42	30	12	1.000	42	19	0.0129	42	24	0.0026	
	positive	96	69	27		96	25		92	27		
Progesterone receptor status											
	negative	98	63	35	0.002	98	40	0.0045	93	44	0.0019	
	positive	46	41	5		46	8		46	9		
Cytokeratin 5/6 IHC											
	negative (0)	118	85	33	0.540	118	34	0.0100	114	38	0.0349	
	positive (1+-3+)	41	32	9		41	20		39	20		
TP53 IHC											
	&#60;10%	85	62	23	1.000	85	28	0.3823	82	28	0.4422	
	>= 10%	48	31	17		48	18		46	19		
HER2 IHC											
	negative (0-1+)	108	83	25	1.000	108	28	0.0081	102	31	0.0008	
	positive (2+-3+)	35	21	14		35	18		35	20		
* Fisher's exact test (two-sided), bold face representing significant data.

+ Log rank test (two-sided), bold face representing significant data.

",IHC,Lymph,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","The reaction was started by adding d-aminolevulinic acid (ALA) to a final concentration of 4 mM in a phosphate buffered solution, and incubation was carried out for 1 h at 37degC and the reaction product was measured at 555 nm and expressed as nmol PBG/mL blood/h.

",ALA,blood,-1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","The reaction was started by adding d-aminolevulinic acid (ALA) to a final concentration of 4 mM in a phosphate buffered solution, and incubation was carried out for 1 h at 37degC and the reaction product was measured at 555 nm and expressed as nmol PBG/mL blood/h.

",PBG,blood,-1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Of note, TIMP-1 serum levels were closely correlated with VEGF-165 at all time-points (Figure 1 and 2).",TIMP-1,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Of note, TIMP-1 serum levels were closely correlated with VEGF-165 at all time-points (Figure 1 and 2).",VEGF-165,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","When we dichotomized those patients whose serum TRACP 5b activities were higher than 5.736 U/L into 2 groups based on response, we were able to demonstrate that patients with a DmaxTRACP 5b &#62; 38.59% had a significantly longer survival than those without.",TRACP,serum,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","More research should be done to further explore this relationship between serum NSE and response to chemotherapy.

",NSE,serum,-1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
",Rauvala et al. studied the level of TIMP-1 in preoperative serum of patients with ovarian cancer [52].,TIMP-1,serum,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Quantification of non-protein thiols (NP-SH) may indicate 90% of GSH content in the blood [40], which is one of the most important reducing agents in different mammal cells [16].",GSH,blood,-1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Quantification of non-protein thiols (NP-SH) may indicate 90% of GSH content in the blood [40], which is one of the most important reducing agents in different mammal cells [16].",NP,blood,-1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","High VEGF-165 before (p = 0.043) as well as after chemotherapy (p = 0.006) was associated with decreased progression-free survival, while high serum-concentration of VEGF-165 after chemotherapy was also associated with decreased overall survival (p = 0.02).

",VEGF-165,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","High VEGF-165 before (p = 0.043) as well as after chemotherapy (p = 0.006) was associated with decreased progression-free survival, while high serum-concentration of VEGF-165 after chemotherapy was also associated with decreased overall survival (p = 0.02).

",VEGF-165,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
",Serum TRACP 5b activity of more than 5.736 U/L is probably related to a significant volume of cancer cells.,TRACP,Serum,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","Methods
For a period of two years, we systematically collected tumor tissue, normal matched mucosa and saliva of patients diagnosed with primary untreated HNSCC.",HNSCC,saliva,-1
"PMC 
BMC_Cancer_2009_Mar_5_9_77.txt
",During the time period 2001-2003 we consecutively collected peripheral blood AML blasts from 7 patients with WBC counts above 1.5 x 109/L eligible for treatment with chemotherapy.,AML,blood,-1
"PMC 
BMC_Cancer_2009_Mar_5_9_77.txt
",During the time period 2001-2003 we consecutively collected peripheral blood AML blasts from 7 patients with WBC counts above 1.5 x 109/L eligible for treatment with chemotherapy.,WBC,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Briefly, after the experimental treatment was applied, 20-ml samples of whole blood, both PHA-stimulated and non-stimulated, were dissolved in 0.5% LMPA, spread onto microscope slides precoated with 0.5% agarose, and covered with an additional 0.5% LMPA layer.",LMPA,blood,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Briefly, after the experimental treatment was applied, 20-ml samples of whole blood, both PHA-stimulated and non-stimulated, were dissolved in 0.5% LMPA, spread onto microscope slides precoated with 0.5% agarose, and covered with an additional 0.5% LMPA layer.",LMPA,blood,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Briefly, after the experimental treatment was applied, 20-ml samples of whole blood, both PHA-stimulated and non-stimulated, were dissolved in 0.5% LMPA, spread onto microscope slides precoated with 0.5% agarose, and covered with an additional 0.5% LMPA layer.",PHA,blood,1
"PMC 
BMC_Cancer_2010_Aug_19_10_444.txt
","The resulting tumours were characterized by increased development of extracellular matrix, as well as an increase of murine S100A4 concentration and activity of MMP-2 in the tumour interstitial fluid.

",S100A4,interstitial fluid,1
"PMC 
BMC_Cancer_2010_Aug_19_10_444.txt
","The resulting tumours were characterized by increased development of extracellular matrix, as well as an increase of murine S100A4 concentration and activity of MMP-2 in the tumour interstitial fluid.

",MMP-2,interstitial fluid,1
"PMC 
BMC_Cancer_2009_Oct_6_9_353.txt
","We also found miRNAs with high diagnostic potential e.g. high MI value, that were not yet related to cancer as for example hsa-miR-527 or hsa-mir-361-5p that were both up-regulated in blood cells of lung cancer patients.

",MI,blood,-1
"PMC 
BMC_Cancer_2010_Apr_21_10_155.txt
","Table 6 Study Assessment Schedule

			Baseline			Postintervention (16 weeks)	
Assessment	Screening	Day 0	Day 1	Day 2	Day 3-5	Day 112	Day 113	
Chart Review	x							
Patient Approached	x							
Informed Consent	x							
Day 1 Testing								
 Blood draw		x				x		
 Body Composition		x				x		
 Pulmonary Function		x				x		
 CPET		x				x		
 Echocardiogram		x				x		
Day 2 Testing								
 Strength testing			x				x	
 Muscle biopsy			x				x	
Day 3 Testing								
 Repeat CPET				x				
 Randomization				x				
 Intervention initiation					x			
Table 7 Study Measurements and Sub-Studies

Physical measurements and tests	
 Height, weight, and body mass index	
 Body composition	
 Resting and exercise heart rate	
 Resting and exercise blood pressure	
 Resting and exercise 12-lead ECG	
 Peak and submaximal oxygen consumption	
 Ventilatory threshold	
	
Mechanistic physiological measurements	
 Resting and exercise echocardiogram	
 Skeletal muscle function (fiber type distribution, oxidative capacity, and muscular strength)	
 Pulmonary function	
 Hemoglobin concentration	
 Resting and exercise oxygen saturation	
 Each intervention (exercise or attention control) session: heart rate, blood pressure, oxygen saturation, RPE	
	
Patient-reported outcomes (questionnaire-based)	
 Medications	
 Quality of life	
 Fatigue	
 Dyspnea	
 Depression	
 Adverse events (Common Terminology Criteria for Adverse Events; CTCAE v.4.0)	
	
Substudies	
 Genetic studies to examine differences to exercise stimulus	
 Predictors of exercise adherence	
 Pilot studies for exercise-induced changes in peripheral gene expression	
Primary Endpoint
VO2peak will be evaluated using a physician-supervised incremental cycle ergometer test with 12-lead ECG monitoring (Mac(r) 5000, GE Healthcare) will be performed by ACSM-certified exercise physiologists blinded to the patient's randomization group.",CTCAE,blood,1
"PMC 
BMC_Cancer_2010_Apr_21_10_155.txt
","Table 6 Study Assessment Schedule

			Baseline			Postintervention (16 weeks)	
Assessment	Screening	Day 0	Day 1	Day 2	Day 3-5	Day 112	Day 113	
Chart Review	x							
Patient Approached	x							
Informed Consent	x							
Day 1 Testing								
 Blood draw		x				x		
 Body Composition		x				x		
 Pulmonary Function		x				x		
 CPET		x				x		
 Echocardiogram		x				x		
Day 2 Testing								
 Strength testing			x				x	
 Muscle biopsy			x				x	
Day 3 Testing								
 Repeat CPET				x				
 Randomization				x				
 Intervention initiation					x			
Table 7 Study Measurements and Sub-Studies

Physical measurements and tests	
 Height, weight, and body mass index	
 Body composition	
 Resting and exercise heart rate	
 Resting and exercise blood pressure	
 Resting and exercise 12-lead ECG	
 Peak and submaximal oxygen consumption	
 Ventilatory threshold	
	
Mechanistic physiological measurements	
 Resting and exercise echocardiogram	
 Skeletal muscle function (fiber type distribution, oxidative capacity, and muscular strength)	
 Pulmonary function	
 Hemoglobin concentration	
 Resting and exercise oxygen saturation	
 Each intervention (exercise or attention control) session: heart rate, blood pressure, oxygen saturation, RPE	
	
Patient-reported outcomes (questionnaire-based)	
 Medications	
 Quality of life	
 Fatigue	
 Dyspnea	
 Depression	
 Adverse events (Common Terminology Criteria for Adverse Events; CTCAE v.4.0)	
	
Substudies	
 Genetic studies to examine differences to exercise stimulus	
 Predictors of exercise adherence	
 Pilot studies for exercise-induced changes in peripheral gene expression	
Primary Endpoint
VO2peak will be evaluated using a physician-supervised incremental cycle ergometer test with 12-lead ECG monitoring (Mac(r) 5000, GE Healthcare) will be performed by ACSM-certified exercise physiologists blinded to the patient's randomization group.",CTCAE,blood,1
"PMC 
BMC_Cancer_2010_Apr_21_10_155.txt
","Table 6 Study Assessment Schedule

			Baseline			Postintervention (16 weeks)	
Assessment	Screening	Day 0	Day 1	Day 2	Day 3-5	Day 112	Day 113	
Chart Review	x							
Patient Approached	x							
Informed Consent	x							
Day 1 Testing								
 Blood draw		x				x		
 Body Composition		x				x		
 Pulmonary Function		x				x		
 CPET		x				x		
 Echocardiogram		x				x		
Day 2 Testing								
 Strength testing			x				x	
 Muscle biopsy			x				x	
Day 3 Testing								
 Repeat CPET				x				
 Randomization				x				
 Intervention initiation					x			
Table 7 Study Measurements and Sub-Studies

Physical measurements and tests	
 Height, weight, and body mass index	
 Body composition	
 Resting and exercise heart rate	
 Resting and exercise blood pressure	
 Resting and exercise 12-lead ECG	
 Peak and submaximal oxygen consumption	
 Ventilatory threshold	
	
Mechanistic physiological measurements	
 Resting and exercise echocardiogram	
 Skeletal muscle function (fiber type distribution, oxidative capacity, and muscular strength)	
 Pulmonary function	
 Hemoglobin concentration	
 Resting and exercise oxygen saturation	
 Each intervention (exercise or attention control) session: heart rate, blood pressure, oxygen saturation, RPE	
	
Patient-reported outcomes (questionnaire-based)	
 Medications	
 Quality of life	
 Fatigue	
 Dyspnea	
 Depression	
 Adverse events (Common Terminology Criteria for Adverse Events; CTCAE v.4.0)	
	
Substudies	
 Genetic studies to examine differences to exercise stimulus	
 Predictors of exercise adherence	
 Pilot studies for exercise-induced changes in peripheral gene expression	
Primary Endpoint
VO2peak will be evaluated using a physician-supervised incremental cycle ergometer test with 12-lead ECG monitoring (Mac(r) 5000, GE Healthcare) will be performed by ACSM-certified exercise physiologists blinded to the patient's randomization group.",CTCAE,Blood,1
"PMC 
BMC_Cancer_2010_Apr_21_10_155.txt
","Table 6 Study Assessment Schedule

			Baseline			Postintervention (16 weeks)	
Assessment	Screening	Day 0	Day 1	Day 2	Day 3-5	Day 112	Day 113	
Chart Review	x							
Patient Approached	x							
Informed Consent	x							
Day 1 Testing								
 Blood draw		x				x		
 Body Composition		x				x		
 Pulmonary Function		x				x		
 CPET		x				x		
 Echocardiogram		x				x		
Day 2 Testing								
 Strength testing			x				x	
 Muscle biopsy			x				x	
Day 3 Testing								
 Repeat CPET				x				
 Randomization				x				
 Intervention initiation					x			
Table 7 Study Measurements and Sub-Studies

Physical measurements and tests	
 Height, weight, and body mass index	
 Body composition	
 Resting and exercise heart rate	
 Resting and exercise blood pressure	
 Resting and exercise 12-lead ECG	
 Peak and submaximal oxygen consumption	
 Ventilatory threshold	
	
Mechanistic physiological measurements	
 Resting and exercise echocardiogram	
 Skeletal muscle function (fiber type distribution, oxidative capacity, and muscular strength)	
 Pulmonary function	
 Hemoglobin concentration	
 Resting and exercise oxygen saturation	
 Each intervention (exercise or attention control) session: heart rate, blood pressure, oxygen saturation, RPE	
	
Patient-reported outcomes (questionnaire-based)	
 Medications	
 Quality of life	
 Fatigue	
 Dyspnea	
 Depression	
 Adverse events (Common Terminology Criteria for Adverse Events; CTCAE v.4.0)	
	
Substudies	
 Genetic studies to examine differences to exercise stimulus	
 Predictors of exercise adherence	
 Pilot studies for exercise-induced changes in peripheral gene expression	
Primary Endpoint
VO2peak will be evaluated using a physician-supervised incremental cycle ergometer test with 12-lead ECG monitoring (Mac(r) 5000, GE Healthcare) will be performed by ACSM-certified exercise physiologists blinded to the patient's randomization group.",RPE,blood,1
"PMC 
BMC_Cancer_2010_Apr_21_10_155.txt
","Table 6 Study Assessment Schedule

			Baseline			Postintervention (16 weeks)	
Assessment	Screening	Day 0	Day 1	Day 2	Day 3-5	Day 112	Day 113	
Chart Review	x							
Patient Approached	x							
Informed Consent	x							
Day 1 Testing								
 Blood draw		x				x		
 Body Composition		x				x		
 Pulmonary Function		x				x		
 CPET		x				x		
 Echocardiogram		x				x		
Day 2 Testing								
 Strength testing			x				x	
 Muscle biopsy			x				x	
Day 3 Testing								
 Repeat CPET				x				
 Randomization				x				
 Intervention initiation					x			
Table 7 Study Measurements and Sub-Studies

Physical measurements and tests	
 Height, weight, and body mass index	
 Body composition	
 Resting and exercise heart rate	
 Resting and exercise blood pressure	
 Resting and exercise 12-lead ECG	
 Peak and submaximal oxygen consumption	
 Ventilatory threshold	
	
Mechanistic physiological measurements	
 Resting and exercise echocardiogram	
 Skeletal muscle function (fiber type distribution, oxidative capacity, and muscular strength)	
 Pulmonary function	
 Hemoglobin concentration	
 Resting and exercise oxygen saturation	
 Each intervention (exercise or attention control) session: heart rate, blood pressure, oxygen saturation, RPE	
	
Patient-reported outcomes (questionnaire-based)	
 Medications	
 Quality of life	
 Fatigue	
 Dyspnea	
 Depression	
 Adverse events (Common Terminology Criteria for Adverse Events; CTCAE v.4.0)	
	
Substudies	
 Genetic studies to examine differences to exercise stimulus	
 Predictors of exercise adherence	
 Pilot studies for exercise-induced changes in peripheral gene expression	
Primary Endpoint
VO2peak will be evaluated using a physician-supervised incremental cycle ergometer test with 12-lead ECG monitoring (Mac(r) 5000, GE Healthcare) will be performed by ACSM-certified exercise physiologists blinded to the patient's randomization group.",RPE,blood,1
"PMC 
BMC_Cancer_2010_Apr_21_10_155.txt
","Table 6 Study Assessment Schedule

			Baseline			Postintervention (16 weeks)	
Assessment	Screening	Day 0	Day 1	Day 2	Day 3-5	Day 112	Day 113	
Chart Review	x							
Patient Approached	x							
Informed Consent	x							
Day 1 Testing								
 Blood draw		x				x		
 Body Composition		x				x		
 Pulmonary Function		x				x		
 CPET		x				x		
 Echocardiogram		x				x		
Day 2 Testing								
 Strength testing			x				x	
 Muscle biopsy			x				x	
Day 3 Testing								
 Repeat CPET				x				
 Randomization				x				
 Intervention initiation					x			
Table 7 Study Measurements and Sub-Studies

Physical measurements and tests	
 Height, weight, and body mass index	
 Body composition	
 Resting and exercise heart rate	
 Resting and exercise blood pressure	
 Resting and exercise 12-lead ECG	
 Peak and submaximal oxygen consumption	
 Ventilatory threshold	
	
Mechanistic physiological measurements	
 Resting and exercise echocardiogram	
 Skeletal muscle function (fiber type distribution, oxidative capacity, and muscular strength)	
 Pulmonary function	
 Hemoglobin concentration	
 Resting and exercise oxygen saturation	
 Each intervention (exercise or attention control) session: heart rate, blood pressure, oxygen saturation, RPE	
	
Patient-reported outcomes (questionnaire-based)	
 Medications	
 Quality of life	
 Fatigue	
 Dyspnea	
 Depression	
 Adverse events (Common Terminology Criteria for Adverse Events; CTCAE v.4.0)	
	
Substudies	
 Genetic studies to examine differences to exercise stimulus	
 Predictors of exercise adherence	
 Pilot studies for exercise-induced changes in peripheral gene expression	
Primary Endpoint
VO2peak will be evaluated using a physician-supervised incremental cycle ergometer test with 12-lead ECG monitoring (Mac(r) 5000, GE Healthcare) will be performed by ACSM-certified exercise physiologists blinded to the patient's randomization group.",RPE,Blood,1
"PMC 
BMC_Cancer_2010_Apr_21_10_155.txt
","Table 6 Study Assessment Schedule

			Baseline			Postintervention (16 weeks)	
Assessment	Screening	Day 0	Day 1	Day 2	Day 3-5	Day 112	Day 113	
Chart Review	x							
Patient Approached	x							
Informed Consent	x							
Day 1 Testing								
 Blood draw		x				x		
 Body Composition		x				x		
 Pulmonary Function		x				x		
 CPET		x				x		
 Echocardiogram		x				x		
Day 2 Testing								
 Strength testing			x				x	
 Muscle biopsy			x				x	
Day 3 Testing								
 Repeat CPET				x				
 Randomization				x				
 Intervention initiation					x			
Table 7 Study Measurements and Sub-Studies

Physical measurements and tests	
 Height, weight, and body mass index	
 Body composition	
 Resting and exercise heart rate	
 Resting and exercise blood pressure	
 Resting and exercise 12-lead ECG	
 Peak and submaximal oxygen consumption	
 Ventilatory threshold	
	
Mechanistic physiological measurements	
 Resting and exercise echocardiogram	
 Skeletal muscle function (fiber type distribution, oxidative capacity, and muscular strength)	
 Pulmonary function	
 Hemoglobin concentration	
 Resting and exercise oxygen saturation	
 Each intervention (exercise or attention control) session: heart rate, blood pressure, oxygen saturation, RPE	
	
Patient-reported outcomes (questionnaire-based)	
 Medications	
 Quality of life	
 Fatigue	
 Dyspnea	
 Depression	
 Adverse events (Common Terminology Criteria for Adverse Events; CTCAE v.4.0)	
	
Substudies	
 Genetic studies to examine differences to exercise stimulus	
 Predictors of exercise adherence	
 Pilot studies for exercise-induced changes in peripheral gene expression	
Primary Endpoint
VO2peak will be evaluated using a physician-supervised incremental cycle ergometer test with 12-lead ECG monitoring (Mac(r) 5000, GE Healthcare) will be performed by ACSM-certified exercise physiologists blinded to the patient's randomization group.",CPET,blood,1
"PMC 
BMC_Cancer_2010_Apr_21_10_155.txt
","Table 6 Study Assessment Schedule

			Baseline			Postintervention (16 weeks)	
Assessment	Screening	Day 0	Day 1	Day 2	Day 3-5	Day 112	Day 113	
Chart Review	x							
Patient Approached	x							
Informed Consent	x							
Day 1 Testing								
 Blood draw		x				x		
 Body Composition		x				x		
 Pulmonary Function		x				x		
 CPET		x				x		
 Echocardiogram		x				x		
Day 2 Testing								
 Strength testing			x				x	
 Muscle biopsy			x				x	
Day 3 Testing								
 Repeat CPET				x				
 Randomization				x				
 Intervention initiation					x			
Table 7 Study Measurements and Sub-Studies

Physical measurements and tests	
 Height, weight, and body mass index	
 Body composition	
 Resting and exercise heart rate	
 Resting and exercise blood pressure	
 Resting and exercise 12-lead ECG	
 Peak and submaximal oxygen consumption	
 Ventilatory threshold	
	
Mechanistic physiological measurements	
 Resting and exercise echocardiogram	
 Skeletal muscle function (fiber type distribution, oxidative capacity, and muscular strength)	
 Pulmonary function	
 Hemoglobin concentration	
 Resting and exercise oxygen saturation	
 Each intervention (exercise or attention control) session: heart rate, blood pressure, oxygen saturation, RPE	
	
Patient-reported outcomes (questionnaire-based)	
 Medications	
 Quality of life	
 Fatigue	
 Dyspnea	
 Depression	
 Adverse events (Common Terminology Criteria for Adverse Events; CTCAE v.4.0)	
	
Substudies	
 Genetic studies to examine differences to exercise stimulus	
 Predictors of exercise adherence	
 Pilot studies for exercise-induced changes in peripheral gene expression	
Primary Endpoint
VO2peak will be evaluated using a physician-supervised incremental cycle ergometer test with 12-lead ECG monitoring (Mac(r) 5000, GE Healthcare) will be performed by ACSM-certified exercise physiologists blinded to the patient's randomization group.",CPET,blood,1
"PMC 
BMC_Cancer_2010_Apr_21_10_155.txt
","Table 6 Study Assessment Schedule

			Baseline			Postintervention (16 weeks)	
Assessment	Screening	Day 0	Day 1	Day 2	Day 3-5	Day 112	Day 113	
Chart Review	x							
Patient Approached	x							
Informed Consent	x							
Day 1 Testing								
 Blood draw		x				x		
 Body Composition		x				x		
 Pulmonary Function		x				x		
 CPET		x				x		
 Echocardiogram		x				x		
Day 2 Testing								
 Strength testing			x				x	
 Muscle biopsy			x				x	
Day 3 Testing								
 Repeat CPET				x				
 Randomization				x				
 Intervention initiation					x			
Table 7 Study Measurements and Sub-Studies

Physical measurements and tests	
 Height, weight, and body mass index	
 Body composition	
 Resting and exercise heart rate	
 Resting and exercise blood pressure	
 Resting and exercise 12-lead ECG	
 Peak and submaximal oxygen consumption	
 Ventilatory threshold	
	
Mechanistic physiological measurements	
 Resting and exercise echocardiogram	
 Skeletal muscle function (fiber type distribution, oxidative capacity, and muscular strength)	
 Pulmonary function	
 Hemoglobin concentration	
 Resting and exercise oxygen saturation	
 Each intervention (exercise or attention control) session: heart rate, blood pressure, oxygen saturation, RPE	
	
Patient-reported outcomes (questionnaire-based)	
 Medications	
 Quality of life	
 Fatigue	
 Dyspnea	
 Depression	
 Adverse events (Common Terminology Criteria for Adverse Events; CTCAE v.4.0)	
	
Substudies	
 Genetic studies to examine differences to exercise stimulus	
 Predictors of exercise adherence	
 Pilot studies for exercise-induced changes in peripheral gene expression	
Primary Endpoint
VO2peak will be evaluated using a physician-supervised incremental cycle ergometer test with 12-lead ECG monitoring (Mac(r) 5000, GE Healthcare) will be performed by ACSM-certified exercise physiologists blinded to the patient's randomization group.",CPET,Blood,1
"PMC 
BMC_Cancer_2010_Apr_21_10_155.txt
","Table 6 Study Assessment Schedule

			Baseline			Postintervention (16 weeks)	
Assessment	Screening	Day 0	Day 1	Day 2	Day 3-5	Day 112	Day 113	
Chart Review	x							
Patient Approached	x							
Informed Consent	x							
Day 1 Testing								
 Blood draw		x				x		
 Body Composition		x				x		
 Pulmonary Function		x				x		
 CPET		x				x		
 Echocardiogram		x				x		
Day 2 Testing								
 Strength testing			x				x	
 Muscle biopsy			x				x	
Day 3 Testing								
 Repeat CPET				x				
 Randomization				x				
 Intervention initiation					x			
Table 7 Study Measurements and Sub-Studies

Physical measurements and tests	
 Height, weight, and body mass index	
 Body composition	
 Resting and exercise heart rate	
 Resting and exercise blood pressure	
 Resting and exercise 12-lead ECG	
 Peak and submaximal oxygen consumption	
 Ventilatory threshold	
	
Mechanistic physiological measurements	
 Resting and exercise echocardiogram	
 Skeletal muscle function (fiber type distribution, oxidative capacity, and muscular strength)	
 Pulmonary function	
 Hemoglobin concentration	
 Resting and exercise oxygen saturation	
 Each intervention (exercise or attention control) session: heart rate, blood pressure, oxygen saturation, RPE	
	
Patient-reported outcomes (questionnaire-based)	
 Medications	
 Quality of life	
 Fatigue	
 Dyspnea	
 Depression	
 Adverse events (Common Terminology Criteria for Adverse Events; CTCAE v.4.0)	
	
Substudies	
 Genetic studies to examine differences to exercise stimulus	
 Predictors of exercise adherence	
 Pilot studies for exercise-induced changes in peripheral gene expression	
Primary Endpoint
VO2peak will be evaluated using a physician-supervised incremental cycle ergometer test with 12-lead ECG monitoring (Mac(r) 5000, GE Healthcare) will be performed by ACSM-certified exercise physiologists blinded to the patient's randomization group.",CPET,blood,1
"PMC 
BMC_Cancer_2010_Apr_21_10_155.txt
","Table 6 Study Assessment Schedule

			Baseline			Postintervention (16 weeks)	
Assessment	Screening	Day 0	Day 1	Day 2	Day 3-5	Day 112	Day 113	
Chart Review	x							
Patient Approached	x							
Informed Consent	x							
Day 1 Testing								
 Blood draw		x				x		
 Body Composition		x				x		
 Pulmonary Function		x				x		
 CPET		x				x		
 Echocardiogram		x				x		
Day 2 Testing								
 Strength testing			x				x	
 Muscle biopsy			x				x	
Day 3 Testing								
 Repeat CPET				x				
 Randomization				x				
 Intervention initiation					x			
Table 7 Study Measurements and Sub-Studies

Physical measurements and tests	
 Height, weight, and body mass index	
 Body composition	
 Resting and exercise heart rate	
 Resting and exercise blood pressure	
 Resting and exercise 12-lead ECG	
 Peak and submaximal oxygen consumption	
 Ventilatory threshold	
	
Mechanistic physiological measurements	
 Resting and exercise echocardiogram	
 Skeletal muscle function (fiber type distribution, oxidative capacity, and muscular strength)	
 Pulmonary function	
 Hemoglobin concentration	
 Resting and exercise oxygen saturation	
 Each intervention (exercise or attention control) session: heart rate, blood pressure, oxygen saturation, RPE	
	
Patient-reported outcomes (questionnaire-based)	
 Medications	
 Quality of life	
 Fatigue	
 Dyspnea	
 Depression	
 Adverse events (Common Terminology Criteria for Adverse Events; CTCAE v.4.0)	
	
Substudies	
 Genetic studies to examine differences to exercise stimulus	
 Predictors of exercise adherence	
 Pilot studies for exercise-induced changes in peripheral gene expression	
Primary Endpoint
VO2peak will be evaluated using a physician-supervised incremental cycle ergometer test with 12-lead ECG monitoring (Mac(r) 5000, GE Healthcare) will be performed by ACSM-certified exercise physiologists blinded to the patient's randomization group.",CPET,blood,1
"PMC 
BMC_Cancer_2010_Apr_21_10_155.txt
","Table 6 Study Assessment Schedule

			Baseline			Postintervention (16 weeks)	
Assessment	Screening	Day 0	Day 1	Day 2	Day 3-5	Day 112	Day 113	
Chart Review	x							
Patient Approached	x							
Informed Consent	x							
Day 1 Testing								
 Blood draw		x				x		
 Body Composition		x				x		
 Pulmonary Function		x				x		
 CPET		x				x		
 Echocardiogram		x				x		
Day 2 Testing								
 Strength testing			x				x	
 Muscle biopsy			x				x	
Day 3 Testing								
 Repeat CPET				x				
 Randomization				x				
 Intervention initiation					x			
Table 7 Study Measurements and Sub-Studies

Physical measurements and tests	
 Height, weight, and body mass index	
 Body composition	
 Resting and exercise heart rate	
 Resting and exercise blood pressure	
 Resting and exercise 12-lead ECG	
 Peak and submaximal oxygen consumption	
 Ventilatory threshold	
	
Mechanistic physiological measurements	
 Resting and exercise echocardiogram	
 Skeletal muscle function (fiber type distribution, oxidative capacity, and muscular strength)	
 Pulmonary function	
 Hemoglobin concentration	
 Resting and exercise oxygen saturation	
 Each intervention (exercise or attention control) session: heart rate, blood pressure, oxygen saturation, RPE	
	
Patient-reported outcomes (questionnaire-based)	
 Medications	
 Quality of life	
 Fatigue	
 Dyspnea	
 Depression	
 Adverse events (Common Terminology Criteria for Adverse Events; CTCAE v.4.0)	
	
Substudies	
 Genetic studies to examine differences to exercise stimulus	
 Predictors of exercise adherence	
 Pilot studies for exercise-induced changes in peripheral gene expression	
Primary Endpoint
VO2peak will be evaluated using a physician-supervised incremental cycle ergometer test with 12-lead ECG monitoring (Mac(r) 5000, GE Healthcare) will be performed by ACSM-certified exercise physiologists blinded to the patient's randomization group.",CPET,Blood,1
"PMC 
BMC_Cancer_2010_Apr_21_10_155.txt
","Table 6 Study Assessment Schedule

			Baseline			Postintervention (16 weeks)	
Assessment	Screening	Day 0	Day 1	Day 2	Day 3-5	Day 112	Day 113	
Chart Review	x							
Patient Approached	x							
Informed Consent	x							
Day 1 Testing								
 Blood draw		x				x		
 Body Composition		x				x		
 Pulmonary Function		x				x		
 CPET		x				x		
 Echocardiogram		x				x		
Day 2 Testing								
 Strength testing			x				x	
 Muscle biopsy			x				x	
Day 3 Testing								
 Repeat CPET				x				
 Randomization				x				
 Intervention initiation					x			
Table 7 Study Measurements and Sub-Studies

Physical measurements and tests	
 Height, weight, and body mass index	
 Body composition	
 Resting and exercise heart rate	
 Resting and exercise blood pressure	
 Resting and exercise 12-lead ECG	
 Peak and submaximal oxygen consumption	
 Ventilatory threshold	
	
Mechanistic physiological measurements	
 Resting and exercise echocardiogram	
 Skeletal muscle function (fiber type distribution, oxidative capacity, and muscular strength)	
 Pulmonary function	
 Hemoglobin concentration	
 Resting and exercise oxygen saturation	
 Each intervention (exercise or attention control) session: heart rate, blood pressure, oxygen saturation, RPE	
	
Patient-reported outcomes (questionnaire-based)	
 Medications	
 Quality of life	
 Fatigue	
 Dyspnea	
 Depression	
 Adverse events (Common Terminology Criteria for Adverse Events; CTCAE v.4.0)	
	
Substudies	
 Genetic studies to examine differences to exercise stimulus	
 Predictors of exercise adherence	
 Pilot studies for exercise-induced changes in peripheral gene expression	
Primary Endpoint
VO2peak will be evaluated using a physician-supervised incremental cycle ergometer test with 12-lead ECG monitoring (Mac(r) 5000, GE Healthcare) will be performed by ACSM-certified exercise physiologists blinded to the patient's randomization group.",ECG,blood,1
"PMC 
BMC_Cancer_2010_Apr_21_10_155.txt
","Table 6 Study Assessment Schedule

			Baseline			Postintervention (16 weeks)	
Assessment	Screening	Day 0	Day 1	Day 2	Day 3-5	Day 112	Day 113	
Chart Review	x							
Patient Approached	x							
Informed Consent	x							
Day 1 Testing								
 Blood draw		x				x		
 Body Composition		x				x		
 Pulmonary Function		x				x		
 CPET		x				x		
 Echocardiogram		x				x		
Day 2 Testing								
 Strength testing			x				x	
 Muscle biopsy			x				x	
Day 3 Testing								
 Repeat CPET				x				
 Randomization				x				
 Intervention initiation					x			
Table 7 Study Measurements and Sub-Studies

Physical measurements and tests	
 Height, weight, and body mass index	
 Body composition	
 Resting and exercise heart rate	
 Resting and exercise blood pressure	
 Resting and exercise 12-lead ECG	
 Peak and submaximal oxygen consumption	
 Ventilatory threshold	
	
Mechanistic physiological measurements	
 Resting and exercise echocardiogram	
 Skeletal muscle function (fiber type distribution, oxidative capacity, and muscular strength)	
 Pulmonary function	
 Hemoglobin concentration	
 Resting and exercise oxygen saturation	
 Each intervention (exercise or attention control) session: heart rate, blood pressure, oxygen saturation, RPE	
	
Patient-reported outcomes (questionnaire-based)	
 Medications	
 Quality of life	
 Fatigue	
 Dyspnea	
 Depression	
 Adverse events (Common Terminology Criteria for Adverse Events; CTCAE v.4.0)	
	
Substudies	
 Genetic studies to examine differences to exercise stimulus	
 Predictors of exercise adherence	
 Pilot studies for exercise-induced changes in peripheral gene expression	
Primary Endpoint
VO2peak will be evaluated using a physician-supervised incremental cycle ergometer test with 12-lead ECG monitoring (Mac(r) 5000, GE Healthcare) will be performed by ACSM-certified exercise physiologists blinded to the patient's randomization group.",ECG,blood,1
"PMC 
BMC_Cancer_2010_Apr_21_10_155.txt
","Table 6 Study Assessment Schedule

			Baseline			Postintervention (16 weeks)	
Assessment	Screening	Day 0	Day 1	Day 2	Day 3-5	Day 112	Day 113	
Chart Review	x							
Patient Approached	x							
Informed Consent	x							
Day 1 Testing								
 Blood draw		x				x		
 Body Composition		x				x		
 Pulmonary Function		x				x		
 CPET		x				x		
 Echocardiogram		x				x		
Day 2 Testing								
 Strength testing			x				x	
 Muscle biopsy			x				x	
Day 3 Testing								
 Repeat CPET				x				
 Randomization				x				
 Intervention initiation					x			
Table 7 Study Measurements and Sub-Studies

Physical measurements and tests	
 Height, weight, and body mass index	
 Body composition	
 Resting and exercise heart rate	
 Resting and exercise blood pressure	
 Resting and exercise 12-lead ECG	
 Peak and submaximal oxygen consumption	
 Ventilatory threshold	
	
Mechanistic physiological measurements	
 Resting and exercise echocardiogram	
 Skeletal muscle function (fiber type distribution, oxidative capacity, and muscular strength)	
 Pulmonary function	
 Hemoglobin concentration	
 Resting and exercise oxygen saturation	
 Each intervention (exercise or attention control) session: heart rate, blood pressure, oxygen saturation, RPE	
	
Patient-reported outcomes (questionnaire-based)	
 Medications	
 Quality of life	
 Fatigue	
 Dyspnea	
 Depression	
 Adverse events (Common Terminology Criteria for Adverse Events; CTCAE v.4.0)	
	
Substudies	
 Genetic studies to examine differences to exercise stimulus	
 Predictors of exercise adherence	
 Pilot studies for exercise-induced changes in peripheral gene expression	
Primary Endpoint
VO2peak will be evaluated using a physician-supervised incremental cycle ergometer test with 12-lead ECG monitoring (Mac(r) 5000, GE Healthcare) will be performed by ACSM-certified exercise physiologists blinded to the patient's randomization group.",ECG,Blood,1
"PMC 
BMC_Cancer_2010_Apr_21_10_155.txt
","Table 6 Study Assessment Schedule

			Baseline			Postintervention (16 weeks)	
Assessment	Screening	Day 0	Day 1	Day 2	Day 3-5	Day 112	Day 113	
Chart Review	x							
Patient Approached	x							
Informed Consent	x							
Day 1 Testing								
 Blood draw		x				x		
 Body Composition		x				x		
 Pulmonary Function		x				x		
 CPET		x				x		
 Echocardiogram		x				x		
Day 2 Testing								
 Strength testing			x				x	
 Muscle biopsy			x				x	
Day 3 Testing								
 Repeat CPET				x				
 Randomization				x				
 Intervention initiation					x			
Table 7 Study Measurements and Sub-Studies

Physical measurements and tests	
 Height, weight, and body mass index	
 Body composition	
 Resting and exercise heart rate	
 Resting and exercise blood pressure	
 Resting and exercise 12-lead ECG	
 Peak and submaximal oxygen consumption	
 Ventilatory threshold	
	
Mechanistic physiological measurements	
 Resting and exercise echocardiogram	
 Skeletal muscle function (fiber type distribution, oxidative capacity, and muscular strength)	
 Pulmonary function	
 Hemoglobin concentration	
 Resting and exercise oxygen saturation	
 Each intervention (exercise or attention control) session: heart rate, blood pressure, oxygen saturation, RPE	
	
Patient-reported outcomes (questionnaire-based)	
 Medications	
 Quality of life	
 Fatigue	
 Dyspnea	
 Depression	
 Adverse events (Common Terminology Criteria for Adverse Events; CTCAE v.4.0)	
	
Substudies	
 Genetic studies to examine differences to exercise stimulus	
 Predictors of exercise adherence	
 Pilot studies for exercise-induced changes in peripheral gene expression	
Primary Endpoint
VO2peak will be evaluated using a physician-supervised incremental cycle ergometer test with 12-lead ECG monitoring (Mac(r) 5000, GE Healthcare) will be performed by ACSM-certified exercise physiologists blinded to the patient's randomization group.",ACSM,blood,1
"PMC 
BMC_Cancer_2010_Apr_21_10_155.txt
","Table 6 Study Assessment Schedule

			Baseline			Postintervention (16 weeks)	
Assessment	Screening	Day 0	Day 1	Day 2	Day 3-5	Day 112	Day 113	
Chart Review	x							
Patient Approached	x							
Informed Consent	x							
Day 1 Testing								
 Blood draw		x				x		
 Body Composition		x				x		
 Pulmonary Function		x				x		
 CPET		x				x		
 Echocardiogram		x				x		
Day 2 Testing								
 Strength testing			x				x	
 Muscle biopsy			x				x	
Day 3 Testing								
 Repeat CPET				x				
 Randomization				x				
 Intervention initiation					x			
Table 7 Study Measurements and Sub-Studies

Physical measurements and tests	
 Height, weight, and body mass index	
 Body composition	
 Resting and exercise heart rate	
 Resting and exercise blood pressure	
 Resting and exercise 12-lead ECG	
 Peak and submaximal oxygen consumption	
 Ventilatory threshold	
	
Mechanistic physiological measurements	
 Resting and exercise echocardiogram	
 Skeletal muscle function (fiber type distribution, oxidative capacity, and muscular strength)	
 Pulmonary function	
 Hemoglobin concentration	
 Resting and exercise oxygen saturation	
 Each intervention (exercise or attention control) session: heart rate, blood pressure, oxygen saturation, RPE	
	
Patient-reported outcomes (questionnaire-based)	
 Medications	
 Quality of life	
 Fatigue	
 Dyspnea	
 Depression	
 Adverse events (Common Terminology Criteria for Adverse Events; CTCAE v.4.0)	
	
Substudies	
 Genetic studies to examine differences to exercise stimulus	
 Predictors of exercise adherence	
 Pilot studies for exercise-induced changes in peripheral gene expression	
Primary Endpoint
VO2peak will be evaluated using a physician-supervised incremental cycle ergometer test with 12-lead ECG monitoring (Mac(r) 5000, GE Healthcare) will be performed by ACSM-certified exercise physiologists blinded to the patient's randomization group.",ACSM,blood,1
"PMC 
BMC_Cancer_2010_Apr_21_10_155.txt
","Table 6 Study Assessment Schedule

			Baseline			Postintervention (16 weeks)	
Assessment	Screening	Day 0	Day 1	Day 2	Day 3-5	Day 112	Day 113	
Chart Review	x							
Patient Approached	x							
Informed Consent	x							
Day 1 Testing								
 Blood draw		x				x		
 Body Composition		x				x		
 Pulmonary Function		x				x		
 CPET		x				x		
 Echocardiogram		x				x		
Day 2 Testing								
 Strength testing			x				x	
 Muscle biopsy			x				x	
Day 3 Testing								
 Repeat CPET				x				
 Randomization				x				
 Intervention initiation					x			
Table 7 Study Measurements and Sub-Studies

Physical measurements and tests	
 Height, weight, and body mass index	
 Body composition	
 Resting and exercise heart rate	
 Resting and exercise blood pressure	
 Resting and exercise 12-lead ECG	
 Peak and submaximal oxygen consumption	
 Ventilatory threshold	
	
Mechanistic physiological measurements	
 Resting and exercise echocardiogram	
 Skeletal muscle function (fiber type distribution, oxidative capacity, and muscular strength)	
 Pulmonary function	
 Hemoglobin concentration	
 Resting and exercise oxygen saturation	
 Each intervention (exercise or attention control) session: heart rate, blood pressure, oxygen saturation, RPE	
	
Patient-reported outcomes (questionnaire-based)	
 Medications	
 Quality of life	
 Fatigue	
 Dyspnea	
 Depression	
 Adverse events (Common Terminology Criteria for Adverse Events; CTCAE v.4.0)	
	
Substudies	
 Genetic studies to examine differences to exercise stimulus	
 Predictors of exercise adherence	
 Pilot studies for exercise-induced changes in peripheral gene expression	
Primary Endpoint
VO2peak will be evaluated using a physician-supervised incremental cycle ergometer test with 12-lead ECG monitoring (Mac(r) 5000, GE Healthcare) will be performed by ACSM-certified exercise physiologists blinded to the patient's randomization group.",ACSM,Blood,1
"PMC 
BMC_Cancer_2010_Apr_21_10_155.txt
","Table 6 Study Assessment Schedule

			Baseline			Postintervention (16 weeks)	
Assessment	Screening	Day 0	Day 1	Day 2	Day 3-5	Day 112	Day 113	
Chart Review	x							
Patient Approached	x							
Informed Consent	x							
Day 1 Testing								
 Blood draw		x				x		
 Body Composition		x				x		
 Pulmonary Function		x				x		
 CPET		x				x		
 Echocardiogram		x				x		
Day 2 Testing								
 Strength testing			x				x	
 Muscle biopsy			x				x	
Day 3 Testing								
 Repeat CPET				x				
 Randomization				x				
 Intervention initiation					x			
Table 7 Study Measurements and Sub-Studies

Physical measurements and tests	
 Height, weight, and body mass index	
 Body composition	
 Resting and exercise heart rate	
 Resting and exercise blood pressure	
 Resting and exercise 12-lead ECG	
 Peak and submaximal oxygen consumption	
 Ventilatory threshold	
	
Mechanistic physiological measurements	
 Resting and exercise echocardiogram	
 Skeletal muscle function (fiber type distribution, oxidative capacity, and muscular strength)	
 Pulmonary function	
 Hemoglobin concentration	
 Resting and exercise oxygen saturation	
 Each intervention (exercise or attention control) session: heart rate, blood pressure, oxygen saturation, RPE	
	
Patient-reported outcomes (questionnaire-based)	
 Medications	
 Quality of life	
 Fatigue	
 Dyspnea	
 Depression	
 Adverse events (Common Terminology Criteria for Adverse Events; CTCAE v.4.0)	
	
Substudies	
 Genetic studies to examine differences to exercise stimulus	
 Predictors of exercise adherence	
 Pilot studies for exercise-induced changes in peripheral gene expression	
Primary Endpoint
VO2peak will be evaluated using a physician-supervised incremental cycle ergometer test with 12-lead ECG monitoring (Mac(r) 5000, GE Healthcare) will be performed by ACSM-certified exercise physiologists blinded to the patient's randomization group.",ECG,blood,1
"PMC 
BMC_Cancer_2010_Apr_21_10_155.txt
","Table 6 Study Assessment Schedule

			Baseline			Postintervention (16 weeks)	
Assessment	Screening	Day 0	Day 1	Day 2	Day 3-5	Day 112	Day 113	
Chart Review	x							
Patient Approached	x							
Informed Consent	x							
Day 1 Testing								
 Blood draw		x				x		
 Body Composition		x				x		
 Pulmonary Function		x				x		
 CPET		x				x		
 Echocardiogram		x				x		
Day 2 Testing								
 Strength testing			x				x	
 Muscle biopsy			x				x	
Day 3 Testing								
 Repeat CPET				x				
 Randomization				x				
 Intervention initiation					x			
Table 7 Study Measurements and Sub-Studies

Physical measurements and tests	
 Height, weight, and body mass index	
 Body composition	
 Resting and exercise heart rate	
 Resting and exercise blood pressure	
 Resting and exercise 12-lead ECG	
 Peak and submaximal oxygen consumption	
 Ventilatory threshold	
	
Mechanistic physiological measurements	
 Resting and exercise echocardiogram	
 Skeletal muscle function (fiber type distribution, oxidative capacity, and muscular strength)	
 Pulmonary function	
 Hemoglobin concentration	
 Resting and exercise oxygen saturation	
 Each intervention (exercise or attention control) session: heart rate, blood pressure, oxygen saturation, RPE	
	
Patient-reported outcomes (questionnaire-based)	
 Medications	
 Quality of life	
 Fatigue	
 Dyspnea	
 Depression	
 Adverse events (Common Terminology Criteria for Adverse Events; CTCAE v.4.0)	
	
Substudies	
 Genetic studies to examine differences to exercise stimulus	
 Predictors of exercise adherence	
 Pilot studies for exercise-induced changes in peripheral gene expression	
Primary Endpoint
VO2peak will be evaluated using a physician-supervised incremental cycle ergometer test with 12-lead ECG monitoring (Mac(r) 5000, GE Healthcare) will be performed by ACSM-certified exercise physiologists blinded to the patient's randomization group.",ECG,blood,1
"PMC 
BMC_Cancer_2010_Apr_21_10_155.txt
","Table 6 Study Assessment Schedule

			Baseline			Postintervention (16 weeks)	
Assessment	Screening	Day 0	Day 1	Day 2	Day 3-5	Day 112	Day 113	
Chart Review	x							
Patient Approached	x							
Informed Consent	x							
Day 1 Testing								
 Blood draw		x				x		
 Body Composition		x				x		
 Pulmonary Function		x				x		
 CPET		x				x		
 Echocardiogram		x				x		
Day 2 Testing								
 Strength testing			x				x	
 Muscle biopsy			x				x	
Day 3 Testing								
 Repeat CPET				x				
 Randomization				x				
 Intervention initiation					x			
Table 7 Study Measurements and Sub-Studies

Physical measurements and tests	
 Height, weight, and body mass index	
 Body composition	
 Resting and exercise heart rate	
 Resting and exercise blood pressure	
 Resting and exercise 12-lead ECG	
 Peak and submaximal oxygen consumption	
 Ventilatory threshold	
	
Mechanistic physiological measurements	
 Resting and exercise echocardiogram	
 Skeletal muscle function (fiber type distribution, oxidative capacity, and muscular strength)	
 Pulmonary function	
 Hemoglobin concentration	
 Resting and exercise oxygen saturation	
 Each intervention (exercise or attention control) session: heart rate, blood pressure, oxygen saturation, RPE	
	
Patient-reported outcomes (questionnaire-based)	
 Medications	
 Quality of life	
 Fatigue	
 Dyspnea	
 Depression	
 Adverse events (Common Terminology Criteria for Adverse Events; CTCAE v.4.0)	
	
Substudies	
 Genetic studies to examine differences to exercise stimulus	
 Predictors of exercise adherence	
 Pilot studies for exercise-induced changes in peripheral gene expression	
Primary Endpoint
VO2peak will be evaluated using a physician-supervised incremental cycle ergometer test with 12-lead ECG monitoring (Mac(r) 5000, GE Healthcare) will be performed by ACSM-certified exercise physiologists blinded to the patient's randomization group.",ECG,Blood,1
"PMC 
BMC_Cancer_2009_Oct_6_9_353.txt
","Second, we calculated the MI values for the comparison between the miRNAs in blood cells of tumor patients and controls.",MI,blood,-1
"PMC 
BMC_Cancer_2010_Aug_18_10_439.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-4392071898210.1186/1471-2407-10-439Research ArticleRapid method for determination of DNA repair capacity in human peripheral blood lymphocytes amongst smokers El-Zein Randa A 1relzein@mdanderson.orgMonroy Claudia M 1cmonroy@mdanderson.orgCortes Andrea 1accortes@mdanderson.orgSpitz Margaret R 1mspitz@mdanderson.orgGreisinger Anthony 2anthony.greisinger@kelsey-seybold.comEtzel Carol J 1cetzel@mdanderson.org1 The University of Texas M. D. Anderson Cancer Center, Department of Epidemiology, Houston, Texas, USA2 Kelsey Research Foundation, Houston, Texas, USA2010 18 8 2010 10 439 439 12 4 2010 18 8 2010 Copyright (c)2010 El-Zein et al; licensee BioMed Central Ltd.2010El-Zein et al; licensee BioMed Central Ltd.",BMC,blood,1
"PMC 
BMC_Cancer_2010_Aug_18_10_439.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-4392071898210.1186/1471-2407-10-439Research ArticleRapid method for determination of DNA repair capacity in human peripheral blood lymphocytes amongst smokers El-Zein Randa A 1relzein@mdanderson.orgMonroy Claudia M 1cmonroy@mdanderson.orgCortes Andrea 1accortes@mdanderson.orgSpitz Margaret R 1mspitz@mdanderson.orgGreisinger Anthony 2anthony.greisinger@kelsey-seybold.comEtzel Carol J 1cetzel@mdanderson.org1 The University of Texas M. D. Anderson Cancer Center, Department of Epidemiology, Houston, Texas, USA2 Kelsey Research Foundation, Houston, Texas, USA2010 18 8 2010 10 439 439 12 4 2010 18 8 2010 Copyright (c)2010 El-Zein et al; licensee BioMed Central Ltd.2010El-Zein et al; licensee BioMed Central Ltd.",USA2010,blood,1
"PMC 
BMC_Cancer_2010_Aug_18_10_439.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-4392071898210.1186/1471-2407-10-439Research ArticleRapid method for determination of DNA repair capacity in human peripheral blood lymphocytes amongst smokers El-Zein Randa A 1relzein@mdanderson.orgMonroy Claudia M 1cmonroy@mdanderson.orgCortes Andrea 1accortes@mdanderson.orgSpitz Margaret R 1mspitz@mdanderson.orgGreisinger Anthony 2anthony.greisinger@kelsey-seybold.comEtzel Carol J 1cetzel@mdanderson.org1 The University of Texas M. D. Anderson Cancer Center, Department of Epidemiology, Houston, Texas, USA2 Kelsey Research Foundation, Houston, Texas, USA2010 18 8 2010 10 439 439 12 4 2010 18 8 2010 Copyright (c)2010 El-Zein et al; licensee BioMed Central Ltd.2010El-Zein et al; licensee BioMed Central Ltd.",Cancer1471,blood,1
"PMC 
BMC_Cancer_2010_Aug_18_10_439.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-4392071898210.1186/1471-2407-10-439Research ArticleRapid method for determination of DNA repair capacity in human peripheral blood lymphocytes amongst smokers El-Zein Randa A 1relzein@mdanderson.orgMonroy Claudia M 1cmonroy@mdanderson.orgCortes Andrea 1accortes@mdanderson.orgSpitz Margaret R 1mspitz@mdanderson.orgGreisinger Anthony 2anthony.greisinger@kelsey-seybold.comEtzel Carol J 1cetzel@mdanderson.org1 The University of Texas M. D. Anderson Cancer Center, Department of Epidemiology, Houston, Texas, USA2 Kelsey Research Foundation, Houston, Texas, USA2010 18 8 2010 10 439 439 12 4 2010 18 8 2010 Copyright (c)2010 El-Zein et al; licensee BioMed Central Ltd.2010El-Zein et al; licensee BioMed Central Ltd.",DNA,blood,1
"PMC 
BMC_Cancer_2010_Aug_18_10_439.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-4392071898210.1186/1471-2407-10-439Research ArticleRapid method for determination of DNA repair capacity in human peripheral blood lymphocytes amongst smokers El-Zein Randa A 1relzein@mdanderson.orgMonroy Claudia M 1cmonroy@mdanderson.orgCortes Andrea 1accortes@mdanderson.orgSpitz Margaret R 1mspitz@mdanderson.orgGreisinger Anthony 2anthony.greisinger@kelsey-seybold.comEtzel Carol J 1cetzel@mdanderson.org1 The University of Texas M. D. Anderson Cancer Center, Department of Epidemiology, Houston, Texas, USA2 Kelsey Research Foundation, Houston, Texas, USA2010 18 8 2010 10 439 439 12 4 2010 18 8 2010 Copyright (c)2010 El-Zein et al; licensee BioMed Central Ltd.2010El-Zein et al; licensee BioMed Central Ltd.",USA2,blood,1
"PMC 
BMC_Cancer_2010_Aug_11_10_419.txt
","Macrophage cell line RAW264.7
The macrophage cell RAW 264.7 was provided by the American Type Culture Collection (Rockville, MD, USA), and was maintained in Dulbecco's modified Eagle's medium, supplemented with 10% fetal bovine serum, at 37degC in a humid incubator with 5% CO2.

",CO2,serum,1
"PMC 
BMC_Cancer_2010_Aug_11_10_419.txt
","Macrophage cell line RAW264.7
The macrophage cell RAW 264.7 was provided by the American Type Culture Collection (Rockville, MD, USA), and was maintained in Dulbecco's modified Eagle's medium, supplemented with 10% fetal bovine serum, at 37degC in a humid incubator with 5% CO2.

",USA,serum,1
"PMC 
BMC_Cancer_2010_Aug_11_10_419.txt
","Macrophage cell line RAW264.7
The macrophage cell RAW 264.7 was provided by the American Type Culture Collection (Rockville, MD, USA), and was maintained in Dulbecco's modified Eagle's medium, supplemented with 10% fetal bovine serum, at 37degC in a humid incubator with 5% CO2.

",RAW,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Discussion
To investigate the role of new serologic biomarkers in therapy monitoring and to determine their potential prognostic significance in ovarian cancer, TIMP-1, VEGF-165 and CA-125 were analyzed in 148 serum samples from 37 patients with epithelial ovarian cancer.",TIMP-1,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Discussion
To investigate the role of new serologic biomarkers in therapy monitoring and to determine their potential prognostic significance in ovarian cancer, TIMP-1, VEGF-165 and CA-125 were analyzed in 148 serum samples from 37 patients with epithelial ovarian cancer.",CA-125,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Discussion
To investigate the role of new serologic biomarkers in therapy monitoring and to determine their potential prognostic significance in ovarian cancer, TIMP-1, VEGF-165 and CA-125 were analyzed in 148 serum samples from 37 patients with epithelial ovarian cancer.",VEGF-165,serum,1
"PMC 
BMC_Cancer_2010_Apr_14_10_140.txt
","In a series of lymph node negative breast cancer patients, PHH3 was the strongest prognostic variable [19].",PHH3,lymph,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","The European Group of Tumor Markers identified the MUC-1 mucin glycoproteins CA 15.3 and BR 27.29 as the best serum markers for breast cancer, but they could not recommend these proteins for diagnosis due to low sensitivity [18].

",MUC-1,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","However, other studies found a lack of sufficient diagnostic ability in serum proteins, including CA 15.3 [13,17-20], CA 125 [20], CA 19.9 [20], CA 125 [20], BR 27.29 [13,18], and carcinoembryonic antigen (CEA) [13].",CEA,serum,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_434.txt
","N/A	N/A	
SqCC: Squamous cell carcinoma; Adeno: Adenocarcinoma; LCC: Large cell carcinoma; Bronch: Bronchioalveolar; LNs: Lymph nodes; TNM: Tumour-to-node metastasis (7th TNM classification version); M0: absence of metastasis. *pleural invasion with no pleural penetration/no pleural nodules.

",TNM,Lymph,1
"PMC 
BMC_Cancer_2010_Aug_17_10_434.txt
","N/A	N/A	
SqCC: Squamous cell carcinoma; Adeno: Adenocarcinoma; LCC: Large cell carcinoma; Bronch: Bronchioalveolar; LNs: Lymph nodes; TNM: Tumour-to-node metastasis (7th TNM classification version); M0: absence of metastasis. *pleural invasion with no pleural penetration/no pleural nodules.

",M0,Lymph,1
"PMC 
BMC_Cancer_2010_Aug_17_10_434.txt
","N/A	N/A	
SqCC: Squamous cell carcinoma; Adeno: Adenocarcinoma; LCC: Large cell carcinoma; Bronch: Bronchioalveolar; LNs: Lymph nodes; TNM: Tumour-to-node metastasis (7th TNM classification version); M0: absence of metastasis. *pleural invasion with no pleural penetration/no pleural nodules.

",LCC,Lymph,1
"PMC 
BMC_Cancer_2010_Aug_17_10_434.txt
","N/A	N/A	
SqCC: Squamous cell carcinoma; Adeno: Adenocarcinoma; LCC: Large cell carcinoma; Bronch: Bronchioalveolar; LNs: Lymph nodes; TNM: Tumour-to-node metastasis (7th TNM classification version); M0: absence of metastasis. *pleural invasion with no pleural penetration/no pleural nodules.

",TNM,Lymph,1
"PMC 
BMC_Cancer_2009_Sep_20_9_335.txt
","The reviewed studies provided limited evidence that within the framework of screening for breast cancer, an additional ultrasound examination after a negative mammogram is useful for the detection of primarily invasive cancers in women with mammographically dense breast tissue (ACR types 3 and 4, with more than 50% parenchymal gland), with the mean size of invasive cancers thus identified being 9.9 mm and in 90% with negative lymph node status.

",ACR,lymph,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","However, the serum proteins of benign and malignant lesions were indistinguishable (AUC = 0.55 +- 0.06).",AUC,serum,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Furthermore, enzyme inhibition can lead to accumulation of its substrate, 5-aminolevulinate (ALA), in the blood, which in turn can intensify oxidative stress by generating carbon-centered reactive species or by releasing iron from proteins such as ferritin [28].

",ALA,blood,-1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
",(b) Expression of CYC-1 in serum samples of the same patient before and after surgery.,CYC-1,serum,-1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","Therefore we examine if baseline serum TRACP 5b activity and its interval change after treatment can be used as prognostic markers for overall survival time in BC patients with bone metastasis. Confounding factors including age, tumor markers including carcinoembryonic antigen (CEA) and CA 15.3, ER, HER2 over-expression, and",ER,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","Therefore we examine if baseline serum TRACP 5b activity and its interval change after treatment can be used as prognostic markers for overall survival time in BC patients with bone metastasis. Confounding factors including age, tumor markers including carcinoembryonic antigen (CEA) and CA 15.3, ER, HER2 over-expression, and",HER2,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","Therefore we examine if baseline serum TRACP 5b activity and its interval change after treatment can be used as prognostic markers for overall survival time in BC patients with bone metastasis. Confounding factors including age, tumor markers including carcinoembryonic antigen (CEA) and CA 15.3, ER, HER2 over-expression, and",CEA,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","Therefore we examine if baseline serum TRACP 5b activity and its interval change after treatment can be used as prognostic markers for overall survival time in BC patients with bone metastasis. Confounding factors including age, tumor markers including carcinoembryonic antigen (CEA) and CA 15.3, ER, HER2 over-expression, and",TRACP,serum,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
",The findings support an association between MMP-9 and MMP-9/NGAL urine levels with the presence of disease and response to therapy [26].,MMP-9,urine,-1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
",Figure 5 (a) Expression of CYC-1 in the serum of osteosarcoma patients and healthy individuals.,CYC-1,serum,1
"PMC 
BMC_Cancer_2010_Aug_17_10_437.txt
","(a) Representative images of p65 immunostaining of a primary tumor with lymph node involvement (N+) (Tm), the corresponding lymph node contain metastases (Ln) from the same patient and a primary tumor without lymph node involvement (N-) (Tn).",p65,lymph,1
"PMC 
BMC_Cancer_2010_Aug_17_10_437.txt
","(a) Representative images of p65 immunostaining of a primary tumor with lymph node involvement (N+) (Tm), the corresponding lymph node contain metastases (Ln) from the same patient and a primary tumor without lymph node involvement (N-) (Tn).",p65,lymph,1
"PMC 
BMC_Cancer_2010_Aug_17_10_437.txt
","(a) Representative images of p65 immunostaining of a primary tumor with lymph node involvement (N+) (Tm), the corresponding lymph node contain metastases (Ln) from the same patient and a primary tumor without lymph node involvement (N-) (Tn).",p65,lymph,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Serum NGAL and MMP-9/NGAL levels were determined in duplicate by solid phase ELISA techniques (R&D Systems, Minneapolis, MN, US).",NGAL,Serum,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Serum NGAL and MMP-9/NGAL levels were determined in duplicate by solid phase ELISA techniques (R&D Systems, Minneapolis, MN, US).",MN,Serum,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Serum NGAL and MMP-9/NGAL levels were determined in duplicate by solid phase ELISA techniques (R&D Systems, Minneapolis, MN, US).",ELISA,Serum,1
"PMC 
BMC_Cancer_2009_Sep_8_9_317.txt
","B: CP and NP are matched cancer and non-cancer prostate specimens; bone, liver and LN (lymph node) are prostate cancer metastasis specimens.",NP,lymph,1
"PMC 
BMC_Cancer_2009_Sep_8_9_317.txt
","B: CP and NP are matched cancer and non-cancer prostate specimens; bone, liver and LN (lymph node) are prostate cancer metastasis specimens.",CP,lymph,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Whether serum levels of MMP-9, NGAL and their complex can reflect the relative risk of patients with benign diseases for developing breast cancer remains to be investigated in future studies.

",NGAL,serum,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Whether serum levels of MMP-9, NGAL and their complex can reflect the relative risk of patients with benign diseases for developing breast cancer remains to be investigated in future studies.

",MMP-9,serum,1
"PMC 
BMC_Cancer_2009_Oct_14_9_364.txt
","As shown in Table 1, women living in the lowest SES areas had the lowest percentage of early stage (I): 41.4% vs 45.7-46.7%, and highest percentage of advanced stages (III, IV): 13.0% vs 9.5-9.9% and were more likely to have >= 4 lymph nodes positive: 16.0% vs 12.3-12.8%.",SES,lymph,1
"PMC 
BMC_Cancer_2009_Oct_14_9_364.txt
","As shown in Table 1, women living in the lowest SES areas had the lowest percentage of early stage (I): 41.4% vs 45.7-46.7%, and highest percentage of advanced stages (III, IV): 13.0% vs 9.5-9.9% and were more likely to have >= 4 lymph nodes positive: 16.0% vs 12.3-12.8%.",III,lymph,1
"PMC 
BMC_Cancer_2009_Nov_3_9_389.txt
","This finding is highly consistent with previous report on Chinese HCC patients [15,17] where dichotomized serum albumin and tumor size, number of tumor nodules, venous infiltration, and tumor stage were significantly associated with cancer prognosis after surgery.

",HCC,serum,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
","Furthermore, the levels of CYC-1 in serum samples of the same patient before and after surgery were compared.",CYC-1,serum,-1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
",We further calculated the median baseline serum TRACP 5b activities in different patient groups stratified by the OS.,TRACP,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
",We further calculated the median baseline serum TRACP 5b activities in different patient groups stratified by the OS.,OS,serum,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
",The result indicated that the level of CYC-1 in serum samples from patients with OS was significantly higher than that from healthy controls (p &#60; 0.05 by wilcoxon rank sum test).,CYC-1,serum,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
",The result indicated that the level of CYC-1 in serum samples from patients with OS was significantly higher than that from healthy controls (p &#60; 0.05 by wilcoxon rank sum test).,OS,serum,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Our findings suggest that both MMP-9 and NGAL serum levels are correlated with breast cancer progression since they seem to follow a gradual increase with disease severity, supporting their potential role as early biomarkers.

",MMP-9,serum,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Our findings suggest that both MMP-9 and NGAL serum levels are correlated with breast cancer progression since they seem to follow a gradual increase with disease severity, supporting their potential role as early biomarkers.

",NGAL,serum,1
"PMC 
BMC_Cancer_2010_Apr_27_10_161.txt
","Sex	
	
Male	111	4.52	0.187	0.852	
Female	67	4.48			
	
Nerve infiltration	
	
Yes	99	4.45	0.805	0.42	
No	70	4.64			
	
Lymph node metastasis	
	
Yes	36	4.69	0.731	0.466	
No	134	4.49			
	
Histological grades	F		
	
",Yes,Lymph,1
"PMC 
BMC_Cancer_2010_Apr_27_10_161.txt
","Sex	
	
Male	111	4.52	0.187	0.852	
Female	67	4.48			
	
Nerve infiltration	
	
Yes	99	4.45	0.805	0.42	
No	70	4.64			
	
Lymph node metastasis	
	
Yes	36	4.69	0.731	0.466	
No	134	4.49			
	
Histological grades	F		
	
",Yes,Lymph,1
"PMC 
BMC_Cancer_2009_Oct_14_9_364.txt
","Unknown	8331	7.6	7.3	8.5	6.2		
Number of positive lymph nodes				&#60;0.0001	
 None	60700	64.9	64.0	65.4	60.2		
 1-3	21948	22.8	23.2	21.9	23.9		
 >= 4	12896	12.3	12.8	12.7	16.0		
First course treatment received					
 Surgery	106076	95.3	94.5	93.6	93.8	&#60;0.0001	
 Radiation	58144	57.3	55.1	47.8	47.7	&#60;0.0001	
+ AJCC: American Joint Committee on Cancer.

",AJCC,lymph,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
",Serum TRACP 5b activity is a marker of osteoclast number and becomes elevated in the serum of individuals with increased bone turnover rate such as pre-pubertal children and post-menopausal women [9-11].,TRACP,Serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
",Serum TRACP 5b activity is a marker of osteoclast number and becomes elevated in the serum of individuals with increased bone turnover rate such as pre-pubertal children and post-menopausal women [9-11].,TRACP,serum,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","LNCaP cells were serum starved for 24 hr, pretreated with DMSO (control), Erlotinib (10 mM), MP470 (10 mM), or MP470-Erlotinib (10 mM each) for 2 hr, and then treated with pervanadate (100 mM) for 10 min.",MP470,serum,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","LNCaP cells were serum starved for 24 hr, pretreated with DMSO (control), Erlotinib (10 mM), MP470 (10 mM), or MP470-Erlotinib (10 mM each) for 2 hr, and then treated with pervanadate (100 mM) for 10 min.",DMSO,serum,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","LNCaP (a) and T47D (b) cells were serum starved for 24 hr, pretreated with 10 mM drug as indicated for 2 hr, and then treated with pervanadate (100 mM) for 10 min.",T47D,serum,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
",". LNCaP and NIH3T3 cells were serum-starved for 24 hr, pre-treated with Erlotinib or MP470 or IM, Erlotinib plus MP470 or Erlotinib plus IM at 2, 5 and 10 mM for 4 hr, and then treated for 10 min with 100 mM pervanadate, a global protein tyrosine phosphatase inhibitor that is commonly used to maintain tyrosine kinase phosphorylation in cells [36].",MP470,serum,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
",". LNCaP and NIH3T3 cells were serum-starved for 24 hr, pre-treated with Erlotinib or MP470 or IM, Erlotinib plus MP470 or Erlotinib plus IM at 2, 5 and 10 mM for 4 hr, and then treated for 10 min with 100 mM pervanadate, a global protein tyrosine phosphatase inhibitor that is commonly used to maintain tyrosine kinase phosphorylation in cells [36].",NIH3T3,serum,-1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
",". LNCaP and NIH3T3 cells were serum-starved for 24 hr, pre-treated with Erlotinib or MP470 or IM, Erlotinib plus MP470 or Erlotinib plus IM at 2, 5 and 10 mM for 4 hr, and then treated for 10 min with 100 mM pervanadate, a global protein tyrosine phosphatase inhibitor that is commonly used to maintain tyrosine kinase phosphorylation in cells [36].",MP470,serum,-1
"PMC 
BMC_Cancer_2010_Aug_12_10_422.txt
","DNA extraction and genotyping
Cases and controls were asked to provide 5 ml peripheral venous blood.",DNA,blood,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 3 Baseline characteristics among the 66 patients who received palliative systemic treatment

Characteristic	Frequency	%	
	Median (years)	54 (range, 22-78)	
Age	&#60;60	42	63.6	
	>= 60	24	36.4	
	
Sex	Male	41	62.1	
	Female	25	37.9	
	
	Absent	61	92.4	
Carcinoid symptom	Present	3	4.5	
	Unavailable	2	3.0	
	
	Pancreas	2	3.0	
	GI	15	22.7	
Origin	Lung	15	22.7	
	Etc.*	22	33.3	
	Unknown	12	18.2	
	
	Local	10	15.2	
Prior stage	Regional	9	13.6	
	Distant	47	71.2	
	
Grade	1	20	30.3	
	2	1	1.5	
	3	10	15.2	
	Large	8	12.1	
	Small	5	7.6	
	Unclassified	15	22.7	
	Unavailable	7	10.6	
	
	24-hour urine 5-HIAA (mmol/day)+	Median (range)	33.5 (6.8-341.2)	
		&#60;31.4	5	45.5%	
Biomarkers		>= 31.4	6	54.5%	
		Median (range)	1.36 (0.2-23.1)	
	Serum NSE (nmol/l)++	&#60;1.0	8	36.4%	
		>=",NSE,Serum,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 3 Baseline characteristics among the 66 patients who received palliative systemic treatment

Characteristic	Frequency	%	
	Median (years)	54 (range, 22-78)	
Age	&#60;60	42	63.6	
	>= 60	24	36.4	
	
Sex	Male	41	62.1	
	Female	25	37.9	
	
	Absent	61	92.4	
Carcinoid symptom	Present	3	4.5	
	Unavailable	2	3.0	
	
	Pancreas	2	3.0	
	GI	15	22.7	
Origin	Lung	15	22.7	
	Etc.*	22	33.3	
	Unknown	12	18.2	
	
	Local	10	15.2	
Prior stage	Regional	9	13.6	
	Distant	47	71.2	
	
Grade	1	20	30.3	
	2	1	1.5	
	3	10	15.2	
	Large	8	12.1	
	Small	5	7.6	
	Unclassified	15	22.7	
	Unavailable	7	10.6	
	
	24-hour urine 5-HIAA (mmol/day)+	Median (range)	33.5 (6.8-341.2)	
		&#60;31.4	5	45.5%	
Biomarkers		>= 31.4	6	54.5%	
		Median (range)	1.36 (0.2-23.1)	
	Serum NSE (nmol/l)++	&#60;1.0	8	36.4%	
		>=",NSE,urine,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","In the current study, we observed a significant increase between pre- and postoperative serum VEGF-165 levels (p = 0.01, Figure 1, Table 2).",VEGF-165,serum,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
",Cells [1 x 105] were plated in 24 well tissue culture plates in DMEM containing charcoal stripped foetal calf serum (CSFCS) and cultured for 24 hours before being infected with Ad-ERE-Luc at a MOI of 100.,ERE,serum,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
",Cells [1 x 105] were plated in 24 well tissue culture plates in DMEM containing charcoal stripped foetal calf serum (CSFCS) and cultured for 24 hours before being infected with Ad-ERE-Luc at a MOI of 100.,DMEM,serum,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
",Cells [1 x 105] were plated in 24 well tissue culture plates in DMEM containing charcoal stripped foetal calf serum (CSFCS) and cultured for 24 hours before being infected with Ad-ERE-Luc at a MOI of 100.,MOI,serum,1
"PMC 
BMC_Cancer_2009_Sep_16_9_330.txt
",Cells [1 x 105] were plated in 24 well tissue culture plates in DMEM containing charcoal stripped foetal calf serum (CSFCS) and cultured for 24 hours before being infected with Ad-ERE-Luc at a MOI of 100.,CSFCS,serum,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","In prostate cancer, Akt has been shown to be constitutively activated due to loss of PTEN, which negatively regulates PI3K. Clinical reports indicate that Akt is significantly over-expressed in prostate tumors compared to benign prostatic tissue, and its level is directly correlated with tumor progression and prostate-specific antigen (PSA) serum levels, as well as a higher Gleason score [23,26].",PTEN,serum,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","In prostate cancer, Akt has been shown to be constitutively activated due to loss of PTEN, which negatively regulates PI3K. Clinical reports indicate that Akt is significantly over-expressed in prostate tumors compared to benign prostatic tissue, and its level is directly correlated with tumor progression and prostate-specific antigen (PSA) serum levels, as well as a higher Gleason score [23,26].",PSA,serum,1
"PMC 
BMC_Cancer_2009_Nov_3_9_389.txt
","In a simple Cox model, the endpoints were found to be significantly associated with tumor size, serum AFP levels of alpha fetoprotein (AFP), total albumin concentration (ALBU), venous infiltration (VENINV), tumor stage (pTNM and AJCC), and the number of tumor nodule (NOTN).",AJCC,serum,1
"PMC 
BMC_Cancer_2009_Nov_3_9_389.txt
","In a simple Cox model, the endpoints were found to be significantly associated with tumor size, serum AFP levels of alpha fetoprotein (AFP), total albumin concentration (ALBU), venous infiltration (VENINV), tumor stage (pTNM and AJCC), and the number of tumor nodule (NOTN).",AFP,serum,1
"PMC 
BMC_Cancer_2009_Nov_3_9_389.txt
","In a simple Cox model, the endpoints were found to be significantly associated with tumor size, serum AFP levels of alpha fetoprotein (AFP), total albumin concentration (ALBU), venous infiltration (VENINV), tumor stage (pTNM and AJCC), and the number of tumor nodule (NOTN).",AFP,serum,1
"PMC 
BMC_Cancer_2009_Nov_3_9_389.txt
","In a simple Cox model, the endpoints were found to be significantly associated with tumor size, serum AFP levels of alpha fetoprotein (AFP), total albumin concentration (ALBU), venous infiltration (VENINV), tumor stage (pTNM and AJCC), and the number of tumor nodule (NOTN).",VENINV,serum,1
"PMC 
BMC_Cancer_2009_Nov_3_9_389.txt
","In a simple Cox model, the endpoints were found to be significantly associated with tumor size, serum AFP levels of alpha fetoprotein (AFP), total albumin concentration (ALBU), venous infiltration (VENINV), tumor stage (pTNM and AJCC), and the number of tumor nodule (NOTN).",NOTN,serum,1
"PMC 
BMC_Cancer_2009_Nov_3_9_389.txt
","In a simple Cox model, the endpoints were found to be significantly associated with tumor size, serum AFP levels of alpha fetoprotein (AFP), total albumin concentration (ALBU), venous infiltration (VENINV), tumor stage (pTNM and AJCC), and the number of tumor nodule (NOTN).",ALBU,serum,1
"PMC 
BMC_Cancer_2009_Nov_3_9_389.txt
","In a simple Cox model, the endpoints were found to be significantly associated with tumor size, serum AFP levels of alpha fetoprotein (AFP), total albumin concentration (ALBU), venous infiltration (VENINV), tumor stage (pTNM and AJCC), and the number of tumor nodule (NOTN).",pTNM,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
",In the current study we hypothesize that an elevated serum TRACP 5b activity may reflect a higher tumor burden and further signify a worse outcome in BC patients with bone metastasis.,TRACP,serum,1
"PMC 
BMC_Cancer_2010_Aug_18_10_439.txt
","Measurement of 8-OHdG levels
Baseline serum levels of 8-OHdG was measured using the commercially available 8-OHdG ELISA Kit (BIOXYTECH(r) OXIS International Inc., Foster City, CA, USA) following manufacturer's recommendations.",OXIS,serum,1
"PMC 
BMC_Cancer_2010_Aug_18_10_439.txt
","Measurement of 8-OHdG levels
Baseline serum levels of 8-OHdG was measured using the commercially available 8-OHdG ELISA Kit (BIOXYTECH(r) OXIS International Inc., Foster City, CA, USA) following manufacturer's recommendations.",USA,serum,1
"PMC 
BMC_Cancer_2010_Aug_18_10_439.txt
","Measurement of 8-OHdG levels
Baseline serum levels of 8-OHdG was measured using the commercially available 8-OHdG ELISA Kit (BIOXYTECH(r) OXIS International Inc., Foster City, CA, USA) following manufacturer's recommendations.",ELISA,serum,1
"PMC 
BMC_Cancer_2009_May_6_9_134.txt
","Moreover, we demonstrated that NGAL mRNA up-regulation correlated significantly with MMP-9 and some important clinicopathological characteristics such as depth of invasion, lymph node metastasis, venous involvement and advanced pTNM stage (p &#60; 0.05). Depth of invasion, lymph node metastasis and pTNM stage of rectal cancer have powerful predictive value to prognosis.",mRNA,lymph,1
"PMC 
BMC_Cancer_2009_May_6_9_134.txt
","Moreover, we demonstrated that NGAL mRNA up-regulation correlated significantly with MMP-9 and some important clinicopathological characteristics such as depth of invasion, lymph node metastasis, venous involvement and advanced pTNM stage (p &#60; 0.05). Depth of invasion, lymph node metastasis and pTNM stage of rectal cancer have powerful predictive value to prognosis.",mRNA,lymph,1
"PMC 
BMC_Cancer_2009_May_6_9_134.txt
","Moreover, we demonstrated that NGAL mRNA up-regulation correlated significantly with MMP-9 and some important clinicopathological characteristics such as depth of invasion, lymph node metastasis, venous involvement and advanced pTNM stage (p &#60; 0.05). Depth of invasion, lymph node metastasis and pTNM stage of rectal cancer have powerful predictive value to prognosis.",pTNM,lymph,1
"PMC 
BMC_Cancer_2009_May_6_9_134.txt
","Moreover, we demonstrated that NGAL mRNA up-regulation correlated significantly with MMP-9 and some important clinicopathological characteristics such as depth of invasion, lymph node metastasis, venous involvement and advanced pTNM stage (p &#60; 0.05). Depth of invasion, lymph node metastasis and pTNM stage of rectal cancer have powerful predictive value to prognosis.",pTNM,lymph,1
"PMC 
BMC_Cancer_2009_May_6_9_134.txt
","Moreover, we demonstrated that NGAL mRNA up-regulation correlated significantly with MMP-9 and some important clinicopathological characteristics such as depth of invasion, lymph node metastasis, venous involvement and advanced pTNM stage (p &#60; 0.05). Depth of invasion, lymph node metastasis and pTNM stage of rectal cancer have powerful predictive value to prognosis.",MMP-9,lymph,1
"PMC 
BMC_Cancer_2009_May_6_9_134.txt
","Moreover, we demonstrated that NGAL mRNA up-regulation correlated significantly with MMP-9 and some important clinicopathological characteristics such as depth of invasion, lymph node metastasis, venous involvement and advanced pTNM stage (p &#60; 0.05). Depth of invasion, lymph node metastasis and pTNM stage of rectal cancer have powerful predictive value to prognosis.",MMP-9,lymph,1
"PMC 
BMC_Cancer_2009_May_6_9_134.txt
","Moreover, we demonstrated that NGAL mRNA up-regulation correlated significantly with MMP-9 and some important clinicopathological characteristics such as depth of invasion, lymph node metastasis, venous involvement and advanced pTNM stage (p &#60; 0.05). Depth of invasion, lymph node metastasis and pTNM stage of rectal cancer have powerful predictive value to prognosis.",pTNM,lymph,1
"PMC 
BMC_Cancer_2009_May_6_9_134.txt
","Moreover, we demonstrated that NGAL mRNA up-regulation correlated significantly with MMP-9 and some important clinicopathological characteristics such as depth of invasion, lymph node metastasis, venous involvement and advanced pTNM stage (p &#60; 0.05). Depth of invasion, lymph node metastasis and pTNM stage of rectal cancer have powerful predictive value to prognosis.",pTNM,lymph,1
"PMC 
BMC_Cancer_2009_May_6_9_134.txt
","Moreover, we demonstrated that NGAL mRNA up-regulation correlated significantly with MMP-9 and some important clinicopathological characteristics such as depth of invasion, lymph node metastasis, venous involvement and advanced pTNM stage (p &#60; 0.05). Depth of invasion, lymph node metastasis and pTNM stage of rectal cancer have powerful predictive value to prognosis.",NGAL,lymph,1
"PMC 
BMC_Cancer_2009_May_6_9_134.txt
","Moreover, we demonstrated that NGAL mRNA up-regulation correlated significantly with MMP-9 and some important clinicopathological characteristics such as depth of invasion, lymph node metastasis, venous involvement and advanced pTNM stage (p &#60; 0.05). Depth of invasion, lymph node metastasis and pTNM stage of rectal cancer have powerful predictive value to prognosis.",NGAL,lymph,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Response (% decrease of CA-125)	
		
	p-value	correlation coefficient r	
TIMP-1 before surgery	0.375	0.174	
	
TIMP-1 before CTX	0.150	0.265	
	
TIMP-1 during CTX	0.480	0.127	
	
TIMP-1 after CTX	0.554	0.107	
	
VEGF before surgery	0.725	-0.07	
	
VEGF before CTX	0.729	0.065	
	
VEGF during CTX	0.414	-0.147	
	
VEGF after CTX	0.671	-0.077	
P-values according to the Pearson correlation coefficients using continous serum values and relative decrease of CA-125.

",TIMP-1,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Response (% decrease of CA-125)	
		
	p-value	correlation coefficient r	
TIMP-1 before surgery	0.375	0.174	
	
TIMP-1 before CTX	0.150	0.265	
	
TIMP-1 during CTX	0.480	0.127	
	
TIMP-1 after CTX	0.554	0.107	
	
VEGF before surgery	0.725	-0.07	
	
VEGF before CTX	0.729	0.065	
	
VEGF during CTX	0.414	-0.147	
	
VEGF after CTX	0.671	-0.077	
P-values according to the Pearson correlation coefficients using continous serum values and relative decrease of CA-125.

",CA-125,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Response (% decrease of CA-125)	
		
	p-value	correlation coefficient r	
TIMP-1 before surgery	0.375	0.174	
	
TIMP-1 before CTX	0.150	0.265	
	
TIMP-1 during CTX	0.480	0.127	
	
TIMP-1 after CTX	0.554	0.107	
	
VEGF before surgery	0.725	-0.07	
	
VEGF before CTX	0.729	0.065	
	
VEGF during CTX	0.414	-0.147	
	
VEGF after CTX	0.671	-0.077	
P-values according to the Pearson correlation coefficients using continous serum values and relative decrease of CA-125.

",VEGF,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Response (% decrease of CA-125)	
		
	p-value	correlation coefficient r	
TIMP-1 before surgery	0.375	0.174	
	
TIMP-1 before CTX	0.150	0.265	
	
TIMP-1 during CTX	0.480	0.127	
	
TIMP-1 after CTX	0.554	0.107	
	
VEGF before surgery	0.725	-0.07	
	
VEGF before CTX	0.729	0.065	
	
VEGF during CTX	0.414	-0.147	
	
VEGF after CTX	0.671	-0.077	
P-values according to the Pearson correlation coefficients using continous serum values and relative decrease of CA-125.

",VEGF,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Response (% decrease of CA-125)	
		
	p-value	correlation coefficient r	
TIMP-1 before surgery	0.375	0.174	
	
TIMP-1 before CTX	0.150	0.265	
	
TIMP-1 during CTX	0.480	0.127	
	
TIMP-1 after CTX	0.554	0.107	
	
VEGF before surgery	0.725	-0.07	
	
VEGF before CTX	0.729	0.065	
	
VEGF during CTX	0.414	-0.147	
	
VEGF after CTX	0.671	-0.077	
P-values according to the Pearson correlation coefficients using continous serum values and relative decrease of CA-125.

",CTX,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Response (% decrease of CA-125)	
		
	p-value	correlation coefficient r	
TIMP-1 before surgery	0.375	0.174	
	
TIMP-1 before CTX	0.150	0.265	
	
TIMP-1 during CTX	0.480	0.127	
	
TIMP-1 after CTX	0.554	0.107	
	
VEGF before surgery	0.725	-0.07	
	
VEGF before CTX	0.729	0.065	
	
VEGF during CTX	0.414	-0.147	
	
VEGF after CTX	0.671	-0.077	
P-values according to the Pearson correlation coefficients using continous serum values and relative decrease of CA-125.

",CTX,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Response (% decrease of CA-125)	
		
	p-value	correlation coefficient r	
TIMP-1 before surgery	0.375	0.174	
	
TIMP-1 before CTX	0.150	0.265	
	
TIMP-1 during CTX	0.480	0.127	
	
TIMP-1 after CTX	0.554	0.107	
	
VEGF before surgery	0.725	-0.07	
	
VEGF before CTX	0.729	0.065	
	
VEGF during CTX	0.414	-0.147	
	
VEGF after CTX	0.671	-0.077	
P-values according to the Pearson correlation coefficients using continous serum values and relative decrease of CA-125.

",TIMP-1,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Response (% decrease of CA-125)	
		
	p-value	correlation coefficient r	
TIMP-1 before surgery	0.375	0.174	
	
TIMP-1 before CTX	0.150	0.265	
	
TIMP-1 during CTX	0.480	0.127	
	
TIMP-1 after CTX	0.554	0.107	
	
VEGF before surgery	0.725	-0.07	
	
VEGF before CTX	0.729	0.065	
	
VEGF during CTX	0.414	-0.147	
	
VEGF after CTX	0.671	-0.077	
P-values according to the Pearson correlation coefficients using continous serum values and relative decrease of CA-125.

",CA-125,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Response (% decrease of CA-125)	
		
	p-value	correlation coefficient r	
TIMP-1 before surgery	0.375	0.174	
	
TIMP-1 before CTX	0.150	0.265	
	
TIMP-1 during CTX	0.480	0.127	
	
TIMP-1 after CTX	0.554	0.107	
	
VEGF before surgery	0.725	-0.07	
	
VEGF before CTX	0.729	0.065	
	
VEGF during CTX	0.414	-0.147	
	
VEGF after CTX	0.671	-0.077	
P-values according to the Pearson correlation coefficients using continous serum values and relative decrease of CA-125.

",VEGF,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Response (% decrease of CA-125)	
		
	p-value	correlation coefficient r	
TIMP-1 before surgery	0.375	0.174	
	
TIMP-1 before CTX	0.150	0.265	
	
TIMP-1 during CTX	0.480	0.127	
	
TIMP-1 after CTX	0.554	0.107	
	
VEGF before surgery	0.725	-0.07	
	
VEGF before CTX	0.729	0.065	
	
VEGF during CTX	0.414	-0.147	
	
VEGF after CTX	0.671	-0.077	
P-values according to the Pearson correlation coefficients using continous serum values and relative decrease of CA-125.

",VEGF,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Response (% decrease of CA-125)	
		
	p-value	correlation coefficient r	
TIMP-1 before surgery	0.375	0.174	
	
TIMP-1 before CTX	0.150	0.265	
	
TIMP-1 during CTX	0.480	0.127	
	
TIMP-1 after CTX	0.554	0.107	
	
VEGF before surgery	0.725	-0.07	
	
VEGF before CTX	0.729	0.065	
	
VEGF during CTX	0.414	-0.147	
	
VEGF after CTX	0.671	-0.077	
P-values according to the Pearson correlation coefficients using continous serum values and relative decrease of CA-125.

",CTX,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Response (% decrease of CA-125)	
		
	p-value	correlation coefficient r	
TIMP-1 before surgery	0.375	0.174	
	
TIMP-1 before CTX	0.150	0.265	
	
TIMP-1 during CTX	0.480	0.127	
	
TIMP-1 after CTX	0.554	0.107	
	
VEGF before surgery	0.725	-0.07	
	
VEGF before CTX	0.729	0.065	
	
VEGF during CTX	0.414	-0.147	
	
VEGF after CTX	0.671	-0.077	
P-values according to the Pearson correlation coefficients using continous serum values and relative decrease of CA-125.

",CTX,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Response (% decrease of CA-125)	
		
	p-value	correlation coefficient r	
TIMP-1 before surgery	0.375	0.174	
	
TIMP-1 before CTX	0.150	0.265	
	
TIMP-1 during CTX	0.480	0.127	
	
TIMP-1 after CTX	0.554	0.107	
	
VEGF before surgery	0.725	-0.07	
	
VEGF before CTX	0.729	0.065	
	
VEGF during CTX	0.414	-0.147	
	
VEGF after CTX	0.671	-0.077	
P-values according to the Pearson correlation coefficients using continous serum values and relative decrease of CA-125.

",CTX,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Response (% decrease of CA-125)	
		
	p-value	correlation coefficient r	
TIMP-1 before surgery	0.375	0.174	
	
TIMP-1 before CTX	0.150	0.265	
	
TIMP-1 during CTX	0.480	0.127	
	
TIMP-1 after CTX	0.554	0.107	
	
VEGF before surgery	0.725	-0.07	
	
VEGF before CTX	0.729	0.065	
	
VEGF during CTX	0.414	-0.147	
	
VEGF after CTX	0.671	-0.077	
P-values according to the Pearson correlation coefficients using continous serum values and relative decrease of CA-125.

",CTX,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Response (% decrease of CA-125)	
		
	p-value	correlation coefficient r	
TIMP-1 before surgery	0.375	0.174	
	
TIMP-1 before CTX	0.150	0.265	
	
TIMP-1 during CTX	0.480	0.127	
	
TIMP-1 after CTX	0.554	0.107	
	
VEGF before surgery	0.725	-0.07	
	
VEGF before CTX	0.729	0.065	
	
VEGF during CTX	0.414	-0.147	
	
VEGF after CTX	0.671	-0.077	
P-values according to the Pearson correlation coefficients using continous serum values and relative decrease of CA-125.

",TIMP-1,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Response (% decrease of CA-125)	
		
	p-value	correlation coefficient r	
TIMP-1 before surgery	0.375	0.174	
	
TIMP-1 before CTX	0.150	0.265	
	
TIMP-1 during CTX	0.480	0.127	
	
TIMP-1 after CTX	0.554	0.107	
	
VEGF before surgery	0.725	-0.07	
	
VEGF before CTX	0.729	0.065	
	
VEGF during CTX	0.414	-0.147	
	
VEGF after CTX	0.671	-0.077	
P-values according to the Pearson correlation coefficients using continous serum values and relative decrease of CA-125.

",TIMP-1,serum,1
"PMC 
BMC_Cancer_2009_Nov_20_9_406.txt
","DNA and RNA isolation and cDNA synthesis
Control DNA samples were obtained from peripheral blood samples.",cDNA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_20_9_406.txt
","DNA and RNA isolation and cDNA synthesis
Control DNA samples were obtained from peripheral blood samples.",DNA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_20_9_406.txt
","DNA and RNA isolation and cDNA synthesis
Control DNA samples were obtained from peripheral blood samples.",RNA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_20_9_406.txt
","DNA and RNA isolation and cDNA synthesis
Control DNA samples were obtained from peripheral blood samples.",DNA,blood,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","Also, the number of EPCs (positive for Sca-1, Flk-1 and c-Kit) in the blood and liver of cirrhotic mice were determined by flow cytometry and immunohistochemistry.",Flk-1,blood,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","Also, the number of EPCs (positive for Sca-1, Flk-1 and c-Kit) in the blood and liver of cirrhotic mice were determined by flow cytometry and immunohistochemistry.",Sca-1,blood,-1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-1381942649410.1186/1471-2407-9-138Research Articled-ALA-D activity is a reliable marker for oxidative stress in bone marrow transplant patients Goncalves Thissiane L 12thissianegoncalves@yahoo.com.brBenvegnu Dalila M 2dalilabenvegnu@yahoo.com.brBonfanti Gabriela 2gabibonfanti@yahoo.com.brFrediani Andressa V 1dessinhaf@yahoo.com.brRocha Joao Batista T 1jbtrocha@yahoo.com.br1 Departamento de Quimica, CCNE, Universidade Federal de Santa Maria, Santa Maria, R.S., Brazil2 Departamento de Analises Clinicas e Toxicologicas, CCS, Universidade Federal de Santa Maria, Santa Maria, RS, Brazil2009 8 5 2009 9 138 138 26 9 2008 8 5 2009 Copyright (c)2009 Goncalves et al; licensee",T,bone marrow,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-1381942649410.1186/1471-2407-9-138Research Articled-ALA-D activity is a reliable marker for oxidative stress in bone marrow transplant patients Goncalves Thissiane L 12thissianegoncalves@yahoo.com.brBenvegnu Dalila M 2dalilabenvegnu@yahoo.com.brBonfanti Gabriela 2gabibonfanti@yahoo.com.brFrediani Andressa V 1dessinhaf@yahoo.com.brRocha Joao Batista T 1jbtrocha@yahoo.com.br1 Departamento de Quimica, CCNE, Universidade Federal de Santa Maria, Santa Maria, R.S., Brazil2 Departamento de Analises Clinicas e Toxicologicas, CCS, Universidade Federal de Santa Maria, Santa Maria, RS, Brazil2009 8 5 2009 9 138 138 26 9 2008 8 5 2009 Copyright (c)2009 Goncalves et al; licensee",Brazil2009,bone marrow,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-1381942649410.1186/1471-2407-9-138Research Articled-ALA-D activity is a reliable marker for oxidative stress in bone marrow transplant patients Goncalves Thissiane L 12thissianegoncalves@yahoo.com.brBenvegnu Dalila M 2dalilabenvegnu@yahoo.com.brBonfanti Gabriela 2gabibonfanti@yahoo.com.brFrediani Andressa V 1dessinhaf@yahoo.com.brRocha Joao Batista T 1jbtrocha@yahoo.com.br1 Departamento de Quimica, CCNE, Universidade Federal de Santa Maria, Santa Maria, R.S., Brazil2 Departamento de Analises Clinicas e Toxicologicas, CCS, Universidade Federal de Santa Maria, Santa Maria, RS, Brazil2009 8 5 2009 9 138 138 26 9 2008 8 5 2009 Copyright (c)2009 Goncalves et al; licensee",RS,bone marrow,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-1381942649410.1186/1471-2407-9-138Research Articled-ALA-D activity is a reliable marker for oxidative stress in bone marrow transplant patients Goncalves Thissiane L 12thissianegoncalves@yahoo.com.brBenvegnu Dalila M 2dalilabenvegnu@yahoo.com.brBonfanti Gabriela 2gabibonfanti@yahoo.com.brFrediani Andressa V 1dessinhaf@yahoo.com.brRocha Joao Batista T 1jbtrocha@yahoo.com.br1 Departamento de Quimica, CCNE, Universidade Federal de Santa Maria, Santa Maria, R.S., Brazil2 Departamento de Analises Clinicas e Toxicologicas, CCS, Universidade Federal de Santa Maria, Santa Maria, RS, Brazil2009 8 5 2009 9 138 138 26 9 2008 8 5 2009 Copyright (c)2009 Goncalves et al; licensee",Brazil2,bone marrow,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-1381942649410.1186/1471-2407-9-138Research Articled-ALA-D activity is a reliable marker for oxidative stress in bone marrow transplant patients Goncalves Thissiane L 12thissianegoncalves@yahoo.com.brBenvegnu Dalila M 2dalilabenvegnu@yahoo.com.brBonfanti Gabriela 2gabibonfanti@yahoo.com.brFrediani Andressa V 1dessinhaf@yahoo.com.brRocha Joao Batista T 1jbtrocha@yahoo.com.br1 Departamento de Quimica, CCNE, Universidade Federal de Santa Maria, Santa Maria, R.S., Brazil2 Departamento de Analises Clinicas e Toxicologicas, CCS, Universidade Federal de Santa Maria, Santa Maria, RS, Brazil2009 8 5 2009 9 138 138 26 9 2008 8 5 2009 Copyright (c)2009 Goncalves et al; licensee",CCNE,bone marrow,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-1381942649410.1186/1471-2407-9-138Research Articled-ALA-D activity is a reliable marker for oxidative stress in bone marrow transplant patients Goncalves Thissiane L 12thissianegoncalves@yahoo.com.brBenvegnu Dalila M 2dalilabenvegnu@yahoo.com.brBonfanti Gabriela 2gabibonfanti@yahoo.com.brFrediani Andressa V 1dessinhaf@yahoo.com.brRocha Joao Batista T 1jbtrocha@yahoo.com.br1 Departamento de Quimica, CCNE, Universidade Federal de Santa Maria, Santa Maria, R.S., Brazil2 Departamento de Analises Clinicas e Toxicologicas, CCS, Universidade Federal de Santa Maria, Santa Maria, RS, Brazil2009 8 5 2009 9 138 138 26 9 2008 8 5 2009 Copyright (c)2009 Goncalves et al; licensee",BMC,bone marrow,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-1381942649410.1186/1471-2407-9-138Research Articled-ALA-D activity is a reliable marker for oxidative stress in bone marrow transplant patients Goncalves Thissiane L 12thissianegoncalves@yahoo.com.brBenvegnu Dalila M 2dalilabenvegnu@yahoo.com.brBonfanti Gabriela 2gabibonfanti@yahoo.com.brFrediani Andressa V 1dessinhaf@yahoo.com.brRocha Joao Batista T 1jbtrocha@yahoo.com.br1 Departamento de Quimica, CCNE, Universidade Federal de Santa Maria, Santa Maria, R.S., Brazil2 Departamento de Analises Clinicas e Toxicologicas, CCS, Universidade Federal de Santa Maria, Santa Maria, RS, Brazil2009 8 5 2009 9 138 138 26 9 2008 8 5 2009 Copyright (c)2009 Goncalves et al; licensee",Cancer1471,bone marrow,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-1381942649410.1186/1471-2407-9-138Research Articled-ALA-D activity is a reliable marker for oxidative stress in bone marrow transplant patients Goncalves Thissiane L 12thissianegoncalves@yahoo.com.brBenvegnu Dalila M 2dalilabenvegnu@yahoo.com.brBonfanti Gabriela 2gabibonfanti@yahoo.com.brFrediani Andressa V 1dessinhaf@yahoo.com.brRocha Joao Batista T 1jbtrocha@yahoo.com.br1 Departamento de Quimica, CCNE, Universidade Federal de Santa Maria, Santa Maria, R.S., Brazil2 Departamento de Analises Clinicas e Toxicologicas, CCS, Universidade Federal de Santa Maria, Santa Maria, RS, Brazil2009 8 5 2009 9 138 138 26 9 2008 8 5 2009 Copyright (c)2009 Goncalves et al; licensee",CCS,bone marrow,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","When subgroups according to adjuvant treatment were analyzed separately we found no significant associations between TIMP-1 and age, number of tumor-positive lymph nodes, tumor size, grade, adjuvant RT, or type of surgery in any of the subgroups.",TIMP-1,lymph,1
"PMC 
BMC_Cancer_2010_Aug_17_10_437.txt
","Results
Expression of NF-kB p65 in Primary SCCHN Tumors and Lymph Node Metastases
The expression of NF-kB p65 in primary SCCHN tumors and lymph node metastases was examined using immunohistochemistry.",SCCHN,Lymph,1
"PMC 
BMC_Cancer_2010_Aug_17_10_437.txt
","Results
Expression of NF-kB p65 in Primary SCCHN Tumors and Lymph Node Metastases
The expression of NF-kB p65 in primary SCCHN tumors and lymph node metastases was examined using immunohistochemistry.",SCCHN,lymph,1
"PMC 
BMC_Cancer_2010_Aug_17_10_437.txt
","Results
Expression of NF-kB p65 in Primary SCCHN Tumors and Lymph Node Metastases
The expression of NF-kB p65 in primary SCCHN tumors and lymph node metastases was examined using immunohistochemistry.",p65,Lymph,1
"PMC 
BMC_Cancer_2010_Aug_17_10_437.txt
","Results
Expression of NF-kB p65 in Primary SCCHN Tumors and Lymph Node Metastases
The expression of NF-kB p65 in primary SCCHN tumors and lymph node metastases was examined using immunohistochemistry.",p65,lymph,1
"PMC 
BMC_Cancer_2010_Aug_17_10_437.txt
","Results
Expression of NF-kB p65 in Primary SCCHN Tumors and Lymph Node Metastases
The expression of NF-kB p65 in primary SCCHN tumors and lymph node metastases was examined using immunohistochemistry.",SCCHN,Lymph,1
"PMC 
BMC_Cancer_2010_Aug_17_10_437.txt
","Results
Expression of NF-kB p65 in Primary SCCHN Tumors and Lymph Node Metastases
The expression of NF-kB p65 in primary SCCHN tumors and lymph node metastases was examined using immunohistochemistry.",SCCHN,lymph,1
"PMC 
BMC_Cancer_2010_Aug_17_10_437.txt
","Results
Expression of NF-kB p65 in Primary SCCHN Tumors and Lymph Node Metastases
The expression of NF-kB p65 in primary SCCHN tumors and lymph node metastases was examined using immunohistochemistry.",p65,Lymph,1
"PMC 
BMC_Cancer_2010_Aug_17_10_437.txt
","Results
Expression of NF-kB p65 in Primary SCCHN Tumors and Lymph Node Metastases
The expression of NF-kB p65 in primary SCCHN tumors and lymph node metastases was examined using immunohistochemistry.",p65,lymph,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3701983563110.1186/1471-2407-9-370Research ArticleClinical relevance of nine transcriptional molecular markers for the diagnosis of head and neck squamous cell carcinoma in tissue and saliva rinse Lallemant Benjamin 1234benjamin.lallemant@chu-nimes.frEvrard Alexandre 2345alexandre.evrard@univ-montp1.frCombescure Christophe 67christophe.combescure@hcuge.chChapuis Heliette 8heliette.chapuis@chu-nimes.frChambon Guillaume 1guillaume.chambon@chu-nimes.frRaynal Caroline 2345caroline.raynal@univ-montp1.frReynaud Christophe 1christophe.reynaud@chu-nimes.frSabra Omar 1sabraomar@hotmail.comJoubert Dominique 234djoubert@igf.cnrs.frHollande Frederic 234frederic.hollande@univ-montp1.frLallemant Jean-Gabriel 1jean.gabriel.lallemant@chu-nimes.frLumbroso Serge 2345serge.lumbroso@chu-nimes.frBrouillet Jean-Paul 2345jean.paul.brouillet@chu-nimes.fr1 Service d'ORL et Chirurgie Maxillo-faciale, Centre Hospitalier Universitaire de Nimes, Place du Pr.",Pr,saliva,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3701983563110.1186/1471-2407-9-370Research ArticleClinical relevance of nine transcriptional molecular markers for the diagnosis of head and neck squamous cell carcinoma in tissue and saliva rinse Lallemant Benjamin 1234benjamin.lallemant@chu-nimes.frEvrard Alexandre 2345alexandre.evrard@univ-montp1.frCombescure Christophe 67christophe.combescure@hcuge.chChapuis Heliette 8heliette.chapuis@chu-nimes.frChambon Guillaume 1guillaume.chambon@chu-nimes.frRaynal Caroline 2345caroline.raynal@univ-montp1.frReynaud Christophe 1christophe.reynaud@chu-nimes.frSabra Omar 1sabraomar@hotmail.comJoubert Dominique 234djoubert@igf.cnrs.frHollande Frederic 234frederic.hollande@univ-montp1.frLallemant Jean-Gabriel 1jean.gabriel.lallemant@chu-nimes.frLumbroso Serge 2345serge.lumbroso@chu-nimes.frBrouillet Jean-Paul 2345jean.paul.brouillet@chu-nimes.fr1 Service d'ORL et Chirurgie Maxillo-faciale, Centre Hospitalier Universitaire de Nimes, Place du Pr.",BMC,saliva,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-3701983563110.1186/1471-2407-9-370Research ArticleClinical relevance of nine transcriptional molecular markers for the diagnosis of head and neck squamous cell carcinoma in tissue and saliva rinse Lallemant Benjamin 1234benjamin.lallemant@chu-nimes.frEvrard Alexandre 2345alexandre.evrard@univ-montp1.frCombescure Christophe 67christophe.combescure@hcuge.chChapuis Heliette 8heliette.chapuis@chu-nimes.frChambon Guillaume 1guillaume.chambon@chu-nimes.frRaynal Caroline 2345caroline.raynal@univ-montp1.frReynaud Christophe 1christophe.reynaud@chu-nimes.frSabra Omar 1sabraomar@hotmail.comJoubert Dominique 234djoubert@igf.cnrs.frHollande Frederic 234frederic.hollande@univ-montp1.frLallemant Jean-Gabriel 1jean.gabriel.lallemant@chu-nimes.frLumbroso Serge 2345serge.lumbroso@chu-nimes.frBrouillet Jean-Paul 2345jean.paul.brouillet@chu-nimes.fr1 Service d'ORL et Chirurgie Maxillo-faciale, Centre Hospitalier Universitaire de Nimes, Place du Pr.",Cancer1471,saliva,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Moreover, we found a significant consecutive decrease of serum VEGF-165 during chemotherapy (p &#60; 0.001).",VEGF-165,serum,1
"PMC 
BMC_Cancer_2010_Aug_19_10_444.txt
","The gels were pre-run before loading of serum-free CM and run overnight at 4degC at 50 V. Gels were briefly washed and incubated at 37degC overnight for gel degradation (washing buffers: 2 x 30 min with 50 mM Tris-HCl pH 7.5, 2.5% Triton X-100 and 2 x 10 min in 50 mM Tris-HCl pH 7.5.",X-100,serum,-1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","The aim of our study is to evaluate the serum levels of MMP-9, NGAL and MMP-9/NGAL complex in patients with breast abnormalities and investigate their correlation with breast disease severity.

",NGAL,serum,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","The aim of our study is to evaluate the serum levels of MMP-9, NGAL and MMP-9/NGAL complex in patients with breast abnormalities and investigate their correlation with breast disease severity.

",MMP-9,serum,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","It has thus been suggested that MMP-9 and NGAL are mainly secreted in blood by neutrophils infiltrating the tumor, and are separately excreted in urine where they subsequently form complexes [22].",MMP-9,blood,-1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","It has thus been suggested that MMP-9 and NGAL are mainly secreted in blood by neutrophils infiltrating the tumor, and are separately excreted in urine where they subsequently form complexes [22].",MMP-9,urine,-1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","It has thus been suggested that MMP-9 and NGAL are mainly secreted in blood by neutrophils infiltrating the tumor, and are separately excreted in urine where they subsequently form complexes [22].",NGAL,blood,-1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","It has thus been suggested that MMP-9 and NGAL are mainly secreted in blood by neutrophils infiltrating the tumor, and are separately excreted in urine where they subsequently form complexes [22].",NGAL,urine,-1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","Methods
Study population
We analyzed retrospectively biochemical and clinical data from 100 BC patients with newly diagnosed bone metastasis who had participated in our previous studies of serum TRACP 5b activity in BC [12,13].",TRACP,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","The serum samples and controls were diluted 1:10 (VEGF-165) and 1:50 (TIMP-1) with sample diluent buffer (containing bovine serum albumin, buffer salts and 0.09% sodium acide).",VEGF-165,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","The serum samples and controls were diluted 1:10 (VEGF-165) and 1:50 (TIMP-1) with sample diluent buffer (containing bovine serum albumin, buffer salts and 0.09% sodium acide).",VEGF-165,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","The serum samples and controls were diluted 1:10 (VEGF-165) and 1:50 (TIMP-1) with sample diluent buffer (containing bovine serum albumin, buffer salts and 0.09% sodium acide).",TIMP-1,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","The serum samples and controls were diluted 1:10 (VEGF-165) and 1:50 (TIMP-1) with sample diluent buffer (containing bovine serum albumin, buffer salts and 0.09% sodium acide).",TIMP-1,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","patients	37	
Age (years)		
	
mean	58	
	
median	61	
	
range	26-78	
	
FIGO-Stage		
	
I	1	
	
II	1	
	
III	29	
	
IV	6	
	
Histologic subtype		
	
serous	31	
	
endometriod	1	
	
clear cell	1	
	
undifferentiated	4	
	
Grading		
	
1	0	
	
2	9	
	
3	27	
	
not determined/unknown	1	
	
Lymph node metastasis		
	
pN0	11	
	
pN1	18	
	
NX	8	
	
Perioperative Ascites		
	
&#60;500 ml	15	
	
&#62;500 ml	21	
	
not determined	1	
	
Residual tumor after surgery		
	
microscopic	22	
	
macroscopic	14	
	
not determined	1	
	
Survival (months)		
	
progression-free survival		
	
mean	20	
	
median	16	
	
range	2-71	
	
overall survival		
	
mean	36	
	
median	32	
	
range	8-98	
Serum samples
Serum samples were collected at 4 predefined time-points: 1. before surgery (within 7 days before surgery); 2.",FIGO,Serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","patients	37	
Age (years)		
	
mean	58	
	
median	61	
	
range	26-78	
	
FIGO-Stage		
	
I	1	
	
II	1	
	
III	29	
	
IV	6	
	
Histologic subtype		
	
serous	31	
	
endometriod	1	
	
clear cell	1	
	
undifferentiated	4	
	
Grading		
	
1	0	
	
2	9	
	
3	27	
	
not determined/unknown	1	
	
Lymph node metastasis		
	
pN0	11	
	
pN1	18	
	
NX	8	
	
Perioperative Ascites		
	
&#60;500 ml	15	
	
&#62;500 ml	21	
	
not determined	1	
	
Residual tumor after surgery		
	
microscopic	22	
	
macroscopic	14	
	
not determined	1	
	
Survival (months)		
	
progression-free survival		
	
mean	20	
	
median	16	
	
range	2-71	
	
overall survival		
	
mean	36	
	
median	32	
	
range	8-98	
Serum samples
Serum samples were collected at 4 predefined time-points: 1. before surgery (within 7 days before surgery); 2.",FIGO,Lymph,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","patients	37	
Age (years)		
	
mean	58	
	
median	61	
	
range	26-78	
	
FIGO-Stage		
	
I	1	
	
II	1	
	
III	29	
	
IV	6	
	
Histologic subtype		
	
serous	31	
	
endometriod	1	
	
clear cell	1	
	
undifferentiated	4	
	
Grading		
	
1	0	
	
2	9	
	
3	27	
	
not determined/unknown	1	
	
Lymph node metastasis		
	
pN0	11	
	
pN1	18	
	
NX	8	
	
Perioperative Ascites		
	
&#60;500 ml	15	
	
&#62;500 ml	21	
	
not determined	1	
	
Residual tumor after surgery		
	
microscopic	22	
	
macroscopic	14	
	
not determined	1	
	
Survival (months)		
	
progression-free survival		
	
mean	20	
	
median	16	
	
range	2-71	
	
overall survival		
	
mean	36	
	
median	32	
	
range	8-98	
Serum samples
Serum samples were collected at 4 predefined time-points: 1. before surgery (within 7 days before surgery); 2.",FIGO,Ascites,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","patients	37	
Age (years)		
	
mean	58	
	
median	61	
	
range	26-78	
	
FIGO-Stage		
	
I	1	
	
II	1	
	
III	29	
	
IV	6	
	
Histologic subtype		
	
serous	31	
	
endometriod	1	
	
clear cell	1	
	
undifferentiated	4	
	
Grading		
	
1	0	
	
2	9	
	
3	27	
	
not determined/unknown	1	
	
Lymph node metastasis		
	
pN0	11	
	
pN1	18	
	
NX	8	
	
Perioperative Ascites		
	
&#60;500 ml	15	
	
&#62;500 ml	21	
	
not determined	1	
	
Residual tumor after surgery		
	
microscopic	22	
	
macroscopic	14	
	
not determined	1	
	
Survival (months)		
	
progression-free survival		
	
mean	20	
	
median	16	
	
range	2-71	
	
overall survival		
	
mean	36	
	
median	32	
	
range	8-98	
Serum samples
Serum samples were collected at 4 predefined time-points: 1. before surgery (within 7 days before surgery); 2.",FIGO,Serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","patients	37	
Age (years)		
	
mean	58	
	
median	61	
	
range	26-78	
	
FIGO-Stage		
	
I	1	
	
II	1	
	
III	29	
	
IV	6	
	
Histologic subtype		
	
serous	31	
	
endometriod	1	
	
clear cell	1	
	
undifferentiated	4	
	
Grading		
	
1	0	
	
2	9	
	
3	27	
	
not determined/unknown	1	
	
Lymph node metastasis		
	
pN0	11	
	
pN1	18	
	
NX	8	
	
Perioperative Ascites		
	
&#60;500 ml	15	
	
&#62;500 ml	21	
	
not determined	1	
	
Residual tumor after surgery		
	
microscopic	22	
	
macroscopic	14	
	
not determined	1	
	
Survival (months)		
	
progression-free survival		
	
mean	20	
	
median	16	
	
range	2-71	
	
overall survival		
	
mean	36	
	
median	32	
	
range	8-98	
Serum samples
Serum samples were collected at 4 predefined time-points: 1. before surgery (within 7 days before surgery); 2.",pN1,Serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","patients	37	
Age (years)		
	
mean	58	
	
median	61	
	
range	26-78	
	
FIGO-Stage		
	
I	1	
	
II	1	
	
III	29	
	
IV	6	
	
Histologic subtype		
	
serous	31	
	
endometriod	1	
	
clear cell	1	
	
undifferentiated	4	
	
Grading		
	
1	0	
	
2	9	
	
3	27	
	
not determined/unknown	1	
	
Lymph node metastasis		
	
pN0	11	
	
pN1	18	
	
NX	8	
	
Perioperative Ascites		
	
&#60;500 ml	15	
	
&#62;500 ml	21	
	
not determined	1	
	
Residual tumor after surgery		
	
microscopic	22	
	
macroscopic	14	
	
not determined	1	
	
Survival (months)		
	
progression-free survival		
	
mean	20	
	
median	16	
	
range	2-71	
	
overall survival		
	
mean	36	
	
median	32	
	
range	8-98	
Serum samples
Serum samples were collected at 4 predefined time-points: 1. before surgery (within 7 days before surgery); 2.",pN1,Lymph,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","patients	37	
Age (years)		
	
mean	58	
	
median	61	
	
range	26-78	
	
FIGO-Stage		
	
I	1	
	
II	1	
	
III	29	
	
IV	6	
	
Histologic subtype		
	
serous	31	
	
endometriod	1	
	
clear cell	1	
	
undifferentiated	4	
	
Grading		
	
1	0	
	
2	9	
	
3	27	
	
not determined/unknown	1	
	
Lymph node metastasis		
	
pN0	11	
	
pN1	18	
	
NX	8	
	
Perioperative Ascites		
	
&#60;500 ml	15	
	
&#62;500 ml	21	
	
not determined	1	
	
Residual tumor after surgery		
	
microscopic	22	
	
macroscopic	14	
	
not determined	1	
	
Survival (months)		
	
progression-free survival		
	
mean	20	
	
median	16	
	
range	2-71	
	
overall survival		
	
mean	36	
	
median	32	
	
range	8-98	
Serum samples
Serum samples were collected at 4 predefined time-points: 1. before surgery (within 7 days before surgery); 2.",pN1,Ascites,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","patients	37	
Age (years)		
	
mean	58	
	
median	61	
	
range	26-78	
	
FIGO-Stage		
	
I	1	
	
II	1	
	
III	29	
	
IV	6	
	
Histologic subtype		
	
serous	31	
	
endometriod	1	
	
clear cell	1	
	
undifferentiated	4	
	
Grading		
	
1	0	
	
2	9	
	
3	27	
	
not determined/unknown	1	
	
Lymph node metastasis		
	
pN0	11	
	
pN1	18	
	
NX	8	
	
Perioperative Ascites		
	
&#60;500 ml	15	
	
&#62;500 ml	21	
	
not determined	1	
	
Residual tumor after surgery		
	
microscopic	22	
	
macroscopic	14	
	
not determined	1	
	
Survival (months)		
	
progression-free survival		
	
mean	20	
	
median	16	
	
range	2-71	
	
overall survival		
	
mean	36	
	
median	32	
	
range	8-98	
Serum samples
Serum samples were collected at 4 predefined time-points: 1. before surgery (within 7 days before surgery); 2.",pN1,Serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","patients	37	
Age (years)		
	
mean	58	
	
median	61	
	
range	26-78	
	
FIGO-Stage		
	
I	1	
	
II	1	
	
III	29	
	
IV	6	
	
Histologic subtype		
	
serous	31	
	
endometriod	1	
	
clear cell	1	
	
undifferentiated	4	
	
Grading		
	
1	0	
	
2	9	
	
3	27	
	
not determined/unknown	1	
	
Lymph node metastasis		
	
pN0	11	
	
pN1	18	
	
NX	8	
	
Perioperative Ascites		
	
&#60;500 ml	15	
	
&#62;500 ml	21	
	
not determined	1	
	
Residual tumor after surgery		
	
microscopic	22	
	
macroscopic	14	
	
not determined	1	
	
Survival (months)		
	
progression-free survival		
	
mean	20	
	
median	16	
	
range	2-71	
	
overall survival		
	
mean	36	
	
median	32	
	
range	8-98	
Serum samples
Serum samples were collected at 4 predefined time-points: 1. before surgery (within 7 days before surgery); 2.",III,Serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","patients	37	
Age (years)		
	
mean	58	
	
median	61	
	
range	26-78	
	
FIGO-Stage		
	
I	1	
	
II	1	
	
III	29	
	
IV	6	
	
Histologic subtype		
	
serous	31	
	
endometriod	1	
	
clear cell	1	
	
undifferentiated	4	
	
Grading		
	
1	0	
	
2	9	
	
3	27	
	
not determined/unknown	1	
	
Lymph node metastasis		
	
pN0	11	
	
pN1	18	
	
NX	8	
	
Perioperative Ascites		
	
&#60;500 ml	15	
	
&#62;500 ml	21	
	
not determined	1	
	
Residual tumor after surgery		
	
microscopic	22	
	
macroscopic	14	
	
not determined	1	
	
Survival (months)		
	
progression-free survival		
	
mean	20	
	
median	16	
	
range	2-71	
	
overall survival		
	
mean	36	
	
median	32	
	
range	8-98	
Serum samples
Serum samples were collected at 4 predefined time-points: 1. before surgery (within 7 days before surgery); 2.",III,Lymph,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","patients	37	
Age (years)		
	
mean	58	
	
median	61	
	
range	26-78	
	
FIGO-Stage		
	
I	1	
	
II	1	
	
III	29	
	
IV	6	
	
Histologic subtype		
	
serous	31	
	
endometriod	1	
	
clear cell	1	
	
undifferentiated	4	
	
Grading		
	
1	0	
	
2	9	
	
3	27	
	
not determined/unknown	1	
	
Lymph node metastasis		
	
pN0	11	
	
pN1	18	
	
NX	8	
	
Perioperative Ascites		
	
&#60;500 ml	15	
	
&#62;500 ml	21	
	
not determined	1	
	
Residual tumor after surgery		
	
microscopic	22	
	
macroscopic	14	
	
not determined	1	
	
Survival (months)		
	
progression-free survival		
	
mean	20	
	
median	16	
	
range	2-71	
	
overall survival		
	
mean	36	
	
median	32	
	
range	8-98	
Serum samples
Serum samples were collected at 4 predefined time-points: 1. before surgery (within 7 days before surgery); 2.",III,Ascites,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","patients	37	
Age (years)		
	
mean	58	
	
median	61	
	
range	26-78	
	
FIGO-Stage		
	
I	1	
	
II	1	
	
III	29	
	
IV	6	
	
Histologic subtype		
	
serous	31	
	
endometriod	1	
	
clear cell	1	
	
undifferentiated	4	
	
Grading		
	
1	0	
	
2	9	
	
3	27	
	
not determined/unknown	1	
	
Lymph node metastasis		
	
pN0	11	
	
pN1	18	
	
NX	8	
	
Perioperative Ascites		
	
&#60;500 ml	15	
	
&#62;500 ml	21	
	
not determined	1	
	
Residual tumor after surgery		
	
microscopic	22	
	
macroscopic	14	
	
not determined	1	
	
Survival (months)		
	
progression-free survival		
	
mean	20	
	
median	16	
	
range	2-71	
	
overall survival		
	
mean	36	
	
median	32	
	
range	8-98	
Serum samples
Serum samples were collected at 4 predefined time-points: 1. before surgery (within 7 days before surgery); 2.",III,Serum,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
",Jin et al. implemented 2-D Fluorescence Difference Gel Electrophoresis (2-D DIGE) and MALDI-TOF-MS to analyze the serum proteins in patients with OS.,DIGE,serum,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
",Jin et al. implemented 2-D Fluorescence Difference Gel Electrophoresis (2-D DIGE) and MALDI-TOF-MS to analyze the serum proteins in patients with OS.,OS,serum,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
",Jin et al. implemented 2-D Fluorescence Difference Gel Electrophoresis (2-D DIGE) and MALDI-TOF-MS to analyze the serum proteins in patients with OS.,MALDI,serum,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
",Jin et al. implemented 2-D Fluorescence Difference Gel Electrophoresis (2-D DIGE) and MALDI-TOF-MS to analyze the serum proteins in patients with OS.,TOF,serum,1
"PMC 
BMC_Cancer_2009_Mar_27_9_96.txt
","By using one-dimensional chromatographic separations and linear ion trap MS detection, the quantitation of 5 intermediate-abundance serum proteins by MRM, with good precision and accuracy, at ~1-30 mg/mL levels, was reported [27].

",MRM,serum,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Methods
Lipid peroxidation, vitamin C and thiol group levels as well as catalase, superoxide dismutase and d-ALA-D activity were determined in 37 healthy controls, 13 patients undergoing autologous peripheral blood stem cell transplantation and 24 patients undergoing allogeneic BMT.

",BMT,blood,-1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
",Cox proportional regression model was used to evaluate the correlation between the overall survival time (OS) and baseline serum TRACP 5b activity and its interval changes.,OS,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
",Cox proportional regression model was used to evaluate the correlation between the overall survival time (OS) and baseline serum TRACP 5b activity and its interval changes.,TRACP,serum,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","MMP1 overexpression is the most promising marker, and its detection could help identify tumor cells in tissue or saliva.
",MMP1,saliva,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Background
Bone marrow transplantation (BMT) is often used in the treatment of various diseases.",BMT,Bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Therefore, MMP-9 detection in sera could provide significant information of the tumor biological features.",MMP-9,sera,1
"PMC 
BMC_Cancer_2010_Aug_18_10_439.txt
","This kit is a competitive ELISA for quantitative measurement of 8-OHdG in tissue, serum or plasma resulting from oxidative damage to DNA.

",ELISA,serum,1
"PMC 
BMC_Cancer_2010_Aug_18_10_439.txt
","This kit is a competitive ELISA for quantitative measurement of 8-OHdG in tissue, serum or plasma resulting from oxidative damage to DNA.

",ELISA,plasma,1
"PMC 
BMC_Cancer_2010_Aug_18_10_439.txt
","This kit is a competitive ELISA for quantitative measurement of 8-OHdG in tissue, serum or plasma resulting from oxidative damage to DNA.

",DNA,serum,1
"PMC 
BMC_Cancer_2010_Aug_18_10_439.txt
","This kit is a competitive ELISA for quantitative measurement of 8-OHdG in tissue, serum or plasma resulting from oxidative damage to DNA.

",DNA,plasma,1
"PMC 
BMC_Cancer_2009_Nov_17_9_400.txt
",These having hepatitis B surface antigen (HBsAg)-positive and anti-HCV-positive in their peripheral serum were defined as groups infected HBV and HCV.,HCV,serum,1
"PMC 
BMC_Cancer_2009_Nov_17_9_400.txt
",These having hepatitis B surface antigen (HBsAg)-positive and anti-HCV-positive in their peripheral serum were defined as groups infected HBV and HCV.,HCV,serum,1
"PMC 
BMC_Cancer_2009_Nov_17_9_400.txt
",These having hepatitis B surface antigen (HBsAg)-positive and anti-HCV-positive in their peripheral serum were defined as groups infected HBV and HCV.,HBV,serum,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Moreover, blood d-ALA-D activity seems to be an additional biomarker of oxidative stress in BMT patients.
",BMT,blood,1
"PMC 
BMC_Cancer_2009_Oct_20_9_374.txt
","All media was supplemented with 10% fetal bovine serum (JRH Biosciences), 2 mM L-glutamine (Gibco) and Penicillin-Streptomycin solution (0.1 U/mL penicillin and 0.1 mg/mL streptomycin) (Gibco), except for the HT29 cells which were cultured in 0.72 mM L-glutamine.

",HT29,serum,1
"PMC 
BMC_Cancer_2009_Oct_20_9_374.txt
","All media was supplemented with 10% fetal bovine serum (JRH Biosciences), 2 mM L-glutamine (Gibco) and Penicillin-Streptomycin solution (0.1 U/mL penicillin and 0.1 mg/mL streptomycin) (Gibco), except for the HT29 cells which were cultured in 0.72 mM L-glutamine.

",JRH,serum,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
",Another possible explanation could be that DNA repair status in non-stimulated whole blood cells are less active than stimulated whole blood cells to remove this kind of DNA damage [48].,DNA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
",Another possible explanation could be that DNA repair status in non-stimulated whole blood cells are less active than stimulated whole blood cells to remove this kind of DNA damage [48].,DNA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
",Another possible explanation could be that DNA repair status in non-stimulated whole blood cells are less active than stimulated whole blood cells to remove this kind of DNA damage [48].,DNA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
",Another possible explanation could be that DNA repair status in non-stimulated whole blood cells are less active than stimulated whole blood cells to remove this kind of DNA damage [48].,DNA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","With the purpose to quantified apurinic or apyrimidine (AP) sites we employed a specific restriction enzyme. Etoposide effects were determined on whole blood cells cultured in absence or presence of phytohemagglutinin (PHA) treated during 2 and 24 hours of cultured.

",PHA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Results
Alkaline (pH &#62; 13) single cell gel electrophoresis (SCGE) assay experiments revealed etoposide-induced increases in DNA damage in phytohemaglutinine (PHA)-stimulated blood and non-stimulated blood cells.",SCGE,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Results
Alkaline (pH &#62; 13) single cell gel electrophoresis (SCGE) assay experiments revealed etoposide-induced increases in DNA damage in phytohemaglutinine (PHA)-stimulated blood and non-stimulated blood cells.",SCGE,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Results
Alkaline (pH &#62; 13) single cell gel electrophoresis (SCGE) assay experiments revealed etoposide-induced increases in DNA damage in phytohemaglutinine (PHA)-stimulated blood and non-stimulated blood cells.",DNA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Results
Alkaline (pH &#62; 13) single cell gel electrophoresis (SCGE) assay experiments revealed etoposide-induced increases in DNA damage in phytohemaglutinine (PHA)-stimulated blood and non-stimulated blood cells.",DNA,blood,-1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","Therefore we divided our patients into subgroups arbitrarily by the scale of baseline TRACP 5b activities, i.e. top 1/3 versus remaining 2/3 with the cutoff value of 5.736 U/L. We indeed found that those patients with baseline serum TRACP 5b activity higher than 5.736 U/L had a significantly shorter survival than the remainders.

",TRACP,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","Therefore we divided our patients into subgroups arbitrarily by the scale of baseline TRACP 5b activities, i.e. top 1/3 versus remaining 2/3 with the cutoff value of 5.736 U/L. We indeed found that those patients with baseline serum TRACP 5b activity higher than 5.736 U/L had a significantly shorter survival than the remainders.

",TRACP,serum,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Conclusion
Our results indicate that etoposide induces DNA damage specifically at DNA-AP sites in quiescent blood cells.",DNA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Conclusion
Our results indicate that etoposide induces DNA damage specifically at DNA-AP sites in quiescent blood cells.",DNA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","When the assay was performed at a less alkaline pH, 12.3, we observed DNA damage in PHA-stimulated blood cells consistent with the existence of alkali labile sites (ALSs).",DNA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","When the assay was performed at a less alkaline pH, 12.3, we observed DNA damage in PHA-stimulated blood cells consistent with the existence of alkali labile sites (ALSs).",PHA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Conclusion
In summary, our data show that etoposide can produce differential forms of DNA damage in PHA-stimulated and non-stimulated blood cells.",PHA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Conclusion
In summary, our data show that etoposide can produce differential forms of DNA damage in PHA-stimulated and non-stimulated blood cells.",DNA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","It is our view that the induction of damage at DNA-AP sites observed in non-stimulated whole blood cells herein was due to interaction of the drug metabolites with cellular targets beyond topoisomerase IIb (which was not present at high levels), such as DNA and/or proteins.",DNA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","It is our view that the induction of damage at DNA-AP sites observed in non-stimulated whole blood cells herein was due to interaction of the drug metabolites with cellular targets beyond topoisomerase IIb (which was not present at high levels), such as DNA and/or proteins.",DNA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","More DNA AP-sites were revealed by Exo III and ALSs were recognized by the SCGE assay only in the non-stimulated blood cells treated with etoposide.

",DNA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","More DNA AP-sites were revealed by Exo III and ALSs were recognized by the SCGE assay only in the non-stimulated blood cells treated with etoposide.

",III,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","More DNA AP-sites were revealed by Exo III and ALSs were recognized by the SCGE assay only in the non-stimulated blood cells treated with etoposide.

",SCGE,blood,-1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","The OS in patients with the highest one-third of serum TRACP 5b activity was significantly longer (HR = 3.524; p &#60; 0.001) than for those with the lower two-thirds of serum TRACP 5b (Table 2, Figure 1).",TRACP,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","The OS in patients with the highest one-third of serum TRACP 5b activity was significantly longer (HR = 3.524; p &#60; 0.001) than for those with the lower two-thirds of serum TRACP 5b (Table 2, Figure 1).",TRACP,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","The OS in patients with the highest one-third of serum TRACP 5b activity was significantly longer (HR = 3.524; p &#60; 0.001) than for those with the lower two-thirds of serum TRACP 5b (Table 2, Figure 1).",HR,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","The OS in patients with the highest one-third of serum TRACP 5b activity was significantly longer (HR = 3.524; p &#60; 0.001) than for those with the lower two-thirds of serum TRACP 5b (Table 2, Figure 1).",HR,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","The OS in patients with the highest one-third of serum TRACP 5b activity was significantly longer (HR = 3.524; p &#60; 0.001) than for those with the lower two-thirds of serum TRACP 5b (Table 2, Figure 1).",OS,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","The OS in patients with the highest one-third of serum TRACP 5b activity was significantly longer (HR = 3.524; p &#60; 0.001) than for those with the lower two-thirds of serum TRACP 5b (Table 2, Figure 1).",OS,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","The OS in patients with the highest one-third of serum TRACP 5b activity was significantly longer (HR = 3.524; p &#60; 0.001) than for those with the lower two-thirds of serum TRACP 5b (Table 2, Figure 1).",TRACP,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","The OS in patients with the highest one-third of serum TRACP 5b activity was significantly longer (HR = 3.524; p &#60; 0.001) than for those with the lower two-thirds of serum TRACP 5b (Table 2, Figure 1).",TRACP,serum,1
"PMC 
BMC_Cancer_2010_Aug_17_10_437.txt
","Worldwide, more than 650,000 new cases with HNC are diagnosed every year [2], and two-thirds of patients with HNC present with locally advanced lesions and/or regional lymph node involvement.",HNC,lymph,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_437.txt
","Worldwide, more than 650,000 new cases with HNC are diagnosed every year [2], and two-thirds of patients with HNC present with locally advanced lesions and/or regional lymph node involvement.",HNC,lymph,-1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
",M-200: melphalan (200 mg/m2) given only 1 day (day minus 3) before the transplantation for multiple myeloma in autologous peripheral blood stem cell transplantation (PBSCT) or allogeneic BMT.,PBSCT,blood,-1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
",M-200: melphalan (200 mg/m2) given only 1 day (day minus 3) before the transplantation for multiple myeloma in autologous peripheral blood stem cell transplantation (PBSCT) or allogeneic BMT.,M-200,blood,-1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
",M-200: melphalan (200 mg/m2) given only 1 day (day minus 3) before the transplantation for multiple myeloma in autologous peripheral blood stem cell transplantation (PBSCT) or allogeneic BMT.,BMT,blood,-1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Sample collection
Blood (4 mL) was collected during routine examinations by venous arm puncture in EDTA vaccutainer tubes in the Hematology and Oncology Laboratory.",EDTA,Blood,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","The subjects included in the study were classified in three groups: Group I - Control: healthy volunteers of HUSM Blood Bank served as control group and they were receiving no treatment for any diseases; Group II (autol.): autologous PBSCT patients; Group III (allog.): allogeneic BMT patients.

",PBSCT,Blood,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","The subjects included in the study were classified in three groups: Group I - Control: healthy volunteers of HUSM Blood Bank served as control group and they were receiving no treatment for any diseases; Group II (autol.): autologous PBSCT patients; Group III (allog.): allogeneic BMT patients.

",III,Blood,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","The subjects included in the study were classified in three groups: Group I - Control: healthy volunteers of HUSM Blood Bank served as control group and they were receiving no treatment for any diseases; Group II (autol.): autologous PBSCT patients; Group III (allog.): allogeneic BMT patients.

",BMT,Blood,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","The subjects included in the study were classified in three groups: Group I - Control: healthy volunteers of HUSM Blood Bank served as control group and they were receiving no treatment for any diseases; Group II (autol.): autologous PBSCT patients; Group III (allog.): allogeneic BMT patients.

",HUSM,Blood,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Thus, treatment with anthracycline-based chemotherapy appears to be associated with a very small benefit in both TIMP-1 high and low patients but it should be kept in mind that the anthracycline-treated subgroup is characterized by very poor prognostic features (larger tumors, many tumor-involved lymph nodes, Table 1).",TIMP-1,lymph,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","At the time of diagnosis of metastatic/recurrent disease, the median value of 5-hydroxyindoleacetic acid (5-HIAA) from 24-hour urine samples was 23.0 mmol/day (range, 2.6-1324.6) and the median value of serum levels for neuron-specific enolase (NSE) was 1.6",NSE,urine,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","At the time of diagnosis of metastatic/recurrent disease, the median value of 5-hydroxyindoleacetic acid (5-HIAA) from 24-hour urine samples was 23.0 mmol/day (range, 2.6-1324.6) and the median value of serum levels for neuron-specific enolase (NSE) was 1.6",NSE,serum,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","These results demonstrate oxidative DNA damage generated by etoposide in non-stimulated blood cells, among others sources of ALS generation [35].

",ALS,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","These results demonstrate oxidative DNA damage generated by etoposide in non-stimulated blood cells, among others sources of ALS generation [35].

",DNA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Table 1 Viability of non-stimulated and PHA-stimulated blood cells treated with etoposide as determined by dual-cell stain method.

",PHA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Results
Viability
Our observations of the cells following the dual cell-stain method for PHA-stimulated and non-stimulated whole blood cells revealed that cell viability was high after etoposide treatment for 2 h and 24 h. As shown in table 1, we observed cell viability rates that exceeded 70%.

",PHA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
",Figure 2 DNA damage in non-stimulated and PHA-stimulated blood cells caused by 2-h and 24-h etoposide treatment at the indicated doses detected by Comet Assay at pH = 12.3.,DNA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
",Figure 2 DNA damage in non-stimulated and PHA-stimulated blood cells caused by 2-h and 24-h etoposide treatment at the indicated doses detected by Comet Assay at pH = 12.3.,PHA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","However, SCGE assay performed at pH 12.3, which detect SSBs and DRSs, but not ALSs, showed genotoxic effects in the PHA-stimulated whole blood cells only at both treatment durations (Figure 2).",PHA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","However, SCGE assay performed at pH 12.3, which detect SSBs and DRSs, but not ALSs, showed genotoxic effects in the PHA-stimulated whole blood cells only at both treatment durations (Figure 2).",SCGE,blood,-1
"PMC 
BMC_Cancer_2009_May_8_9_137.txt
","Written informed consent was obtained from all study subjects, after which each subject provided a venous blood sample that was collected into EDTA-coated tubes.",EDTA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","According to our findings, serum levels of MMP-9, NGAL, and MMP-9/NGAL were not associated with obesity since no correlation with patients' BMI was observed.

",BMI,serum,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","According to our findings, serum levels of MMP-9, NGAL, and MMP-9/NGAL were not associated with obesity since no correlation with patients' BMI was observed.

",NGAL,serum,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","According to our findings, serum levels of MMP-9, NGAL, and MMP-9/NGAL were not associated with obesity since no correlation with patients' BMI was observed.

",MMP-9,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-1641947662910.1186/1471-2407-9-164Research ArticleDo serum biomarkers really measure breast cancer?",BMC,serum,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-9-1641947662910.1186/1471-2407-9-164Research ArticleDo serum biomarkers really measure breast cancer?",Cancer1471,serum,1
"PMC 
BMC_Cancer_2010_Apr_16_10_145.txt
","0.02a			
	2-5 cm	36	52.9%	22	35.9%				
	&#62;5 cm	8	11.8%	9	4.7%				
	unknown	0		4					
	
Lymph node status	N0	33	50.8%	39	67.2%	0.06a			
	N1	21	32.3%	17	29.3%				
	N2	9	13.8%	1	1.7%				
	N3	2	3.1%	",N1,Lymph,1
"PMC 
BMC_Cancer_2010_Apr_16_10_145.txt
","0.02a			
	2-5 cm	36	52.9%	22	35.9%				
	&#62;5 cm	8	11.8%	9	4.7%				
	unknown	0		4					
	
Lymph node status	N0	33	50.8%	39	67.2%	0.06a			
	N1	21	32.3%	17	29.3%				
	N2	9	13.8%	1	1.7%				
	N3	2	3.1%	",N0,Lymph,1
"PMC 
BMC_Cancer_2010_Apr_16_10_145.txt
","0.02a			
	2-5 cm	36	52.9%	22	35.9%				
	&#62;5 cm	8	11.8%	9	4.7%				
	unknown	0		4					
	
Lymph node status	N0	33	50.8%	39	67.2%	0.06a			
	N1	21	32.3%	17	29.3%				
	N2	9	13.8%	1	1.7%				
	N3	2	3.1%	",N2,Lymph,1
"PMC 
BMC_Cancer_2010_Apr_16_10_145.txt
","0.02a			
	2-5 cm	36	52.9%	22	35.9%				
	&#62;5 cm	8	11.8%	9	4.7%				
	unknown	0		4					
	
Lymph node status	N0	33	50.8%	39	67.2%	0.06a			
	N1	21	32.3%	17	29.3%				
	N2	9	13.8%	1	1.7%				
	N3	2	3.1%	",N3,Lymph,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Blood d-ALA-D activities in groups II and III were not significantly different from each other (table 6).

",III,Blood,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Table 6 Blood d-Aminolevulinate dehydratase (d-ALA-D) activity over time

Groups	Before CR	CR	Day 10 after
BMT	Day 20 after
BMT	
Group I
(control)	",CR,Blood,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Table 6 Blood d-Aminolevulinate dehydratase (d-ALA-D) activity over time

Groups	Before CR	CR	Day 10 after
BMT	Day 20 after
BMT	
Group I
(control)	",BMT,Blood,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Table 6 Blood d-Aminolevulinate dehydratase (d-ALA-D) activity over time

Groups	Before CR	CR	Day 10 after
BMT	Day 20 after
BMT	
Group I
(control)	",CR,Blood,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Table 6 Blood d-Aminolevulinate dehydratase (d-ALA-D) activity over time

Groups	Before CR	CR	Day 10 after
BMT	Day 20 after
BMT	
Group I
(control)	",BMT,Blood,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
","To make the complete growth medium, add the following components to the base medium: 0.3 mg/ml G418, fetal bovine serum to a final concentration of 10%.",G418,serum,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
","Furthermore, significant decrease of CYC-1 protein was observed in serum samples of 3 of 4 patients after surgical removal of the tumor.",CYC-1,serum,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
","In this study, we found that the levels of CYC-1 in serum samples from OS patients were higher than those from healthy controls.",OS,serum,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
","In this study, we found that the levels of CYC-1 in serum samples from OS patients were higher than those from healthy controls.",CYC-1,serum,1
"PMC 
BMC_Cancer_2009_Sep_3_9_310.txt
","Higher tumor stage [hazard ratio (HR), 1.92; 95% confidence interval (95% CI), 1.14-3.23] and presence of lymph node metastasis (HR, 2.17; 95% CI 1.59-2.95) were significantly and independently associated with death.

",HR,lymph,1
"PMC 
BMC_Cancer_2009_Sep_3_9_310.txt
","Higher tumor stage [hazard ratio (HR), 1.92; 95% confidence interval (95% CI), 1.14-3.23] and presence of lymph node metastasis (HR, 2.17; 95% CI 1.59-2.95) were significantly and independently associated with death.

",HR,lymph,1
"PMC 
BMC_Cancer_2009_Sep_3_9_310.txt
","Higher tumor stage [hazard ratio (HR), 1.92; 95% confidence interval (95% CI), 1.14-3.23] and presence of lymph node metastasis (HR, 2.17; 95% CI 1.59-2.95) were significantly and independently associated with death.

",CI,lymph,1
"PMC 
BMC_Cancer_2009_Sep_3_9_310.txt
","Higher tumor stage [hazard ratio (HR), 1.92; 95% confidence interval (95% CI), 1.14-3.23] and presence of lymph node metastasis (HR, 2.17; 95% CI 1.59-2.95) were significantly and independently associated with death.

",CI,lymph,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
","Using this method, we identified a number of potential biomarkers for OS and further confirmed our findings by analyzing serum samples from patients with OS.

",OS,serum,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
","Using this method, we identified a number of potential biomarkers for OS and further confirmed our findings by analyzing serum samples from patients with OS.

",OS,serum,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
","OS originates from stroma osteoblast in human bone marrow, and it is difficult to obtain the control corresponding to the OS tissue.",OS,bone marrow,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
","OS originates from stroma osteoblast in human bone marrow, and it is difficult to obtain the control corresponding to the OS tissue.",OS,bone marrow,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
","Since the intrinsic characters of OS differ from other cancers such as liver cancer and prostate cancer, OS cell lines were chosen rather than peripheral blood mononuclear cells and tissue samples for gene microarray analysis.",OS,blood,-1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
","Since the intrinsic characters of OS differ from other cancers such as liver cancer and prostate cancer, OS cell lines were chosen rather than peripheral blood mononuclear cells and tissue samples for gene microarray analysis.",OS,blood,-1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
","The complete growth medium for MG-63 was ATCC-formulated Eagle's Minimum Essential Medium, supplemented with 10% heat-inactivated fetal bovine serum.",MG-63,serum,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
","The complete growth medium for MG-63 was ATCC-formulated Eagle's Minimum Essential Medium, supplemented with 10% heat-inactivated fetal bovine serum.",ATCC,serum,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","The blood collected for IL-6 serum level assessments was collected in plain tubes, and the levels of serum IL-6 were measured using commercially available enzyme-linked immunosorbent assays (ELISAs) (Quantikine h IL-6 Immunoassay, R&D Systems, USA).",IL-6,blood,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","The blood collected for IL-6 serum level assessments was collected in plain tubes, and the levels of serum IL-6 were measured using commercially available enzyme-linked immunosorbent assays (ELISAs) (Quantikine h IL-6 Immunoassay, R&D Systems, USA).",IL-6,serum,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","The blood collected for IL-6 serum level assessments was collected in plain tubes, and the levels of serum IL-6 were measured using commercially available enzyme-linked immunosorbent assays (ELISAs) (Quantikine h IL-6 Immunoassay, R&D Systems, USA).",IL-6,serum,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","The blood collected for IL-6 serum level assessments was collected in plain tubes, and the levels of serum IL-6 were measured using commercially available enzyme-linked immunosorbent assays (ELISAs) (Quantikine h IL-6 Immunoassay, R&D Systems, USA).",IL-6,blood,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","The blood collected for IL-6 serum level assessments was collected in plain tubes, and the levels of serum IL-6 were measured using commercially available enzyme-linked immunosorbent assays (ELISAs) (Quantikine h IL-6 Immunoassay, R&D Systems, USA).",IL-6,serum,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","The blood collected for IL-6 serum level assessments was collected in plain tubes, and the levels of serum IL-6 were measured using commercially available enzyme-linked immunosorbent assays (ELISAs) (Quantikine h IL-6 Immunoassay, R&D Systems, USA).",IL-6,serum,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","The blood collected for IL-6 serum level assessments was collected in plain tubes, and the levels of serum IL-6 were measured using commercially available enzyme-linked immunosorbent assays (ELISAs) (Quantikine h IL-6 Immunoassay, R&D Systems, USA).",IL-6,blood,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","The blood collected for IL-6 serum level assessments was collected in plain tubes, and the levels of serum IL-6 were measured using commercially available enzyme-linked immunosorbent assays (ELISAs) (Quantikine h IL-6 Immunoassay, R&D Systems, USA).",IL-6,serum,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","The blood collected for IL-6 serum level assessments was collected in plain tubes, and the levels of serum IL-6 were measured using commercially available enzyme-linked immunosorbent assays (ELISAs) (Quantikine h IL-6 Immunoassay, R&D Systems, USA).",IL-6,serum,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","The blood collected for IL-6 serum level assessments was collected in plain tubes, and the levels of serum IL-6 were measured using commercially available enzyme-linked immunosorbent assays (ELISAs) (Quantikine h IL-6 Immunoassay, R&D Systems, USA).",USA,blood,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","The blood collected for IL-6 serum level assessments was collected in plain tubes, and the levels of serum IL-6 were measured using commercially available enzyme-linked immunosorbent assays (ELISAs) (Quantikine h IL-6 Immunoassay, R&D Systems, USA).",USA,serum,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","The blood collected for IL-6 serum level assessments was collected in plain tubes, and the levels of serum IL-6 were measured using commercially available enzyme-linked immunosorbent assays (ELISAs) (Quantikine h IL-6 Immunoassay, R&D Systems, USA).",USA,serum,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
","SELDI-TOF-MS analysis
Serum samples were analyzed by SELDI-TOF mass spectrometry using the CM10 protein chip of Ciphergen (Fremont, CA, USA).",SELDI,Serum,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
","SELDI-TOF-MS analysis
Serum samples were analyzed by SELDI-TOF mass spectrometry using the CM10 protein chip of Ciphergen (Fremont, CA, USA).",TOF,Serum,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
","SELDI-TOF-MS analysis
Serum samples were analyzed by SELDI-TOF mass spectrometry using the CM10 protein chip of Ciphergen (Fremont, CA, USA).",SELDI,Serum,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
","SELDI-TOF-MS analysis
Serum samples were analyzed by SELDI-TOF mass spectrometry using the CM10 protein chip of Ciphergen (Fremont, CA, USA).",USA,Serum,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
","SELDI-TOF-MS analysis
Serum samples were analyzed by SELDI-TOF mass spectrometry using the CM10 protein chip of Ciphergen (Fremont, CA, USA).",TOF,Serum,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
","SELDI-TOF-MS analysis
Serum samples were analyzed by SELDI-TOF mass spectrometry using the CM10 protein chip of Ciphergen (Fremont, CA, USA).",CM10,Serum,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Our results also document a positive correlation between MMP-9 serum levels and the severity score of breast disease (p &#60; 0.006).

",MMP-9,serum,1
"PMC 
BMC_Cancer_2009_Oct_20_9_374.txt
","For example, such biomarkers could be assayed for individuals at high risk of CRC in non-invasive tissues such as blood or stool.",CRC,blood,-1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Finally, rising CA-125 does not always precede disease recurrence, thus, additional serum markers are required.

",CA-125,serum,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","(1542.29/1998.24)	1803.36
(1271.20/1932.00)	
CR: conditioning regimen; BMT: bone marrow transplantation; Units - NP-SH: nmol NP-SH/mL erythrocytes.",CR,bone marrow,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","(1542.29/1998.24)	1803.36
(1271.20/1932.00)	
CR: conditioning regimen; BMT: bone marrow transplantation; Units - NP-SH: nmol NP-SH/mL erythrocytes.",NP,bone marrow,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","(1542.29/1998.24)	1803.36
(1271.20/1932.00)	
CR: conditioning regimen; BMT: bone marrow transplantation; Units - NP-SH: nmol NP-SH/mL erythrocytes.",NP,bone marrow,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","(1542.29/1998.24)	1803.36
(1271.20/1932.00)	
CR: conditioning regimen; BMT: bone marrow transplantation; Units - NP-SH: nmol NP-SH/mL erythrocytes.",BMT,bone marrow,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","3.67(2.14/5.52)	2.31(1.56/3.10)ac	1.91(1.49/2.42)ac	2.20(1.36/2.70)ac	
CR: conditioning regimen; BMT: bone marrow transplantation; Units-ALA-D: nmol PBG/ml blood/h.

",BMT,blood,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","3.67(2.14/5.52)	2.31(1.56/3.10)ac	1.91(1.49/2.42)ac	2.20(1.36/2.70)ac	
CR: conditioning regimen; BMT: bone marrow transplantation; Units-ALA-D: nmol PBG/ml blood/h.

",BMT,bone marrow,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","3.67(2.14/5.52)	2.31(1.56/3.10)ac	1.91(1.49/2.42)ac	2.20(1.36/2.70)ac	
CR: conditioning regimen; BMT: bone marrow transplantation; Units-ALA-D: nmol PBG/ml blood/h.

",CR,blood,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","3.67(2.14/5.52)	2.31(1.56/3.10)ac	1.91(1.49/2.42)ac	2.20(1.36/2.70)ac	
CR: conditioning regimen; BMT: bone marrow transplantation; Units-ALA-D: nmol PBG/ml blood/h.

",CR,bone marrow,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","3.67(2.14/5.52)	2.31(1.56/3.10)ac	1.91(1.49/2.42)ac	2.20(1.36/2.70)ac	
CR: conditioning regimen; BMT: bone marrow transplantation; Units-ALA-D: nmol PBG/ml blood/h.

",PBG,blood,-1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","3.67(2.14/5.52)	2.31(1.56/3.10)ac	1.91(1.49/2.42)ac	2.20(1.36/2.70)ac	
CR: conditioning regimen; BMT: bone marrow transplantation; Units-ALA-D: nmol PBG/ml blood/h.

",PBG,bone marrow,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","3.67(2.14/5.52)	2.31(1.56/3.10)ac	1.91(1.49/2.42)ac	2.20(1.36/2.70)ac	
CR: conditioning regimen; BMT: bone marrow transplantation; Units-ALA-D: nmol PBG/ml blood/h.

",ALA,blood,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","3.67(2.14/5.52)	2.31(1.56/3.10)ac	1.91(1.49/2.42)ac	2.20(1.36/2.70)ac	
CR: conditioning regimen; BMT: bone marrow transplantation; Units-ALA-D: nmol PBG/ml blood/h.

",ALA,bone marrow,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","As shown in figure 6, we found that a 2-h treatment course with the antioxidant AA (200 mM) concurrent with the 2-h etoposide treatment reduced the DNA damage induced by etoposide in non-stimulated whole blood cells.",DNA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Because non-stimulated cells are not cycling, they have relatively low Topoisomerase II activity compared to PHA-stimulated whole blood cells, and thus would be expected to be relatively insensitive to DNA-damaging effects of etoposide.

",PHA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Because non-stimulated cells are not cycling, they have relatively low Topoisomerase II activity compared to PHA-stimulated whole blood cells, and thus would be expected to be relatively insensitive to DNA-damaging effects of etoposide.

",DNA,blood,-1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","d-Aminolevulinate dehydratase (d-ALA-D) activity
d-Aminolevulinate dehydratase (d-ALA-D) activity was assayed in whole blood by the method of Berlin and Schaller [41] by measuring the rate of porphobilinogen (PBG) formation in 1 h at 37degC.",PBG,blood,-1
"PMC 
BMC_Cancer_2010_Aug_17_10_437.txt
","Of the three groups, nuclear staining for p65 was most prevalent in lymph node contain metastases (61%) (Fig.",p65,lymph,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Quantitative analysis of CA-125
CA-125 serum levels were quantified using the second-generation electrochemiluminescence immunoassay (ECLIA) and the Roche Modular Analytics E170 system (Elecsys module, Roche Diagnostics, Mannheim, Germany) with 20 ml serum samples.

",CA-125,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Quantitative analysis of CA-125
CA-125 serum levels were quantified using the second-generation electrochemiluminescence immunoassay (ECLIA) and the Roche Modular Analytics E170 system (Elecsys module, Roche Diagnostics, Mannheim, Germany) with 20 ml serum samples.

",CA-125,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Quantitative analysis of CA-125
CA-125 serum levels were quantified using the second-generation electrochemiluminescence immunoassay (ECLIA) and the Roche Modular Analytics E170 system (Elecsys module, Roche Diagnostics, Mannheim, Germany) with 20 ml serum samples.

",CA-125,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Quantitative analysis of CA-125
CA-125 serum levels were quantified using the second-generation electrochemiluminescence immunoassay (ECLIA) and the Roche Modular Analytics E170 system (Elecsys module, Roche Diagnostics, Mannheim, Germany) with 20 ml serum samples.

",CA-125,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Quantitative analysis of CA-125
CA-125 serum levels were quantified using the second-generation electrochemiluminescence immunoassay (ECLIA) and the Roche Modular Analytics E170 system (Elecsys module, Roche Diagnostics, Mannheim, Germany) with 20 ml serum samples.

",ECLIA,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Quantitative analysis of CA-125
CA-125 serum levels were quantified using the second-generation electrochemiluminescence immunoassay (ECLIA) and the Roche Modular Analytics E170 system (Elecsys module, Roche Diagnostics, Mannheim, Germany) with 20 ml serum samples.

",ECLIA,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Quantitative analysis of CA-125
CA-125 serum levels were quantified using the second-generation electrochemiluminescence immunoassay (ECLIA) and the Roche Modular Analytics E170 system (Elecsys module, Roche Diagnostics, Mannheim, Germany) with 20 ml serum samples.

",E170,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Quantitative analysis of CA-125
CA-125 serum levels were quantified using the second-generation electrochemiluminescence immunoassay (ECLIA) and the Roche Modular Analytics E170 system (Elecsys module, Roche Diagnostics, Mannheim, Germany) with 20 ml serum samples.

",E170,serum,1
"PMC 
BMC_Cancer_2009_May_13_9_146.txt
","Likewise, systemic toxicity was evaluated during 24 hours after each CIGB-300 administration, including cardiovascular monitoring during the injections and vital signs measurements (temperature, heart and respiratory frequencies, and blood pressure) 30 min. after the end of the injection, then every hour during 4 hours and every 4 hours thereafter.

",CIGB-300,blood,-1
"PMC 
BMC_Cancer_2010_Aug_18_10_439.txt
","In our current study, we elucidate the association between plasma levels of 8-OHdG and the OGG1 repair capacity among lung cancer cases and controls.

",OGG1,plasma,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Table 4 Plasma protein thiol (P-SH) group levels over time

Groups	Before CR	CR	Day 10 after
BMT	Day 20 after
BMT	
Group I
(control)	463.50
(445.20/487.80)	432.00
(406.20/469.35)	459.00
(433.76/498.00)	429.66
(403.75/451.75)	
Group II
(autol.)	364.51
(335.82/407.42)a	352.64
(306.15/371.64)a	",CR,Plasma,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Table 4 Plasma protein thiol (P-SH) group levels over time

Groups	Before CR	CR	Day 10 after
BMT	Day 20 after
BMT	
Group I
(control)	463.50
(445.20/487.80)	432.00
(406.20/469.35)	459.00
(433.76/498.00)	429.66
(403.75/451.75)	
Group II
(autol.)	364.51
(335.82/407.42)a	352.64
(306.15/371.64)a	",BMT,Plasma,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Table 4 Plasma protein thiol (P-SH) group levels over time

Groups	Before CR	CR	Day 10 after
BMT	Day 20 after
BMT	
Group I
(control)	463.50
(445.20/487.80)	432.00
(406.20/469.35)	459.00
(433.76/498.00)	429.66
(403.75/451.75)	
Group II
(autol.)	364.51
(335.82/407.42)a	352.64
(306.15/371.64)a	",CR,Plasma,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Table 4 Plasma protein thiol (P-SH) group levels over time

Groups	Before CR	CR	Day 10 after
BMT	Day 20 after
BMT	
Group I
(control)	463.50
(445.20/487.80)	432.00
(406.20/469.35)	459.00
(433.76/498.00)	429.66
(403.75/451.75)	
Group II
(autol.)	364.51
(335.82/407.42)a	352.64
(306.15/371.64)a	",BMT,Plasma,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","21.12(17.76/29.70)a	21.89(17.60/26.40)a	20.46(15.45/32.21)a	19.36(15.62/27.61)a	
Group III
(allog.)	18.26(15.40/22.00)	19.14(16.60/23.10)a	29.23(21.34/40.72)acd	27.50(18.92/38.50)acd	
CR: conditioning regimen; BMT: bone marrow transplantation; Units - TBARS: nmol TBARS/mL plasma.",TBARS,plasma,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","21.12(17.76/29.70)a	21.89(17.60/26.40)a	20.46(15.45/32.21)a	19.36(15.62/27.61)a	
Group III
(allog.)	18.26(15.40/22.00)	19.14(16.60/23.10)a	29.23(21.34/40.72)acd	27.50(18.92/38.50)acd	
CR: conditioning regimen; BMT: bone marrow transplantation; Units - TBARS: nmol TBARS/mL plasma.",TBARS,bone marrow,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","21.12(17.76/29.70)a	21.89(17.60/26.40)a	20.46(15.45/32.21)a	19.36(15.62/27.61)a	
Group III
(allog.)	18.26(15.40/22.00)	19.14(16.60/23.10)a	29.23(21.34/40.72)acd	27.50(18.92/38.50)acd	
CR: conditioning regimen; BMT: bone marrow transplantation; Units - TBARS: nmol TBARS/mL plasma.",BMT,plasma,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","21.12(17.76/29.70)a	21.89(17.60/26.40)a	20.46(15.45/32.21)a	19.36(15.62/27.61)a	
Group III
(allog.)	18.26(15.40/22.00)	19.14(16.60/23.10)a	29.23(21.34/40.72)acd	27.50(18.92/38.50)acd	
CR: conditioning regimen; BMT: bone marrow transplantation; Units - TBARS: nmol TBARS/mL plasma.",BMT,bone marrow,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","21.12(17.76/29.70)a	21.89(17.60/26.40)a	20.46(15.45/32.21)a	19.36(15.62/27.61)a	
Group III
(allog.)	18.26(15.40/22.00)	19.14(16.60/23.10)a	29.23(21.34/40.72)acd	27.50(18.92/38.50)acd	
CR: conditioning regimen; BMT: bone marrow transplantation; Units - TBARS: nmol TBARS/mL plasma.",III,plasma,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","21.12(17.76/29.70)a	21.89(17.60/26.40)a	20.46(15.45/32.21)a	19.36(15.62/27.61)a	
Group III
(allog.)	18.26(15.40/22.00)	19.14(16.60/23.10)a	29.23(21.34/40.72)acd	27.50(18.92/38.50)acd	
CR: conditioning regimen; BMT: bone marrow transplantation; Units - TBARS: nmol TBARS/mL plasma.",III,bone marrow,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","21.12(17.76/29.70)a	21.89(17.60/26.40)a	20.46(15.45/32.21)a	19.36(15.62/27.61)a	
Group III
(allog.)	18.26(15.40/22.00)	19.14(16.60/23.10)a	29.23(21.34/40.72)acd	27.50(18.92/38.50)acd	
CR: conditioning regimen; BMT: bone marrow transplantation; Units - TBARS: nmol TBARS/mL plasma.",CR,plasma,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","21.12(17.76/29.70)a	21.89(17.60/26.40)a	20.46(15.45/32.21)a	19.36(15.62/27.61)a	
Group III
(allog.)	18.26(15.40/22.00)	19.14(16.60/23.10)a	29.23(21.34/40.72)acd	27.50(18.92/38.50)acd	
CR: conditioning regimen; BMT: bone marrow transplantation; Units - TBARS: nmol TBARS/mL plasma.",CR,bone marrow,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","21.12(17.76/29.70)a	21.89(17.60/26.40)a	20.46(15.45/32.21)a	19.36(15.62/27.61)a	
Group III
(allog.)	18.26(15.40/22.00)	19.14(16.60/23.10)a	29.23(21.34/40.72)acd	27.50(18.92/38.50)acd	
CR: conditioning regimen; BMT: bone marrow transplantation; Units - TBARS: nmol TBARS/mL plasma.",TBARS,plasma,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","21.12(17.76/29.70)a	21.89(17.60/26.40)a	20.46(15.45/32.21)a	19.36(15.62/27.61)a	
Group III
(allog.)	18.26(15.40/22.00)	19.14(16.60/23.10)a	29.23(21.34/40.72)acd	27.50(18.92/38.50)acd	
CR: conditioning regimen; BMT: bone marrow transplantation; Units - TBARS: nmol TBARS/mL plasma.",TBARS,bone marrow,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Table 2 Plasma lipid peroxidation (TBARS) levels over time

Groups	Before CR	CR	Day 10 after
BMT	Day 20 after
BMT	
Group I
(control)	15.01(12.76/19.25)	14.40(11.66/16.06)	14.52(11.56/15.30)	15.02(12.55/16.58)	
Group II
(autol.)	",TBARS,Plasma,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Table 2 Plasma lipid peroxidation (TBARS) levels over time

Groups	Before CR	CR	Day 10 after
BMT	Day 20 after
BMT	
Group I
(control)	15.01(12.76/19.25)	14.40(11.66/16.06)	14.52(11.56/15.30)	15.02(12.55/16.58)	
Group II
(autol.)	",CR,Plasma,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Table 2 Plasma lipid peroxidation (TBARS) levels over time

Groups	Before CR	CR	Day 10 after
BMT	Day 20 after
BMT	
Group I
(control)	15.01(12.76/19.25)	14.40(11.66/16.06)	14.52(11.56/15.30)	15.02(12.55/16.58)	
Group II
(autol.)	",BMT,Plasma,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Table 2 Plasma lipid peroxidation (TBARS) levels over time

Groups	Before CR	CR	Day 10 after
BMT	Day 20 after
BMT	
Group I
(control)	15.01(12.76/19.25)	14.40(11.66/16.06)	14.52(11.56/15.30)	15.02(12.55/16.58)	
Group II
(autol.)	",CR,Plasma,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Table 2 Plasma lipid peroxidation (TBARS) levels over time

Groups	Before CR	CR	Day 10 after
BMT	Day 20 after
BMT	
Group I
(control)	15.01(12.76/19.25)	14.40(11.66/16.06)	14.52(11.56/15.30)	15.02(12.55/16.58)	
Group II
(autol.)	",BMT,Plasma,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Table 3 Plasma vitamin C (VIT C) levels over time

Groups	Before CR	CR	Day 10 after
BMT	Day 20 after
BMT	
Group I
(control)	22.75(16.92/26.40)	17.80(12.90/21.84)	17.80(15.40/22.13)	19.20(16.38/24.26)	
Group II
(autol.)	",CR,Plasma,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Table 3 Plasma vitamin C (VIT C) levels over time

Groups	Before CR	CR	Day 10 after
BMT	Day 20 after
BMT	
Group I
(control)	22.75(16.92/26.40)	17.80(12.90/21.84)	17.80(15.40/22.13)	19.20(16.38/24.26)	
Group II
(autol.)	",BMT,Plasma,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Table 3 Plasma vitamin C (VIT C) levels over time

Groups	Before CR	CR	Day 10 after
BMT	Day 20 after
BMT	
Group I
(control)	22.75(16.92/26.40)	17.80(12.90/21.84)	17.80(15.40/22.13)	19.20(16.38/24.26)	
Group II
(autol.)	",VIT,Plasma,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Table 3 Plasma vitamin C (VIT C) levels over time

Groups	Before CR	CR	Day 10 after
BMT	Day 20 after
BMT	
Group I
(control)	22.75(16.92/26.40)	17.80(12.90/21.84)	17.80(15.40/22.13)	19.20(16.38/24.26)	
Group II
(autol.)	",CR,Plasma,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Table 3 Plasma vitamin C (VIT C) levels over time

Groups	Before CR	CR	Day 10 after
BMT	Day 20 after
BMT	
Group I
(control)	22.75(16.92/26.40)	17.80(12.90/21.84)	17.80(15.40/22.13)	19.20(16.38/24.26)	
Group II
(autol.)	",BMT,Plasma,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Vitamin C
Plasma vitamin C (VIT C) concentrations were significantly decreased in groups II (autol.) and III (allog.), before CR (p &#60; 0.05), during CR and on days 10 and 20 after BMT (p &#60; 0.005), when compared with group I (control).",BMT,Plasma,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Vitamin C
Plasma vitamin C (VIT C) concentrations were significantly decreased in groups II (autol.) and III (allog.), before CR (p &#60; 0.05), during CR and on days 10 and 20 after BMT (p &#60; 0.005), when compared with group I (control).",CR,Plasma,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Vitamin C
Plasma vitamin C (VIT C) concentrations were significantly decreased in groups II (autol.) and III (allog.), before CR (p &#60; 0.05), during CR and on days 10 and 20 after BMT (p &#60; 0.005), when compared with group I (control).",VIT,Plasma,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Vitamin C
Plasma vitamin C (VIT C) concentrations were significantly decreased in groups II (autol.) and III (allog.), before CR (p &#60; 0.05), during CR and on days 10 and 20 after BMT (p &#60; 0.005), when compared with group I (control).",III,Plasma,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Vitamin C
Plasma vitamin C (VIT C) concentrations were significantly decreased in groups II (autol.) and III (allog.), before CR (p &#60; 0.05), during CR and on days 10 and 20 after BMT (p &#60; 0.005), when compared with group I (control).",CR,Plasma,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","The ALS index data indicated that ALSs, which can be generated by an oxidative stress [6,33], constituted the primary form of DNA damage induced by etoposide in whole blood cells.

",DNA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","The ALS index data indicated that ALSs, which can be generated by an oxidative stress [6,33], constituted the primary form of DNA damage induced by etoposide in whole blood cells.

",ALS,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","If the AP site damage observed in the present study was dependent upon an interaction with this enzyme, we should have also observed this kind of damage in PHA-stimulated whole blood cells.",PHA,blood,-1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Results
Lipid peroxidation
Plasma TBARS levels were significantly higher in group II (autol.) than group I (control), before CR, during CR and on days 10 and 20 after BMT, (p &#60; 0.05).",TBARS,Plasma,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Results
Lipid peroxidation
Plasma TBARS levels were significantly higher in group II (autol.) than group I (control), before CR, during CR and on days 10 and 20 after BMT, (p &#60; 0.05).",CR,Plasma,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Results
Lipid peroxidation
Plasma TBARS levels were significantly higher in group II (autol.) than group I (control), before CR, during CR and on days 10 and 20 after BMT, (p &#60; 0.05).",CR,Plasma,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Results
Lipid peroxidation
Plasma TBARS levels were significantly higher in group II (autol.) than group I (control), before CR, during CR and on days 10 and 20 after BMT, (p &#60; 0.05).",BMT,Plasma,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Since data had no homogeneity of variance, statistical analysis was performed using Kruskal-Wallis ANOVA followed by Mann-Whitney U test to compare the difference among the groups, Friedman ANOVA followed by Wilcoxon test to analyze changes in blood indices over time and Spearman correlation to analyze correlations between biochemical estimations.",ANOVA,blood,-1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Since data had no homogeneity of variance, statistical analysis was performed using Kruskal-Wallis ANOVA followed by Mann-Whitney U test to compare the difference among the groups, Friedman ANOVA followed by Wilcoxon test to analyze changes in blood indices over time and Spearman correlation to analyze correlations between biochemical estimations.",ANOVA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Figure 6 DNA damage induced by etoposide (0, 2.07, 20.7 or 207 mM) in non-stimulated blood cells treated for 2-h (open bars) and DNA damage inhibition produced by AA in non-stimulated blood cells treated for 2 h with etoposide (solid bars).",DNA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Figure 6 DNA damage induced by etoposide (0, 2.07, 20.7 or 207 mM) in non-stimulated blood cells treated for 2-h (open bars) and DNA damage inhibition produced by AA in non-stimulated blood cells treated for 2 h with etoposide (solid bars).",DNA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Figure 6 DNA damage induced by etoposide (0, 2.07, 20.7 or 207 mM) in non-stimulated blood cells treated for 2-h (open bars) and DNA damage inhibition produced by AA in non-stimulated blood cells treated for 2 h with etoposide (solid bars).",DNA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Figure 6 DNA damage induced by etoposide (0, 2.07, 20.7 or 207 mM) in non-stimulated blood cells treated for 2-h (open bars) and DNA damage inhibition produced by AA in non-stimulated blood cells treated for 2 h with etoposide (solid bars).",DNA,blood,-1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","However, when only patients with baseline serum TRACP 5b activities in the highest tertile (>=5.736 U/L) were analyzed (n = 27), DmaxTRACP 5b, stratified by LSC as a dichotomous variable, i.e. DmaxTRACP 5b &#62; or <= 38.59%, significantly correlated with OS (HR = 0.213, p = 0.0015; Table 2 and Figure 3).

",LSC,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","However, when only patients with baseline serum TRACP 5b activities in the highest tertile (>=5.736 U/L) were analyzed (n = 27), DmaxTRACP 5b, stratified by LSC as a dichotomous variable, i.e. DmaxTRACP 5b &#62; or <= 38.59%, significantly correlated with OS (HR = 0.213, p = 0.0015; Table 2 and Figure 3).

",HR,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","However, when only patients with baseline serum TRACP 5b activities in the highest tertile (>=5.736 U/L) were analyzed (n = 27), DmaxTRACP 5b, stratified by LSC as a dichotomous variable, i.e. DmaxTRACP 5b &#62; or <= 38.59%, significantly correlated with OS (HR = 0.213, p = 0.0015; Table 2 and Figure 3).

",TRACP,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","However, when only patients with baseline serum TRACP 5b activities in the highest tertile (>=5.736 U/L) were analyzed (n = 27), DmaxTRACP 5b, stratified by LSC as a dichotomous variable, i.e. DmaxTRACP 5b &#62; or <= 38.59%, significantly correlated with OS (HR = 0.213, p = 0.0015; Table 2 and Figure 3).

",OS,serum,1
"PMC 
BMC_Cancer_2009_Mar_30_9_99.txt
","The cancer cells were maintained in 1x Dulbecco's Modification of Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) (Invitrogen), 4.5 g/L L-glutamine and sodium pyruvate (Mediatech), and 1% Penicillin/Streptomycin (P/S).",FBS,serum,1
"PMC 
BMC_Cancer_2009_Mar_30_9_99.txt
","The cancer cells were maintained in 1x Dulbecco's Modification of Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) (Invitrogen), 4.5 g/L L-glutamine and sodium pyruvate (Mediatech), and 1% Penicillin/Streptomycin (P/S).",DMEM,serum,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 5 Overall survival and time-to-progression (n = 66)

Characteristic	OS* (months)	95% CI	1-year survival rate (%)	P-value	TTP (months)	95% CI	1-year survival rate (%)	P-value	

Age
	&#60;60

>= 60	26.0

25.0	18.9-33.1

14.2-35.8	69.2

69.9	
.656
	6.0

6.0	2.8-9.2

0.8-11.2	26.9

35.4	
.611
	
	

Sex
	Male

Female	22.0

27.0	15.9-28.1

19.3-34.7	69.1

69.6	
.134
	6.0

6.0	0.0-14.2

2.7-9.3	28.0

34.6	
.771
	
	
	Pancreas	28.0	18.0-38.0	77.1	.981	7.0	0.0-15.0	41.6		
Origin	GI	22.0	0.0-46.9	63.2		2.0	0.8-3.2	25.0	.258	
	Lung	9.0	-	50.0		1.0	-	-		
	

Liver metastasis
	Absent

Present	25.0

22.0	20.8-29.2

13.3-30.7	77.0

65.0	
.310
	12.0

4.0	9.2-14.8

1.3-6.7	40.7

23.8	
.011
	
	
	1	36.0	13.2-58.8	72.4		12.0	8.3-15.7	57.5		
	2-3	17.0	1.1-32.9	53.0	.612	4.0	1.2-6.8	34.3		
Grade		.681	
	Large	12.0	0.0-29.8	50.0		2.0	0.0-4.5	45.0		
	Small	17.0	10.1-23.9	100.0		12.0	2.6-21.4	30.0		
	
	24-hour urine 5-HIAA (mmol/day)	&#60;31.4	20.0	0.0-52.2	",OS,urine,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 5 Overall survival and time-to-progression (n = 66)

Characteristic	OS* (months)	95% CI	1-year survival rate (%)	P-value	TTP (months)	95% CI	1-year survival rate (%)	P-value	

Age
	&#60;60

>= 60	26.0

25.0	18.9-33.1

14.2-35.8	69.2

69.9	
.656
	6.0

6.0	2.8-9.2

0.8-11.2	26.9

35.4	
.611
	
	

Sex
	Male

Female	22.0

27.0	15.9-28.1

19.3-34.7	69.1

69.6	
.134
	6.0

6.0	0.0-14.2

2.7-9.3	28.0

34.6	
.771
	
	
	Pancreas	28.0	18.0-38.0	77.1	.981	7.0	0.0-15.0	41.6		
Origin	GI	22.0	0.0-46.9	63.2		2.0	0.8-3.2	25.0	.258	
	Lung	9.0	-	50.0		1.0	-	-		
	

Liver metastasis
	Absent

Present	25.0

22.0	20.8-29.2

13.3-30.7	77.0

65.0	
.310
	12.0

4.0	9.2-14.8

1.3-6.7	40.7

23.8	
.011
	
	
	1	36.0	13.2-58.8	72.4		12.0	8.3-15.7	57.5		
	2-3	17.0	1.1-32.9	53.0	.612	4.0	1.2-6.8	34.3		
Grade		.681	
	Large	12.0	0.0-29.8	50.0		2.0	0.0-4.5	45.0		
	Small	17.0	10.1-23.9	100.0		12.0	2.6-21.4	30.0		
	
	24-hour urine 5-HIAA (mmol/day)	&#60;31.4	20.0	0.0-52.2	",CI,urine,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 5 Overall survival and time-to-progression (n = 66)

Characteristic	OS* (months)	95% CI	1-year survival rate (%)	P-value	TTP (months)	95% CI	1-year survival rate (%)	P-value	

Age
	&#60;60

>= 60	26.0

25.0	18.9-33.1

14.2-35.8	69.2

69.9	
.656
	6.0

6.0	2.8-9.2

0.8-11.2	26.9

35.4	
.611
	
	

Sex
	Male

Female	22.0

27.0	15.9-28.1

19.3-34.7	69.1

69.6	
.134
	6.0

6.0	0.0-14.2

2.7-9.3	28.0

34.6	
.771
	
	
	Pancreas	28.0	18.0-38.0	77.1	.981	7.0	0.0-15.0	41.6		
Origin	GI	22.0	0.0-46.9	63.2		2.0	0.8-3.2	25.0	.258	
	Lung	9.0	-	50.0		1.0	-	-		
	

Liver metastasis
	Absent

Present	25.0

22.0	20.8-29.2

13.3-30.7	77.0

65.0	
.310
	12.0

4.0	9.2-14.8

1.3-6.7	40.7

23.8	
.011
	
	
	1	36.0	13.2-58.8	72.4		12.0	8.3-15.7	57.5		
	2-3	17.0	1.1-32.9	53.0	.612	4.0	1.2-6.8	34.3		
Grade		.681	
	Large	12.0	0.0-29.8	50.0		2.0	0.0-4.5	45.0		
	Small	17.0	10.1-23.9	100.0		12.0	2.6-21.4	30.0		
	
	24-hour urine 5-HIAA (mmol/day)	&#60;31.4	20.0	0.0-52.2	",TTP,urine,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Table 5 Overall survival and time-to-progression (n = 66)

Characteristic	OS* (months)	95% CI	1-year survival rate (%)	P-value	TTP (months)	95% CI	1-year survival rate (%)	P-value	

Age
	&#60;60

>= 60	26.0

25.0	18.9-33.1

14.2-35.8	69.2

69.9	
.656
	6.0

6.0	2.8-9.2

0.8-11.2	26.9

35.4	
.611
	
	

Sex
	Male

Female	22.0

27.0	15.9-28.1

19.3-34.7	69.1

69.6	
.134
	6.0

6.0	0.0-14.2

2.7-9.3	28.0

34.6	
.771
	
	
	Pancreas	28.0	18.0-38.0	77.1	.981	7.0	0.0-15.0	41.6		
Origin	GI	22.0	0.0-46.9	63.2		2.0	0.8-3.2	25.0	.258	
	Lung	9.0	-	50.0		1.0	-	-		
	

Liver metastasis
	Absent

Present	25.0

22.0	20.8-29.2

13.3-30.7	77.0

65.0	
.310
	12.0

4.0	9.2-14.8

1.3-6.7	40.7

23.8	
.011
	
	
	1	36.0	13.2-58.8	72.4		12.0	8.3-15.7	57.5		
	2-3	17.0	1.1-32.9	53.0	.612	4.0	1.2-6.8	34.3		
Grade		.681	
	Large	12.0	0.0-29.8	50.0		2.0	0.0-4.5	45.0		
	Small	17.0	10.1-23.9	100.0		12.0	2.6-21.4	30.0		
	
	24-hour urine 5-HIAA (mmol/day)	&#60;31.4	20.0	0.0-52.2	",CI,urine,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","In those patients with baseline serum TRACP 5b activities higher than 5.736 U/L, a DmaxTRACP 5b greater than LSC after treatment had significantly longer OS compared to the rest of the group after adjustment of other prognostic factors.",TRACP,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","In those patients with baseline serum TRACP 5b activities higher than 5.736 U/L, a DmaxTRACP 5b greater than LSC after treatment had significantly longer OS compared to the rest of the group after adjustment of other prognostic factors.",LSC,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","In those patients with baseline serum TRACP 5b activities higher than 5.736 U/L, a DmaxTRACP 5b greater than LSC after treatment had significantly longer OS compared to the rest of the group after adjustment of other prognostic factors.",OS,serum,1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","Several hypotheses have been suggested to explain this occurrence, including differences in TS levels in primary tumors and locoregional lymph node metastases, modulation of 5-FU resistance by other molecules such as p53 and DPD, differences in 5-FU scheduling, as well as methodological problems and biases in the assessment of TS in individual studies[10,25].",TS,lymph,1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","Several hypotheses have been suggested to explain this occurrence, including differences in TS levels in primary tumors and locoregional lymph node metastases, modulation of 5-FU resistance by other molecules such as p53 and DPD, differences in 5-FU scheduling, as well as methodological problems and biases in the assessment of TS in individual studies[10,25].",p53,lymph,1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","Several hypotheses have been suggested to explain this occurrence, including differences in TS levels in primary tumors and locoregional lymph node metastases, modulation of 5-FU resistance by other molecules such as p53 and DPD, differences in 5-FU scheduling, as well as methodological problems and biases in the assessment of TS in individual studies[10,25].",TS,lymph,1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","Several hypotheses have been suggested to explain this occurrence, including differences in TS levels in primary tumors and locoregional lymph node metastases, modulation of 5-FU resistance by other molecules such as p53 and DPD, differences in 5-FU scheduling, as well as methodological problems and biases in the assessment of TS in individual studies[10,25].",FU,lymph,1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","Several hypotheses have been suggested to explain this occurrence, including differences in TS levels in primary tumors and locoregional lymph node metastases, modulation of 5-FU resistance by other molecules such as p53 and DPD, differences in 5-FU scheduling, as well as methodological problems and biases in the assessment of TS in individual studies[10,25].",DPD,lymph,1
"PMC 
BMC_Cancer_2009_Sep_24_9_339.txt
","Several hypotheses have been suggested to explain this occurrence, including differences in TS levels in primary tumors and locoregional lymph node metastases, modulation of 5-FU resistance by other molecules such as p53 and DPD, differences in 5-FU scheduling, as well as methodological problems and biases in the assessment of TS in individual studies[10,25].",FU,lymph,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","TIMP-1 in plasma and serum has been suggested as a marker of prognosis [12,15-17] and additionally, high blood levels of TIMP-1 have been shown to predict resistance to endocrine therapy in patients with metastatic breast cancer [9,10].",TIMP-1,plasma,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","TIMP-1 in plasma and serum has been suggested as a marker of prognosis [12,15-17] and additionally, high blood levels of TIMP-1 have been shown to predict resistance to endocrine therapy in patients with metastatic breast cancer [9,10].",TIMP-1,blood,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","TIMP-1 in plasma and serum has been suggested as a marker of prognosis [12,15-17] and additionally, high blood levels of TIMP-1 have been shown to predict resistance to endocrine therapy in patients with metastatic breast cancer [9,10].",TIMP-1,serum,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","TIMP-1 in plasma and serum has been suggested as a marker of prognosis [12,15-17] and additionally, high blood levels of TIMP-1 have been shown to predict resistance to endocrine therapy in patients with metastatic breast cancer [9,10].",TIMP-1,plasma,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","TIMP-1 in plasma and serum has been suggested as a marker of prognosis [12,15-17] and additionally, high blood levels of TIMP-1 have been shown to predict resistance to endocrine therapy in patients with metastatic breast cancer [9,10].",TIMP-1,blood,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","TIMP-1 in plasma and serum has been suggested as a marker of prognosis [12,15-17] and additionally, high blood levels of TIMP-1 have been shown to predict resistance to endocrine therapy in patients with metastatic breast cancer [9,10].",TIMP-1,serum,1
"PMC 
BMC_Cancer_2009_Sep_6_9_315.txt
","6)		
 &#62;49	16	9 (56.3)	7 (43.7)		
Pathological classification(WHO)				0.062	
Type I-II	17	12(70.6)	5 (29.4)		
Type III	20	8 (40.0)	12 (60.0)		
Depth of invasion
T classification				0.474	
 T1-2	27	14(51.9)	13 (48.1)		
 T3-4	10	6(60)	4(40)		
Lymph node metastasis
N classification				0.034c	
N0	9	2 (22.2)	7 (77.8)		
N1-3	28	18(64.3)	10 (35.7)		
Distant metastasis				0.036c	
 Yes	5	5(100.0)	0(0.0)		
 ",T,Lymph,1
"PMC 
BMC_Cancer_2009_Sep_6_9_315.txt
","6)		
 &#62;49	16	9 (56.3)	7 (43.7)		
Pathological classification(WHO)				0.062	
Type I-II	17	12(70.6)	5 (29.4)		
Type III	20	8 (40.0)	12 (60.0)		
Depth of invasion
T classification				0.474	
 T1-2	27	14(51.9)	13 (48.1)		
 T3-4	10	6(60)	4(40)		
Lymph node metastasis
N classification				0.034c	
N0	9	2 (22.2)	7 (77.8)		
N1-3	28	18(64.3)	10 (35.7)		
Distant metastasis				0.036c	
 Yes	5	5(100.0)	0(0.0)		
 ",N0,Lymph,1
"PMC 
BMC_Cancer_2009_Sep_6_9_315.txt
","6)		
 &#62;49	16	9 (56.3)	7 (43.7)		
Pathological classification(WHO)				0.062	
Type I-II	17	12(70.6)	5 (29.4)		
Type III	20	8 (40.0)	12 (60.0)		
Depth of invasion
T classification				0.474	
 T1-2	27	14(51.9)	13 (48.1)		
 T3-4	10	6(60)	4(40)		
Lymph node metastasis
N classification				0.034c	
N0	9	2 (22.2)	7 (77.8)		
N1-3	28	18(64.3)	10 (35.7)		
Distant metastasis				0.036c	
 Yes	5	5(100.0)	0(0.0)		
 ",III,Lymph,1
"PMC 
BMC_Cancer_2009_Sep_6_9_315.txt
","6)		
 &#62;49	16	9 (56.3)	7 (43.7)		
Pathological classification(WHO)				0.062	
Type I-II	17	12(70.6)	5 (29.4)		
Type III	20	8 (40.0)	12 (60.0)		
Depth of invasion
T classification				0.474	
 T1-2	27	14(51.9)	13 (48.1)		
 T3-4	10	6(60)	4(40)		
Lymph node metastasis
N classification				0.034c	
N0	9	2 (22.2)	7 (77.8)		
N1-3	28	18(64.3)	10 (35.7)		
Distant metastasis				0.036c	
 Yes	5	5(100.0)	0(0.0)		
 ",Yes,Lymph,1
"PMC 
BMC_Cancer_2009_Sep_6_9_315.txt
","6)		
 &#62;49	16	9 (56.3)	7 (43.7)		
Pathological classification(WHO)				0.062	
Type I-II	17	12(70.6)	5 (29.4)		
Type III	20	8 (40.0)	12 (60.0)		
Depth of invasion
T classification				0.474	
 T1-2	27	14(51.9)	13 (48.1)		
 T3-4	10	6(60)	4(40)		
Lymph node metastasis
N classification				0.034c	
N0	9	2 (22.2)	7 (77.8)		
N1-3	28	18(64.3)	10 (35.7)		
Distant metastasis				0.036c	
 Yes	5	5(100.0)	0(0.0)		
 ",T3,Lymph,1
"PMC 
BMC_Cancer_2009_Sep_6_9_315.txt
","6)		
 &#62;49	16	9 (56.3)	7 (43.7)		
Pathological classification(WHO)				0.062	
Type I-II	17	12(70.6)	5 (29.4)		
Type III	20	8 (40.0)	12 (60.0)		
Depth of invasion
T classification				0.474	
 T1-2	27	14(51.9)	13 (48.1)		
 T3-4	10	6(60)	4(40)		
Lymph node metastasis
N classification				0.034c	
N0	9	2 (22.2)	7 (77.8)		
N1-3	28	18(64.3)	10 (35.7)		
Distant metastasis				0.036c	
 Yes	5	5(100.0)	0(0.0)		
 ",N1,Lymph,1
"PMC 
BMC_Cancer_2009_Sep_6_9_315.txt
","6)		
 &#62;49	16	9 (56.3)	7 (43.7)		
Pathological classification(WHO)				0.062	
Type I-II	17	12(70.6)	5 (29.4)		
Type III	20	8 (40.0)	12 (60.0)		
Depth of invasion
T classification				0.474	
 T1-2	27	14(51.9)	13 (48.1)		
 T3-4	10	6(60)	4(40)		
Lymph node metastasis
N classification				0.034c	
N0	9	2 (22.2)	7 (77.8)		
N1-3	28	18(64.3)	10 (35.7)		
Distant metastasis				0.036c	
 Yes	5	5(100.0)	0(0.0)		
 ",T1,Lymph,1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
",A regional NET was defined as a neoplasm that extended beyond the limits of the organ of origin directly into surrounding organs or tissue or a neoplasm involving regional lymph nodes.,NET,lymph,1
"PMC 
BMC_Cancer_2009_Nov_17_9_400.txt
","Additionally, we also analyzed the association between AFB1-DNA adduct levels of peripheral blood leukocytes and those of the cancerous tissue of 119 HCC patients previously studied [31].",AFB1-DNA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_17_9_400.txt
","Additionally, we also analyzed the association between AFB1-DNA adduct levels of peripheral blood leukocytes and those of the cancerous tissue of 119 HCC patients previously studied [31].",HCC,blood,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
",Urinary 5-HIAA [15] and serum NSE [9] have been well known as a prognostic factor.,NSE,serum,-1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","0.110*		0.688*		
Correlations between serum concentration of CA-125, TIMP-1 and VEGF (below/above median) and clinicopathological factors.",VEGF,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","0.110*		0.688*		
Correlations between serum concentration of CA-125, TIMP-1 and VEGF (below/above median) and clinicopathological factors.",TIMP-1,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","0.110*		0.688*		
Correlations between serum concentration of CA-125, TIMP-1 and VEGF (below/above median) and clinicopathological factors.",CA-125,serum,-1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Conclusions
TIMP-1 and VEGF serum levels changed significantly during first-line therapy of ovarian cancer patients and predicted prognosis.",TIMP-1,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Conclusions
TIMP-1 and VEGF serum levels changed significantly during first-line therapy of ovarian cancer patients and predicted prognosis.",VEGF,serum,1
"PMC 
BMC_Cancer_2009_May_6_9_134.txt
","NGAL mRNA up-regulation correlated significantly with depth of invasion (p = 0.028), lymph node metastasis (p = 0.009), venous involvement (p = 0.023) and advanced pTNM stage (p = 0.011).",NGAL,lymph,1
"PMC 
BMC_Cancer_2009_May_6_9_134.txt
","NGAL mRNA up-regulation correlated significantly with depth of invasion (p = 0.028), lymph node metastasis (p = 0.009), venous involvement (p = 0.023) and advanced pTNM stage (p = 0.011).",pTNM,lymph,1
"PMC 
BMC_Cancer_2009_May_6_9_134.txt
","NGAL mRNA up-regulation correlated significantly with depth of invasion (p = 0.028), lymph node metastasis (p = 0.009), venous involvement (p = 0.023) and advanced pTNM stage (p = 0.011).",mRNA,lymph,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","However, the real cutoff value to differentiate high from low serum TRACP 5b activity is unknown.",TRACP,serum,1
"PMC 
BMC_Cancer_2010_Aug_11_10_420.txt
","DNA isolation
DNA was extracted from peripheral blood lymphocytes of individuals using the non-enzymatic, rapid method without modification [9].

",DNA,blood,-1
"PMC 
BMC_Cancer_2010_Aug_11_10_420.txt
","DNA isolation
DNA was extracted from peripheral blood lymphocytes of individuals using the non-enzymatic, rapid method without modification [9].

",DNA,blood,-1
"PMC 
BMC_Cancer_2009_May_6_9_134.txt
","NS	
Gender			NS	
 Male	13	31		
 Female	18	38		
Grade			NS	
 Well-differentiated	4	3		
 Moderately differentiated	20	51		
 Poorly differentiated	7	15		
Depth of invasion			0.028	
 pT1	5	2		
 pT2	13	23		
 pT3	12	33		
 pT4	1	11		
Lymph node metastasis			0.009	
 Absent	17	19		
 Present	14	50		
Venous involvement			0.023	
 Absent	26	42		
 Present	5	27		
pTNM stage			0.011	
 pI	4	2		
 pII	13	14		
 pIII	13	44		
 pIV	1	9		
ratio <= 1: The expression of NGAL mRNA was not up-regulated; ratio &#62; 1: The expression of NGAL mRNA was up-regulated; NS:Not significant.

",NS,Lymph,1
"PMC 
BMC_Cancer_2009_May_6_9_134.txt
","NS	
Gender			NS	
 Male	13	31		
 Female	18	38		
Grade			NS	
 Well-differentiated	4	3		
 Moderately differentiated	20	51		
 Poorly differentiated	7	15		
Depth of invasion			0.028	
 pT1	5	2		
 pT2	13	23		
 pT3	12	33		
 pT4	1	11		
Lymph node metastasis			0.009	
 Absent	17	19		
 Present	14	50		
Venous involvement			0.023	
 Absent	26	42		
 Present	5	27		
pTNM stage			0.011	
 pI	4	2		
 pII	13	14		
 pIII	13	44		
 pIV	1	9		
ratio <= 1: The expression of NGAL mRNA was not up-regulated; ratio &#62; 1: The expression of NGAL mRNA was up-regulated; NS:Not significant.

",NS,Lymph,1
"PMC 
BMC_Cancer_2009_May_6_9_134.txt
","NS	
Gender			NS	
 Male	13	31		
 Female	18	38		
Grade			NS	
 Well-differentiated	4	3		
 Moderately differentiated	20	51		
 Poorly differentiated	7	15		
Depth of invasion			0.028	
 pT1	5	2		
 pT2	13	23		
 pT3	12	33		
 pT4	1	11		
Lymph node metastasis			0.009	
 Absent	17	19		
 Present	14	50		
Venous involvement			0.023	
 Absent	26	42		
 Present	5	27		
pTNM stage			0.011	
 pI	4	2		
 pII	13	14		
 pIII	13	44		
 pIV	1	9		
ratio <= 1: The expression of NGAL mRNA was not up-regulated; ratio &#62; 1: The expression of NGAL mRNA was up-regulated; NS:Not significant.

",pT2,Lymph,1
"PMC 
BMC_Cancer_2009_May_6_9_134.txt
","NS	
Gender			NS	
 Male	13	31		
 Female	18	38		
Grade			NS	
 Well-differentiated	4	3		
 Moderately differentiated	20	51		
 Poorly differentiated	7	15		
Depth of invasion			0.028	
 pT1	5	2		
 pT2	13	23		
 pT3	12	33		
 pT4	1	11		
Lymph node metastasis			0.009	
 Absent	17	19		
 Present	14	50		
Venous involvement			0.023	
 Absent	26	42		
 Present	5	27		
pTNM stage			0.011	
 pI	4	2		
 pII	13	14		
 pIII	13	44		
 pIV	1	9		
ratio <= 1: The expression of NGAL mRNA was not up-regulated; ratio &#62; 1: The expression of NGAL mRNA was up-regulated; NS:Not significant.

",mRNA,Lymph,1
"PMC 
BMC_Cancer_2009_May_6_9_134.txt
","NS	
Gender			NS	
 Male	13	31		
 Female	18	38		
Grade			NS	
 Well-differentiated	4	3		
 Moderately differentiated	20	51		
 Poorly differentiated	7	15		
Depth of invasion			0.028	
 pT1	5	2		
 pT2	13	23		
 pT3	12	33		
 pT4	1	11		
Lymph node metastasis			0.009	
 Absent	17	19		
 Present	14	50		
Venous involvement			0.023	
 Absent	26	42		
 Present	5	27		
pTNM stage			0.011	
 pI	4	2		
 pII	13	14		
 pIII	13	44		
 pIV	1	9		
ratio <= 1: The expression of NGAL mRNA was not up-regulated; ratio &#62; 1: The expression of NGAL mRNA was up-regulated; NS:Not significant.

",pTNM,Lymph,1
"PMC 
BMC_Cancer_2009_May_6_9_134.txt
","NS	
Gender			NS	
 Male	13	31		
 Female	18	38		
Grade			NS	
 Well-differentiated	4	3		
 Moderately differentiated	20	51		
 Poorly differentiated	7	15		
Depth of invasion			0.028	
 pT1	5	2		
 pT2	13	23		
 pT3	12	33		
 pT4	1	11		
Lymph node metastasis			0.009	
 Absent	17	19		
 Present	14	50		
Venous involvement			0.023	
 Absent	26	42		
 Present	5	27		
pTNM stage			0.011	
 pI	4	2		
 pII	13	14		
 pIII	13	44		
 pIV	1	9		
ratio <= 1: The expression of NGAL mRNA was not up-regulated; ratio &#62; 1: The expression of NGAL mRNA was up-regulated; NS:Not significant.

",NS,Lymph,1
"PMC 
BMC_Cancer_2009_May_6_9_134.txt
","NS	
Gender			NS	
 Male	13	31		
 Female	18	38		
Grade			NS	
 Well-differentiated	4	3		
 Moderately differentiated	20	51		
 Poorly differentiated	7	15		
Depth of invasion			0.028	
 pT1	5	2		
 pT2	13	23		
 pT3	12	33		
 pT4	1	11		
Lymph node metastasis			0.009	
 Absent	17	19		
 Present	14	50		
Venous involvement			0.023	
 Absent	26	42		
 Present	5	27		
pTNM stage			0.011	
 pI	4	2		
 pII	13	14		
 pIII	13	44		
 pIV	1	9		
ratio <= 1: The expression of NGAL mRNA was not up-regulated; ratio &#62; 1: The expression of NGAL mRNA was up-regulated; NS:Not significant.

",NGAL,Lymph,1
"PMC 
BMC_Cancer_2009_May_6_9_134.txt
","NS	
Gender			NS	
 Male	13	31		
 Female	18	38		
Grade			NS	
 Well-differentiated	4	3		
 Moderately differentiated	20	51		
 Poorly differentiated	7	15		
Depth of invasion			0.028	
 pT1	5	2		
 pT2	13	23		
 pT3	12	33		
 pT4	1	11		
Lymph node metastasis			0.009	
 Absent	17	19		
 Present	14	50		
Venous involvement			0.023	
 Absent	26	42		
 Present	5	27		
pTNM stage			0.011	
 pI	4	2		
 pII	13	14		
 pIII	13	44		
 pIV	1	9		
ratio <= 1: The expression of NGAL mRNA was not up-regulated; ratio &#62; 1: The expression of NGAL mRNA was up-regulated; NS:Not significant.

",NGAL,Lymph,1
"PMC 
BMC_Cancer_2009_May_6_9_134.txt
","NS	
Gender			NS	
 Male	13	31		
 Female	18	38		
Grade			NS	
 Well-differentiated	4	3		
 Moderately differentiated	20	51		
 Poorly differentiated	7	15		
Depth of invasion			0.028	
 pT1	5	2		
 pT2	13	23		
 pT3	12	33		
 pT4	1	11		
Lymph node metastasis			0.009	
 Absent	17	19		
 Present	14	50		
Venous involvement			0.023	
 Absent	26	42		
 Present	5	27		
pTNM stage			0.011	
 pI	4	2		
 pII	13	14		
 pIII	13	44		
 pIV	1	9		
ratio <= 1: The expression of NGAL mRNA was not up-regulated; ratio &#62; 1: The expression of NGAL mRNA was up-regulated; NS:Not significant.

",pT1,Lymph,1
"PMC 
BMC_Cancer_2009_May_6_9_134.txt
","NS	
Gender			NS	
 Male	13	31		
 Female	18	38		
Grade			NS	
 Well-differentiated	4	3		
 Moderately differentiated	20	51		
 Poorly differentiated	7	15		
Depth of invasion			0.028	
 pT1	5	2		
 pT2	13	23		
 pT3	12	33		
 pT4	1	11		
Lymph node metastasis			0.009	
 Absent	17	19		
 Present	14	50		
Venous involvement			0.023	
 Absent	26	42		
 Present	5	27		
pTNM stage			0.011	
 pI	4	2		
 pII	13	14		
 pIII	13	44		
 pIV	1	9		
ratio <= 1: The expression of NGAL mRNA was not up-regulated; ratio &#62; 1: The expression of NGAL mRNA was up-regulated; NS:Not significant.

",mRNA,Lymph,1
"PMC 
BMC_Cancer_2009_May_6_9_134.txt
","NS	
Gender			NS	
 Male	13	31		
 Female	18	38		
Grade			NS	
 Well-differentiated	4	3		
 Moderately differentiated	20	51		
 Poorly differentiated	7	15		
Depth of invasion			0.028	
 pT1	5	2		
 pT2	13	23		
 pT3	12	33		
 pT4	1	11		
Lymph node metastasis			0.009	
 Absent	17	19		
 Present	14	50		
Venous involvement			0.023	
 Absent	26	42		
 Present	5	27		
pTNM stage			0.011	
 pI	4	2		
 pII	13	14		
 pIII	13	44		
 pIV	1	9		
ratio <= 1: The expression of NGAL mRNA was not up-regulated; ratio &#62; 1: The expression of NGAL mRNA was up-regulated; NS:Not significant.

",pII,Lymph,1
"PMC 
BMC_Cancer_2009_May_6_9_134.txt
","NS	
Gender			NS	
 Male	13	31		
 Female	18	38		
Grade			NS	
 Well-differentiated	4	3		
 Moderately differentiated	20	51		
 Poorly differentiated	7	15		
Depth of invasion			0.028	
 pT1	5	2		
 pT2	13	23		
 pT3	12	33		
 pT4	1	11		
Lymph node metastasis			0.009	
 Absent	17	19		
 Present	14	50		
Venous involvement			0.023	
 Absent	26	42		
 Present	5	27		
pTNM stage			0.011	
 pI	4	2		
 pII	13	14		
 pIII	13	44		
 pIV	1	9		
ratio <= 1: The expression of NGAL mRNA was not up-regulated; ratio &#62; 1: The expression of NGAL mRNA was up-regulated; NS:Not significant.

",NS,Lymph,1
"PMC 
BMC_Cancer_2009_May_6_9_134.txt
","NS	
Gender			NS	
 Male	13	31		
 Female	18	38		
Grade			NS	
 Well-differentiated	4	3		
 Moderately differentiated	20	51		
 Poorly differentiated	7	15		
Depth of invasion			0.028	
 pT1	5	2		
 pT2	13	23		
 pT3	12	33		
 pT4	1	11		
Lymph node metastasis			0.009	
 Absent	17	19		
 Present	14	50		
Venous involvement			0.023	
 Absent	26	42		
 Present	5	27		
pTNM stage			0.011	
 pI	4	2		
 pII	13	14		
 pIII	13	44		
 pIV	1	9		
ratio <= 1: The expression of NGAL mRNA was not up-regulated; ratio &#62; 1: The expression of NGAL mRNA was up-regulated; NS:Not significant.

",pT4,Lymph,1
"PMC 
BMC_Cancer_2009_May_6_9_134.txt
","NS	
Gender			NS	
 Male	13	31		
 Female	18	38		
Grade			NS	
 Well-differentiated	4	3		
 Moderately differentiated	20	51		
 Poorly differentiated	7	15		
Depth of invasion			0.028	
 pT1	5	2		
 pT2	13	23		
 pT3	12	33		
 pT4	1	11		
Lymph node metastasis			0.009	
 Absent	17	19		
 Present	14	50		
Venous involvement			0.023	
 Absent	26	42		
 Present	5	27		
pTNM stage			0.011	
 pI	4	2		
 pII	13	14		
 pIII	13	44		
 pIV	1	9		
ratio <= 1: The expression of NGAL mRNA was not up-regulated; ratio &#62; 1: The expression of NGAL mRNA was up-regulated; NS:Not significant.

",pIV,Lymph,1
"PMC 
BMC_Cancer_2009_May_6_9_134.txt
","NS	
Gender			NS	
 Male	13	31		
 Female	18	38		
Grade			NS	
 Well-differentiated	4	3		
 Moderately differentiated	20	51		
 Poorly differentiated	7	15		
Depth of invasion			0.028	
 pT1	5	2		
 pT2	13	23		
 pT3	12	33		
 pT4	1	11		
Lymph node metastasis			0.009	
 Absent	17	19		
 Present	14	50		
Venous involvement			0.023	
 Absent	26	42		
 Present	5	27		
pTNM stage			0.011	
 pI	4	2		
 pII	13	14		
 pIII	13	44		
 pIV	1	9		
ratio <= 1: The expression of NGAL mRNA was not up-regulated; ratio &#62; 1: The expression of NGAL mRNA was up-regulated; NS:Not significant.

",pT3,Lymph,1
"PMC 
BMC_Cancer_2009_May_6_9_134.txt
","NS	
Gender			NS	
 Male	13	31		
 Female	18	38		
Grade			NS	
 Well-differentiated	4	3		
 Moderately differentiated	20	51		
 Poorly differentiated	7	15		
Depth of invasion			0.028	
 pT1	5	2		
 pT2	13	23		
 pT3	12	33		
 pT4	1	11		
Lymph node metastasis			0.009	
 Absent	17	19		
 Present	14	50		
Venous involvement			0.023	
 Absent	26	42		
 Present	5	27		
pTNM stage			0.011	
 pI	4	2		
 pII	13	14		
 pIII	13	44		
 pIV	1	9		
ratio <= 1: The expression of NGAL mRNA was not up-regulated; ratio &#62; 1: The expression of NGAL mRNA was up-regulated; NS:Not significant.

",pIII,Lymph,1
"PMC 
BMC_Cancer_2010_Aug_16_10_431.txt
",The -460 T &#62; C SNP is located in the promoter region and may influence the promoter activity [10]; the -634 G &#62; C SNP lies within the 5'-untranslated region and may affect the transcriptional factor binding affinity [11]; the +936 C &#62; T SNP is located in the 3'-untranslated region and has been associated with lower VEGF plasma levels [12].,SNP,plasma,1
"PMC 
BMC_Cancer_2010_Aug_16_10_431.txt
",The -460 T &#62; C SNP is located in the promoter region and may influence the promoter activity [10]; the -634 G &#62; C SNP lies within the 5'-untranslated region and may affect the transcriptional factor binding affinity [11]; the +936 C &#62; T SNP is located in the 3'-untranslated region and has been associated with lower VEGF plasma levels [12].,VEGF,plasma,1
"PMC 
BMC_Cancer_2010_Aug_16_10_431.txt
",The -460 T &#62; C SNP is located in the promoter region and may influence the promoter activity [10]; the -634 G &#62; C SNP lies within the 5'-untranslated region and may affect the transcriptional factor binding affinity [11]; the +936 C &#62; T SNP is located in the 3'-untranslated region and has been associated with lower VEGF plasma levels [12].,SNP,plasma,1
"PMC 
BMC_Cancer_2010_Aug_16_10_431.txt
",The -460 T &#62; C SNP is located in the promoter region and may influence the promoter activity [10]; the -634 G &#62; C SNP lies within the 5'-untranslated region and may affect the transcriptional factor binding affinity [11]; the +936 C &#62; T SNP is located in the 3'-untranslated region and has been associated with lower VEGF plasma levels [12].,SNP,plasma,1
"PMC 
BMC_Cancer_2010_Aug_16_10_431.txt
",The -460 T &#62; C SNP is located in the promoter region and may influence the promoter activity [10]; the -634 G &#62; C SNP lies within the 5'-untranslated region and may affect the transcriptional factor binding affinity [11]; the +936 C &#62; T SNP is located in the 3'-untranslated region and has been associated with lower VEGF plasma levels [12].,T,plasma,1
"PMC 
BMC_Cancer_2010_Aug_16_10_431.txt
",The -460 T &#62; C SNP is located in the promoter region and may influence the promoter activity [10]; the -634 G &#62; C SNP lies within the 5'-untranslated region and may affect the transcriptional factor binding affinity [11]; the +936 C &#62; T SNP is located in the 3'-untranslated region and has been associated with lower VEGF plasma levels [12].,T,plasma,1
"PMC 
BMC_Cancer_2009_Nov_17_9_400.txt
","With informed consent, the characteristic information of all study subjects, including sex, age, ethnicity, HBsAg and anti-HCV, were ascertained as described previously [7], at the same time 4 ml of peripheral blood was also collected.

",HCV,blood,-1
"PMC 
BMC_Cancer_2009_Nov_17_9_400.txt
","In this study, we evaluated the AFB1-exposure levels by means of AFB1-DNA adducts levels of DNA samples from all subjects' peripheral blood leukocytes resulting from the fact that the DNA samples of liver tissue were not obtained from the controls.",AFB1-DNA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_17_9_400.txt
","In this study, we evaluated the AFB1-exposure levels by means of AFB1-DNA adducts levels of DNA samples from all subjects' peripheral blood leukocytes resulting from the fact that the DNA samples of liver tissue were not obtained from the controls.",DNA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_17_9_400.txt
","In this study, we evaluated the AFB1-exposure levels by means of AFB1-DNA adducts levels of DNA samples from all subjects' peripheral blood leukocytes resulting from the fact that the DNA samples of liver tissue were not obtained from the controls.",DNA,blood,-1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","Our preliminary results suggests that with 100% specificity, MMP1 detection in saliva rinse is potentially useful for non invasive diagnosis of HNSCC of the oral cavity or oropharynx, but technical improvement is needed since sensitivity was only 20%.

",HNSCC,saliva,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","Our preliminary results suggests that with 100% specificity, MMP1 detection in saliva rinse is potentially useful for non invasive diagnosis of HNSCC of the oral cavity or oropharynx, but technical improvement is needed since sensitivity was only 20%.

",MMP1,saliva,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","The sections were blocked with blocking solution (0.2% BSA, 0.01% saponin and 1% normal rabbit serum in PBS) for 1 hr at room temperature.",BSA,serum,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","The sections were blocked with blocking solution (0.2% BSA, 0.01% saponin and 1% normal rabbit serum in PBS) for 1 hr at room temperature.",PBS,serum,1
"PMC 
BMC_Cancer_2010_Aug_18_10_439.txt
","We compared the DNA repair capacity in peripheral blood lymphocytes following H2O2 exposure in 30 lung cancer patients, 30 non-, 30 former and 30 current smoker controls matched by age and gender.

",H2O2,blood,1
"PMC 
BMC_Cancer_2010_Aug_18_10_439.txt
","We compared the DNA repair capacity in peripheral blood lymphocytes following H2O2 exposure in 30 lung cancer patients, 30 non-, 30 former and 30 current smoker controls matched by age and gender.

",DNA,blood,1
"PMC 
BMC_Cancer_2009_Mar_5_9_77.txt
","Another indication of apoptotic cell clearance was a 9-fold increase in mRNA expression of GalNAc4S-6ST (N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase), and a high level of this molecule has been detected on apoptotic human peripheral blood lymphocytes [43].",mRNA,blood,-1
"PMC 
BMC_Cancer_2009_Sep_6_9_315.txt
","Recently, it has been reported that plasma Cripto-1 might represent a novel biomarker for the early detection of breast and colon carcinomas[8].",Cripto-1,plasma,-1
"PMC 
BMC_Cancer_2009_Mar_24_9_91.txt
",A threshold of serum PSA of 4.0 ng/ml was established as criterion for biopsy.,PSA,serum,1
"PMC 
BMC_Cancer_2009_Sep_20_9_335.txt
","Supplemental breast ultrasound after negative mammographic screening permitted diagnosis of primarily invasive carcinomas in 0.32% of women in breast density type categories 2-4 of the American College of Radiology (ACR); mean tumor size for those identified was 9.9 mm, 90% with negative lymph node status.",ACR,lymph,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","A negative prognostic impact of serum TIMP-1 has also been observed in breast cancer, colorectal cancer and other malignancies [53,54].",TIMP-1,serum,1
"PMC 
BMC_Cancer_2009_Mar_24_9_91.txt
","The present study does not consider the possible effect of concurrent prostate infections and benign prostatic hyperplasia on the serum PSA concentrations in the screened subjects, as has been described [11-13].",PSA,serum,1
"PMC 
BMC_Cancer_2009_Mar_24_9_91.txt
","Is now clear that the 2.5 ng/ml value of serum PSA is a better threshold for PCa detection, but this study was designed and conducted in a period in which this PSA serum concentration was under study as a parameter for the screenings [7,10].",PSA,serum,1
"PMC 
BMC_Cancer_2009_Mar_24_9_91.txt
","Is now clear that the 2.5 ng/ml value of serum PSA is a better threshold for PCa detection, but this study was designed and conducted in a period in which this PSA serum concentration was under study as a parameter for the screenings [7,10].",PSA,serum,1
"PMC 
BMC_Cancer_2009_Mar_24_9_91.txt
","Is now clear that the 2.5 ng/ml value of serum PSA is a better threshold for PCa detection, but this study was designed and conducted in a period in which this PSA serum concentration was under study as a parameter for the screenings [7,10].",PSA,serum,1
"PMC 
BMC_Cancer_2009_Mar_24_9_91.txt
","Is now clear that the 2.5 ng/ml value of serum PSA is a better threshold for PCa detection, but this study was designed and conducted in a period in which this PSA serum concentration was under study as a parameter for the screenings [7,10].",PSA,serum,1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","The level of immunostaining was categorized into three grades: - = negative; 5%-50% = low; &#62;50% = moderate-high, as reported by Au NH [16]

EPCs labeled with CM-Dil
Mouse bone marrow derived EPCs were induced and cultured using the EGM-2 MV Bullet Kit (CC-3202, Clonetics/BioWhittaker) as in our previous study [9].",EGM-2,bone marrow,1
"PMC 
BMC_Cancer_2010_Aug_17_10_435.txt
","The level of immunostaining was categorized into three grades: - = negative; 5%-50% = low; &#62;50% = moderate-high, as reported by Au NH [16]

EPCs labeled with CM-Dil
Mouse bone marrow derived EPCs were induced and cultured using the EGM-2 MV Bullet Kit (CC-3202, Clonetics/BioWhittaker) as in our previous study [9].",CC-3202,bone marrow,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","Conclusion
Our study, deemed as a concept proving study, has shed light on the relative diagnostic and prognostic value of serum TRACP 5b in BC patients with bone metastasis.",TRACP,serum,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","MMP-9, NGAL and MMP-9/NGAL complex serum levels were not significantly correlated with either age or BMI of patients (p &#62; 0.1).

",MMP-9,serum,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","MMP-9, NGAL and MMP-9/NGAL complex serum levels were not significantly correlated with either age or BMI of patients (p &#62; 0.1).

",NGAL,serum,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","MMP-9, NGAL and MMP-9/NGAL complex serum levels were not significantly correlated with either age or BMI of patients (p &#62; 0.1).

",BMI,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","Negative	11	32		
ER**	Positive	16	47	0.156	
	Negative	12	16		
HER**	Positive	6	12	1.00	
	Negative	19	38		
Prior chemotherapy **	None	4	14	0.619	
	One line	16	30		
	>= 2 lines	7	16		
*: Student t test (2-tailed)

**: Chi-Square

Serum TRACP 5b Interval Changes and the Overall Survival Time
",TRACP,Serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","Negative	11	32		
ER**	Positive	16	47	0.156	
	Negative	12	16		
HER**	Positive	6	12	1.00	
	Negative	19	38		
Prior chemotherapy **	None	4	14	0.619	
	One line	16	30		
	>= 2 lines	7	16		
*: Student t test (2-tailed)

**: Chi-Square

Serum TRACP 5b Interval Changes and the Overall Survival Time
",ER,Serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","Negative	11	32		
ER**	Positive	16	47	0.156	
	Negative	12	16		
HER**	Positive	6	12	1.00	
	Negative	19	38		
Prior chemotherapy **	None	4	14	0.619	
	One line	16	30		
	>= 2 lines	7	16		
*: Student t test (2-tailed)

**: Chi-Square

Serum TRACP 5b Interval Changes and the Overall Survival Time
",HER,Serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Correlations between serum VEGF-165 and TIMP-1 concentrations and treatment response according to CA-125 are shown in Table 5.

",VEGF-165,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Correlations between serum VEGF-165 and TIMP-1 concentrations and treatment response according to CA-125 are shown in Table 5.

",TIMP-1,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Correlations between serum VEGF-165 and TIMP-1 concentrations and treatment response according to CA-125 are shown in Table 5.

",CA-125,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
",The maximal interval change between baseline and follow-up serum TRACP 5b activities (DmaxTRACP 5b) within 6 months of enrollment in each individual patient was calculated as [(baseline TRACP 5b activity - TRACP 5b activity at maximal alteration)]/baseline TRACP 5b activity x 100%.,TRACP,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
",The maximal interval change between baseline and follow-up serum TRACP 5b activities (DmaxTRACP 5b) within 6 months of enrollment in each individual patient was calculated as [(baseline TRACP 5b activity - TRACP 5b activity at maximal alteration)]/baseline TRACP 5b activity x 100%.,TRACP,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
",The maximal interval change between baseline and follow-up serum TRACP 5b activities (DmaxTRACP 5b) within 6 months of enrollment in each individual patient was calculated as [(baseline TRACP 5b activity - TRACP 5b activity at maximal alteration)]/baseline TRACP 5b activity x 100%.,TRACP,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
",The maximal interval change between baseline and follow-up serum TRACP 5b activities (DmaxTRACP 5b) within 6 months of enrollment in each individual patient was calculated as [(baseline TRACP 5b activity - TRACP 5b activity at maximal alteration)]/baseline TRACP 5b activity x 100%.,TRACP,serum,1
"PMC 
BMC_Cancer_2009_Oct_22_9_376.txt
","Although we can not discriminate CYFRA 21-1 from CK19 via the qRT-PCR in feces, the fecal CK19 can still partially reflect the sloughed CRC cells because of a coincidence between the data of feces and colonic tumor specimens (data not shown).",PCR,feces,1
"PMC 
BMC_Cancer_2009_Oct_22_9_376.txt
","Although we can not discriminate CYFRA 21-1 from CK19 via the qRT-PCR in feces, the fecal CK19 can still partially reflect the sloughed CRC cells because of a coincidence between the data of feces and colonic tumor specimens (data not shown).",PCR,feces,1
"PMC 
BMC_Cancer_2009_Oct_22_9_376.txt
","Although we can not discriminate CYFRA 21-1 from CK19 via the qRT-PCR in feces, the fecal CK19 can still partially reflect the sloughed CRC cells because of a coincidence between the data of feces and colonic tumor specimens (data not shown).",CK19,feces,1
"PMC 
BMC_Cancer_2009_Oct_22_9_376.txt
","Although we can not discriminate CYFRA 21-1 from CK19 via the qRT-PCR in feces, the fecal CK19 can still partially reflect the sloughed CRC cells because of a coincidence between the data of feces and colonic tumor specimens (data not shown).",CK19,feces,1
"PMC 
BMC_Cancer_2009_Oct_22_9_376.txt
","Although we can not discriminate CYFRA 21-1 from CK19 via the qRT-PCR in feces, the fecal CK19 can still partially reflect the sloughed CRC cells because of a coincidence between the data of feces and colonic tumor specimens (data not shown).",qRT,feces,1
"PMC 
BMC_Cancer_2009_Oct_22_9_376.txt
","Although we can not discriminate CYFRA 21-1 from CK19 via the qRT-PCR in feces, the fecal CK19 can still partially reflect the sloughed CRC cells because of a coincidence between the data of feces and colonic tumor specimens (data not shown).",qRT,feces,1
"PMC 
BMC_Cancer_2009_Oct_22_9_376.txt
","Although we can not discriminate CYFRA 21-1 from CK19 via the qRT-PCR in feces, the fecal CK19 can still partially reflect the sloughed CRC cells because of a coincidence between the data of feces and colonic tumor specimens (data not shown).",CK19,feces,1
"PMC 
BMC_Cancer_2009_Oct_22_9_376.txt
","Although we can not discriminate CYFRA 21-1 from CK19 via the qRT-PCR in feces, the fecal CK19 can still partially reflect the sloughed CRC cells because of a coincidence between the data of feces and colonic tumor specimens (data not shown).",CK19,feces,1
"PMC 
BMC_Cancer_2009_Oct_22_9_376.txt
","Although we can not discriminate CYFRA 21-1 from CK19 via the qRT-PCR in feces, the fecal CK19 can still partially reflect the sloughed CRC cells because of a coincidence between the data of feces and colonic tumor specimens (data not shown).",CYFRA,feces,1
"PMC 
BMC_Cancer_2009_Oct_22_9_376.txt
","Although we can not discriminate CYFRA 21-1 from CK19 via the qRT-PCR in feces, the fecal CK19 can still partially reflect the sloughed CRC cells because of a coincidence between the data of feces and colonic tumor specimens (data not shown).",CYFRA,feces,1
"PMC 
BMC_Cancer_2009_Oct_22_9_376.txt
","Although we can not discriminate CYFRA 21-1 from CK19 via the qRT-PCR in feces, the fecal CK19 can still partially reflect the sloughed CRC cells because of a coincidence between the data of feces and colonic tumor specimens (data not shown).",CRC,feces,1
"PMC 
BMC_Cancer_2009_Oct_22_9_376.txt
","Although we can not discriminate CYFRA 21-1 from CK19 via the qRT-PCR in feces, the fecal CK19 can still partially reflect the sloughed CRC cells because of a coincidence between the data of feces and colonic tumor specimens (data not shown).",CRC,feces,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
",In our opinion mRNA overexpression due to tumour alterations is more likely to be detected in the salivary floating-cells pellets than in the more RNA-diluted free cell saliva.,RNA,saliva,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
",In our opinion mRNA overexpression due to tumour alterations is more likely to be detected in the salivary floating-cells pellets than in the more RNA-diluted free cell saliva.,mRNA,saliva,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
",Figure 2 Serum levels of NGAL depicted as box-plots.,NGAL,Serum,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","Figure 5 Correlation between serum IL-6 and CRP levels in gastric cancer.

",IL-6,serum,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","Figure 5 Correlation between serum IL-6 and CRP levels in gastric cancer.

",CRP,serum,1
"PMC 
BMC_Cancer_2009_May_11_9_142.txt
","LNCaP (a) and NIH3T3 (b) cells were serum starved for 24 hr, pretreated with drugs as indicated for 2 hr, and then treated with pervanadate (100 mM) for 10 min.",NIH3T3,serum,1
"PMC 
BMC_Cancer_2010_Aug_17_10_437.txt
","In the control group, eight lymph nodes were positive for lymph node metastases, whereas two of the lymph nodes in the PDTC group had metastases, and one lymph node in the BAY 11-7085 group contained a metastasis (Fig.",PDTC,lymph,1
"PMC 
BMC_Cancer_2010_Aug_17_10_437.txt
","In the control group, eight lymph nodes were positive for lymph node metastases, whereas two of the lymph nodes in the PDTC group had metastases, and one lymph node in the BAY 11-7085 group contained a metastasis (Fig.",PDTC,lymph,1
"PMC 
BMC_Cancer_2010_Aug_17_10_437.txt
","In the control group, eight lymph nodes were positive for lymph node metastases, whereas two of the lymph nodes in the PDTC group had metastases, and one lymph node in the BAY 11-7085 group contained a metastasis (Fig.",PDTC,lymph,1
"PMC 
BMC_Cancer_2010_Aug_17_10_437.txt
","In the control group, eight lymph nodes were positive for lymph node metastases, whereas two of the lymph nodes in the PDTC group had metastases, and one lymph node in the BAY 11-7085 group contained a metastasis (Fig.",PDTC,lymph,1
"PMC 
BMC_Cancer_2010_Aug_17_10_437.txt
","In the control group, eight lymph nodes were positive for lymph node metastases, whereas two of the lymph nodes in the PDTC group had metastases, and one lymph node in the BAY 11-7085 group contained a metastasis (Fig.",BAY,lymph,1
"PMC 
BMC_Cancer_2010_Aug_17_10_437.txt
","In the control group, eight lymph nodes were positive for lymph node metastases, whereas two of the lymph nodes in the PDTC group had metastases, and one lymph node in the BAY 11-7085 group contained a metastasis (Fig.",BAY,lymph,1
"PMC 
BMC_Cancer_2010_Aug_17_10_437.txt
","In the control group, eight lymph nodes were positive for lymph node metastases, whereas two of the lymph nodes in the PDTC group had metastases, and one lymph node in the BAY 11-7085 group contained a metastasis (Fig.",BAY,lymph,1
"PMC 
BMC_Cancer_2010_Aug_17_10_437.txt
","In the control group, eight lymph nodes were positive for lymph node metastases, whereas two of the lymph nodes in the PDTC group had metastases, and one lymph node in the BAY 11-7085 group contained a metastasis (Fig.",BAY,lymph,1
"PMC 
BMC_Cancer_2009_Mar_4_9_75.txt
","MCF-7 cells were maintained as monolayer cultures in Dulbecco's modified Eagle's medium (DMEM; Gibco, New York) supplemented with 10% fetal bovine serum (FBS; Hyclone, UT), 100 U/ml penicillin G and 100 mg/ml streptomycin.",MCF-7,serum,1
"PMC 
BMC_Cancer_2009_Mar_4_9_75.txt
","MCF-7 cells were maintained as monolayer cultures in Dulbecco's modified Eagle's medium (DMEM; Gibco, New York) supplemented with 10% fetal bovine serum (FBS; Hyclone, UT), 100 U/ml penicillin G and 100 mg/ml streptomycin.",DMEM,serum,1
"PMC 
BMC_Cancer_2009_Mar_4_9_75.txt
","MCF-7 cells were maintained as monolayer cultures in Dulbecco's modified Eagle's medium (DMEM; Gibco, New York) supplemented with 10% fetal bovine serum (FBS; Hyclone, UT), 100 U/ml penicillin G and 100 mg/ml streptomycin.",FBS,serum,1
"PMC 
BMC_Cancer_2009_Oct_22_9_376.txt
","One of these mutant molecules, cytokeratin 19 (CK19), is differentially expressed in the peripheral blood [8,9] and lymph nodes [10] of patients with breast cancer, or in epithelial cells of CRC patients with advanced Dukes' stage [11].",CRC,blood,-1
"PMC 
BMC_Cancer_2009_Oct_22_9_376.txt
","One of these mutant molecules, cytokeratin 19 (CK19), is differentially expressed in the peripheral blood [8,9] and lymph nodes [10] of patients with breast cancer, or in epithelial cells of CRC patients with advanced Dukes' stage [11].",CRC,lymph,-1
"PMC 
BMC_Cancer_2009_Oct_22_9_376.txt
","One of these mutant molecules, cytokeratin 19 (CK19), is differentially expressed in the peripheral blood [8,9] and lymph nodes [10] of patients with breast cancer, or in epithelial cells of CRC patients with advanced Dukes' stage [11].",CK19,blood,-1
"PMC 
BMC_Cancer_2009_Oct_22_9_376.txt
","One of these mutant molecules, cytokeratin 19 (CK19), is differentially expressed in the peripheral blood [8,9] and lymph nodes [10] of patients with breast cancer, or in epithelial cells of CRC patients with advanced Dukes' stage [11].",CK19,lymph,-1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","Fifteen informed, consenting subjects participated as a control group to determine the least significant change (LSC) of serum TRACP 5b activity.",TRACP,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","Fifteen informed, consenting subjects participated as a control group to determine the least significant change (LSC) of serum TRACP 5b activity.",LSC,serum,1
"PMC 
BMC_Cancer_2009_Nov_16_9_397.txt
","All study participants had available DNA extracted from whole blood and provided written informed consent for participation in genetic analysis studies under a protocol approved by the Howard University Institutional Review Board as well as from the HUH Division of Urology.

",DNA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_397.txt
","All study participants had available DNA extracted from whole blood and provided written informed consent for participation in genetic analysis studies under a protocol approved by the Howard University Institutional Review Board as well as from the HUH Division of Urology.

",HUH,blood,-1
"PMC 
BMC_Cancer_2009_Sep_4_9_312.txt
","Risk factor information was collected through interviews, clinical data was abstracted from medical records, and DNA was extracted from peripheral blood (Gentra).",DNA,blood,-1
"PMC 
BMC_Cancer_2009_Mar_5_9_77.txt
","Studies by others have suggested that apoptotic AML blasts will not be detected in peripheral blood samples during chemotherapy [27,28].",AML,blood,-1
"PMC 
BMC_Cancer_2009_Sep_8_9_317.txt
",MAOB was found to be expressed in lymph node metastases.,MAOB,lymph,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Conclusion
This study is the first comprehensive longitudinal analysis of serum VEGF-165 and TIMP-1 in patients with ovarian cancer.",VEGF-165,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Conclusion
This study is the first comprehensive longitudinal analysis of serum VEGF-165 and TIMP-1 in patients with ovarian cancer.",TIMP-1,serum,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
",The obtained data were analyzed by Biomarker Wizard software to screen serum proteome biomarkers for OS.,OS,serum,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","In this study, we used the alkaline SCGE assay at pH 12.3 and pH &#62;13 in non-stimulated and PHA-stimulated human blood cells to assess the genotoxicity associated with etoposide-induced oxidative stress in non-transformed cells.",SCGE,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","In this study, we used the alkaline SCGE assay at pH 12.3 and pH &#62;13 in non-stimulated and PHA-stimulated human blood cells to assess the genotoxicity associated with etoposide-induced oxidative stress in non-transformed cells.",PHA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","If etoposide treatment generates the production of reactive oxygen species, principally phenoxyl radicals, in non-stimulated whole blood cells, then exposure to an antioxidant should reduce the extent of DNA damage induced.

",DNA,blood,-1
"PMC 
BMC_Cancer_2010_Apr_7_10_128.txt
","Stably transfected 293 cells
HEK293 cells were always grown in high glucose DMEM (Invitrogen) with 10% fetal bovine serum, sodium pyruvate (Cellgro), and MEM nonessential amino acids (Cellgro) to 70% confluency in 100 mm dishes.",HEK293,serum,1
"PMC 
BMC_Cancer_2010_Apr_7_10_128.txt
","Stably transfected 293 cells
HEK293 cells were always grown in high glucose DMEM (Invitrogen) with 10% fetal bovine serum, sodium pyruvate (Cellgro), and MEM nonessential amino acids (Cellgro) to 70% confluency in 100 mm dishes.",DMEM,serum,1
"PMC 
BMC_Cancer_2010_Apr_7_10_128.txt
","Stably transfected 293 cells
HEK293 cells were always grown in high glucose DMEM (Invitrogen) with 10% fetal bovine serum, sodium pyruvate (Cellgro), and MEM nonessential amino acids (Cellgro) to 70% confluency in 100 mm dishes.",MEM,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
",The resulting groups were compared regarding the following parameters: age: &#60;61 years versus 61 years and older; ascites: &#60;500 ml versus &#62;500 ml; residual tumor after surgery: microscopic versus macroscopic; lymph node status: no metastasis versus lymph-node metastasis; grading: G2 versus G3.,G2,ascites,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
",The resulting groups were compared regarding the following parameters: age: &#60;61 years versus 61 years and older; ascites: &#60;500 ml versus &#62;500 ml; residual tumor after surgery: microscopic versus macroscopic; lymph node status: no metastasis versus lymph-node metastasis; grading: G2 versus G3.,G2,lymph,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
",The resulting groups were compared regarding the following parameters: age: &#60;61 years versus 61 years and older; ascites: &#60;500 ml versus &#62;500 ml; residual tumor after surgery: microscopic versus macroscopic; lymph node status: no metastasis versus lymph-node metastasis; grading: G2 versus G3.,G2,lymph,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
",The resulting groups were compared regarding the following parameters: age: &#60;61 years versus 61 years and older; ascites: &#60;500 ml versus &#62;500 ml; residual tumor after surgery: microscopic versus macroscopic; lymph node status: no metastasis versus lymph-node metastasis; grading: G2 versus G3.,G3,ascites,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
",The resulting groups were compared regarding the following parameters: age: &#60;61 years versus 61 years and older; ascites: &#60;500 ml versus &#62;500 ml; residual tumor after surgery: microscopic versus macroscopic; lymph node status: no metastasis versus lymph-node metastasis; grading: G2 versus G3.,G3,lymph,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
",The resulting groups were compared regarding the following parameters: age: &#60;61 years versus 61 years and older; ascites: &#60;500 ml versus &#62;500 ml; residual tumor after surgery: microscopic versus macroscopic; lymph node status: no metastasis versus lymph-node metastasis; grading: G2 versus G3.,G3,lymph,1
"PMC 
BMC_Cancer_2009_May_28_9_164.txt
","Selected serum proteins
The iterated BMA algorithm chose the best-fitting probit models.",BMA,serum,1
"PMC 
BMC_Cancer_2010_Apr_7_10_129.txt
","Methods
Cell culture and generation of lentivirus vectors
The 293T and SW780 cell lines were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum.",SW780,serum,1
"PMC 
BMC_Cancer_2010_Apr_7_10_129.txt
","Methods
Cell culture and generation of lentivirus vectors
The 293T and SW780 cell lines were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum.",T,serum,1
"PMC 
BMC_Cancer_2010_Apr_18_10_147.txt
","Cases	Controls	
			
	n	%	n	%	
Sex					
Male	315	60.3	404	56.7	
Female	207	39.7	308	42.7	
Age (years)					
<=40	195	37.4	242	34.0	
41-50	134	25.7	186	26.1	
51-60	93	17.8	166	23.3	
&#62;60	100	19.1	118	16.6	
Tumor stage					
I	126	24.2			
II	208	39.8			
III	177	33.9			
IV	11	2.1			
EBV Infection status					
Positive	329	63.1			
Negative	162	31.0			
Data missing	31	5.9			
Metastasis					
Present	283	54.2			
Absent	239	45.8			
Polymorphism analysis
Genomic DNA was isolated from the peripheral blood lymphocytes of the study subjects.",III,blood,1
"PMC 
BMC_Cancer_2010_Apr_18_10_147.txt
","Cases	Controls	
			
	n	%	n	%	
Sex					
Male	315	60.3	404	56.7	
Female	207	39.7	308	42.7	
Age (years)					
<=40	195	37.4	242	34.0	
41-50	134	25.7	186	26.1	
51-60	93	17.8	166	23.3	
&#62;60	100	19.1	118	16.6	
Tumor stage					
I	126	24.2			
II	208	39.8			
III	177	33.9			
IV	11	2.1			
EBV Infection status					
Positive	329	63.1			
Negative	162	31.0			
Data missing	31	5.9			
Metastasis					
Present	283	54.2			
Absent	239	45.8			
Polymorphism analysis
Genomic DNA was isolated from the peripheral blood lymphocytes of the study subjects.",EBV,blood,1
"PMC 
BMC_Cancer_2010_Apr_18_10_147.txt
","Cases	Controls	
			
	n	%	n	%	
Sex					
Male	315	60.3	404	56.7	
Female	207	39.7	308	42.7	
Age (years)					
<=40	195	37.4	242	34.0	
41-50	134	25.7	186	26.1	
51-60	93	17.8	166	23.3	
&#62;60	100	19.1	118	16.6	
Tumor stage					
I	126	24.2			
II	208	39.8			
III	177	33.9			
IV	11	2.1			
EBV Infection status					
Positive	329	63.1			
Negative	162	31.0			
Data missing	31	5.9			
Metastasis					
Present	283	54.2			
Absent	239	45.8			
Polymorphism analysis
Genomic DNA was isolated from the peripheral blood lymphocytes of the study subjects.",DNA,blood,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","They found an elevated preoperative serum TIMP-1 to be associated with unfavourable clinical outcome, as previously suggested in a smaller study by Manenti et al. [40].",TIMP-1,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
",The maximal interval change within 6 months for serum TRACP 5b activity was used to stratify patients into two groups according to whether the interval change was greater or less than the LSC.,TRACP,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
",The maximal interval change within 6 months for serum TRACP 5b activity was used to stratify patients into two groups according to whether the interval change was greater or less than the LSC.,LSC,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Given the high inter-study-variability of VEGF serum levels, a longitudinal measurement of individual patient levels might be a better approach than the assessment of absolute values at single time-points.

",VEGF,serum,1
"PMC 
BMC_Cancer_2010_Aug_17_10_434.txt
","In an archival study using exfoliated epithelial cells in sputum, hnRNP A2/B1 over-expression was considered to be a promising new diagnostic marker able to accurately predict lung carcinogenesis at least a year before the appearance of any cytological findings [19,20].",B1,sputum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","When comparing different study results there is a high variability of VEGF serum levels, which might be caused by differences in assay techniques (many assays have no specificity for different VEGF-isoforms), storage of specimens and the small number of samples analyzed in most studies.",VEGF,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","When comparing different study results there is a high variability of VEGF serum levels, which might be caused by differences in assay techniques (many assays have no specificity for different VEGF-isoforms), storage of specimens and the small number of samples analyzed in most studies.",VEGF,serum,1
"PMC 
BMC_Cancer_2009_Sep_8_9_317.txt
","Also, CNTN1 has been shown to promote differentiation in CD90+ bone marrow stromal cells [55].",CNTN1,bone marrow,-1
"PMC 
BMC_Cancer_2009_Sep_8_9_317.txt
","Also, CNTN1 has been shown to promote differentiation in CD90+ bone marrow stromal cells [55].",CD90,bone marrow,-1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","Conclusion
Preoperative serum IL-6 and CRP levels were related to cancer stage and might be markers of tumor invasion, LN metastasis and TNM stage.",TNM,serum,-1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","Conclusion
Preoperative serum IL-6 and CRP levels were related to cancer stage and might be markers of tumor invasion, LN metastasis and TNM stage.",IL-6,serum,-1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","Conclusion
Preoperative serum IL-6 and CRP levels were related to cancer stage and might be markers of tumor invasion, LN metastasis and TNM stage.",CRP,serum,-1
"PMC 
BMC_Cancer_2009_Oct_6_9_354.txt
",".

Methylation status in peripheral blood
No RASSF1 or CDKN2A methylation was observed in DNA extracted from peripheral blood lymphocytes, while one sample (1.3%), a T4N0 M0 (stage IVa) squamous cancer of the oral cavity, showed MGMT methylation in the DNA sample obtained from blood cells.

",MGMT,blood,-1
"PMC 
BMC_Cancer_2009_Oct_6_9_354.txt
",".

Methylation status in peripheral blood
No RASSF1 or CDKN2A methylation was observed in DNA extracted from peripheral blood lymphocytes, while one sample (1.3%), a T4N0 M0 (stage IVa) squamous cancer of the oral cavity, showed MGMT methylation in the DNA sample obtained from blood cells.

",MGMT,blood,-1
"PMC 
BMC_Cancer_2009_Oct_6_9_354.txt
",".

Methylation status in peripheral blood
No RASSF1 or CDKN2A methylation was observed in DNA extracted from peripheral blood lymphocytes, while one sample (1.3%), a T4N0 M0 (stage IVa) squamous cancer of the oral cavity, showed MGMT methylation in the DNA sample obtained from blood cells.

",MGMT,blood,-1
"PMC 
BMC_Cancer_2009_Oct_6_9_354.txt
",".

Methylation status in peripheral blood
No RASSF1 or CDKN2A methylation was observed in DNA extracted from peripheral blood lymphocytes, while one sample (1.3%), a T4N0 M0 (stage IVa) squamous cancer of the oral cavity, showed MGMT methylation in the DNA sample obtained from blood cells.

",CDKN2A,blood,-1
"PMC 
BMC_Cancer_2009_Oct_6_9_354.txt
",".

Methylation status in peripheral blood
No RASSF1 or CDKN2A methylation was observed in DNA extracted from peripheral blood lymphocytes, while one sample (1.3%), a T4N0 M0 (stage IVa) squamous cancer of the oral cavity, showed MGMT methylation in the DNA sample obtained from blood cells.

",CDKN2A,blood,-1
"PMC 
BMC_Cancer_2009_Oct_6_9_354.txt
",".

Methylation status in peripheral blood
No RASSF1 or CDKN2A methylation was observed in DNA extracted from peripheral blood lymphocytes, while one sample (1.3%), a T4N0 M0 (stage IVa) squamous cancer of the oral cavity, showed MGMT methylation in the DNA sample obtained from blood cells.

",CDKN2A,blood,-1
"PMC 
BMC_Cancer_2009_Oct_6_9_354.txt
",".

Methylation status in peripheral blood
No RASSF1 or CDKN2A methylation was observed in DNA extracted from peripheral blood lymphocytes, while one sample (1.3%), a T4N0 M0 (stage IVa) squamous cancer of the oral cavity, showed MGMT methylation in the DNA sample obtained from blood cells.

",DNA,blood,-1
"PMC 
BMC_Cancer_2009_Oct_6_9_354.txt
",".

Methylation status in peripheral blood
No RASSF1 or CDKN2A methylation was observed in DNA extracted from peripheral blood lymphocytes, while one sample (1.3%), a T4N0 M0 (stage IVa) squamous cancer of the oral cavity, showed MGMT methylation in the DNA sample obtained from blood cells.

",DNA,blood,-1
"PMC 
BMC_Cancer_2009_Oct_6_9_354.txt
",".

Methylation status in peripheral blood
No RASSF1 or CDKN2A methylation was observed in DNA extracted from peripheral blood lymphocytes, while one sample (1.3%), a T4N0 M0 (stage IVa) squamous cancer of the oral cavity, showed MGMT methylation in the DNA sample obtained from blood cells.

",DNA,blood,-1
"PMC 
BMC_Cancer_2009_Oct_6_9_354.txt
",".

Methylation status in peripheral blood
No RASSF1 or CDKN2A methylation was observed in DNA extracted from peripheral blood lymphocytes, while one sample (1.3%), a T4N0 M0 (stage IVa) squamous cancer of the oral cavity, showed MGMT methylation in the DNA sample obtained from blood cells.

",M0,blood,-1
"PMC 
BMC_Cancer_2009_Oct_6_9_354.txt
",".

Methylation status in peripheral blood
No RASSF1 or CDKN2A methylation was observed in DNA extracted from peripheral blood lymphocytes, while one sample (1.3%), a T4N0 M0 (stage IVa) squamous cancer of the oral cavity, showed MGMT methylation in the DNA sample obtained from blood cells.

",M0,blood,-1
"PMC 
BMC_Cancer_2009_Oct_6_9_354.txt
",".

Methylation status in peripheral blood
No RASSF1 or CDKN2A methylation was observed in DNA extracted from peripheral blood lymphocytes, while one sample (1.3%), a T4N0 M0 (stage IVa) squamous cancer of the oral cavity, showed MGMT methylation in the DNA sample obtained from blood cells.

",M0,blood,-1
"PMC 
BMC_Cancer_2009_Oct_6_9_354.txt
",".

Methylation status in peripheral blood
No RASSF1 or CDKN2A methylation was observed in DNA extracted from peripheral blood lymphocytes, while one sample (1.3%), a T4N0 M0 (stage IVa) squamous cancer of the oral cavity, showed MGMT methylation in the DNA sample obtained from blood cells.

",DNA,blood,-1
"PMC 
BMC_Cancer_2009_Oct_6_9_354.txt
",".

Methylation status in peripheral blood
No RASSF1 or CDKN2A methylation was observed in DNA extracted from peripheral blood lymphocytes, while one sample (1.3%), a T4N0 M0 (stage IVa) squamous cancer of the oral cavity, showed MGMT methylation in the DNA sample obtained from blood cells.

",DNA,blood,-1
"PMC 
BMC_Cancer_2009_Oct_6_9_354.txt
",".

Methylation status in peripheral blood
No RASSF1 or CDKN2A methylation was observed in DNA extracted from peripheral blood lymphocytes, while one sample (1.3%), a T4N0 M0 (stage IVa) squamous cancer of the oral cavity, showed MGMT methylation in the DNA sample obtained from blood cells.

",DNA,blood,-1
"PMC 
BMC_Cancer_2009_Oct_6_9_354.txt
",".

Methylation status in peripheral blood
No RASSF1 or CDKN2A methylation was observed in DNA extracted from peripheral blood lymphocytes, while one sample (1.3%), a T4N0 M0 (stage IVa) squamous cancer of the oral cavity, showed MGMT methylation in the DNA sample obtained from blood cells.

",RASSF1,blood,-1
"PMC 
BMC_Cancer_2009_Oct_6_9_354.txt
",".

Methylation status in peripheral blood
No RASSF1 or CDKN2A methylation was observed in DNA extracted from peripheral blood lymphocytes, while one sample (1.3%), a T4N0 M0 (stage IVa) squamous cancer of the oral cavity, showed MGMT methylation in the DNA sample obtained from blood cells.

",RASSF1,blood,-1
"PMC 
BMC_Cancer_2009_Oct_6_9_354.txt
",".

Methylation status in peripheral blood
No RASSF1 or CDKN2A methylation was observed in DNA extracted from peripheral blood lymphocytes, while one sample (1.3%), a T4N0 M0 (stage IVa) squamous cancer of the oral cavity, showed MGMT methylation in the DNA sample obtained from blood cells.

",RASSF1,blood,-1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","We tested the hypothesis that baseline serum TRACP 5b activity and its interval change are potential prognostic markers of survival in BC patients with bone metastasis.

",TRACP,serum,1
"PMC 
BMC_Cancer_2010_Aug_17_10_437.txt
","All five of these cell lines were maintained in RPMI 1640 with 10% fetal bovine serum (FBS) supplemented with 1 mM L-glutamine, 100 U/ml penicillin and 100 U/ml streptomycin and were kept at 37degC and 5% CO2.

",RPMI,serum,1
"PMC 
BMC_Cancer_2010_Aug_17_10_437.txt
","All five of these cell lines were maintained in RPMI 1640 with 10% fetal bovine serum (FBS) supplemented with 1 mM L-glutamine, 100 U/ml penicillin and 100 U/ml streptomycin and were kept at 37degC and 5% CO2.

",FBS,serum,1
"PMC 
BMC_Cancer_2010_Aug_17_10_437.txt
","All five of these cell lines were maintained in RPMI 1640 with 10% fetal bovine serum (FBS) supplemented with 1 mM L-glutamine, 100 U/ml penicillin and 100 U/ml streptomycin and were kept at 37degC and 5% CO2.

",CO2,serum,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","The blood samples for CRP analysis were collected in serum separation tubes, and the serum CRP levels were measured via immunoturbidimetry (Denka Seiken Co. Ltd., Japan).

",CRP,serum,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","The blood samples for CRP analysis were collected in serum separation tubes, and the serum CRP levels were measured via immunoturbidimetry (Denka Seiken Co. Ltd., Japan).

",CRP,blood,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","The blood samples for CRP analysis were collected in serum separation tubes, and the serum CRP levels were measured via immunoturbidimetry (Denka Seiken Co. Ltd., Japan).

",CRP,serum,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","The blood samples for CRP analysis were collected in serum separation tubes, and the serum CRP levels were measured via immunoturbidimetry (Denka Seiken Co. Ltd., Japan).

",CRP,serum,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","The blood samples for CRP analysis were collected in serum separation tubes, and the serum CRP levels were measured via immunoturbidimetry (Denka Seiken Co. Ltd., Japan).

",CRP,blood,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","The blood samples for CRP analysis were collected in serum separation tubes, and the serum CRP levels were measured via immunoturbidimetry (Denka Seiken Co. Ltd., Japan).

",CRP,serum,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","Results
Increases in cancer invasion and staging are generally associated with increases in preoperative serum IL-6 levels. IL-6 and",IL-6,serum,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","Results
Increases in cancer invasion and staging are generally associated with increases in preoperative serum IL-6 levels. IL-6 and",IL-6,serum,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Similarly, high levels of plasma and serum TIMP-1 are associated with a decreased response to endocrine therapy in metastatic breast cancer patients [9,10].",TIMP-1,serum,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Similarly, high levels of plasma and serum TIMP-1 are associated with a decreased response to endocrine therapy in metastatic breast cancer patients [9,10].",TIMP-1,plasma,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","Median overall survival time (Days)		481(1-4465)	
Median initial TRACP-5b activity (U/L)		3.894 (1.21-24.245)	
Median CEA (ng/ml)		3.5 (1-8165)	
Median CA-153 (U/ml)		42.15 (6.59-3040)	
ER	positive	63	
	negative	28	
	unknown	9	
Her-2/neu	positive	18	
	negative	57	
	unknown	25	
Visceral metastasis present		57	
Bone metastasis only		43	
Prior chemotherapy	None	18	
	One line	46	
	>= 2 lines	23	
	unknown	13	
Least Significant Change of TRACP 5b
The LSC of serum TRACP 5b activity over time was calculated from 4 consecutive monthly samples from 15 patients with early BC without distant metastasis.",LSC,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","Median overall survival time (Days)		481(1-4465)	
Median initial TRACP-5b activity (U/L)		3.894 (1.21-24.245)	
Median CEA (ng/ml)		3.5 (1-8165)	
Median CA-153 (U/ml)		42.15 (6.59-3040)	
ER	positive	63	
	negative	28	
	unknown	9	
Her-2/neu	positive	18	
	negative	57	
	unknown	25	
Visceral metastasis present		57	
Bone metastasis only		43	
Prior chemotherapy	None	18	
	One line	46	
	>= 2 lines	23	
	unknown	13	
Least Significant Change of TRACP 5b
The LSC of serum TRACP 5b activity over time was calculated from 4 consecutive monthly samples from 15 patients with early BC without distant metastasis.",CA-153,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","Median overall survival time (Days)		481(1-4465)	
Median initial TRACP-5b activity (U/L)		3.894 (1.21-24.245)	
Median CEA (ng/ml)		3.5 (1-8165)	
Median CA-153 (U/ml)		42.15 (6.59-3040)	
ER	positive	63	
	negative	28	
	unknown	9	
Her-2/neu	positive	18	
	negative	57	
	unknown	25	
Visceral metastasis present		57	
Bone metastasis only		43	
Prior chemotherapy	None	18	
	One line	46	
	>= 2 lines	23	
	unknown	13	
Least Significant Change of TRACP 5b
The LSC of serum TRACP 5b activity over time was calculated from 4 consecutive monthly samples from 15 patients with early BC without distant metastasis.",TRACP,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","Median overall survival time (Days)		481(1-4465)	
Median initial TRACP-5b activity (U/L)		3.894 (1.21-24.245)	
Median CEA (ng/ml)		3.5 (1-8165)	
Median CA-153 (U/ml)		42.15 (6.59-3040)	
ER	positive	63	
	negative	28	
	unknown	9	
Her-2/neu	positive	18	
	negative	57	
	unknown	25	
Visceral metastasis present		57	
Bone metastasis only		43	
Prior chemotherapy	None	18	
	One line	46	
	>= 2 lines	23	
	unknown	13	
Least Significant Change of TRACP 5b
The LSC of serum TRACP 5b activity over time was calculated from 4 consecutive monthly samples from 15 patients with early BC without distant metastasis.",CEA,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","Median overall survival time (Days)		481(1-4465)	
Median initial TRACP-5b activity (U/L)		3.894 (1.21-24.245)	
Median CEA (ng/ml)		3.5 (1-8165)	
Median CA-153 (U/ml)		42.15 (6.59-3040)	
ER	positive	63	
	negative	28	
	unknown	9	
Her-2/neu	positive	18	
	negative	57	
	unknown	25	
Visceral metastasis present		57	
Bone metastasis only		43	
Prior chemotherapy	None	18	
	One line	46	
	>= 2 lines	23	
	unknown	13	
Least Significant Change of TRACP 5b
The LSC of serum TRACP 5b activity over time was calculated from 4 consecutive monthly samples from 15 patients with early BC without distant metastasis.",ER,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","Median overall survival time (Days)		481(1-4465)	
Median initial TRACP-5b activity (U/L)		3.894 (1.21-24.245)	
Median CEA (ng/ml)		3.5 (1-8165)	
Median CA-153 (U/ml)		42.15 (6.59-3040)	
ER	positive	63	
	negative	28	
	unknown	9	
Her-2/neu	positive	18	
	negative	57	
	unknown	25	
Visceral metastasis present		57	
Bone metastasis only		43	
Prior chemotherapy	None	18	
	One line	46	
	>= 2 lines	23	
	unknown	13	
Least Significant Change of TRACP 5b
The LSC of serum TRACP 5b activity over time was calculated from 4 consecutive monthly samples from 15 patients with early BC without distant metastasis.",TRACP,serum,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","We hypothesized that high levels of TIMP-1 are associated with decreased benefit from adjuvant chemotherapy and we investigated this hypothesis in a cohort of 525 premenopausal lymph node-positive breast cancer patients, who constitute a subgroup of a large cohort previously described in several studies [14,18,19].",TIMP-1,lymph,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Table 2 Serum concentrations of CA-125, TIMP-1 and VEGF at different time-points during therapy

	Before surgery	After surgery/before CTX	during CTX	after CTX	
		
	mean	median	range	mean	median	range	mean	median	range	mean	median	range	
CA-125 [kU/L]	1948	413	20-20880	325	84	15-5965	113	21	6-2562	",VEGF,Serum,-1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Table 2 Serum concentrations of CA-125, TIMP-1 and VEGF at different time-points during therapy

	Before surgery	After surgery/before CTX	during CTX	after CTX	
		
	mean	median	range	mean	median	range	mean	median	range	mean	median	range	
CA-125 [kU/L]	1948	413	20-20880	325	84	15-5965	113	21	6-2562	",CTX,Serum,-1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Table 2 Serum concentrations of CA-125, TIMP-1 and VEGF at different time-points during therapy

	Before surgery	After surgery/before CTX	during CTX	after CTX	
		
	mean	median	range	mean	median	range	mean	median	range	mean	median	range	
CA-125 [kU/L]	1948	413	20-20880	325	84	15-5965	113	21	6-2562	",TIMP-1,Serum,-1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Table 2 Serum concentrations of CA-125, TIMP-1 and VEGF at different time-points during therapy

	Before surgery	After surgery/before CTX	during CTX	after CTX	
		
	mean	median	range	mean	median	range	mean	median	range	mean	median	range	
CA-125 [kU/L]	1948	413	20-20880	325	84	15-5965	113	21	6-2562	",CTX,Serum,-1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Table 2 Serum concentrations of CA-125, TIMP-1 and VEGF at different time-points during therapy

	Before surgery	After surgery/before CTX	during CTX	after CTX	
		
	mean	median	range	mean	median	range	mean	median	range	mean	median	range	
CA-125 [kU/L]	1948	413	20-20880	325	84	15-5965	113	21	6-2562	",CA-125,Serum,-1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Table 2 Serum concentrations of CA-125, TIMP-1 and VEGF at different time-points during therapy

	Before surgery	After surgery/before CTX	during CTX	after CTX	
		
	mean	median	range	mean	median	range	mean	median	range	mean	median	range	
CA-125 [kU/L]	1948	413	20-20880	325	84	15-5965	113	21	6-2562	",CTX,Serum,-1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Table 2 Serum concentrations of CA-125, TIMP-1 and VEGF at different time-points during therapy

	Before surgery	After surgery/before CTX	during CTX	after CTX	
		
	mean	median	range	mean	median	range	mean	median	range	mean	median	range	
CA-125 [kU/L]	1948	413	20-20880	325	84	15-5965	113	21	6-2562	",CA-125,Serum,-1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
","We are interested in analyzing the serum samples with Q10 chips to find more potential biomarkers.

",Q10,serum,1
"PMC 
BMC_Cancer_2010_Apr_28_10_168.txt
","Methods
Cell culture
Human head and neck squamous carcinoma cell lines, HSC2, SCC-4 and cell culture from an oral lesion (OL), AMOL [19], were grown in monolayer cultures in Dulbecco's modified eagle medium (DMEM) and Ham F-12 (DMEM-F12) (Sigma, MO) supplemented with 10% fetal bovine serum (FBS), 2.5 mM L-glutamine, 1x sodium pyruvate (supplied as 100x stock with a concentration of 11,004 mg/L), 1 mM NEAA (non-essential amino acids), 100 mg/ml streptomycin and 100 U/ml penicillin in a humidified incubator (5% carbon-dioxide, 95% air) at 37degC as described previously [19].

",FBS,serum,1
"PMC 
BMC_Cancer_2010_Apr_28_10_168.txt
","Methods
Cell culture
Human head and neck squamous carcinoma cell lines, HSC2, SCC-4 and cell culture from an oral lesion (OL), AMOL [19], were grown in monolayer cultures in Dulbecco's modified eagle medium (DMEM) and Ham F-12 (DMEM-F12) (Sigma, MO) supplemented with 10% fetal bovine serum (FBS), 2.5 mM L-glutamine, 1x sodium pyruvate (supplied as 100x stock with a concentration of 11,004 mg/L), 1 mM NEAA (non-essential amino acids), 100 mg/ml streptomycin and 100 U/ml penicillin in a humidified incubator (5% carbon-dioxide, 95% air) at 37degC as described previously [19].

",DMEM,serum,1
"PMC 
BMC_Cancer_2010_Apr_28_10_168.txt
","Methods
Cell culture
Human head and neck squamous carcinoma cell lines, HSC2, SCC-4 and cell culture from an oral lesion (OL), AMOL [19], were grown in monolayer cultures in Dulbecco's modified eagle medium (DMEM) and Ham F-12 (DMEM-F12) (Sigma, MO) supplemented with 10% fetal bovine serum (FBS), 2.5 mM L-glutamine, 1x sodium pyruvate (supplied as 100x stock with a concentration of 11,004 mg/L), 1 mM NEAA (non-essential amino acids), 100 mg/ml streptomycin and 100 U/ml penicillin in a humidified incubator (5% carbon-dioxide, 95% air) at 37degC as described previously [19].

",HSC2,serum,1
"PMC 
BMC_Cancer_2010_Apr_28_10_168.txt
","Methods
Cell culture
Human head and neck squamous carcinoma cell lines, HSC2, SCC-4 and cell culture from an oral lesion (OL), AMOL [19], were grown in monolayer cultures in Dulbecco's modified eagle medium (DMEM) and Ham F-12 (DMEM-F12) (Sigma, MO) supplemented with 10% fetal bovine serum (FBS), 2.5 mM L-glutamine, 1x sodium pyruvate (supplied as 100x stock with a concentration of 11,004 mg/L), 1 mM NEAA (non-essential amino acids), 100 mg/ml streptomycin and 100 U/ml penicillin in a humidified incubator (5% carbon-dioxide, 95% air) at 37degC as described previously [19].

",F12,serum,1
"PMC 
BMC_Cancer_2010_Apr_28_10_168.txt
","Methods
Cell culture
Human head and neck squamous carcinoma cell lines, HSC2, SCC-4 and cell culture from an oral lesion (OL), AMOL [19], were grown in monolayer cultures in Dulbecco's modified eagle medium (DMEM) and Ham F-12 (DMEM-F12) (Sigma, MO) supplemented with 10% fetal bovine serum (FBS), 2.5 mM L-glutamine, 1x sodium pyruvate (supplied as 100x stock with a concentration of 11,004 mg/L), 1 mM NEAA (non-essential amino acids), 100 mg/ml streptomycin and 100 U/ml penicillin in a humidified incubator (5% carbon-dioxide, 95% air) at 37degC as described previously [19].

",NEAA,serum,1
"PMC 
BMC_Cancer_2010_Apr_28_10_168.txt
","Methods
Cell culture
Human head and neck squamous carcinoma cell lines, HSC2, SCC-4 and cell culture from an oral lesion (OL), AMOL [19], were grown in monolayer cultures in Dulbecco's modified eagle medium (DMEM) and Ham F-12 (DMEM-F12) (Sigma, MO) supplemented with 10% fetal bovine serum (FBS), 2.5 mM L-glutamine, 1x sodium pyruvate (supplied as 100x stock with a concentration of 11,004 mg/L), 1 mM NEAA (non-essential amino acids), 100 mg/ml streptomycin and 100 U/ml penicillin in a humidified incubator (5% carbon-dioxide, 95% air) at 37degC as described previously [19].

",F-12,serum,1
"PMC 
BMC_Cancer_2010_Apr_28_10_168.txt
","Methods
Cell culture
Human head and neck squamous carcinoma cell lines, HSC2, SCC-4 and cell culture from an oral lesion (OL), AMOL [19], were grown in monolayer cultures in Dulbecco's modified eagle medium (DMEM) and Ham F-12 (DMEM-F12) (Sigma, MO) supplemented with 10% fetal bovine serum (FBS), 2.5 mM L-glutamine, 1x sodium pyruvate (supplied as 100x stock with a concentration of 11,004 mg/L), 1 mM NEAA (non-essential amino acids), 100 mg/ml streptomycin and 100 U/ml penicillin in a humidified incubator (5% carbon-dioxide, 95% air) at 37degC as described previously [19].

",SCC-4,serum,1
"PMC 
BMC_Cancer_2010_Apr_28_10_168.txt
","Methods
Cell culture
Human head and neck squamous carcinoma cell lines, HSC2, SCC-4 and cell culture from an oral lesion (OL), AMOL [19], were grown in monolayer cultures in Dulbecco's modified eagle medium (DMEM) and Ham F-12 (DMEM-F12) (Sigma, MO) supplemented with 10% fetal bovine serum (FBS), 2.5 mM L-glutamine, 1x sodium pyruvate (supplied as 100x stock with a concentration of 11,004 mg/L), 1 mM NEAA (non-essential amino acids), 100 mg/ml streptomycin and 100 U/ml penicillin in a humidified incubator (5% carbon-dioxide, 95% air) at 37degC as described previously [19].

",AMOL,serum,1
"PMC 
BMC_Cancer_2010_Apr_28_10_168.txt
","Methods
Cell culture
Human head and neck squamous carcinoma cell lines, HSC2, SCC-4 and cell culture from an oral lesion (OL), AMOL [19], were grown in monolayer cultures in Dulbecco's modified eagle medium (DMEM) and Ham F-12 (DMEM-F12) (Sigma, MO) supplemented with 10% fetal bovine serum (FBS), 2.5 mM L-glutamine, 1x sodium pyruvate (supplied as 100x stock with a concentration of 11,004 mg/L), 1 mM NEAA (non-essential amino acids), 100 mg/ml streptomycin and 100 U/ml penicillin in a humidified incubator (5% carbon-dioxide, 95% air) at 37degC as described previously [19].

",DMEM,serum,1
"PMC 
BMC_Cancer_2010_Aug_19_10_442.txt
","Cell cultures, reagents and treatments
HepG2 hepatocellular carcinoma cells were used and were cultured in RPMI 1640 medium (Gibco, Paisley, Scotland, UK) supplemented with 10% fetal bovine serum (Gibco, Paisley, Scotland, UK), L-Glutamine 2 mM (Gibco, Paisley, Scotland, UK), penicillin 100 IU/ml and streptomycin 100 mg/ml (Gibco, Paisley, Scotland, UK), at 37degC in 5% CO2.",CO2,serum,1
"PMC 
BMC_Cancer_2010_Aug_19_10_442.txt
","Cell cultures, reagents and treatments
HepG2 hepatocellular carcinoma cells were used and were cultured in RPMI 1640 medium (Gibco, Paisley, Scotland, UK) supplemented with 10% fetal bovine serum (Gibco, Paisley, Scotland, UK), L-Glutamine 2 mM (Gibco, Paisley, Scotland, UK), penicillin 100 IU/ml and streptomycin 100 mg/ml (Gibco, Paisley, Scotland, UK), at 37degC in 5% CO2.",RPMI,serum,1
"PMC 
BMC_Cancer_2010_Aug_19_10_442.txt
","Cell cultures, reagents and treatments
HepG2 hepatocellular carcinoma cells were used and were cultured in RPMI 1640 medium (Gibco, Paisley, Scotland, UK) supplemented with 10% fetal bovine serum (Gibco, Paisley, Scotland, UK), L-Glutamine 2 mM (Gibco, Paisley, Scotland, UK), penicillin 100 IU/ml and streptomycin 100 mg/ml (Gibco, Paisley, Scotland, UK), at 37degC in 5% CO2.",HepG2,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-1392038822210.1186/1471-2407-10-139Research ArticleTIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients Mahner Sven 1Sven.Mahner@gmx.deWoelber Linn 1lwoelber@uke.uni-hamburg.deEulenburg Christine 2c.eulenburg@uke.uni-hamburg.deSchwarz Joerg 14schwarz@schwarz-cranz.deCarney Walter 3walter.carney@siemens.comJaenicke Fritz 1jaenicke@uke.uni-hamburg.deMilde-Langosch Karin 1milde@uke.uni-hamburg.deMueller Volkmar 1vmueller@uke.uni-hamburg.de1 Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany2 Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany3 Oncogene Science/Siemens Health Care DX, Cambridge, MA, USA4 Department of Gynecology, Asklepios Klinik Nord - Heidberg, Hamburg, Germany2010 13 4 2010 10 139 139 18 9 2009 13 4 2010 Copyright (c)2010 Mahner et al; licensee BioMed Central Ltd.2010Mahner et al; licensee BioMed Central Ltd.",USA4,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-1392038822210.1186/1471-2407-10-139Research ArticleTIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients Mahner Sven 1Sven.Mahner@gmx.deWoelber Linn 1lwoelber@uke.uni-hamburg.deEulenburg Christine 2c.eulenburg@uke.uni-hamburg.deSchwarz Joerg 14schwarz@schwarz-cranz.deCarney Walter 3walter.carney@siemens.comJaenicke Fritz 1jaenicke@uke.uni-hamburg.deMilde-Langosch Karin 1milde@uke.uni-hamburg.deMueller Volkmar 1vmueller@uke.uni-hamburg.de1 Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany2 Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany3 Oncogene Science/Siemens Health Care DX, Cambridge, MA, USA4 Department of Gynecology, Asklepios Klinik Nord - Heidberg, Hamburg, Germany2010 13 4 2010 10 139 139 18 9 2009 13 4 2010 Copyright (c)2010 Mahner et al; licensee BioMed Central Ltd.2010Mahner et al; licensee BioMed Central Ltd.",Germany2,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-1392038822210.1186/1471-2407-10-139Research ArticleTIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients Mahner Sven 1Sven.Mahner@gmx.deWoelber Linn 1lwoelber@uke.uni-hamburg.deEulenburg Christine 2c.eulenburg@uke.uni-hamburg.deSchwarz Joerg 14schwarz@schwarz-cranz.deCarney Walter 3walter.carney@siemens.comJaenicke Fritz 1jaenicke@uke.uni-hamburg.deMilde-Langosch Karin 1milde@uke.uni-hamburg.deMueller Volkmar 1vmueller@uke.uni-hamburg.de1 Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany2 Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany3 Oncogene Science/Siemens Health Care DX, Cambridge, MA, USA4 Department of Gynecology, Asklepios Klinik Nord - Heidberg, Hamburg, Germany2010 13 4 2010 10 139 139 18 9 2009 13 4 2010 Copyright (c)2010 Mahner et al; licensee BioMed Central Ltd.2010Mahner et al; licensee BioMed Central Ltd.",VEGF-165,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-1392038822210.1186/1471-2407-10-139Research ArticleTIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients Mahner Sven 1Sven.Mahner@gmx.deWoelber Linn 1lwoelber@uke.uni-hamburg.deEulenburg Christine 2c.eulenburg@uke.uni-hamburg.deSchwarz Joerg 14schwarz@schwarz-cranz.deCarney Walter 3walter.carney@siemens.comJaenicke Fritz 1jaenicke@uke.uni-hamburg.deMilde-Langosch Karin 1milde@uke.uni-hamburg.deMueller Volkmar 1vmueller@uke.uni-hamburg.de1 Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany2 Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany3 Oncogene Science/Siemens Health Care DX, Cambridge, MA, USA4 Department of Gynecology, Asklepios Klinik Nord - Heidberg, Hamburg, Germany2010 13 4 2010 10 139 139 18 9 2009 13 4 2010 Copyright (c)2010 Mahner et al; licensee BioMed Central Ltd.2010Mahner et al; licensee BioMed Central Ltd.",ArticleTIMP-1,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-1392038822210.1186/1471-2407-10-139Research ArticleTIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients Mahner Sven 1Sven.Mahner@gmx.deWoelber Linn 1lwoelber@uke.uni-hamburg.deEulenburg Christine 2c.eulenburg@uke.uni-hamburg.deSchwarz Joerg 14schwarz@schwarz-cranz.deCarney Walter 3walter.carney@siemens.comJaenicke Fritz 1jaenicke@uke.uni-hamburg.deMilde-Langosch Karin 1milde@uke.uni-hamburg.deMueller Volkmar 1vmueller@uke.uni-hamburg.de1 Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany2 Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany3 Oncogene Science/Siemens Health Care DX, Cambridge, MA, USA4 Department of Gynecology, Asklepios Klinik Nord - Heidberg, Hamburg, Germany2010 13 4 2010 10 139 139 18 9 2009 13 4 2010 Copyright (c)2010 Mahner et al; licensee BioMed Central Ltd.2010Mahner et al; licensee BioMed Central Ltd.",Germany3,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-1392038822210.1186/1471-2407-10-139Research ArticleTIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients Mahner Sven 1Sven.Mahner@gmx.deWoelber Linn 1lwoelber@uke.uni-hamburg.deEulenburg Christine 2c.eulenburg@uke.uni-hamburg.deSchwarz Joerg 14schwarz@schwarz-cranz.deCarney Walter 3walter.carney@siemens.comJaenicke Fritz 1jaenicke@uke.uni-hamburg.deMilde-Langosch Karin 1milde@uke.uni-hamburg.deMueller Volkmar 1vmueller@uke.uni-hamburg.de1 Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany2 Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany3 Oncogene Science/Siemens Health Care DX, Cambridge, MA, USA4 Department of Gynecology, Asklepios Klinik Nord - Heidberg, Hamburg, Germany2010 13 4 2010 10 139 139 18 9 2009 13 4 2010 Copyright (c)2010 Mahner et al; licensee BioMed Central Ltd.2010Mahner et al; licensee BioMed Central Ltd.",BMC,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-1392038822210.1186/1471-2407-10-139Research ArticleTIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients Mahner Sven 1Sven.Mahner@gmx.deWoelber Linn 1lwoelber@uke.uni-hamburg.deEulenburg Christine 2c.eulenburg@uke.uni-hamburg.deSchwarz Joerg 14schwarz@schwarz-cranz.deCarney Walter 3walter.carney@siemens.comJaenicke Fritz 1jaenicke@uke.uni-hamburg.deMilde-Langosch Karin 1milde@uke.uni-hamburg.deMueller Volkmar 1vmueller@uke.uni-hamburg.de1 Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany2 Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany3 Oncogene Science/Siemens Health Care DX, Cambridge, MA, USA4 Department of Gynecology, Asklepios Klinik Nord - Heidberg, Hamburg, Germany2010 13 4 2010 10 139 139 18 9 2009 13 4 2010 Copyright (c)2010 Mahner et al; licensee BioMed Central Ltd.2010Mahner et al; licensee BioMed Central Ltd.",Cancer1471,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","

==== Front
BMC CancerBMC Cancer1471-2407BioMed Central 1471-2407-10-1392038822210.1186/1471-2407-10-139Research ArticleTIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients Mahner Sven 1Sven.Mahner@gmx.deWoelber Linn 1lwoelber@uke.uni-hamburg.deEulenburg Christine 2c.eulenburg@uke.uni-hamburg.deSchwarz Joerg 14schwarz@schwarz-cranz.deCarney Walter 3walter.carney@siemens.comJaenicke Fritz 1jaenicke@uke.uni-hamburg.deMilde-Langosch Karin 1milde@uke.uni-hamburg.deMueller Volkmar 1vmueller@uke.uni-hamburg.de1 Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany2 Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany3 Oncogene Science/Siemens Health Care DX, Cambridge, MA, USA4 Department of Gynecology, Asklepios Klinik Nord - Heidberg, Hamburg, Germany2010 13 4 2010 10 139 139 18 9 2009 13 4 2010 Copyright (c)2010 Mahner et al; licensee BioMed Central Ltd.2010Mahner et al; licensee BioMed Central Ltd.",Germany2010,serum,1
"PMC 
BMC_Cancer_2009_Sep_3_9_310.txt
","FasL and FADD also showed modest correlations with one or more cancer risk factors, but none of the markers was significantly associated with either tumor stage or lymph node metastasis, the only two clinical factors that predicted survival in these ESCC cases.",FasL,lymph,1
"PMC 
BMC_Cancer_2009_Sep_3_9_310.txt
","FasL and FADD also showed modest correlations with one or more cancer risk factors, but none of the markers was significantly associated with either tumor stage or lymph node metastasis, the only two clinical factors that predicted survival in these ESCC cases.",FADD,lymph,1
"PMC 
BMC_Cancer_2009_Sep_3_9_310.txt
","FasL and FADD also showed modest correlations with one or more cancer risk factors, but none of the markers was significantly associated with either tumor stage or lymph node metastasis, the only two clinical factors that predicted survival in these ESCC cases.",ESCC,lymph,1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","IL1A -889, IL1B -511, IL1B +3953, and IL1RN were not associated with clinicopathological parameters, i.e., tumor status (p = 0.5, p = 0.8, p = 0.2, p = 0.3), tumor grade (p = 0.9, p = 0.9, p = 0.3, p = 0.3), lymph node involvement (p = 0.6, p = 0.8, p = 0.8, p = 0.9), presence of estrogen or progesterone receptor (p = 0.9, p = 0.7, p = 0.9, p = 0.9), and patient's age at diagnosis (p = 0.2, p = 0.4, p = 0.7, p = 0.8), respectively.

",IL1A,lymph,1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","IL1A -889, IL1B -511, IL1B +3953, and IL1RN were not associated with clinicopathological parameters, i.e., tumor status (p = 0.5, p = 0.8, p = 0.2, p = 0.3), tumor grade (p = 0.9, p = 0.9, p = 0.3, p = 0.3), lymph node involvement (p = 0.6, p = 0.8, p = 0.8, p = 0.9), presence of estrogen or progesterone receptor (p = 0.9, p = 0.7, p = 0.9, p = 0.9), and patient's age at diagnosis (p = 0.2, p = 0.4, p = 0.7, p = 0.8), respectively.

",IL1B,lymph,1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","IL1A -889, IL1B -511, IL1B +3953, and IL1RN were not associated with clinicopathological parameters, i.e., tumor status (p = 0.5, p = 0.8, p = 0.2, p = 0.3), tumor grade (p = 0.9, p = 0.9, p = 0.3, p = 0.3), lymph node involvement (p = 0.6, p = 0.8, p = 0.8, p = 0.9), presence of estrogen or progesterone receptor (p = 0.9, p = 0.7, p = 0.9, p = 0.9), and patient's age at diagnosis (p = 0.2, p = 0.4, p = 0.7, p = 0.8), respectively.

",IL1RN,lymph,1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","IL1A -889, IL1B -511, IL1B +3953, and IL1RN were not associated with clinicopathological parameters, i.e., tumor status (p = 0.5, p = 0.8, p = 0.2, p = 0.3), tumor grade (p = 0.9, p = 0.9, p = 0.3, p = 0.3), lymph node involvement (p = 0.6, p = 0.8, p = 0.8, p = 0.9), presence of estrogen or progesterone receptor (p = 0.9, p = 0.7, p = 0.9, p = 0.9), and patient's age at diagnosis (p = 0.2, p = 0.4, p = 0.7, p = 0.8), respectively.

",IL1B,lymph,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Although the detection of NGAL and its complex with MMP-9 in systemic circulation seems reasonable, no studies of NGAL and MMP-9/NGAL in sera are currently available with the exception of two recent publications on coronary artery disease and polycystic ovary syndrome [29,30].",MMP-9,sera,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Although the detection of NGAL and its complex with MMP-9 in systemic circulation seems reasonable, no studies of NGAL and MMP-9/NGAL in sera are currently available with the exception of two recent publications on coronary artery disease and polycystic ovary syndrome [29,30].",NGAL,sera,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","Although the detection of NGAL and its complex with MMP-9 in systemic circulation seems reasonable, no studies of NGAL and MMP-9/NGAL in sera are currently available with the exception of two recent publications on coronary artery disease and polycystic ovary syndrome [29,30].",NGAL,sera,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
",Baseline bone metabolic rate of individual patients may also confound analysis because age and the presence of osteoporosis have been shown to have impact on serum TRACP 5b activity [12].,TRACP,serum,1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","Parameters have been calculated as followed: IL1A -889 (C/C and C/T vs. T/T), IL1B -511 (C/C and C/T vs. T/T), IL1B +3953 (E1/E1 and E1/E2 vs. E2/E2), IL1RN VNTR intron 2 (long/long and long/2 vs. 2/2), tumor status (pT1 vs. pT2-4), tumor grade (well differentiated vs. moderately and poorly differentiated), lymph node involvement (yes vs. no), presence of estrogen or progesterone receptor (positive vs. negative), and patient's age at diagnosis (<= 50 years vs. &#62; 50 years).

",pT1,lymph,1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","Parameters have been calculated as followed: IL1A -889 (C/C and C/T vs. T/T), IL1B -511 (C/C and C/T vs. T/T), IL1B +3953 (E1/E1 and E1/E2 vs. E2/E2), IL1RN VNTR intron 2 (long/long and long/2 vs. 2/2), tumor status (pT1 vs. pT2-4), tumor grade (well differentiated vs. moderately and poorly differentiated), lymph node involvement (yes vs. no), presence of estrogen or progesterone receptor (positive vs. negative), and patient's age at diagnosis (<= 50 years vs. &#62; 50 years).

",IL1RN,lymph,1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","Parameters have been calculated as followed: IL1A -889 (C/C and C/T vs. T/T), IL1B -511 (C/C and C/T vs. T/T), IL1B +3953 (E1/E1 and E1/E2 vs. E2/E2), IL1RN VNTR intron 2 (long/long and long/2 vs. 2/2), tumor status (pT1 vs. pT2-4), tumor grade (well differentiated vs. moderately and poorly differentiated), lymph node involvement (yes vs. no), presence of estrogen or progesterone receptor (positive vs. negative), and patient's age at diagnosis (<= 50 years vs. &#62; 50 years).

",E1,lymph,1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","Parameters have been calculated as followed: IL1A -889 (C/C and C/T vs. T/T), IL1B -511 (C/C and C/T vs. T/T), IL1B +3953 (E1/E1 and E1/E2 vs. E2/E2), IL1RN VNTR intron 2 (long/long and long/2 vs. 2/2), tumor status (pT1 vs. pT2-4), tumor grade (well differentiated vs. moderately and poorly differentiated), lymph node involvement (yes vs. no), presence of estrogen or progesterone receptor (positive vs. negative), and patient's age at diagnosis (<= 50 years vs. &#62; 50 years).

",T,lymph,1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","Parameters have been calculated as followed: IL1A -889 (C/C and C/T vs. T/T), IL1B -511 (C/C and C/T vs. T/T), IL1B +3953 (E1/E1 and E1/E2 vs. E2/E2), IL1RN VNTR intron 2 (long/long and long/2 vs. 2/2), tumor status (pT1 vs. pT2-4), tumor grade (well differentiated vs. moderately and poorly differentiated), lymph node involvement (yes vs. no), presence of estrogen or progesterone receptor (positive vs. negative), and patient's age at diagnosis (<= 50 years vs. &#62; 50 years).

",T,lymph,1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","Parameters have been calculated as followed: IL1A -889 (C/C and C/T vs. T/T), IL1B -511 (C/C and C/T vs. T/T), IL1B +3953 (E1/E1 and E1/E2 vs. E2/E2), IL1RN VNTR intron 2 (long/long and long/2 vs. 2/2), tumor status (pT1 vs. pT2-4), tumor grade (well differentiated vs. moderately and poorly differentiated), lymph node involvement (yes vs. no), presence of estrogen or progesterone receptor (positive vs. negative), and patient's age at diagnosis (<= 50 years vs. &#62; 50 years).

",T,lymph,1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","Parameters have been calculated as followed: IL1A -889 (C/C and C/T vs. T/T), IL1B -511 (C/C and C/T vs. T/T), IL1B +3953 (E1/E1 and E1/E2 vs. E2/E2), IL1RN VNTR intron 2 (long/long and long/2 vs. 2/2), tumor status (pT1 vs. pT2-4), tumor grade (well differentiated vs. moderately and poorly differentiated), lymph node involvement (yes vs. no), presence of estrogen or progesterone receptor (positive vs. negative), and patient's age at diagnosis (<= 50 years vs. &#62; 50 years).

",pT2,lymph,1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","Parameters have been calculated as followed: IL1A -889 (C/C and C/T vs. T/T), IL1B -511 (C/C and C/T vs. T/T), IL1B +3953 (E1/E1 and E1/E2 vs. E2/E2), IL1RN VNTR intron 2 (long/long and long/2 vs. 2/2), tumor status (pT1 vs. pT2-4), tumor grade (well differentiated vs. moderately and poorly differentiated), lymph node involvement (yes vs. no), presence of estrogen or progesterone receptor (positive vs. negative), and patient's age at diagnosis (<= 50 years vs. &#62; 50 years).

",T,lymph,1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","Parameters have been calculated as followed: IL1A -889 (C/C and C/T vs. T/T), IL1B -511 (C/C and C/T vs. T/T), IL1B +3953 (E1/E1 and E1/E2 vs. E2/E2), IL1RN VNTR intron 2 (long/long and long/2 vs. 2/2), tumor status (pT1 vs. pT2-4), tumor grade (well differentiated vs. moderately and poorly differentiated), lymph node involvement (yes vs. no), presence of estrogen or progesterone receptor (positive vs. negative), and patient's age at diagnosis (<= 50 years vs. &#62; 50 years).

",IL1A,lymph,1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","Parameters have been calculated as followed: IL1A -889 (C/C and C/T vs. T/T), IL1B -511 (C/C and C/T vs. T/T), IL1B +3953 (E1/E1 and E1/E2 vs. E2/E2), IL1RN VNTR intron 2 (long/long and long/2 vs. 2/2), tumor status (pT1 vs. pT2-4), tumor grade (well differentiated vs. moderately and poorly differentiated), lymph node involvement (yes vs. no), presence of estrogen or progesterone receptor (positive vs. negative), and patient's age at diagnosis (<= 50 years vs. &#62; 50 years).

",VNTR,lymph,1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","Parameters have been calculated as followed: IL1A -889 (C/C and C/T vs. T/T), IL1B -511 (C/C and C/T vs. T/T), IL1B +3953 (E1/E1 and E1/E2 vs. E2/E2), IL1RN VNTR intron 2 (long/long and long/2 vs. 2/2), tumor status (pT1 vs. pT2-4), tumor grade (well differentiated vs. moderately and poorly differentiated), lymph node involvement (yes vs. no), presence of estrogen or progesterone receptor (positive vs. negative), and patient's age at diagnosis (<= 50 years vs. &#62; 50 years).

",IL1B,lymph,1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","Parameters have been calculated as followed: IL1A -889 (C/C and C/T vs. T/T), IL1B -511 (C/C and C/T vs. T/T), IL1B +3953 (E1/E1 and E1/E2 vs. E2/E2), IL1RN VNTR intron 2 (long/long and long/2 vs. 2/2), tumor status (pT1 vs. pT2-4), tumor grade (well differentiated vs. moderately and poorly differentiated), lymph node involvement (yes vs. no), presence of estrogen or progesterone receptor (positive vs. negative), and patient's age at diagnosis (<= 50 years vs. &#62; 50 years).

",IL1B,lymph,1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","Parameters have been calculated as followed: IL1A -889 (C/C and C/T vs. T/T), IL1B -511 (C/C and C/T vs. T/T), IL1B +3953 (E1/E1 and E1/E2 vs. E2/E2), IL1RN VNTR intron 2 (long/long and long/2 vs. 2/2), tumor status (pT1 vs. pT2-4), tumor grade (well differentiated vs. moderately and poorly differentiated), lymph node involvement (yes vs. no), presence of estrogen or progesterone receptor (positive vs. negative), and patient's age at diagnosis (<= 50 years vs. &#62; 50 years).

",T,lymph,1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","Parameters have been calculated as followed: IL1A -889 (C/C and C/T vs. T/T), IL1B -511 (C/C and C/T vs. T/T), IL1B +3953 (E1/E1 and E1/E2 vs. E2/E2), IL1RN VNTR intron 2 (long/long and long/2 vs. 2/2), tumor status (pT1 vs. pT2-4), tumor grade (well differentiated vs. moderately and poorly differentiated), lymph node involvement (yes vs. no), presence of estrogen or progesterone receptor (positive vs. negative), and patient's age at diagnosis (<= 50 years vs. &#62; 50 years).

",T,lymph,1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","A multivariate Cox regression model was performed for disease free and overall survival comprising tumor status, tumor grade, lymph node involvement, presence of estrogen or progesterone receptor, and in the respective univariate analysis significantly associated gene polymorphisms (i.e., IL1RN VNTR intron 2 gene polymorphism in the disease free survival analysis and IL1A -889C/T, IL1B +3953, and IL1RN VNTR intron 2 gene polymorphisms in the overall survival analysis).

",IL1A,lymph,1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","A multivariate Cox regression model was performed for disease free and overall survival comprising tumor status, tumor grade, lymph node involvement, presence of estrogen or progesterone receptor, and in the respective univariate analysis significantly associated gene polymorphisms (i.e., IL1RN VNTR intron 2 gene polymorphism in the disease free survival analysis and IL1A -889C/T, IL1B +3953, and IL1RN VNTR intron 2 gene polymorphisms in the overall survival analysis).

",IL1RN,lymph,1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","A multivariate Cox regression model was performed for disease free and overall survival comprising tumor status, tumor grade, lymph node involvement, presence of estrogen or progesterone receptor, and in the respective univariate analysis significantly associated gene polymorphisms (i.e., IL1RN VNTR intron 2 gene polymorphism in the disease free survival analysis and IL1A -889C/T, IL1B +3953, and IL1RN VNTR intron 2 gene polymorphisms in the overall survival analysis).

",VNTR,lymph,1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","A multivariate Cox regression model was performed for disease free and overall survival comprising tumor status, tumor grade, lymph node involvement, presence of estrogen or progesterone receptor, and in the respective univariate analysis significantly associated gene polymorphisms (i.e., IL1RN VNTR intron 2 gene polymorphism in the disease free survival analysis and IL1A -889C/T, IL1B +3953, and IL1RN VNTR intron 2 gene polymorphisms in the overall survival analysis).

",VNTR,lymph,1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","A multivariate Cox regression model was performed for disease free and overall survival comprising tumor status, tumor grade, lymph node involvement, presence of estrogen or progesterone receptor, and in the respective univariate analysis significantly associated gene polymorphisms (i.e., IL1RN VNTR intron 2 gene polymorphism in the disease free survival analysis and IL1A -889C/T, IL1B +3953, and IL1RN VNTR intron 2 gene polymorphisms in the overall survival analysis).

",T,lymph,1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","A multivariate Cox regression model was performed for disease free and overall survival comprising tumor status, tumor grade, lymph node involvement, presence of estrogen or progesterone receptor, and in the respective univariate analysis significantly associated gene polymorphisms (i.e., IL1RN VNTR intron 2 gene polymorphism in the disease free survival analysis and IL1A -889C/T, IL1B +3953, and IL1RN VNTR intron 2 gene polymorphisms in the overall survival analysis).

",IL1B,lymph,1
"PMC 
BMC_Cancer_2009_Mar_6_9_78.txt
","A multivariate Cox regression model was performed for disease free and overall survival comprising tumor status, tumor grade, lymph node involvement, presence of estrogen or progesterone receptor, and in the respective univariate analysis significantly associated gene polymorphisms (i.e., IL1RN VNTR intron 2 gene polymorphism in the disease free survival analysis and IL1A -889C/T, IL1B +3953, and IL1RN VNTR intron 2 gene polymorphisms in the overall survival analysis).

",IL1RN,lymph,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
",Li et al. used SELDI-TOF-MS to perform proteomic profiling on plasma specimens from 29 patients with OS and 20 age-matched patients with osteochondroma.,OS,plasma,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
",Li et al. used SELDI-TOF-MS to perform proteomic profiling on plasma specimens from 29 patients with OS and 20 age-matched patients with osteochondroma.,TOF,plasma,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
",Li et al. used SELDI-TOF-MS to perform proteomic profiling on plasma specimens from 29 patients with OS and 20 age-matched patients with osteochondroma.,SELDI,plasma,1
"PMC 
BMC_Cancer_2009_May_8_9_137.txt
",Disease Free Survival (DFS) was calculated from the day of histological diagnosis to the date of local recurrence of disease and/or regional lymph-node involvement.,DFS,lymph,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Correlations between serum CA-125, VEGF-165 and TIMP-1 concentrations and tumor characteristics were calculated by Chi-square tests.",CA-125,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Correlations between serum CA-125, VEGF-165 and TIMP-1 concentrations and tumor characteristics were calculated by Chi-square tests.",VEGF-165,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Correlations between serum CA-125, VEGF-165 and TIMP-1 concentrations and tumor characteristics were calculated by Chi-square tests.",TIMP-1,serum,1
"PMC 
BMC_Cancer_2009_Oct_22_9_376.txt
","Discussion
Detection of CRC cells in feces using qRT-PCR may be developed for clinical diagnosis [18].",PCR,feces,-1
"PMC 
BMC_Cancer_2009_Oct_22_9_376.txt
","Discussion
Detection of CRC cells in feces using qRT-PCR may be developed for clinical diagnosis [18].",qRT,feces,-1
"PMC 
BMC_Cancer_2009_Oct_22_9_376.txt
","Discussion
Detection of CRC cells in feces using qRT-PCR may be developed for clinical diagnosis [18].",CRC,feces,-1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Control group samples were the leftover blood of HUSM Blood Bank donors, which was collected on the same day of the matched patient.",HUSM,Blood,-1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Control group samples were the leftover blood of HUSM Blood Bank donors, which was collected on the same day of the matched patient.",HUSM,blood,-1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
",The increased plasma level of SAA in OS patients was further validated by Western blotting [8].,OS,plasma,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
",The increased plasma level of SAA in OS patients was further validated by Western blotting [8].,SAA,plasma,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","The results were expressed as nmol TBARS/mL plasma, using MDA as standard [34].

",TBARS,plasma,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","The results were expressed as nmol TBARS/mL plasma, using MDA as standard [34].

",MDA,plasma,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
",Applications of proteomic analyses have showed that amyloidrelated serum protein (SAA) might be utilized as a biomarker for OS.,SAA,serum,-1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
",Applications of proteomic analyses have showed that amyloidrelated serum protein (SAA) might be utilized as a biomarker for OS.,OS,serum,-1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Vitamin C
Plasma vitamin C (VIT C) was estimated as described by Galley et al.",VIT,Plasma,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","In the current study, we observed no correlation between pre- or postoperative serum concentrations of TIMP-1 and outcome (Table 3).",TIMP-1,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","Nevertheless, serum TRACP 5b activity may not be elevated in all BC patients with bone metastasis, only in those with extensive metastasis [14].",TRACP,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Furthermore, there is no clearly defined 'cut-off' to classify serum VEGF concentrations as elevated or normal.",VEGF,serum,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","We do not think that periodontal health changes were responsible of MMP1 elevation in saliva of our patients since no clear differences of periodontal status were noticed between HNSCC patients and control cases or between MMP1 positive and MMP1 negative HNSCC patients.

",MMP1,saliva,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","We do not think that periodontal health changes were responsible of MMP1 elevation in saliva of our patients since no clear differences of periodontal status were noticed between HNSCC patients and control cases or between MMP1 positive and MMP1 negative HNSCC patients.

",MMP1,saliva,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","We do not think that periodontal health changes were responsible of MMP1 elevation in saliva of our patients since no clear differences of periodontal status were noticed between HNSCC patients and control cases or between MMP1 positive and MMP1 negative HNSCC patients.

",HNSCC,saliva,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","We do not think that periodontal health changes were responsible of MMP1 elevation in saliva of our patients since no clear differences of periodontal status were noticed between HNSCC patients and control cases or between MMP1 positive and MMP1 negative HNSCC patients.

",MMP1,saliva,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
","We do not think that periodontal health changes were responsible of MMP1 elevation in saliva of our patients since no clear differences of periodontal status were noticed between HNSCC patients and control cases or between MMP1 positive and MMP1 negative HNSCC patients.

",HNSCC,saliva,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","In the 100 patients studied, 81 had available serial serum TRACP 5b activity determinations.",TRACP,serum,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","If etoposide treatment induces ROS, principally phenoxyl radicals in non-stimulated whole blood cells, then an antioxidant exposure should reduce the DNA damage induced by etoposide.",ROS,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","If etoposide treatment induces ROS, principally phenoxyl radicals in non-stimulated whole blood cells, then an antioxidant exposure should reduce the DNA damage induced by etoposide.",DNA,blood,-1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","VEGF after CTX	0.006	+	0.023	+	
Correlations between serum concentration of CA-125, TIMP-1 and VEGF (below/above median) and survival.",CTX,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","VEGF after CTX	0.006	+	0.023	+	
Correlations between serum concentration of CA-125, TIMP-1 and VEGF (below/above median) and survival.",VEGF,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","VEGF after CTX	0.006	+	0.023	+	
Correlations between serum concentration of CA-125, TIMP-1 and VEGF (below/above median) and survival.",VEGF,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","VEGF after CTX	0.006	+	0.023	+	
Correlations between serum concentration of CA-125, TIMP-1 and VEGF (below/above median) and survival.",TIMP-1,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","VEGF after CTX	0.006	+	0.023	+	
Correlations between serum concentration of CA-125, TIMP-1 and VEGF (below/above median) and survival.",CA-125,serum,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Figure 5 Pearson's correlational analysis between the percent of DNA-AP sites as evidenced by Exo III and ALS index in non-stimulated blood cells treated for 2 h and PHA-stimulated blood cells treated for 24 h with etoposide.

",PHA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Figure 5 Pearson's correlational analysis between the percent of DNA-AP sites as evidenced by Exo III and ALS index in non-stimulated blood cells treated for 2 h and PHA-stimulated blood cells treated for 24 h with etoposide.

",PHA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Figure 5 Pearson's correlational analysis between the percent of DNA-AP sites as evidenced by Exo III and ALS index in non-stimulated blood cells treated for 2 h and PHA-stimulated blood cells treated for 24 h with etoposide.

",ALS,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Figure 5 Pearson's correlational analysis between the percent of DNA-AP sites as evidenced by Exo III and ALS index in non-stimulated blood cells treated for 2 h and PHA-stimulated blood cells treated for 24 h with etoposide.

",ALS,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Figure 5 Pearson's correlational analysis between the percent of DNA-AP sites as evidenced by Exo III and ALS index in non-stimulated blood cells treated for 2 h and PHA-stimulated blood cells treated for 24 h with etoposide.

",DNA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Figure 5 Pearson's correlational analysis between the percent of DNA-AP sites as evidenced by Exo III and ALS index in non-stimulated blood cells treated for 2 h and PHA-stimulated blood cells treated for 24 h with etoposide.

",DNA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Figure 5 Pearson's correlational analysis between the percent of DNA-AP sites as evidenced by Exo III and ALS index in non-stimulated blood cells treated for 2 h and PHA-stimulated blood cells treated for 24 h with etoposide.

",III,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","Figure 5 Pearson's correlational analysis between the percent of DNA-AP sites as evidenced by Exo III and ALS index in non-stimulated blood cells treated for 2 h and PHA-stimulated blood cells treated for 24 h with etoposide.

",III,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
",Figure 3 Percentage of ALS relative to controls after 2-h and 24-h of etoposide treatment for both non-stimulated and PHA stimulated blood cells.,ALS,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
",Figure 3 Percentage of ALS relative to controls after 2-h and 24-h of etoposide treatment for both non-stimulated and PHA stimulated blood cells.,PHA,blood,-1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Serum VEGF-165 and TIMP-1 as well as CA-125 were quantified by ELISA or ECLIA and correlation with response and long-term clinical outcome was analyzed.

",CA-125,Serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Serum VEGF-165 and TIMP-1 as well as CA-125 were quantified by ELISA or ECLIA and correlation with response and long-term clinical outcome was analyzed.

",TIMP-1,Serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Serum VEGF-165 and TIMP-1 as well as CA-125 were quantified by ELISA or ECLIA and correlation with response and long-term clinical outcome was analyzed.

",ELISA,Serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Serum VEGF-165 and TIMP-1 as well as CA-125 were quantified by ELISA or ECLIA and correlation with response and long-term clinical outcome was analyzed.

",VEGF-165,Serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Serum VEGF-165 and TIMP-1 as well as CA-125 were quantified by ELISA or ECLIA and correlation with response and long-term clinical outcome was analyzed.

",ECLIA,Serum,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Protein thiol groups
Plasma protein thiol (P-SH) group levels were significantly lower in groups II (autol.) and III (allog.), before CR (p &#60; 0.01), during CR and on days 10 and 20 after BMT, (p &#60; 0.00001) when compared with group I (control).",III,Plasma,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Protein thiol groups
Plasma protein thiol (P-SH) group levels were significantly lower in groups II (autol.) and III (allog.), before CR (p &#60; 0.01), during CR and on days 10 and 20 after BMT, (p &#60; 0.00001) when compared with group I (control).",CR,Plasma,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Protein thiol groups
Plasma protein thiol (P-SH) group levels were significantly lower in groups II (autol.) and III (allog.), before CR (p &#60; 0.01), during CR and on days 10 and 20 after BMT, (p &#60; 0.00001) when compared with group I (control).",BMT,Plasma,1
"PMC 
BMC_Cancer_2009_May_8_9_138.txt
","Protein thiol groups
Plasma protein thiol (P-SH) group levels were significantly lower in groups II (autol.) and III (allog.), before CR (p &#60; 0.01), during CR and on days 10 and 20 after BMT, (p &#60; 0.00001) when compared with group I (control).",CR,Plasma,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","This finding indicates that AA provided some level of protection for the non-stimulated blood cell DNA in the oxidative micro-environment generated by the etoposide.

",DNA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","(**p &#60; 0.01 vs. control; ***p &#60; 0.001 vs. control).

Because the presence of ALSs in non-stimulated whole blood cells was inferred indirectly by comparing the SCGE assays under the two pH conditions, it was important to test whether these putative ALSs involved AP-sites.",SCGE,blood,-1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","The application of serum TIMP-1 and VEGF to monitor primary therapy and predict clinical outcome of patients with ovarian cancer is unclear.

",TIMP-1,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","The application of serum TIMP-1 and VEGF to monitor primary therapy and predict clinical outcome of patients with ovarian cancer is unclear.

",VEGF,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
",These results suggest that serum VEGF-165 may be helpful in therapy monitoring and surveillance of ovarian cancer patients and can provide additional information to CA-125 measurements.,CA-125,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
",These results suggest that serum VEGF-165 may be helpful in therapy monitoring and surveillance of ovarian cancer patients and can provide additional information to CA-125 measurements.,VEGF-165,serum,1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","This analysis was performed in non-stimulated whole blood cells treated for 2 h with etoposide, a condition which produces a high rate of ALS induction, and the results were compared with the data from the PHA-stimulated whole blood cells exposed to etoposide for 24 h. As shown in figure 4, we observed a relationship between percentage of AP-sites and etoposide concentration in non-stimulated whole blood cells relative to PHA-stimulated blood cells subjected to the longer treatment.

",PHA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","This analysis was performed in non-stimulated whole blood cells treated for 2 h with etoposide, a condition which produces a high rate of ALS induction, and the results were compared with the data from the PHA-stimulated whole blood cells exposed to etoposide for 24 h. As shown in figure 4, we observed a relationship between percentage of AP-sites and etoposide concentration in non-stimulated whole blood cells relative to PHA-stimulated blood cells subjected to the longer treatment.

",PHA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","This analysis was performed in non-stimulated whole blood cells treated for 2 h with etoposide, a condition which produces a high rate of ALS induction, and the results were compared with the data from the PHA-stimulated whole blood cells exposed to etoposide for 24 h. As shown in figure 4, we observed a relationship between percentage of AP-sites and etoposide concentration in non-stimulated whole blood cells relative to PHA-stimulated blood cells subjected to the longer treatment.

",PHA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","This analysis was performed in non-stimulated whole blood cells treated for 2 h with etoposide, a condition which produces a high rate of ALS induction, and the results were compared with the data from the PHA-stimulated whole blood cells exposed to etoposide for 24 h. As shown in figure 4, we observed a relationship between percentage of AP-sites and etoposide concentration in non-stimulated whole blood cells relative to PHA-stimulated blood cells subjected to the longer treatment.

",PHA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","This analysis was performed in non-stimulated whole blood cells treated for 2 h with etoposide, a condition which produces a high rate of ALS induction, and the results were compared with the data from the PHA-stimulated whole blood cells exposed to etoposide for 24 h. As shown in figure 4, we observed a relationship between percentage of AP-sites and etoposide concentration in non-stimulated whole blood cells relative to PHA-stimulated blood cells subjected to the longer treatment.

",ALS,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","This analysis was performed in non-stimulated whole blood cells treated for 2 h with etoposide, a condition which produces a high rate of ALS induction, and the results were compared with the data from the PHA-stimulated whole blood cells exposed to etoposide for 24 h. As shown in figure 4, we observed a relationship between percentage of AP-sites and etoposide concentration in non-stimulated whole blood cells relative to PHA-stimulated blood cells subjected to the longer treatment.

",ALS,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","This analysis was performed in non-stimulated whole blood cells treated for 2 h with etoposide, a condition which produces a high rate of ALS induction, and the results were compared with the data from the PHA-stimulated whole blood cells exposed to etoposide for 24 h. As shown in figure 4, we observed a relationship between percentage of AP-sites and etoposide concentration in non-stimulated whole blood cells relative to PHA-stimulated blood cells subjected to the longer treatment.

",ALS,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","This analysis was performed in non-stimulated whole blood cells treated for 2 h with etoposide, a condition which produces a high rate of ALS induction, and the results were compared with the data from the PHA-stimulated whole blood cells exposed to etoposide for 24 h. As shown in figure 4, we observed a relationship between percentage of AP-sites and etoposide concentration in non-stimulated whole blood cells relative to PHA-stimulated blood cells subjected to the longer treatment.

",ALS,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","This analysis was performed in non-stimulated whole blood cells treated for 2 h with etoposide, a condition which produces a high rate of ALS induction, and the results were compared with the data from the PHA-stimulated whole blood cells exposed to etoposide for 24 h. As shown in figure 4, we observed a relationship between percentage of AP-sites and etoposide concentration in non-stimulated whole blood cells relative to PHA-stimulated blood cells subjected to the longer treatment.

",PHA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","This analysis was performed in non-stimulated whole blood cells treated for 2 h with etoposide, a condition which produces a high rate of ALS induction, and the results were compared with the data from the PHA-stimulated whole blood cells exposed to etoposide for 24 h. As shown in figure 4, we observed a relationship between percentage of AP-sites and etoposide concentration in non-stimulated whole blood cells relative to PHA-stimulated blood cells subjected to the longer treatment.

",PHA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","This analysis was performed in non-stimulated whole blood cells treated for 2 h with etoposide, a condition which produces a high rate of ALS induction, and the results were compared with the data from the PHA-stimulated whole blood cells exposed to etoposide for 24 h. As shown in figure 4, we observed a relationship between percentage of AP-sites and etoposide concentration in non-stimulated whole blood cells relative to PHA-stimulated blood cells subjected to the longer treatment.

",PHA,blood,-1
"PMC 
BMC_Cancer_2009_Nov_16_9_398.txt
","This analysis was performed in non-stimulated whole blood cells treated for 2 h with etoposide, a condition which produces a high rate of ALS induction, and the results were compared with the data from the PHA-stimulated whole blood cells exposed to etoposide for 24 h. As shown in figure 4, we observed a relationship between percentage of AP-sites and etoposide concentration in non-stimulated whole blood cells relative to PHA-stimulated blood cells subjected to the longer treatment.

",PHA,blood,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Table 1 Patient and tumor characteristics and comparisons of patient groups

Characteristic	All patients
N (%)	CMF-treated patients
N (%)	Anthracycline-treated patients
N (%)	Untreated patients
N (%)	P1	
Age						
<= 40 years	164 (31)	110 (34)	28 (28)	26 (25)	0.212	
41-55 years	361 (69)	214 (66)	71 (72)	76 (75)		
	
Involved lymph nodes						
1-3	292 (56)	217 (67)	47 (47)	28 (27)	&#60;0.0012	
&#62;3	233 (44)	107 (33)	52 (53)	74 (73)		
	
Steroid hormone rec. status						
Positive	432 (82)	269 (83)	76 (77)	87 (85)	0.242	
",CMF,lymph,1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","Table 1 Patient and tumor characteristics and comparisons of patient groups

Characteristic	All patients
N (%)	CMF-treated patients
N (%)	Anthracycline-treated patients
N (%)	Untreated patients
N (%)	P1	
Age						
<= 40 years	164 (31)	110 (34)	28 (28)	26 (25)	0.212	
41-55 years	361 (69)	214 (66)	71 (72)	76 (75)		
	
Involved lymph nodes						
1-3	292 (56)	217 (67)	47 (47)	28 (27)	&#60;0.0012	
&#62;3	233 (44)	107 (33)	52 (53)	74 (73)		
	
Steroid hormone rec. status						
Positive	432 (82)	269 (83)	76 (77)	87 (85)	0.242	
",P1,lymph,1
"PMC 
BMC_Cancer_2010_Aug_19_10_444.txt
","All cell lines were grown in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal calf serum (FCS), penicillin (200 U/ml), and streptomycin sulphate (100 U/ml) in a humidified incubator supplied with 5% CO2.",DMEM,serum,1
"PMC 
BMC_Cancer_2010_Aug_19_10_444.txt
","All cell lines were grown in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal calf serum (FCS), penicillin (200 U/ml), and streptomycin sulphate (100 U/ml) in a humidified incubator supplied with 5% CO2.",FCS,serum,1
"PMC 
BMC_Cancer_2010_Aug_19_10_444.txt
","All cell lines were grown in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal calf serum (FCS), penicillin (200 U/ml), and streptomycin sulphate (100 U/ml) in a humidified incubator supplied with 5% CO2.",CO2,serum,1
"PMC 
BMC_Cancer_2009_Sep_3_9_310.txt
","Table 4 Spearman correlations between 7 apoptosis biomarkers and 5 risk factors and 4 clinico-pathologic features1

	FasL	Fas	FADD	pFADD	Caspase8	Caspase10	Bcl2	
Risk factors								
 Male (yes)	0.17**	0.01	0.05	0.02	-0.02	0.03	0.00	
 Age (yrs)	-0.01	0.02	-0.06	-0.05	0.10	0.00	0.00	
 Tobacco use (yes)	0.17**	0.05	0.08	-0.07	0.00	0.10	0.02	
 Alcohol use (daily or weekly)	0.00	-0.02	0.20**	-0.09	0.13*	0.09	0.02	
 Family history UGI cancer (yes)	-0.18**	-0.15*	0.00	0.04	-0.05	0.02	-0.01	
								
Clinico-pathologic features								
 Tumor grade (I -- IV)	-0.10	-0.20**	-0.18**	0.08	-0.07	-0.19**	0.02	
 Tumor stage (1 -- 4)	0.00	-0.14*	-0.05	0.10	0.01	0.03	0.03	
 Lymph node metastasis (yes)	0.02	0.01	-0.04	0.06	0.00	0.01	0.02	
	
Degree differentiation (poor)	-0.15*	-0.26***	-0.21**	0.03	-0.17**	-0.36***	-0.30***	
1 N varies from 235 to 253 and is less than 265 total because none of 7 biomarkers had data for all 265 ESCC cases

* p &#60; 0.05

** p &#60; 0.01

*** p &#60; 0.0001

Relations to survival adjusted for these five risk factors and four clinico-pathologic features are shown in Table 5.",Caspase8,Lymph,1
"PMC 
BMC_Cancer_2009_Sep_3_9_310.txt
","Table 4 Spearman correlations between 7 apoptosis biomarkers and 5 risk factors and 4 clinico-pathologic features1

	FasL	Fas	FADD	pFADD	Caspase8	Caspase10	Bcl2	
Risk factors								
 Male (yes)	0.17**	0.01	0.05	0.02	-0.02	0.03	0.00	
 Age (yrs)	-0.01	0.02	-0.06	-0.05	0.10	0.00	0.00	
 Tobacco use (yes)	0.17**	0.05	0.08	-0.07	0.00	0.10	0.02	
 Alcohol use (daily or weekly)	0.00	-0.02	0.20**	-0.09	0.13*	0.09	0.02	
 Family history UGI cancer (yes)	-0.18**	-0.15*	0.00	0.04	-0.05	0.02	-0.01	
								
Clinico-pathologic features								
 Tumor grade (I -- IV)	-0.10	-0.20**	-0.18**	0.08	-0.07	-0.19**	0.02	
 Tumor stage (1 -- 4)	0.00	-0.14*	-0.05	0.10	0.01	0.03	0.03	
 Lymph node metastasis (yes)	0.02	0.01	-0.04	0.06	0.00	0.01	0.02	
	
Degree differentiation (poor)	-0.15*	-0.26***	-0.21**	0.03	-0.17**	-0.36***	-0.30***	
1 N varies from 235 to 253 and is less than 265 total because none of 7 biomarkers had data for all 265 ESCC cases

* p &#60; 0.05

** p &#60; 0.01

*** p &#60; 0.0001

Relations to survival adjusted for these five risk factors and four clinico-pathologic features are shown in Table 5.",Bcl2,Lymph,1
"PMC 
BMC_Cancer_2009_Sep_3_9_310.txt
","Table 4 Spearman correlations between 7 apoptosis biomarkers and 5 risk factors and 4 clinico-pathologic features1

	FasL	Fas	FADD	pFADD	Caspase8	Caspase10	Bcl2	
Risk factors								
 Male (yes)	0.17**	0.01	0.05	0.02	-0.02	0.03	0.00	
 Age (yrs)	-0.01	0.02	-0.06	-0.05	0.10	0.00	0.00	
 Tobacco use (yes)	0.17**	0.05	0.08	-0.07	0.00	0.10	0.02	
 Alcohol use (daily or weekly)	0.00	-0.02	0.20**	-0.09	0.13*	0.09	0.02	
 Family history UGI cancer (yes)	-0.18**	-0.15*	0.00	0.04	-0.05	0.02	-0.01	
								
Clinico-pathologic features								
 Tumor grade (I -- IV)	-0.10	-0.20**	-0.18**	0.08	-0.07	-0.19**	0.02	
 Tumor stage (1 -- 4)	0.00	-0.14*	-0.05	0.10	0.01	0.03	0.03	
 Lymph node metastasis (yes)	0.02	0.01	-0.04	0.06	0.00	0.01	0.02	
	
Degree differentiation (poor)	-0.15*	-0.26***	-0.21**	0.03	-0.17**	-0.36***	-0.30***	
1 N varies from 235 to 253 and is less than 265 total because none of 7 biomarkers had data for all 265 ESCC cases

* p &#60; 0.05

** p &#60; 0.01

*** p &#60; 0.0001

Relations to survival adjusted for these five risk factors and four clinico-pathologic features are shown in Table 5.",UGI,Lymph,1
"PMC 
BMC_Cancer_2009_Sep_3_9_310.txt
","Table 4 Spearman correlations between 7 apoptosis biomarkers and 5 risk factors and 4 clinico-pathologic features1

	FasL	Fas	FADD	pFADD	Caspase8	Caspase10	Bcl2	
Risk factors								
 Male (yes)	0.17**	0.01	0.05	0.02	-0.02	0.03	0.00	
 Age (yrs)	-0.01	0.02	-0.06	-0.05	0.10	0.00	0.00	
 Tobacco use (yes)	0.17**	0.05	0.08	-0.07	0.00	0.10	0.02	
 Alcohol use (daily or weekly)	0.00	-0.02	0.20**	-0.09	0.13*	0.09	0.02	
 Family history UGI cancer (yes)	-0.18**	-0.15*	0.00	0.04	-0.05	0.02	-0.01	
								
Clinico-pathologic features								
 Tumor grade (I -- IV)	-0.10	-0.20**	-0.18**	0.08	-0.07	-0.19**	0.02	
 Tumor stage (1 -- 4)	0.00	-0.14*	-0.05	0.10	0.01	0.03	0.03	
 Lymph node metastasis (yes)	0.02	0.01	-0.04	0.06	0.00	0.01	0.02	
	
Degree differentiation (poor)	-0.15*	-0.26***	-0.21**	0.03	-0.17**	-0.36***	-0.30***	
1 N varies from 235 to 253 and is less than 265 total because none of 7 biomarkers had data for all 265 ESCC cases

* p &#60; 0.05

** p &#60; 0.01

*** p &#60; 0.0001

Relations to survival adjusted for these five risk factors and four clinico-pathologic features are shown in Table 5.",FADD,Lymph,1
"PMC 
BMC_Cancer_2009_Sep_3_9_310.txt
","Table 4 Spearman correlations between 7 apoptosis biomarkers and 5 risk factors and 4 clinico-pathologic features1

	FasL	Fas	FADD	pFADD	Caspase8	Caspase10	Bcl2	
Risk factors								
 Male (yes)	0.17**	0.01	0.05	0.02	-0.02	0.03	0.00	
 Age (yrs)	-0.01	0.02	-0.06	-0.05	0.10	0.00	0.00	
 Tobacco use (yes)	0.17**	0.05	0.08	-0.07	0.00	0.10	0.02	
 Alcohol use (daily or weekly)	0.00	-0.02	0.20**	-0.09	0.13*	0.09	0.02	
 Family history UGI cancer (yes)	-0.18**	-0.15*	0.00	0.04	-0.05	0.02	-0.01	
								
Clinico-pathologic features								
 Tumor grade (I -- IV)	-0.10	-0.20**	-0.18**	0.08	-0.07	-0.19**	0.02	
 Tumor stage (1 -- 4)	0.00	-0.14*	-0.05	0.10	0.01	0.03	0.03	
 Lymph node metastasis (yes)	0.02	0.01	-0.04	0.06	0.00	0.01	0.02	
	
Degree differentiation (poor)	-0.15*	-0.26***	-0.21**	0.03	-0.17**	-0.36***	-0.30***	
1 N varies from 235 to 253 and is less than 265 total because none of 7 biomarkers had data for all 265 ESCC cases

* p &#60; 0.05

** p &#60; 0.01

*** p &#60; 0.0001

Relations to survival adjusted for these five risk factors and four clinico-pathologic features are shown in Table 5.",pFADD,Lymph,1
"PMC 
BMC_Cancer_2009_Sep_3_9_310.txt
","Table 4 Spearman correlations between 7 apoptosis biomarkers and 5 risk factors and 4 clinico-pathologic features1

	FasL	Fas	FADD	pFADD	Caspase8	Caspase10	Bcl2	
Risk factors								
 Male (yes)	0.17**	0.01	0.05	0.02	-0.02	0.03	0.00	
 Age (yrs)	-0.01	0.02	-0.06	-0.05	0.10	0.00	0.00	
 Tobacco use (yes)	0.17**	0.05	0.08	-0.07	0.00	0.10	0.02	
 Alcohol use (daily or weekly)	0.00	-0.02	0.20**	-0.09	0.13*	0.09	0.02	
 Family history UGI cancer (yes)	-0.18**	-0.15*	0.00	0.04	-0.05	0.02	-0.01	
								
Clinico-pathologic features								
 Tumor grade (I -- IV)	-0.10	-0.20**	-0.18**	0.08	-0.07	-0.19**	0.02	
 Tumor stage (1 -- 4)	0.00	-0.14*	-0.05	0.10	0.01	0.03	0.03	
 Lymph node metastasis (yes)	0.02	0.01	-0.04	0.06	0.00	0.01	0.02	
	
Degree differentiation (poor)	-0.15*	-0.26***	-0.21**	0.03	-0.17**	-0.36***	-0.30***	
1 N varies from 235 to 253 and is less than 265 total because none of 7 biomarkers had data for all 265 ESCC cases

* p &#60; 0.05

** p &#60; 0.01

*** p &#60; 0.0001

Relations to survival adjusted for these five risk factors and four clinico-pathologic features are shown in Table 5.",Caspase10,Lymph,1
"PMC 
BMC_Cancer_2009_Sep_3_9_310.txt
","Table 4 Spearman correlations between 7 apoptosis biomarkers and 5 risk factors and 4 clinico-pathologic features1

	FasL	Fas	FADD	pFADD	Caspase8	Caspase10	Bcl2	
Risk factors								
 Male (yes)	0.17**	0.01	0.05	0.02	-0.02	0.03	0.00	
 Age (yrs)	-0.01	0.02	-0.06	-0.05	0.10	0.00	0.00	
 Tobacco use (yes)	0.17**	0.05	0.08	-0.07	0.00	0.10	0.02	
 Alcohol use (daily or weekly)	0.00	-0.02	0.20**	-0.09	0.13*	0.09	0.02	
 Family history UGI cancer (yes)	-0.18**	-0.15*	0.00	0.04	-0.05	0.02	-0.01	
								
Clinico-pathologic features								
 Tumor grade (I -- IV)	-0.10	-0.20**	-0.18**	0.08	-0.07	-0.19**	0.02	
 Tumor stage (1 -- 4)	0.00	-0.14*	-0.05	0.10	0.01	0.03	0.03	
 Lymph node metastasis (yes)	0.02	0.01	-0.04	0.06	0.00	0.01	0.02	
	
Degree differentiation (poor)	-0.15*	-0.26***	-0.21**	0.03	-0.17**	-0.36***	-0.30***	
1 N varies from 235 to 253 and is less than 265 total because none of 7 biomarkers had data for all 265 ESCC cases

* p &#60; 0.05

** p &#60; 0.01

*** p &#60; 0.0001

Relations to survival adjusted for these five risk factors and four clinico-pathologic features are shown in Table 5.",FasL,Lymph,1
"PMC 
BMC_Cancer_2009_Sep_3_9_310.txt
","Table 4 Spearman correlations between 7 apoptosis biomarkers and 5 risk factors and 4 clinico-pathologic features1

	FasL	Fas	FADD	pFADD	Caspase8	Caspase10	Bcl2	
Risk factors								
 Male (yes)	0.17**	0.01	0.05	0.02	-0.02	0.03	0.00	
 Age (yrs)	-0.01	0.02	-0.06	-0.05	0.10	0.00	0.00	
 Tobacco use (yes)	0.17**	0.05	0.08	-0.07	0.00	0.10	0.02	
 Alcohol use (daily or weekly)	0.00	-0.02	0.20**	-0.09	0.13*	0.09	0.02	
 Family history UGI cancer (yes)	-0.18**	-0.15*	0.00	0.04	-0.05	0.02	-0.01	
								
Clinico-pathologic features								
 Tumor grade (I -- IV)	-0.10	-0.20**	-0.18**	0.08	-0.07	-0.19**	0.02	
 Tumor stage (1 -- 4)	0.00	-0.14*	-0.05	0.10	0.01	0.03	0.03	
 Lymph node metastasis (yes)	0.02	0.01	-0.04	0.06	0.00	0.01	0.02	
	
Degree differentiation (poor)	-0.15*	-0.26***	-0.21**	0.03	-0.17**	-0.36***	-0.30***	
1 N varies from 235 to 253 and is less than 265 total because none of 7 biomarkers had data for all 265 ESCC cases

* p &#60; 0.05

** p &#60; 0.01

*** p &#60; 0.0001

Relations to survival adjusted for these five risk factors and four clinico-pathologic features are shown in Table 5.",ESCC,Lymph,1
"PMC 
BMC_Cancer_2010_Apr_27_10_161.txt
","Cells were grown to 60% to 70% confluency, then starved in serum-free DMEM for 24 hours, then the cells were pretreated with inhibitors for 1 hours incubated in the presence of EGF for 24 hours and extracted and subjected to Western blot analysis.",DMEM,serum,-1
"PMC 
BMC_Cancer_2010_Apr_27_10_161.txt
","Cells were grown to 60% to 70% confluency, then starved in serum-free DMEM for 24 hours, then the cells were pretreated with inhibitors for 1 hours incubated in the presence of EGF for 24 hours and extracted and subjected to Western blot analysis.",EGF,serum,-1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","To our knowledge, this is the first study attempting to investigate the serum expression of MMP-9, NGAL and MMP-9/NGAL complex during diagnostic work-up of patients with breast abnormalities and correlate it with the severity of the disease.",MMP-9,serum,1
"PMC 
BMC_Cancer_2009_Nov_4_9_390.txt
","To our knowledge, this is the first study attempting to investigate the serum expression of MMP-9, NGAL and MMP-9/NGAL complex during diagnostic work-up of patients with breast abnormalities and correlate it with the severity of the disease.",NGAL,serum,1
"PMC 
BMC_Cancer_2010_Apr_1_10_123.txt
","Different levels of expression of GalNAc-T3 were detected in patients with colorectal [12], lung [28], pancreatic [29], gastric [30], gallbladder [31], prostate [32] and extrahepatic bile duct carcinomas [33], and it was identified as an independent factor of prognosis.",T3,bile,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Survival was not significantly different by age (p = .053), sex (p = .461), carcinoid symptom (p = .646), primary tumor origin (p = .660), presence of liver metastasis (p = .995), elevation of biomarkers (p = .653 for urine 5-HIAA; p = .051 for serum NSE), and treatment modality (local treatment only vs. systemic treatment only vs. both treatments, p = .245).",NSE,serum,-1
"PMC 
BMC_Cancer_2010_Aug_23_10_448.txt
","Survival was not significantly different by age (p = .053), sex (p = .461), carcinoid symptom (p = .646), primary tumor origin (p = .660), presence of liver metastasis (p = .995), elevation of biomarkers (p = .653 for urine 5-HIAA; p = .051 for serum NSE), and treatment modality (local treatment only vs. systemic treatment only vs. both treatments, p = .245).",NSE,urine,-1
"PMC 
BMC_Cancer_2009_Oct_22_9_376.txt
","However, this is the first report that demonstrates that the expression levels of CK19 mRNA in feces of patients younger than 60 years may represent an underlying colorectal malignancy because of the prior exclusion of inflammatory bowel coditions.",CK19,feces,1
"PMC 
BMC_Cancer_2009_Oct_22_9_376.txt
","However, this is the first report that demonstrates that the expression levels of CK19 mRNA in feces of patients younger than 60 years may represent an underlying colorectal malignancy because of the prior exclusion of inflammatory bowel coditions.",mRNA,feces,1
"PMC 
BMC_Cancer_2009_Oct_22_9_376.txt
","The similar results were also reported by Wang et al. in blood [29]; however, our data are more specific in CRC because we using the samples directly from colonic tract [18].",CRC,blood,-1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
",TRACP 5b is an enzyme secreted by osteoclasts and its activity can be measured specifically in serum by immunoassay[9].,TRACP,serum,1
"PMC 
BMC_Cancer_2009_Oct_22_9_376.txt
","We reported several fecal molecules that are differentially expressed in CRC patients [21,22], and demonstrated that CK19 expression in feces is possibly correlated with CRC metastasis [20].",CRC,feces,1
"PMC 
BMC_Cancer_2009_Oct_22_9_376.txt
","We reported several fecal molecules that are differentially expressed in CRC patients [21,22], and demonstrated that CK19 expression in feces is possibly correlated with CRC metastasis [20].",CK19,feces,1
"PMC 
BMC_Cancer_2009_Oct_22_9_376.txt
","We reported several fecal molecules that are differentially expressed in CRC patients [21,22], and demonstrated that CK19 expression in feces is possibly correlated with CRC metastasis [20].",CRC,feces,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Serum concentration of CA-125, TIMP-1 and VEGF-165 duringfirst-line therapy
Serum concentrations of CA-125, VEGF-165 and TIMP-1 at the respective time-points are listed in Table 2.",CA-125,Serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Serum concentration of CA-125, TIMP-1 and VEGF-165 duringfirst-line therapy
Serum concentrations of CA-125, VEGF-165 and TIMP-1 at the respective time-points are listed in Table 2.",CA-125,Serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Serum concentration of CA-125, TIMP-1 and VEGF-165 duringfirst-line therapy
Serum concentrations of CA-125, VEGF-165 and TIMP-1 at the respective time-points are listed in Table 2.",CA-125,Serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Serum concentration of CA-125, TIMP-1 and VEGF-165 duringfirst-line therapy
Serum concentrations of CA-125, VEGF-165 and TIMP-1 at the respective time-points are listed in Table 2.",CA-125,Serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Serum concentration of CA-125, TIMP-1 and VEGF-165 duringfirst-line therapy
Serum concentrations of CA-125, VEGF-165 and TIMP-1 at the respective time-points are listed in Table 2.",TIMP-1,Serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Serum concentration of CA-125, TIMP-1 and VEGF-165 duringfirst-line therapy
Serum concentrations of CA-125, VEGF-165 and TIMP-1 at the respective time-points are listed in Table 2.",TIMP-1,Serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Serum concentration of CA-125, TIMP-1 and VEGF-165 duringfirst-line therapy
Serum concentrations of CA-125, VEGF-165 and TIMP-1 at the respective time-points are listed in Table 2.",VEGF-165,Serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Serum concentration of CA-125, TIMP-1 and VEGF-165 duringfirst-line therapy
Serum concentrations of CA-125, VEGF-165 and TIMP-1 at the respective time-points are listed in Table 2.",VEGF-165,Serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Serum concentration of CA-125, TIMP-1 and VEGF-165 duringfirst-line therapy
Serum concentrations of CA-125, VEGF-165 and TIMP-1 at the respective time-points are listed in Table 2.",VEGF-165,Serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Serum concentration of CA-125, TIMP-1 and VEGF-165 duringfirst-line therapy
Serum concentrations of CA-125, VEGF-165 and TIMP-1 at the respective time-points are listed in Table 2.",VEGF-165,Serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Serum concentration of CA-125, TIMP-1 and VEGF-165 duringfirst-line therapy
Serum concentrations of CA-125, VEGF-165 and TIMP-1 at the respective time-points are listed in Table 2.",TIMP-1,Serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Serum concentration of CA-125, TIMP-1 and VEGF-165 duringfirst-line therapy
Serum concentrations of CA-125, VEGF-165 and TIMP-1 at the respective time-points are listed in Table 2.",TIMP-1,Serum,1
"PMC 
BMC_Cancer_2009_Oct_22_9_376.txt
","In CRC patients, the levels of CK19 expression in the blood are associated with the presence of micrometastases [27,28].

",CRC,blood,-1
"PMC 
BMC_Cancer_2009_Oct_22_9_376.txt
","In CRC patients, the levels of CK19 expression in the blood are associated with the presence of micrometastases [27,28].

",CK19,blood,-1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","Since a higher tumor burden is related to a poorer survival, we tested the hypothesis that elevated serum TRACP 5b activity, as a measure of extent of bone disease, could be a marker of poorer prognosis in BC patients with bone metastasis.",TRACP,serum,1
"PMC 
BMC_Cancer_2010_Aug_18_10_439.txt
","Lymphocytes were then resuspended in RPMI 1640 medium supplemented with 1% L-glutamine, 100 U/ml of penicillin and of streptomycin (Gibco Invitrogen Corp., Grand Island, NY), 10% fetal calf serum, 2% PHA (Murex Biotech Ltd., Dartford, England, UK) and cultured in 24-well microplates for 24 h at 37degC in 5% CO2 prior to treatment.

",CO2,serum,1
"PMC 
BMC_Cancer_2010_Aug_18_10_439.txt
","Lymphocytes were then resuspended in RPMI 1640 medium supplemented with 1% L-glutamine, 100 U/ml of penicillin and of streptomycin (Gibco Invitrogen Corp., Grand Island, NY), 10% fetal calf serum, 2% PHA (Murex Biotech Ltd., Dartford, England, UK) and cultured in 24-well microplates for 24 h at 37degC in 5% CO2 prior to treatment.

",PHA,serum,1
"PMC 
BMC_Cancer_2010_Aug_18_10_439.txt
","Lymphocytes were then resuspended in RPMI 1640 medium supplemented with 1% L-glutamine, 100 U/ml of penicillin and of streptomycin (Gibco Invitrogen Corp., Grand Island, NY), 10% fetal calf serum, 2% PHA (Murex Biotech Ltd., Dartford, England, UK) and cultured in 24-well microplates for 24 h at 37degC in 5% CO2 prior to treatment.

",RPMI,serum,1
"PMC 
BMC_Cancer_2010_Apr_1_10_123.txt
","Expression levels for GalNAc-T14 mRNA have been detected in human normal tissue and tumor tissue samples, including skin, pancreas, lung, breast, ovary, endometrium, bladder and lymph.",T14,lymph,1
"PMC 
BMC_Cancer_2010_Apr_1_10_123.txt
","Expression levels for GalNAc-T14 mRNA have been detected in human normal tissue and tumor tissue samples, including skin, pancreas, lung, breast, ovary, endometrium, bladder and lymph.",mRNA,lymph,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","Our results showed that serum TRACP 5b activity interval change might also be a potential prognostic marker, but it needs to be validated independently.",TRACP,serum,1
"PMC 
BMC_Cancer_2010_Aug_17_10_437.txt
","(c1)Of 10 mice in each group, metastases were detected in eight lymph nodes in the control group, two in the PDTC group and one in the BAY 11-7085 group (c2).",PDTC,lymph,1
"PMC 
BMC_Cancer_2010_Aug_17_10_437.txt
","(c1)Of 10 mice in each group, metastases were detected in eight lymph nodes in the control group, two in the PDTC group and one in the BAY 11-7085 group (c2).",BAY,lymph,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","For example, serum TRACP 5b activity may be lower in pre-menopausal patients with bone metastasis.",TRACP,serum,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","The principal objective of this study was to determine the relationship between serum IL-6 and CRP levels and malignant tendencies and prognosis in gastric cancer patients.

",IL-6,serum,1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","The principal objective of this study was to determine the relationship between serum IL-6 and CRP levels and malignant tendencies and prognosis in gastric cancer patients.

",CRP,serum,-1
"PMC 
BMC_Cancer_2009_May_20_9_155.txt
","Thus, it has been reported that serum CRP levels are higher in cases of invasive cancer than in cases of non-invasive cancer [9,10].

",CRP,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
",High serum concentrations of CA-125 before surgery were significantly associated with age (p = 0.046) and large ascites volume (p = 0.004).,CA-125,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
",High serum concentrations of CA-125 before surgery were significantly associated with age (p = 0.046) and large ascites volume (p = 0.004).,CA-125,ascites,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Quantitative analysis of serum VEGF-165 and TIMP-1 levels
Serum VEGF-165 and TIMP-1 were quantified by commercially available ELISA (Siemens Healthcare Diagnostics, Tarrytown, USA).",TIMP-1,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Quantitative analysis of serum VEGF-165 and TIMP-1 levels
Serum VEGF-165 and TIMP-1 were quantified by commercially available ELISA (Siemens Healthcare Diagnostics, Tarrytown, USA).",TIMP-1,Serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Quantitative analysis of serum VEGF-165 and TIMP-1 levels
Serum VEGF-165 and TIMP-1 were quantified by commercially available ELISA (Siemens Healthcare Diagnostics, Tarrytown, USA).",TIMP-1,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Quantitative analysis of serum VEGF-165 and TIMP-1 levels
Serum VEGF-165 and TIMP-1 were quantified by commercially available ELISA (Siemens Healthcare Diagnostics, Tarrytown, USA).",TIMP-1,Serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Quantitative analysis of serum VEGF-165 and TIMP-1 levels
Serum VEGF-165 and TIMP-1 were quantified by commercially available ELISA (Siemens Healthcare Diagnostics, Tarrytown, USA).",ELISA,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Quantitative analysis of serum VEGF-165 and TIMP-1 levels
Serum VEGF-165 and TIMP-1 were quantified by commercially available ELISA (Siemens Healthcare Diagnostics, Tarrytown, USA).",ELISA,Serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Quantitative analysis of serum VEGF-165 and TIMP-1 levels
Serum VEGF-165 and TIMP-1 were quantified by commercially available ELISA (Siemens Healthcare Diagnostics, Tarrytown, USA).",USA,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Quantitative analysis of serum VEGF-165 and TIMP-1 levels
Serum VEGF-165 and TIMP-1 were quantified by commercially available ELISA (Siemens Healthcare Diagnostics, Tarrytown, USA).",USA,Serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Quantitative analysis of serum VEGF-165 and TIMP-1 levels
Serum VEGF-165 and TIMP-1 were quantified by commercially available ELISA (Siemens Healthcare Diagnostics, Tarrytown, USA).",VEGF-165,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Quantitative analysis of serum VEGF-165 and TIMP-1 levels
Serum VEGF-165 and TIMP-1 were quantified by commercially available ELISA (Siemens Healthcare Diagnostics, Tarrytown, USA).",VEGF-165,Serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Quantitative analysis of serum VEGF-165 and TIMP-1 levels
Serum VEGF-165 and TIMP-1 were quantified by commercially available ELISA (Siemens Healthcare Diagnostics, Tarrytown, USA).",VEGF-165,serum,1
"PMC 
BMC_Cancer_2010_Apr_13_10_139.txt
","Quantitative analysis of serum VEGF-165 and TIMP-1 levels
Serum VEGF-165 and TIMP-1 were quantified by commercially available ELISA (Siemens Healthcare Diagnostics, Tarrytown, USA).",VEGF-165,Serum,1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
","The increase of SAA in serum was also confirmed by western blotting and ELISA in this study [5].

",ELISA,serum,-1
"PMC 
BMC_Cancer_2009_May_16_9_150.txt
","The increase of SAA in serum was also confirmed by western blotting and ELISA in this study [5].

",SAA,serum,-1
"PMC 
BMC_Cancer_2009_Sep_10_9_322.txt
","No significant association was found between TIMP-1 and number of tumor-positive lymph nodes, steroid hormone receptor status, tumor size, grade, adjuvant RT, or type of surgery.

",TIMP-1,lymph,1
"PMC 
BMC_Cancer_2009_Oct_18_9_370.txt
",Kim et al reported an elevation of MMP1 in saliva related to refractory periodontitis in microarray study of oral subepithelial connective tissues [41].,MMP1,saliva,-1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","Further analysis demonstrated that among patients in the highest tertile, OS was significantly longer in those patients who had achieved a decrease of serum TRACP 5b activity greater than the LSC (38.59%) (p = 0.0015).

",OS,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","Further analysis demonstrated that among patients in the highest tertile, OS was significantly longer in those patients who had achieved a decrease of serum TRACP 5b activity greater than the LSC (38.59%) (p = 0.0015).

",TRACP,serum,1
"PMC 
BMC_Cancer_2010_Apr_23_10_158.txt
","Further analysis demonstrated that among patients in the highest tertile, OS was significantly longer in those patients who had achieved a decrease of serum TRACP 5b activity greater than the LSC (38.59%) (p = 0.0015).

",LSC,serum,1
"PMC 
BMC_Cancer_2010_Apr_21_10_155.txt
","Cardiac output will be calculated by stroke volume multiplied by heart rate, (2) Hemoglobin (Hb) Concentration (O2 carrying capacity of blood) will be assessed via a venous blood draw according to standard guidelines.",O2,blood,-1
"PMC 
BMC_Cancer_2010_Apr_21_10_155.txt
","Cardiac output will be calculated by stroke volume multiplied by heart rate, (2) Hemoglobin (Hb) Concentration (O2 carrying capacity of blood) will be assessed via a venous blood draw according to standard guidelines.",O2,blood,-1
